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DISC1, a strong genetic candidate for psychiatric illness, is a molecular scaffold 
residing in multiple subcellular compartments, where it regulates the function of 
interacting proteins with key roles in neurodevelopment and plasticity. Both common 
and rare DISC1 missense variants are associated with risk of mental illness and/or 
brain abnormalities in healthy carriers, but the underlying mechanisms are unclear. In 
this thesis, I initially examine the effect of a panel of common and rare single amino 
acid substitutions on DISC1 subcellular targeting, establishing that the rare mutation 
R37W and the common variant L607F disrupt DISC1 nuclear targeting in a 
dominant-negative fashion. This finding predicts that DISC1 nuclear expression is 
severely impaired in 37W and 607F carriers. In addition, I show that the L607F 
substitution results in aberrant cytoplasmic and cytoskeletal distribution of DISC1. In 
the nucleus, DISC1 interacts with the transcription factor ATF4, which is involved in 
the regulation of cellular stress responses and memory consolidation. Here I show 
that at basal cAMP levels, wild-type DISC1 strongly inhibits the transcriptional 
activity of ATF4, and this effect is ablated by 37W and 607F, most likely as a 
consequence of their defective nuclear targeting. 607F additionally reduces 
DISC1/ATF4 interaction, which likely contributes to its weakened inhibitory effect. I 
also demonstrate that DISC1 modulates transcriptional responses to endoplasmic 
reticulum stress, and that this modulatory effect is also ablated by 37W and 607F. By 
providing evidence that single amino acid substitutions of DISC1 associated with 
psychiatric illness impair its regulatory function on ATF4-dependent transcription, I 
highlight a potential mechanism by which these protein variants may impact on 
molecular pathways underlying cognition and stress responses, two processes of 
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NDE1 Nuclear Distribution factor E homologue 1 
NDEL1 Nuclear Distribution factor E homologue-Like 1 
NEK6 NIMA (never in mitosis gene a)-related kinase 6 
NIPK Neuronal cell death inducible putative kinase, aka TRIB3  
NMDAR N-Methyl-D-aspartic acid receptor 
Nrf2 Nuclear factor (erythroid-derived 2)-like 2 
NRG1 Neuregulin 1 
p84 Nuclear matrix protein, 84 kDa 
PCM1 Pericentriolar Material 1 
PDE4 Phosphodiesterase 4 
PERK RNA-dependent protein kinase-like endoplasmic reticulum kinase 
PHD3 Prolyl-4-hydroxylase 3, aka EGLN3 (egl nine homolog 3) 
PKA Protein kinase A, aka cAMP-dependent protein kinase 
PKG cGMP-dependent protein kinase 
PKIα Protein kinase inhibitor alpha 
PKR Protein kinase RNA-activated 
PLP Proteolipid protein 
PML Promyelocytic leukemia 
PP2A Protein phosphatase 2, regulatory subunit A 
PS1 Presenilin 1 
PSD-95    Postsynaptic density protein 95 
Puma p53-upregulated modulator of apoptosis 
PV Parvalbumin 
Rac1 Ras-related C3 botulinum toxin substrate 1 
RankL Receptor activator of nuclear factor kappa B ligand 
RPL41 Ribosomal protein L41 




SAP Shrimp alkaline phosphatase 
Satb2 Special AT-rich sequence-binding homeobox 2 
SCF Skp1/cullin/F-box protein 
SLC7A11 Sodium-independent aspartate/glutamate/cystine transporter, aka xCT 
SMARCE1 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily e, member 1 
SNAT2 System A neutral amino acid transporter 2 
Sox2 SRY (sex determining region Y)-box 2 
SP6 Sp6 transcription factor 
TBB TATA-binding protein 
TFIIB General transcription factor IIB 
TFIIF General transcription factor IIF 
TK Thymidine kinase 
TNIK TRAF2 and NCK interacting kinase 
TRAX Translin-associated factor X, aka TSNAX 
 
Units 
C Degree centigrade 





M Molar (mols per liter) 
mol Mols 
RPM Revolutions per minute 
V Volt 
n Nano (x10-9) 









































A  Amyloid beta 
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
APS Ammonium persulphate 
ATP Adenosine Triphosphate 
BAC Bacterial artificial chromosome 
cAMP Cyclic Adenosine Monophosphate 
cDNA Complementary DNA 
CTP Cytidine Triphosphate 
DABCO 1,4-diazabicyclo[2.2.2]octane 
DAPI 4',6-diamidino-2-phenylindole 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic Acid 
dNTP Deoxyribonucleotide triphosphate 
DTT Dithiothreitol 
EDTA Ethylenediaminetetraacetic Acid 
ENU N-nitroso-ethylurea 
FSK Forskolin 
GABA Gamma-Aminobutyric acid 
GDP Guanosine diphosphate 
GST Glutatione S-transferase (tag) 
GTP Guanosine triphosphate 
HCY Homocysteine 
HEPES 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
HisOH Histidinol 
IBMX 3-isobutyl-1-methylxanthine 
mPKI Myristoylated protein kinase inhibitor peptide (14-22) 
mRNA Messenger RNA 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 




NMDA N-Methyl-D-aspartic acid 
OA Okadaic acid 
PDVF Polyvinylidene difluoride 
PFA Paraformaldehyde 
PolyI:C Polyinosinic:polycytidylic acid 
RNA Ribonucleic acid 
SDS Sodium Dodecyl Sulphate 
shRNA Short hairpin RNA 
siRNA Small interfering RNA 
TEMED Tetramethylethylenediamine 
TG Thapsigargin 
tRNA Transfer RNA 
TTP Thymidine triphosphate 
 
Other abbreviations 
(f)MRI (Functional) magnetic resonance imaging 
3D Three-dimensional 
AARE Amino acid response element 
ANOVA Analysis of variance 
Bt Bos taurus 
BTF Basic transcription factors 
bZIP Basic region-leucine zipper 
CARE C/EBP-ATF4 response element 
CBNE Chromatin-bound nuclear extract 
CCD Charge coupled device 
CD-CV Common disease-common variant 
CE Cytoplasmic extract 




ChIP-seq Chromatin immunoprecipitation and sequencing 
CMV Cytomegalovirus 
CNV Copy number variant 
Co-IP Co-immunoprecipitation 
CRE cAMP response element 
CSKE Cytoskeletal extract 
DALY Disability Adjusted Life Year 
DISC1LZ9 Leucine zipper in DISC1 exon 9 
DMEM Dulbecco Modified Eagle’s minimum essential Medium 
DN Dominant-negative 
DPF Days post fertilisation 
Dr Danio rerio 
DSM Diagnostic and Statistical Manual of Mental Illness 
DZ Dizygotic 
E Embryonic day 
EC50 Half maximal effective concentration 
ECACC European Collection of Cell Cultures 
EMSA Electrophoretic mobility shift assay 
ER Endoplasmic reticulum 
ERP Event-related potential 
FA Fractional anisotropy 
FBS Foetal bovine serum 
GWAS Genome-wide association study 
HBSS Hank’s balanced salt solution 
HGU Human Genetics Unit 
HPA Hypothalamus-pituitary-adrenal 
HPLC High-performance liquid chromatography 
Hs Homo sapiens 





ICD International Classification of Disease 
IP Immunoprecipitation 
iPS Induced pluripotent stem (cells) 




LI Latent inhibition 
LOD Logarithm of odds 
LTD Long-term depression 
LTF Long-term facilitation 
LTP Long term potentiation 
M2H Mammalian-two-hybrid 
Ma Macaca mulatta 
ME Membrane extract 
Mm Mus musculus 
MRC Medical Research Council 
MTOC Microtubule-organising centre 
MZ Monozygotic 
NA Nucleus accumbens 
NC Negative control 
NES Nuclear export signal 
NLS Nuclear localisation signal 
O/N Overnight 
ODDD Oxygen-dependent degradation domain 
ORF Open reading frame 
PBS Phosphate buffered saline 




PFC Prefrontal cortex 
PLA Proximity ligation assay 
PPI Prepulse inhibition 
PSD Post-synaptic density 
Pt Pan troglodytes 
Q-PCR Quantitative PCR 
RACE Rapid amplification of cDNA ends 
RIPA Radio immuno precipitation assay 
Rn Rattus norvegicus 
RNS Reactive nitrogen species 
ROI Region of interest 
ROS Reactive oxygen species 
RT Room temperature 
SCN Suprachiasmatic nucleus 
SF Serine/phenylalanine-rich motif of DISC1 
SNE Soluble nuclear extract 
SNP Single nucleotide polymorphism 
SPR Surface plasmon resonance 




Tr Takifugu rubripes 
UCR Upstream conserved region 
uORF Upstream ORF 
UTR Untranslated region 
UV Ultra violet 
VWM Vanishing white matter 




WHO World Health Organisation 
WM White matter 
WT Wild-type 
Y2H Yeast-two-hybrid 
YLD Years lived with Disability 





1.1 Introduction to psychiatric illness 
1.1.1 The global burden of psychiatric illness 
Psychiatric disorders are defined by the World Health Organisation (WHO) as 
“clinically significant conditions characterised by alterations in thinking, mood 
(emotions) or behaviour associated with personal distress and/or impaired 
functioning” (WHO World Health Report 2001). Psychiatric diseases are 
heterogeneous in the nature, severity, persistence and age of onset of the symptoms, 
which are often disabling and can severely impair the quality of life of the affected 
individuals and their close relatives. It is estimated that more than 25% of people 
worldwide are affected by psychiatric illness at some point during their life (WHO, 
2001).  Due to their relatively high prevalence and disabling symptoms, psychiatric 
disorders are a major economic burden for society (Gustavsson et al, 2011; Ormel et 
al, 2008). A new parameter has been introduced by the WHO to quantify the global 
burden of disease: the Disability Adjusted Life Year (DALY). DALY is the sum of 
the Years of Life Lost to Premature Mortality (YLL) and the Years Lived with 
Disability (YLD). Thus, one DALY corresponds to one lost year of healthy life. In 
the year 2000, psychiatric disorders accounted for 12% of DALYs and 31% of YLDs 
worldwide, and it is estimated that by the year 2015 they will be responsible for 15% 
of DALYs globally (Murray & Lopez, 1996). Depression, schizophrenia and bipolar 
disorder rank among the top ten causes of disability worldwide at all ages, and 
among the top five in individuals aged 15 to 44 (WHO, 2001).  
With an estimated global lifetime prevalence of 16%, anxiety disorders are the most 
common mental illnesses (Kessler et al, 2009). Mood disorders follow, with an 
overall lifetime prevalence of about 12% (Kessler et al, 2009). Depression is the 
most prevalent mood disorder (estimated lifetime prevalence between 8.3% and 
16.2%), and represents the leading cause of YLDs and the fourth leading cause of 
DALYs worldwide (Richards, 2011) and (WHO, 2001). Bipolar disorder, another 




2009), ranks fifth and ninth among the causes of YLDs and DALY, respectively, in 
the younger population (15 to 44 years of age) (WHO, 2001). Finally, with a lifetime 
prevalence of 0.4-0.8% (Perala et al, 2007; Saha et al, 2005), Schizophrenia also 
features among the top causes of disability worldwide, ranking third and eighth 
leading cause of YLDs and DALYs, respectively, among individuals aged 15 to 44 
(WHO, 2001).  
Despite the significant burden it represents for the affected individuals and society, 
psychiatric illness is still poorly understood. As a result, no radically new drugs or 
alternative therapeutic strategies have been identified since the introduction of 
antidepressants and antipsychotics in the 50s (Hyman, 2008). It is hoped that a better 
understanding of the molecular pathogenesis of psychiatric disorders will pave the 
way for the development of improved preventative and therapeutic approaches. 
1.1.2 Major depression, bipolar disorder and schizophrenia 
Due to our still limited understanding of the neurobiology of mental illness and the 
lack of specific biomarkers, diagnosis of psychiatric conditions is currently solely 
based on clinical observations such as symptoms, signs and course of illness 
(Hyman, 2007; Hyman, 2008). Based on expert consensus, two manuals have been 
compiled that list the currently recognised psychiatric conditions and define the 
criteria to diagnose them: the Diagnostic and Statistical Manual of Mental Disorders, 
(DSM), and the International Classification of Disease (ICD). The DSM, currently at 
its fourth edition, focuses on mental illness and is produced by The American 
Psychiatric Association. The ICD, now at its tenth edition, is produced by the WHO 
and covers all human diseases, with chapter V being dedicated to psychiatric 
diagnoses. Both manuals are in current use, but the DSM-IV is used much more 
frequently in research settings. The DSM-IV diagnostic criteria for major depression, 
bipolar disorder and schizophrenia are briefly summarised below. The clinical 
features of schizophrenia will be described in more detail in the next section.  
Major depression, also referred to as unipolar depression, is characterised by 
prolonged depressive episodes during which the sufferer experiences feelings of 




major depressive episode can also include sleep disturbances, altered appetite, loss of 
energy and reduced ability to concentrate, and can lead to recurrent suicidal thoughts.  
Bipolar disorder, also known as manic-depressive disorder, is characterised by major 
depressive episodes alternating with manic or mixed episodes. A manic episode is 
defined as a period of abnormally and persistently elevated mood, during which the 
sufferer experiences inflated self-esteem, decreased need for sleep, increased 
distractibility, increased talkativeness and flights of ideas. Bipolar patients 
experiencing a manic episode are more likely to engage in pleasurable activities and 
risky behaviours. A mixed episode is defined as meeting both the criteria for a major 
depressive episode and a manic episode nearly every day for at least one week.  
Schizophrenia is characterised by the concomitant occurrence of “positive” and 
“negative” symptoms. Positive symptoms include delusions, hallucinations and/or 
disorganised thoughts, whereas negative symptoms are manifested as blunted 
emotional responses, loss of motivation and speech decline. For the diagnostic 
criteria for schizophrenia to be met, the above symptoms must be accompanied by a 
social or occupational dysfunction that compromises the sufferer’s ability to work, 
live independently and/or maintain interpersonal relations.  
1.1.2.1 Clinical features of schizophrenia 
Schizophrenia is a highly heterogeneous syndrome in terms of clinical presentation, 
severity of the symptoms, course of illness, response to treatment and long-term 
outcome (Peralta & Cuesta, 2001). Due to the high variability of its clinical profile, 
the nosological boundaries between schizophrenia and other psychiatric disorders, 
especially mood disorders, are not clearly demarked, which led to the proposition 
that schizophrenia and bipolar disorder may be better conceptualised as a spectrum 
of clinical manifestations rather than distinct diseases (Kendell & Brockington, 1980; 
Owen et al, 2007). In general, the schizophrenia syndrome includes several distinct 
clusters or dimensions of signs and symptoms, which can be classified as positive 
symptoms, negative symptoms, disorganised thought and behaviour, mood 
symptoms and cognitive impairment (Tandon et al, 2009). Positive symptoms 




hallucinations (false perceptions) and delusions (false beliefs) (Tandon et al, 2009). 
Hallucinations can affect all senses, although auditory hallucinations (hearing voices) 
are the most common in schizophrenia patients (Waters et al, 2012). The nature of 
delusions can vary broadly between patients, and it is influenced by the social and 
cultural setting of the affected individual, but persecutory delusions and delusions of 
reference (i.e. the belief that irrelevant and innocuous events or phenomena have a 
specific significance for oneself) are particularly common in schizophrenia (Tandon 
et al, 2009). Negative symptoms are described as a severe impairment or complete 
loss of affective and conative functions (e.g. volition, drive, desire), and can be 
manifested as emotional bluntness, anhedonia, lack of motivation, initiative and 
interest, speech impairment and social withdrawal (Tandon et al, 2009). 
Disorganised thought constitutes a further clinical dimension of schizophrenia, and 
consists in the inability to formulate logical and sequential thoughts, often resulting 
in inconsistent, incongruous and disorganised behaviour (Tandon et al, 2009). Mood 
alterations, and in particular depression, are an integral part of the disease for many 
schizophrenia patients, and they can occur at any stage of the illness, although they 
tend to become more pronounced during psychotic exacerbations (Tandon et al, 
2009). Schizophrenia is also characterised by a generalised cognitive impairment, 
which is a highly prevalent feature of the disease, although its extent varies 
significantly between patients (Tandon et al, 2009). This cognitive impairment is 
commonly present before the onset of positive symptoms, and it precedes the 
beginning of antipsychotic treatment, indicating that it is a core feature of the 
disease, which persists throughout the course of illness (Tandon et al, 2009). 
However, the question of whether cognitive abilities remain stable in schizophrenia 
patients or instead decline gradually as the disease progresses is still under debate 
(Napal et al, 2012). Importantly, similar cognitive defects, albeit of attenuated 
severity, are present in a subgroup of unaffected first-degree relatives of 
schizophrenia patients, indicating that these deficits are a hallmark of disease 
susceptibility (Tandon et al, 2009). Although the intellectual impairment in 
schizophrenia is of a generalised nature (i.e. schizophrenia patients have, on average, 
a lower IQ compared to healthy controls), some spheres of cognition, such as 




and working memory, are more affected than others (Tandon et al, 2009). Unlike 
positive symptoms, the impairment of cognitive function in schizophrenia is not 
significantly improved by antipsychotic treatment, and together with negative 
symptoms, which also respond poorly to medication, it underlies the poor social 
integration and long-term disability of the patients (Tandon et al, 2009).  
The evolution of schizophrenia typically follows a sequential trajectory in which a 
premorbid phase and a prodromal phase precede the onset of illness (Tandon et al, 
2009) (Figure 1.1, taken from Tandon et al, 2009). In the premorbid phase, 
individuals who will later develop schizophrenia often present a range of 
behavioural, cognitive and emotional abnormalities, including impaired attention, 
language deficits, poor academic performance, social withdrawal and emotional 
detachment (Schenkel & Silverstein, 2004). However, it is important to emphasize 
that not all schizophrenia patients experience a premorbid phase, and not all 
individuals that show the typical signs and symptoms of premorbid schizophrenia 
will later develop the disease (Tandon et al, 2009). In the prodromal phase, mood 
alterations, cognitive impairment and negative symptoms are accompanied by mild 
psychotic symptoms (Cornblatt et al, 1999). Between one sixth and one half 
(depending on the population studied and the inclusion criteria) of the individuals 
presenting the signs and symptoms of prodromal schizophrenia will later develop the 
disease (Tandon et al, 2009). The onset of schizophrenia is marked by the first full-
blown psychotic episode, which may include hallucinations, delusions and 
disorganised speech and behaviour, and often results in hospitalisation (Tandon et al, 
2009). The onset of schizophrenia typically occurs during adolescence or early 
adulthood, with earlier age of onset, which is more common in males than females, 
being associated with more severe symptoms and poorer outcome (Tandon et al, 
2009). After the first psychotic episode, positive symptoms typically go through 
intermittent phases of exacerbation and remission, with highly variable patterns 
between patients (Haro et al, 2008). Symptom exacerbation can be triggered by 
stress, substance abuse or non-compliance to treatment (Tandon et al, 2009). In the 
years following the disease onset, positive symptoms tend to become milder, while 
negative symptoms become more prominent and mood remains very variable, 




reached (Tandon et al, 2009) (Figure 1.1). The long-term disease outcome varies 
substantially, with some patients showing partial or complete remission, and others 
deteriorating to a state of severe social and functional deficit (Tandon et al, 2009). In 
general, schizophrenia patients have higher mortality rates, a significant proportion 
of which is due to high rates of suicide, but that can also be reconducted to a high 
prevalence of substance abuse, including nicotine and alcohol, and severe 
comorbidities like cardiovascular disease (Tandon et al, 2009). All together, these 
factors account for the elevated individual and societal burden of schizophrenia.  
 
 
Figure 1.1 The clinical course of schizophrenia, taken from Tandon et al, 2009.  
 
1.1.3 The aetiology of psychiatric illness 
The aetiology of neuropsychiatric disorders is highly complex and still poorly 
understood. Many common psychiatric conditions are thought to result from the 




exposures (Uher, 2008; Uher, 2011; van Os et al, 2008). Our current understanding 
of the genetic and environmental components of the risk of major psychiatric illness 
is summarised below. 
1.1.3.1 Genetic factors 
Family, twin and adoption studies clearly demonstrated that many psychiatric 
disorders, including schizophrenia (Craddock et al, 2005; Gottesman et al, 1987; 
Sullivan et al, 2003), bipolar disorder (Craddock et al, 2005; Smoller & Finn, 2003) 
and depression (Kendler et al, 2006; Sullivan et al, 2000) are familial disorders, and 
that their tendency to aggregate in families is mainly due to shared genetic risk 
factors. The significant genetic component of these disorders is evidenced by the 
high concordance of diagnosis between monozygotic (MZ) twins compared to 
dizygotic (DZ) twins. This is estimated at 50% for schizophrenia, 80% for bipolar 
disorder, and 23-67% for major depression (Craddock & Jones, 1999; Craddock et 
al, 2005; Sullivan et al, 2000). The observation that the risk of developing 
schizophrenia, bipolar disorder or depression decreases as the genetic relatedness to a 
proband diminishes (Craddock & Jones, 1999; Gottesman et al, 1987; Kendler et al, 
2006; Sullivan et al, 2000) constitutes further evidence that these diseases are 
determined, in part, by genetic factors. Accordingly, the risk of being diagnosed with 
schizophrenia or bipolar disorder is markedly increased among the offspring of 
couples in which one parent is affected, and it further increases if both parents are 
affected (Gottesman et al, 2010). Estimates of heritability, that is, the proportion of 
phenotypic variation that can be attributed to genetic variation, are particularly high 
for schizophrenia (80-90%) and bipolar disorder (70-80%), and average at 35% for 
depression (Craddock et al, 2005) (Sullivan et al, 2000). While genetic epidemiology 
of major psychiatric illness has revealed the importance of genes in determining the 
risk of disease, it has also highlighted a significant contribution of environmental 
factors, since the concordance of diagnosis between MZ twins and the disease 
heritability are both below 100% (Sullivan et al, 2003).  
By exposing the genetic component of mental illness, family, twin and adoption 




predisposing genetic loci. However, the search for candidate genes has been hindered 
by the particularly complex genetic architecture and pattern of inheritance of 
common psychiatric disorders (Hyman, 2008). Polygenicity and heterogeneity have 
emerged as the characterising genetic features of these disorders: no single causative 
gene has been identified for any common psychiatric illness to date, but instead it has 
become clear that many distinct combinations of multiple genetic risk factors can 
determine the same condition (Craddock et al, 2005). On the other hand, the same 
genetic risk factor can be associated with multiple psychiatric diagnoses (Blackwood 
et al, 2001; Craddock et al, 2005), suggesting that the underlying biological 
alterations may be at least partially shared. Further evidence for the existence of 
common causative biological processes for schizophrenia, bipolar disorder and major 
depression came from several family studies that detected increased risk of 
depression or schizophrenia within first-degree relatives of bipolar probands and vice 
versa (Berrettini, 2000; Cardno et al, 2002; Craddock & Owen, 2005; Gottesman et 
al, 2010; Lichtenstein et al, 2009; McGuffin & Katz, 1989; McGuffin et al, 2003).  
Two non-mutually exclusive hypotheses have been adopted to explain the high 
degree of genetic heterogeneity that characterises psychiatric illnesses. The 
“common disease-common variant” (CD-CV) hypothesis states that common 
complex diseases such as schizophrenia result from the combination of several low-
penetrance common risk-conferring alleles acting cumulatively in the individual 
(Chakravarti, 1999; Lander, 1996). This hypothesis forms the conceptual basis of 
genome-wide association studies (GWAS), used to investigate genetic causality in 
common diseases through high-density genotyping of single nucleotide 
polymorphisms (SNPs) in large sets of cases and controls (Cichon et al, 2009).  
Some of the susceptibility chromosomal regions identified in whole genome scans 
are shared between schizophrenia, bipolar disorder and major depression, providing 
further evidence for the existence of common underlying biological alterations 
(Green et al, 2010).  
The second hypothesis states that psychiatric diseases are caused by one of several 
possible rare and highly penetrant mutations, with different mutations often 




Pritchard, 2001). The identification of rare disease-causing mutations has 
traditionally relied on linkage, association and cytogenetic studies in large families 
with a high recurrence of psychiatric illness. One such example is the discovery of a 
t(1;11) translocation that disrupts the Disrupted-in-Schizophrenia 1 (DISC1) gene in 
a large Scottish family with a heavy burden of severe psychiatric disease (Blackwood 
et al, 2001), which will be described in detail later in this chapter. Despite the wealth 
of evidence gathered from family-based studies, the overall contribution of rare 
genetic variants to psychiatric illness was initially considered marginal because of 
their low frequency in the general population. However, the advent of new high-
resolution methods of genetic analysis confirmed the importance of rare genetic 
variants in the aetiology of psychiatric illness. Indeed, the study of rare copy number 
variants (CNVs) revealed that these structural variants, which can be found at many 
loci dispersed throughout the genome, are highly enriched in psychiatric patients, 
with some degree of overlap observed between different disorders (Pickard, 2011; 
Sebat et al, 2009). Some of these rare CNVs are recurrent, but the majority are 
detected in single patients (Sebat et al, 2009). Similarly, deep sequencing methods 
are revealing an increased load of putatively damaging exonic de-novo (i.e. not 
inherited, but spontaneously occurring) point mutations in subjects with sporadic 
schizophrenia (Girard et al, 2011).  
Two main conclusions can be drawn from the genetic studies conducted thus far on 
common psychiatric disorders. The first is that they are highly genetically 
heterogeneous, with both common variants of low penetrance and rare, highly 
penetrant variants significantly contributing to the risk of disease. The second 
conclusion is that genetic susceptibility to different mental disorders is conferred by 
partially overlapping sets of loci. This implies the existence of common biological 
underpinnings across psychiatric disorders, and suggests that they may be better 
conceptualised as a continuum or spectrum of clinical phenotypes, rather than 
nosologically distinct entities (Craddock & Owen, 2005).  
1.1.3.2 Environmental factors 
Twin, family and adoption studies strongly support a major influence of genes on the 




variability in the risk of disease that cannot be explained by genetic factors 
(Lichtenstein et al, 2009). Several environmental factors acting at different stages of 
development have been proposed to influence the risk of developing psychotic or 
depressive disorders, accounting for a proportion of the “missing genetic variability” 
in the risk of disease  (Markham & Koenig, 2011).  
Brain development involves a finely-timed series of cellular and molecular events 
that guarantee that neurons are born, migrate and mature in the correct spatial and 
temporal order, resulting in correct wiring and function of the brain. Evidence for 
defective neurodevelopment has been found in post-mortem brains from patients 
with neuropsychiatric disorders, including schizophrenia, bipolar disorder and 
depression (Fatemi & Folsom, 2009; Jaaro-Peled et al, 2009; Lewis & Levitt, 2002; 
Weinberger et al, 1983). According to the neurodevelopmental hypothesis of 
schizophrenia, the disease originates from altered trajectories of neurodevelopment 
caused by both genetic factors and environmental insults acting before the brain 
reaches its maturity, and as early as the gestational period (Fatemi & Folsom, 2009; 
Insel, 2010). Several studies have investigated the influence of defined 
environmental exposures during foetal life on the risk of developing mental illness 
later in life. One of the most replicated environmental risk factors acting prenatally is 
maternal infection during pregnancy, which has been found to significantly increase 
the risk of schizophrenia, but not major depression or bipolar disorder, in the 
offspring (Brown, 2011; Mortensen et al, 2011; Pang et al, 2009). Given the 
diversity of the prenatal infections for which the association with schizophrenia has 
been observed, the most plausible proposed mediating mechanism is the activation of 
the maternal immune response, which in turn releases pro-inflammatory cytokines 
that interfere with foetal neuronal development (Brown, 2011). Another well-
established environmental risk factor acting prenatally is maternal malnutrition 
(Brown, 2011). Retrospective studies based on data collected during major famines 
that occurred in The Netherlands and China during the 40s and 50s revealed an 
increased risk of schizophrenia, bipolar disorder and depression in the children of 
mothers who starved while pregnant (Brown & Susser, 2008; Brown et al, 2000; St 
Clair et al, 2005; Susser et al, 1996; Susser & Lin, 1992; Xu et al, 2009). It is still 




of specific nutrients or exposure to excess maternal glucocorticoids released as a 
consequence of malnutrition (Markham & Koenig, 2011). Other factors, such as 
advanced paternal age, maternal psychological stress exposure during gestation and 
obstetric complications, can contribute to the risk of psychotic and depressive 
disorders in the offspring (Brown, 2002; Field & Diego, 2008; Miller et al, 2011; 
Rice et al, 2010; Rice et al, 2007).  
Other environmental risk factors for psychotic disorders act later in life, during 
childhood and adolescence (Brown, 2011). Psychological trauma (abuse or neglect) 
during childhood, urbanicity and migrant status are all well-replicated risk factors for 
schizophrenia. Adolescent cannabis use is also a proposed risk factor for psychotic 
disorders (Brown, 2011). A dose-response relationship has been observed between 
cannabis consumption in adolescence and risk of schizophrenia, with heavy users 
having up to six-fold increased risk of disease (Brown, 2011). Cannabis is also the 
most common drug of abuse among bipolar subjects, in which it induces manic 
symptoms (Leweke & Koethe, 2008), and heavy cannabis use has been shown to be 
associated with earlier onset of bipolar disorder (Lagerberg et al, 2011). Despite the 
clear association between these and other environmental exposures during peri-
adolescence and risk of psychosis, the direction of cause and effect is still under 
debate (Brown, 2011).  
One important implication of our improving understanding of the influence of 
environmental factors on the risk of mental illness is that relatively simple prevention 
approaches such as vaccination, if implemented at the population level, have the 
potential to significantly reduce the disease incidence (Brown, 2011).  
1.2 DISC1 as a candidate gene for psychiatric illness 
1.2.1 Discovery of DISC1 
In 1968, a survey was conducted in Scotland to search for cytogenetic abnormalities 
in boys that had been admitted to juvenile detention centres. This led to the 
identification of one individual carrying a balanced translocation between 




members of the proband’s family spanning four generations (Jacobs et al, 1970). At 
the time, no further investigations were carried out, and the pedigree was deposited 
in the cytogenetic registry of the Medical Research Council (MRC) Clinical and 
Population Cytogenetics Unit (now Human Genetics Unit) in Edinburgh, which was 
updated annually with clinical information collected by general practitioners. 
Twenty years later, the MRC cytogenetic registry was screened in search of 
pedigrees with associated psychiatric illness, and it emerged that in the intervening 
years several members of the family originally described by Jacobs and colleagues 
(Jacobs et al, 1970) had been diagnosed with severe mental illness, including 
schizophrenia, bipolar disorder and major depression (St Clair et al, 1990). A more 
detailed cytogenetic analysis defined that the chromosomal rearrangement 
segregating in this family was a balanced t(1;11) (q43,q21) translocation, which was 
found to be significantly linked with psychiatric illness within this family (St Clair et 
al, 1990).  
 A systematic in-depth clinical examination of 87 members of this Scottish family, 
37 of whom carried the t(1;11) translocation, was carried out ten years later 
(Blackwood et al, 2001). This study revealed that of the 29 translocation carriers for 
whom clinical data are available, 18 have been diagnosed with a form of major 
mental illness, including schizophrenia, bipolar disorder and major depression, 
whereas none of the 38 examined individuals who do not carry the translocation have 
major psychiatric illness (Blackwood et al, 2001). In this family, the t(1;11) 
translocation is significantly associated with schizophrenia with a LOD score of 3.6, 
and the strength of association increases further when the broader diagnosis of major 
psychiatric illness is considered, reaching a LOD score of 7.1 (Blackwood et al, 
2001). This evidence supports a causative link between the t(1;11) translocation and 
psychiatric illness. Blackwood and colleagues also reported that all tested 
translocation carriers (affected and unaffected) present with altered measures of 
event related potential (ERP) P300, which quantifies the speed and efficiency of 
information processing and is characteristically abnormal in schizophrenia patients 
(Blackwood et al, 2001; Blackwood & Muir, 2004), indicating that the t(1;11) 




In the years preceding the original reports linking the t(1;11) translocation with 
mental illness (Blackwood et al, 2001; St Clair et al, 1990), a considerable amount of 
effort had been directed towards the fine-mapping of the translocation breakpoints in 
search of genes that might be directly affected by this chromosomal rearrangement 
(Devon et al, 1997; Evans et al, 1995; Fletcher et al, 1993; Millar et al, 1998; Millar 
et al, 2000b; Muir et al, 1995; Semple et al, 2001). As a result of this concerted 
effort, the translocation breakpoints were located at 1q42.1 and 11q14.3, and two 
genes on chromosome 1 were found to be directly disrupted by the translocation: 
Distrupted-in-Schizophrenia 1 (DISC1) and Distrupted-in-Schizophrenia 2 (DISC2) 
(Millar et al, 2000b).  DISC1 consists of 13 major exons, and the translocation 
breakpoint lies between exons 8 and 9 (Millar et al, 2000b), whereas DISC2 is 
located antisense to DISC1, in a region spanning DISC1 exon 9, and has no protein 
coding potential, which led to the hypothesis that this gene may be involved in the 
regulation of DISC1 expression (Millar et al, 2001; Millar et al, 2000b). No genes 
were initially identified in the 11q14.3 region (Devon et al, 1997; Millar et al, 1998), 
but later examinations of this breakpoint revealed the presence of a novel gene, 
named DISC1 Fusion Partner 1 (DISC1FP1) (Eykelenboom et al, 2012) or Boymaw 
(Zhou et al, 2010; Zhou et al, 2008b). DISC1FP1 forms aberrant fusion transcripts 
with DISC1 exons 9-13 as a consequence of the t(1;11) translocation, and the 
abnormal chimeric proteins encoded by these fusion transcripts induce mitochondrial 
deficiencies in transfected cells, suggesting that they may have similar deleterious 
effects in the brains of translocation carriers (Eykelenboom et al, 2012). Another 
gene located 150-250 kb upstream of DISC1 has been suggested as being potentially 
affected by the t(1;11) translocation: Translin-Associated factor X (TRAX) (Millar et 
al, 2000a). TRAX and DISC1 form fusion transcripts of as yet unknown function that 
are directly distrupted by the translocation, and may therefore play a role in 
psychopathogenesis in t(1;11) carriers (Millar et al, 2000a). However, no changes in 
TRAX protein expression levels were detected in lymphoblastoid cell lines generated 
from the blood of t(1;11) carriers (Millar et al, 2005b), shifting the focus to the 
functional characterisation of DISC1.  
Biochemical studies conducted on lymphoblastoid cell lines carrying the t(1;11) 




translocation cells from healthy family members, originating the hypothesis that the 
translocation completely prevents the expression of DISC1 from the affected 
chromosome 1, leading to disease via haploinsufficiency (Millar et al, 2005b). Other 
researchers have advanced the alternative hypothesis that a truncated from of DISC1 
consisting of the first 597 amino acids may be produced from the derived 
chromosome 1, and that this mutant protein may both interfere with the function of 
the normal full-length protein and exert detrimental effects per-se. In support of this 
hypothesis, artificially expressed C-terminally truncated DISC1 was found to 
interfere with neuronal function in a dominant-negative fashion in several cell 
(Kamiya et al, 2005; Ozeki et al, 2003; Pletnikov et al, 2007; Taya et al, 2007) and 
mouse (Abazyan et al, 2011; Ayhan et al, 2011; Hikida et al, 2007; Pletnikov et al, 
2008a; Pletnikov et al, 2008b; Shen et al, 2008) models. However, no transcripts 
encoding this putative truncated form of DISC1 have been identified in t(1;11) 
lymphoblastoid cell lines (Eykelenboom et al, 2012), and attempts to detect DISC1 
(1-597) in these patient-derived cells have so far been usuccessful (Millar et al, 
2005b). Since it has not yet been possible to analyse post-mortem brain samples from 
t(1;11) carriers, the existence of DISC1 (1-597) in neurons remains unproven.  
1.2.2 DISC1 linkage and association studies 
Despite the strong linkage detected between the t(1;11) translocation and psychiatric 
illness in the Scottish family, the uniqueness of this chromosomal rearrangement 
meant that it was initially unclear whether the DISC1 locus should be considered a 
genetic susceptibility factor for major mental illness in the general population. 
However, soon after the discovery of DISC1, several independent studies provided a 
wealth of evidence for the wider involvement of this gene in a range of psychiatric 
disorders including schizophrenia, bipolar disorder, major depression, 
schizoaffective disorder and autism (Bradshaw & Porteous, 2012; Chubb et al, 
2008).  
Linkage of the DISC1 locus with major psychiatric illness was first independently 
detected in the Finnish population, in which the 1q32.2-q41 region was linked to 
schizophrenia and schizoaffective disorder, and more detailed analyses determined 




intron 9 (Ekelund et al, 2004; Ekelund et al, 2001; Ekelund et al, 2000; Hovatta et al, 
1999). These findings were subsequently replicated in studies conducted in other 
populations, including Taiwanese, Scottish, British and Icelandic, in which the 1q32-
42 chromosome region was linked to major psychiatric illness (Curtis et al, 2003; 
Detera-Wadleigh et al, 1999; Hamshere et al, 2005; Hwu et al, 2003; Macgregor et 
al, 2004).  
In agreement with the evidence from linkage, a large number of studies found 
genetic association between single nucleotide polymorphisms (SNPs) and/or 
haplotypes within DISC1 and both major psychiatric illness and autism spectrum 
disorders, as well as with altered brain structure, cognition and behavioural 
phenotypes in healthy subjects (Bradshaw & Porteous, 2012; Chubb et al, 2008; 
Johnstone et al, 2011; Zheng et al, 2011). In addition, a recent study has found 
association of DISC1 with agenesis of the corpus callosum, a congenital brain 
malformation (Osbun et al, 2011). A number of reports of negative association have 
also been published (Bradshaw & Porteous, 2012; Chubb et al, 2008; Mathieson et 
al, 2011), and a trend towards positive association with psychiatric illness has 
emerged for DISC1 in some (Sullivan et al, 2008) but not other (O'Donovan et al, 
2009; Richards et al, 2012; Sanders et al, 2008) GWAS studies of schizophrenia, 
bipolar disorder and depression.  
Two common non-synonymous exonic SNPs of DISC1 have been studied in 
particular detail in association studies: rs821616 (Ser704Cys) and rs6675281 
(Leu607Phe) (Bradshaw & Porteous, 2012; Chubb et al, 2008). The Serine to 
Cysteine substitution at amino acid position 704 (Ser704Cys or S704C), is associated 
with schizophrenia and impaired declarative memory in schizophrenia patients 
(Callicott et al, 2005; Lepagnol-Bestel et al, 2010; Qu et al, 2007; Song et al, 2008; 
Takahashi et al, 2009), major depression (Hashimoto et al, 2006), and chronic 
fatigue syndrome (Fukuda et al, 2010a). A recent study found association between a 
DISC1 haplotype containing rs821616 and P300 amplitude and latency in patients 
with schizophrenia or bipolar disorder (Shaikh et al, 2011), confirming the 
previously reported association of DISC1 with P300 deficits (Blackwood et al, 2001; 




schizophrenia (Hotta et al, 2011; Kim et al, 2008) or bipolar disorder (Song et al, 
2010), but one of these detected significant association with poor concentration in 
schizophrenia patients (Kim et al, 2008). Magnetic Resonance Imaging (MRI) and 
functional MRI (fMRI) studies found associations between S704C and brain 
structural and functional changes in normal subjects. For example, Callicott and 
colleagues and Di Giorgio and colleagues reported reduced hippocampal gray matter 
volume and abnormal activation of the hippocampus during memory-related tasks in 
Ser704 carriers, recapitulating observations commonly made in schizophrenia 
patients (Callicott et al, 2005; Di Giorgio et al, 2008). In addition, in verbal fluency 
tests designed to measure the function of the prefrontal cortex (PFC), Ser704 
homozygotes showed greater activation of the PFC, which is indicative of prefrontal 
hypofunction, a typical feature of schizophrenia (Prata et al, 2008).  Ser704 
homozygotes also showed an accelerated rate of cortical thinning during 
development in the left anterior cingulated and temporal cortices (Raznahan et al, 
2011). By contrast, the Cys704 allele was associated with reduced gray matter 
volume in the cingulate cortex, cingulate gyrus and posterior gyrus, larger volume of 
the medial superior frontal gyrus and short insular cortex and reduced integrity and 
fractional anisotropy in prefrontal white matter (Hashimoto et al, 2006; Sprooten et 
al, 2011; Takahashi et al, 2009). Finally, Thomson and colleagues reported a positive 
association between the Cys704 allele and accelerated age-related cognitive decline 
in healthy women (Thomson et al, 2005).  
The Leucine to Phenylalanine substitution at DISC1 amino acid 607 (Leu607Phe or 
L607F) is associated with schizoaffective disorder, schizophrenia and higher 
negative symptom scores in schizophrenia patients (Hodgkinson et al, 2004; Rastogi 
et al, 2009) (Lepagnol-Bestel et al, 2010), although lack of association with 
schizophrenia and bipolar disorder has also been reported for this SNP (Song et al, 
2008; Song et al, 2010). In both schizophrenia patients and healthy controls, the 
Phe607 allele was associated with significantly reduced grey matter volumes in the 
superior prefrontal gyrus and anterior cingulated gyrus (Szeszko et al, 2008). A more 
recent structural and functional MRI study found association between the Phe607 
allele and both reduced cortical thickness in the left supramarginal gyrus and 




memory tests in healthy volunteers (Brauns et al, 2011). In addition, schizophrenia 
patients carrying Phe607 were found to experience significantly more severe positive 
symptoms (hallucinations) (Szeszko et al, 2008). Like the S704C substitution, L607F 
has been associated with the rate of cortical thinning during development, with the 
Phe607 allele determining slower rates of thinning in the bilateral superior frontal 
and left angular cortical giri (Raznahan et al, 2011).  
A third common exonic missense SNP (rs3738401) that determines the Arginine to 
Glutamine substitution at DISC1 amino acid position 264 (Arg264Gln or R264Q) 
has been associated with psychiatric illness and/or cognitive impairment in most 
(Hennah et al, 2005; Hennah et al, 2003; Mouaffak et al, 2011; Palo et al, 2007; 
Song et al, 2008; Zhang et al, 2006) but not all (Hotta et al, 2011; Kim et al, 2008) 
reported studies. In structural MRI studies, the R264Q polymorphism has been 
associated with altered cortical thickness in the lateral occipital gyrus and cingulate 
cortex (Brauns et al, 2011; Carless et al, 2011). Additionally, together with SNP 
rs821616 (S704C), rs3738401 (R264Q) was associated with altered amplitude and 
latency of P300 (Shaikh et al, 2011).  
DISC1 sequencing in patients with schizophrenia and bipolar disorder led to the 
identification of novel ultra-rare missense point mutations associated with disease 
(Song et al, 2008; Song et al, 2010). In their first study, Song and colleagues 
sequenced DISC1 exons and splice junctions in 288 patients with schizophrenia and 
an equal number of healthy controls, identifying seven novel missense mutations that 
were initially only seen in heterozygosis in schizophrenia patients: G14A, R37W, 
S90L, R418H, T603I, A83V and P432L (Song et al, 2008). Further screening of an 
additional 10,000 control alleles revealed that two of these mutations (A83V and 
P432L) were present in the gene pool at a frequency of 1 in 200, whereas none of 
the other five were detected in the control alleles, leading to the conclusion that they 
may be schizophrenia-specific, with an estimated attributable risk of 2% (Song et al, 
2008). Using a similar approach in 504 patients with bipolar disorder and 576 
controls plus an additional 10,000 control alleles, Song and colleagues found four 
protein structural variants in four different patients that were absent from the 




(R418H) had been previously detected in a schizophrenia patient (Song et al, 2008). 
The estimated attributable risk for bipolar disorder was 0.5% for these mutations 
(Song et al, 2010). Although a potential functional role has been hypothesised for 
some of the above novel ultra-rare mutations (Soares et al, 2011), no biological 
studies have been reported to date.  
A more recent sequencing study investigated the contribution to schizophrenia 
susceptibility of genetic variation within DISC1 and ten of its interacting proteins, 
and revealed a significantly increased burden of rare missense mutations in 
schizophrenia patients compared to healthy controls (Moens et al, 2011), adding to 
the evidence in support of the important contribution of rare mutations to the risk of 
psychiatric illness.  
Two ultra-rare CNVs (a 2 Mb duplication and a 2 Mb deletion) spanning the DISC1 
locus were reported in subjects with autism and mental retardation, adding to the 
evidence that suggests the involvement of DISC1 in a wide spectrum of mental 
illnesses (Crepel et al, 2010; Williams et al, 2009).  
The current hypothesis that schizophrenia and other major psychiatric illnesses are 
highly genetically heterogeneous disorders originating from the combination of 
multiple susceptibility alleles, prompted combinatorial studies testing for genetic 
interplay within and between candidate genes. One such study detected a variable 
effect (either protective or risk-conferring) of DISC1 SNP rs821633 in combined 
European cohorts of schizophrenia and bipolar disorder depending on whether this 
SNP was present on its own or in combination with either DISC1 SNP rs821577 or 
rs1538789 (Hennah et al, 2009). Similarly, DISC1 SNP rs1538789 was found to 
increase the risk of psychiatric illness only when combined with DISC1 SNP 
rs821633 (Hennah et al, 2009).  
Other genetic studies focused on well-characterised DISC1 binding proteins: NDE1, 
NDEL1 and CIT. The first of these studies detected positive association of 
schizophrenia with a marker located close to the NDE1 locus only in the presence of 
a previously reported schizophrenia-associated DISC1 haplotype (HEP3) (Hennah et 
al, 2007). In a subsequent case-control study, association with schizophrenia of the 




background of Ser/Ser at DISC1 position 704 (Burdick et al, 2008). On the other 
hand, NDE1 SNP rs3784859 conferred risk of schizophrenia only when combined 
with the Cys704 DISC1 background (Burdick et al, 2008). A more recent 
schizophrenia case-control study detected epistatic interactions between SNPs within 
DISC1 and CIT, and within NDEL1 and CIT, but only the latter survived Bonferroni 
correction (Nicodemus et al, 2010). However, epistasis between CIT and both DISC1 
and NDEL1 was subsequently validated in fMRI measures of hippocampal and 
prefrontal cortical efficiency (Nicodemus et al, 2010). 
In summary, the numerous linkage and association studies conducted over the last 
decade strongly implicate DISC1 in the pathogenesis of psychiatric conditions 
ranging from schizophrenia to autism, but do not concertedly point towards one or a 
few risk-conferring variants. These observations reinforce the blurring of the genetic 
and aetiological boundaries between conditions such as schizophrenia and bipolar 
disorder, and confirm the highly genetically heterogeneous nature of psychiatric 
illness.  
1.2.3 The structure and biology of DISC1 
1.2.3.1 DISC1 splice variants 
The human DISC1 gene comprises a total of 13 exons, producing a full-length 
transcript of around 7.5 kb (Millar et al, 2001; Millar et al, 2000a). DISC1 mRNA 
processing is highly complex, and many alternative transcripts have been described 
to date, although their relative usage and respective functions remain unclear (Millar 
et al, 2001; Nakata et al, 2009; Taylor et al, 2003). Four alternatively spliced DISC1 
mRNA isoforms were originally described and confirmed, namely the Long (L), 
Long variant (Lv), Short (S) and Extremely short (Es) isoform (Chubb et al, 2008). 
The L isoform, or full-length transcript, contains all 13 exons, the Lv isoform lacks 
the 66 nucleotides at the end of exon 11, the S variant utilises an alternate 3' 
untranslated region (UTR) in intron 9 (exon 9a), whereas the Es form arises from an 
alternatively spliced exon 1a in DISC1, terminating two codons after the end of exon 
3 (Chubb et al, 2008). Rare intergenic splicing events have been reported to occur 




transcripts whose translation has not been detected yet (Millar et al, 2000a; Taylor et 
al, 2003). A more recent report that used a combination of PCR and 5' and 3' RACE 
on human hippocampal mRNA, confirmed the expression of the previously described 
DISC1 splice variants, and documented several novel transcripts, bringing the total of 
known DISC1 splice isoforms to 54 (Nakata et al, 2009). Comparison of the 
expression profiles of the many DISC1 splice variants at different developmental 
stages of the human brain revealed that the shorter mRNA isoforms, predicted to 
produce a truncated form of the protein, are expressed at higher levels in the foetal 
brain (Nakata et al, 2009). Interestingly, the same short isoforms are also expressed 
at higher levels in schizophrenic brains compared to normal controls, hinting at 
aberrant DISC1 expression as a potential disease mechanism (Nakata et al, 2009). 
Consistent with this hypothesis, the same study found that the expression of a 
specific DISC1 mRNA isoform lacking exons 8 and 9 was significantly increased in 
post-mortem brains from Phe607 carriers and Cys704 homozygotes, two DISC1 
SNPs that had been previously associated with psychiatric illness (Nakata et al, 
2009). It has to be noted though, that many of the novel DISC1 splice variants 
described by Nakata and colleagues possess premature stop codons, and it remains 
uncertain whether they are translated into functional proteins in the brain (Nakata et 
al, 2009).  
1.2.3.2 DISC1 protein structure 
Of the many DISC1 splice isoforms detected to date, only L can be confidently 
assigned to the corresponding translated product, an 854 amino acid protein of about 
100 kDa (Chubb et al, 2008). Using antibodies directed against different regions of 
the protein, several other human DISC1 isoforms have been detected by western 
blotting, including species of 75, 95-100, 150 and 200 kDa (James et al, 2004; 
Ogawa et al, 2005; Sawamura et al, 2005; Soares et al, 2011). The smaller 75 kDa 
DISC1 isoform may arise from the S transcript, whereas DISC1 species running at 
150 and 200 kDa may likely represent dimers of shorter forms, given DISC1’s 
demonstrated ability to self-associate (Brandon et al, 2004; Kamiya et al, 2005; 




species to the corresponding transcript isoform can be further complicated by 
secondary modifications, such as protein phosphorylation (Ishizuka et al, 2011).  
The full-length 854 amino acid DISC1 protein has no similarity to any other known 
protein, making it a completely novel protein species (Millar et al, 2000b). 
Generally, DISC1 is poorly conserved between species, although orthologues have 
been found both in vertebrates, including mammals, birds and fish (Chubb et al, 
2008; Taylor et al, 2003) and invertebrates (Sanchez-Pulido & Ponting, 2011). To 
date, a detailed 3D characterisation of DISC1 protein structure is lacking, and the 
current structural information has been gained from biophysical studies on purified 
protein fragments and in silico analyses (Chubb et al, 2008; Soares et al, 2011). 
According to structure prediction programs, DISC1 can be grossly subdivided into 
two distinct structural domains: a disordered N-terminal “head” region spanning the 
first 350 amino acids, and a more structured C-terminal region comprising amino 
acids 351-854 (Millar et al, 2000b; Soares et al, 2011) (Figure 1.2, adapted from 
Soares et al, 2011). The head region of DISC1, also often referred to as the “globular 
domain” lacks any predicted complex secondary structures and is poorly conserved, 
except for a few stretches of amino acids (Millar et al, 2000b; Soares et al, 2011; 
Taylor et al, 2003). These include a tetra-arginine nuclear localisation signal 
spanning amino acids 35-44 and a serine/phenylalanine (SF) rich motif of unknown 
function at amino acids 206-217 (Taylor et al, 2003) (Figure 1.2). By contrast, the C-
terminus of DISC1 contains several predicted alpha-helices and coiled-coil regions, 
as well as three predicted leucine zipper motifs at amino acids 458-486, 607-628 and 
808-829 (Chubb et al, 2008; Soares et al, 2011), and it is considerably more 
conserved compared to the N-terminus region (Taylor et al, 2003) (Figure 1.2). 
Given the known involvement of coiled-coil domains in mediating protein-protein 
interactions, the high density of these structural motifs in the C-terminus of DISC1 
was the earliest clue suggesting that DISC1 may be able to bind multiple protein 
partners (Taylor et al, 2003). Since disordered proteins can assume a more structured 
organisation upon binding to other proteins (Fink, 2005), it has been recently 
suggested that the low structural complexity of the head domain of DISC1 may be a 




interactions, such as the one existing between DISC1 and PDE4, which will be 
described in more detail later in this chapter (Soares et al, 2011).  
 
 
Figure 1.2 DISC1 protein structure and conservation, adapted from Soares et al, 
2011. The figure summarises the predicted secondary structure of DISC1, with the 
vertical rectangles representing regular or ambiguous α-helices (pink and light 
green, respectively, and coiled-coils (green). The horizontal yellow lines represent 
disordered regions. The position of the nuclear localisation signal (NLS) and SF-rich 
region is also indicated, along with that of the phosphorylation sites (brown 
triangles). The vertical dashed line marks the position of the t(1;11) translocation 
breakpoint, corresponding to amino acid 597. Ortholog sequence conservation is 
shown below the DISC1 protein schematic.  
 
Initial experiments carried out using recombinant tagged proteins expressed in 
transfected cell lines demonstrated that DISC1 is capable of self-associating, and 
identified the region spanning amino acids 403-504 as a self-association domain 
(Brandon et al, 2004; Kamiya et al, 2005). A more detailed biophysical 
characterisation of DISC1 protein fragments spanning the C-terminal region was 
carried out recently by Leliveld and colleagues (Leliveld et al, 2008; Leliveld et al, 
2009). In their first study, they found DISC1 fragment 598-854 to exist in the form of 
dimers, octamers, multimers and insoluble aggregates under physiological 
conditions, and established that only DISC1 octamers are capable of binding NDEL1 
(Leliveld et al, 2008). Additionally, they showed that DISC1 can be detected in the 




psychiatric illness, but not in healthy controls (Leliveld et al, 2008). In two separate 
studies, octamer-dependent DISC1 binding to NDEL1 was confirmed, and it was 
shown that the assembly of DISC1 into octamers occurs through the formation of 
dimeric intermediates (Leliveld et al, 2009; Narayanan et al, 2011). The oligomeric 
state-dependency of the DISC1-NDEL1 interaction was corroborated by the 
observation that insoluble aggregates of full-length DISC1 fail to bind NDEL1 
(Leliveld et al, 2009). The same study identified two additional regions involved in 
DISC1 self-association: the 668-747 region, necessary for oligomerisation, and the 
765-854 region, which mediates dimerisation (Leliveld et al, 2009). A further report 
from the same group showed co-aggregation of DISC1 and Dysbindin, the product of 
another candidate gene for mental illness, in post-mortem brains of psychiatric 
patients, but not healthy controls (Ottis et al, 2011). Altogether, these findings 
indicate controlled self-assembly as a possible form of DISC1 regulation, and 
suggest that DISC1 aggregation in the brain, with consequent loss of binding or 
aberrant recruitment of interacting partners, may be a potential disease mechanism 
acting in a subset of psychiatric patients.  
1.2.3.3 DISC1 tissue expression and subcellular protein distribution  
Expression of DISC1 at the mRNA and protein level has been detected in multiple 
tissues (Chubb et al, 2008). Studies on foetal and adult human tissues revealed 
DISC1 mRNA expression in the brain, heart, placenta, kidney and pancreas, with the 
first three showing the strongest expression (James et al, 2004; Millar et al, 2000b). 
DISC1 expression in foetal brain, heart, limbs, kidney, liver and lungs has also been 
documented at the protein level, with highest expression in the kidney (James et al, 
2004). A more detailed investigation of DISC1 mRNA expression in adult human 
brain detected widespread expression in several regions, including, but not limited to, 
the amygdala, caudate nucleus, corpus callosum, hippocampus, substantia nigra, 
thalamus, cerebellum, cerebral cortex, medulla, spinal cord and frontal lobe (Millar 
et al, 2000b). Human DISC1 expression is particularly high in the dentate gyrus of 
the hippocampus (James et al, 2004; Lipska et al, 2006), where it is strongly 
expressed in a subset of granule cells (James et al, 2004). In the adult hippocampus, 




Comparable observations have been reported in rodents, where Disc1 is expressed 
mostly in the heart, but also in the brain, kidney, liver and testis (Ma et al, 2002a; 
Ozeki et al, 2003). In the rodent brain, Disc1 has been detected in the dentate gyrus 
of the hippocampus, where expression is particularly high, and in many other 
regions, including the cerebellum, olfactory bulbs, cerebral cortex, hypothalamus, 
amygdala and corpus callosum (Ma et al, 2002a; Miyoshi et al, 2003; Osbun et al, 
2011; Schurov et al, 2004). Disc1 is expressed in the developing rodent hippocampus 
from as early as embryonic day (E) 14, the stage at which this structure becomes 
discernible, with strong expression in the granule cell progenitors and in the dentate 
gyrus, an area where adult neurogenesis occurs (Austin et al, 2004; Meyer & Morris, 
2008). Here, DISC1 co-localises with Ki67, a marker of proliferating cells in the 
subgranular zone (Meyer & Morris, 2008). Additionally, DISC1 expression has been 
observed in the subventricular zone, another area of adult neurogenesis, where it co-
localises with the neural progenitor markers nestin and Sox2 (Mao et al, 2009).  
Limited studies of DISC1 expression have also been conducted in primates, where 
DISC1 mRNA and protein expression was similarly detected in multiple brain 
regions, including the dentate gyrus of the hippocampus, cerebral cortex, amygdala, 
cerebellum and hypothalamus (Austin et al, 2004; Bord et al, 2006).  
Collectively, DISC1 expression studies have consistently shown that it is a widely 
expressed gene, with particularly prominent expression in the hippocampus, a region 
of adult neurogenesis that has been strongly implicated in schizophrenia (Harrison, 
2004).  
At the subcellular level, DISC1 distributes to multiple compartments, as thoroughly 
reviewed by Chubb and colleaguses and Soares and colleagues (Chubb et al, 2008; 
Soares et al, 2011), and summarised in Table 1.1, adapted from Soares et al, 2011. 
This multicompartmentalisation is consistent with the current view that DISC1 is 
involved in a diverse range of cellular processes, and that it attends to its functions 
through the establishment of multiple interactions with different partner proteins in 
distinct cell compartments (Bradshaw & Porteous, 2012; Brandon et al, 2009; 




Localisation of DISC1 to its target subcellular regions is thought to be mediated both 
by signal peptides located within the protein, and by its interaction with specific 
partner proteins (Soares et al, 2011). For example, targeting of DISC1 to the 
centrosome has been proposed to be mediated by binding of kendrin, a protein 
specifically localised to the centrosome (Miyoshi et al, 2004). Similarly, DISC1 
interaction with kinesin is necessary for it transportation along microtubules to the 
growth cones (Shinoda et al, 2007; Taya et al, 2007). Additionally, different DISC1 
protein isoforms may be preferentially targeted to distinct subcellular compartments 







Details and associated functions of DISC1 References 
Centrosome 
Involved in the recruitment of kendrin, dynein and dynactin subunits, LIS1, NDEL1, 
PCM1, ninein and CAMDI to the centrosome. Also interacts here with PDE4B, PDE4D, 
NDE1 and BBS4. These interactions include those important for microtubule aster 
formation, neurite outgrowth and neuronal migration. 
(Bradshaw et al, 2009; Bradshaw et al, 2008; Fukuda et 
al, 2010b; Kamiya et al, 2005; Kamiya et al, 2008; 
Kamiya et al, 2006; Miyoshi et al, 2004; Morris et al, 
2003; Shimizu et al, 2008) 
Cilia 
Found at the base of primary cilia and appears to regulate their formation and/or 
maintenance. Knock-down of endogenous DISC1 leads to marked reduction of primary 
cilia. Other DISC1 interactors seen at the base of primary cilia include BBS4, PCM1. 
(Marley & von Zastrow, 2010) 
Cytoskeleton 
Seen along both actin filaments and microtubules. Expression of truncated DISC1 leads to 
a disorganized microtubule network. 




Seen in association with the membrane structures of the Golgi apparatus in hippocampal 
neurons and astrocytes. May participate in vescicle movement from the Golgi apparatus. 
(Kuroda et al, 2011) 
Growth cones 
Found here in the hippocampus and is involved in recruiting proteins including LIS1, 
NDEL1, 14-3-3ε and girdin via kinesin-based transport along the cytoskeleton. Also 
important for axonal elongation. 
(Enomoto et al, 2009; Miyoshi et al, 2003; Shinoda et 
al, 2007; Taya et al, 2007) 
Membranes 
Found in membrane fractions, where it interacts with APP, which is important in cortical 
precursor formation. 






Found at mitochondria present on microtubules and regulates their trafficking. Can cause 
mitochondria to form “ring” structures. Interacts with mitofilin within the mitochondria 
and is required for correct electron transport chain, monoamine oxidase and Ca
2+
 activity. 
(Atkin et al, 2011; Brandon et al, 2005; James et al, 
2004; Millar et al, 2005a; Ozeki et al, 2003; Park et al, 
2010) 
Nucleus 
Found at the chromatin, promyelocytic leukemia (PML) bodies and outer layers of nuclear 
membrane. Represses ATF4 transcriptional activity and transcription of N-cadherin and 
alters sleep homeostasis in Drosophila. 
(Hattori et al, 2010; James et al, 2004; Kirkpatrick et al, 
2006; Sawamura et al, 2008) 
Synapse 
Seen at the post-synaptic density along with PDE4 and NDE1. Interacts with and inhibits 
TNIK here, leading to degradation of key synaptic proteins. Also affects spine formation 
through modulation of PSD-95/Kal-7/Rac1 complexes here. 
(Bradshaw et al, 2008; Clapcote et al, 2007; Hayashi-
Takagi et al, 2010; Kirkpatrick et al, 2006; Wang et 
al,2010c) 
 
Table 1.1 DISC1 subcellular distribution, adapted from Soares et al, 2011. The cell compartments to which DISC1 has been 




Unlike other subcellular compartments, DISC1 targeting to the nucleus is known to 
be dependent on cis-acting motifs found within the protein, although the existence of 
additional regulatory mechanisms cannot be excluded (Soares et al, 2011). Several in 
silico analyses have identified putative nuclear localisation signals (NLS) and 
nuclear export signals (NES) within DISC1 protein sequence, and these have been 
subsequently investigated in-vitro (Brandon et al, 2005; Ma et al, 2002a; Sawamura 
et al, 2008; Taylor et al, 2003). A detailed description of these studies will be 
provided in the introduction to chapter three of this thesis.  
1.2.3.4 DISC1 binding partners 
Due to the lack of known human paralogs or sequence similarity with any other 
known protein, no prediction could be made on the function of DISC1 at the time of 
its discovery (Millar et al, 2000b), but the presence of several coiled-coil domains in 
its C-terminal region suggested that DISC1 could potentially establish multiple 
protein-protein interactions (Taylor et al, 2003). A series of large-scale screens based 
on yeast-two-hybrid assays or other methods have been successfully carried out to 
shed light on the function of DISC1 via the identification of its interacting proteins 
(Brandon et al, 2004; Camargo et al, 2007; Millar et al, 2003; Miyoshi et al, 2004; 
Morris et al, 2003; Ozeki et al, 2003; Shinoda et al, 2007; Taya et al, 2007). Over 
200 candidate DISC1 interactors have been so far identified, and for several of these 
the interaction with DISC1 has been confirmed by co-localisation, co-
immunoprecipitation or GST pull-downs. For some binding proteins, the interacting 
regions on DISC1 have been mapped using deletion mutants or peptide arrays, as 
recently reviewed by Soares and colleagues (Soares et al, 2011). Based on their gene 
ontology, the many DISC1 interactors can be grouped into several broad functional 
categories, including cell cycle regulation, RNA processing, transcription regulation, 
vescicle transport, cytoskeleton organisation and function, mitochondrial function 
and energy metabolism, signal transduction and neural migration (Camargo et al, 
2007). The discovery of its vast number of binding partners, together with its 
widespread tissue and cell expression, led to the conceptualisation of DISC1 as a 
“scaffold” or “hub” protein to denote its high degree of connectivity, and inspired a 




in search of novel intracellular therapeutic targets for psychiatric illness. Importantly, 
several DISC1 interactors have been independently associated with psychiatric 
illness, emphasising the relevance of DISC1-connected pathways for 
psychopathology (Bradshaw & Porteous, 2012; Moens et al, 2011). Well over 300 
research articles have been published on DISC1 up to January 2012, which puts a 
thorough review of its protein interactions and biological functions beyond the remit 
of this thesis. In the following section, I will thus provide an overview of the most 
promising and best documented roles of DISC1 in neurodevelopment, signalling and 
synaptic function, which are biological aspects of particular interest for psychiatric 
illness. Some of the best-characterised molecular interactions involving DISC1, and 
their roles in neuronal development and function are summarised in figure 1.3, taken 
from Brandon & Sawa, 2011.  
1.2.3.5 DISC1 in neurodevelopment, plasticity and signalling 
In animal cells, the centrosome is the main microtubule-organising centre (MTOC), 
and plays a central role in cell division and migration (Nigg & Raff, 2009). The 
correct organisation of the centrosome and connected microtubule network is 
essential for proper brain development, as fundamental processes depend upon it, 
such as neurogenesis, neuronal migration and differentiation (Higginbotham & 
Gleeson, 2007).  
DISC1 localises to the centrosome, where it complexes with proteins of known 
importance in centrosomal-dependent aspects of neurodevelopment, including 
lissencephaly 1 (LIS1), nuclear distribution element-like 1 (NDEL1), kendrin (or 
pericentrin), pericentriolar material 1 (PCM1), and Bardet-Biedl syndrome 4 protein 
(BBS4) (Bradshaw et al, 2009; Brandon et al, 2004; Kamiya et al, 2008; Millar et al, 
2003; Miyoshi et al, 2004; Morris et al, 2003; Ozeki et al, 2003; Shinoda et al, 2007) 
(Figure 1.3). DISC1 has been shown to anchor several of these proteins to the 
centrosome, thus allowing their correct functioning. For example, recruitment of 
kendrin to the centrosome and its binding to DISC1 are essential for correct 
microtubule network formation (Shimizu et al, 2008). In addition, DISC1 and its 
interactor BBS4 cooperatively recruit PCM1 to the centrosome (Kamiya et al, 2008), 




2010; Ge et al, 2010). In turn, PCM1 facilitates the centrosomal recruitment of 
kendrin (Kamiya et al, 2008).  
 
 
Figure 1.3 Summary of the best-characterised interactions established by DISC1, 
and their functional role in neuronal biology, taken form Brandon & Sawa, 2011. The 
known functions of the various DISC1 complexes are shown in the perimeter of the 
figure, and the direction of the arrows indicates their chronological order during 
neuronal development. BBS, Bardet–Biedl syndrome protein; DIXDC1, dishevelled 
axin domain containing 1; GSK3β, glycogen synthase kinase 3β; KAL7, kalirin 7; 
LIS1, lissencephaly protein 1; NDEL1, nuclear distribution protein nudE-like 1; 
PCM1, pericentriolar material 1; PDE4, phosphodiesterase type 4; PSD95, 
postsynaptic density protein 95; TNIK, TRAF2- and NCK-interacting protein kinase.  
DISC1 is also part of the dynein microtubule motor complex, which is involved in 
retrograde transport along microtubules, and it is necessary for its localisation to the 
centrosome along with LIS1 and NDEL1, hence contributing to normal microtubule 




anterograde motor protein kinesin-1 and the adaptor protein growth factor bound 
protein 2 (Grb2), DISC1 is involved in transport of cargoes including LIS1, NDEL1 
and 14-3-3ε to the distal parts of axons, a process important for neurite outgrowth 
(Shinoda et al, 2007; Taya et al, 2007). Consistently, many independent studies that 
used gene silencing or overexpression techniques in vitro and in vivo have shown 
that DISC1 is necessary for correct neuronal migration and neurite outgrowth, both 
during development and postnatally (Drerup et al, 2009; Duan et al, 2007; Enomoto 
et al, 2009; Kamiya et al, 2005; Kamiya et al, 2008; Kamiya et al, 2006; Kim et al, 
2009; Kubo et al, 2010; Young-Pearse et al, 2010).  
Defects of neuronal migration can also be induced by knock-down of the DISC1 
binding partner DIX domain containing 1 (dixdc1), or by inhibition of the interaction 
between the two proteins (Singh et al, 2010). Dixdc1 also binds to NDEL1, and this 
interaction is necessary for correct neuronal migration, raising the possibility that the 
three proteins may interact in the same pathway (Singh et al, 2010) (Figure 1.3).  
DISC1 and dixdc1 were recently reported to co-regulate neuronal progenitor 
proliferation via concerted inhibition of glycogen synthase kinase 3  (GSK3 ) (Mao 
et al, 2009; Singh et al, 2010) (Figure 1.3). This particular aspect of DISC1 biology 
is of special interest in the field of psychiatric research given that Lithium Chloride, a 
commonly used mood stabiliser and current elective treatment for bipolar disorder, is 
an inhibitor of GSK3 (Beaulieu & Caron, 2008). The synergistic inhibition of 
GSK3  by DISC1 and dixdc1 results in increased proliferation of neural progenitors 
via the activation of -catenin-mediated transcription, which is normally repressed 
by GSK3  (Singh et al, 2010). Additionally, DISC1 has been shown to inhibit the 
kinase activity of GSK3  by directly binding to the enzyme and blocking its 
activating autophosphorylation (Mao et al, 2009).  
DISC1 has also been linked to the Akt-mTOR signalling pathway, which is involved 
in the modulation of several processes important for neuronal development and 
synaptic plasticity, and has been previously implicated in schizophrenia (Arguello & 
Gogos, 2008; Enomoto et al, 2009; Kim et al, 2009). Indeed, Kim and colleagues 
showed that by directly interacting with girdin (or KIAA1212) (Figure 1.3), a protein 




activation of Akt signalling, and suggested that this mechanism underlies the 
maturation defects they observed in adult-born neurons in the dentate gyrus of the 
hippocampus upon DISC1 silencing (Kim et al, 2009). This conclusion was 
supported by their observation that the maturation defects induced by DISC1 
suppression could be rescued by rapamycin, an inhibitor of the Akt effector mTOR 
(Kim et al, 2009). In a parallel study, Enomoto and colleagues confirmed the DISC1-
girdin interaction and its importance for the maturation of adult-born neurons in the 
dentate gyrus, but did not observe any rescuing effect of Akt on the maturation 
defects induced by girdin suppression, suggesting that girdin acts downstream of Akt 
(Enomoto et al, 2009).  
Besides playing a central role in the regulation of neural progenitor proliferation, 
differentiation and maturation, DISC1 has been implicated in synaptic transmission 
and plasticity, which are processes at the basis of learning and memory (Hayashi-
Takagi et al, 2010; Wang et al, 2010c). In human and rodent neurons, DISC1 is 
enriched in the post-synaptic density (PSD), a complex network of proteins forming 
an electron-dense thickening at the tip of dendritic spines, which are the post-
synaptic compartments of the cell (Bradshaw et al, 2008; Hayashi-Takagi et al, 
2010; Kirkpatrick et al, 2006; Wang et al, 2010c). Here, DISC1 interacts with and 
inhibits Traf2- and Nck-interacting kinase (TNIK) (Figure 1.3), an enzyme involved 
in the regulation of the actin cytoskeleton, inducing the degradation of several 
synaptic proteins and reducing the surface expression of the AMPA receptor subunit 
GluR1 (Wang et al, 2010c). In mature rat neurons, DISC1 inhibits the formation of 
spines and GluR1 expression through its interaction with kalirin-7 (Kal7) (Hayashi-
Takagi et al, 2010), a GDP/GTP exchange factor for Rac1 and known regulator of 
spine morphogenesis (Xie et al, 2007). Activation of glutamate signalling via the N-
Methyl D-Aspartate (NMDA) receptor induces dissociation of the DISC1-Kal-7 
complex, releasing the inhibition on Kal-7, which is then free to regulate spine 
structure through activation of Rac1 (Hayashi-Takagi et al, 2010). These findings 
linking DISC1 to the modulation of glutamate signalling are particularly intriguing, 
given that the glutamate system is reportedly hypofunctional in schizophrenia 




Also of particular relevance for psychiatric illness is DISC1 involvement in 
dopamine signalling, whose deregulation has been prominently implicated in the 
pathogenesis of schizophrenia (Howes & Kapur, 2009). DISC1 knock-down in mice 
results in reduction of extracellular dopamine in the PFC, maturation defects in 
dopaminergic axon terminals and increased sensitivity to metamphetamine (Niwa et 
al, 2010), a dopamine enhancing agent that can induce psychosis (Abi-Dargham, 
2005). Moreover, DISC1 knock-down in NIH3T3 cells and primary striatal neurons 
decreases the number of primary cilia, where dopamine receptors D1, D2 and D5 are 
prominently expressed (Marley & von Zastrow, 2010). In “schizophrenia-like” Disc1 
L100P mutant mice, the dopamine-enhancing agent amphetamine has a greater 
psychostimulant effect compared to wild-type littermates, and this can be blocked by 
the D2 recepor antagonist haloperidol, a typical antipsychotic (Lipina et al, 2010).  
1.2.3.6 Regulation of cAMP signalling by DISC1 
DISC1 has been implicated in the regulation of cyclic adenosine monophosphate 
(cAMP) signalling through its interaction with members of the family of type 4 
phosphodiesterases (PDE4) (Millar et al, 2005b; Murdoch et al, 2007) (Figure 1.3). 
Phosphodiesterases are the sole means of cAMP inactivation in the cell, and thus 
represent an essential component of the system that regulates intracellular cAMP 
levels (Alberini et al, 1995; Duman, 2002). The PDE4 family consists of a large 
number of protein isoforms encoded by four distinct genes (PDE4A-D) (Smith & 
Scott, 2006). Their modular structure allows different PDE4 isoforms to be 
preferentially targeted to different subcellular compartments, where feed-back 
mechanisms regulate their activity based on the local cAMP levels (Houslay, 2010; 
Houslay & Adams, 2003). This system forms the basis of compartmentalised cAMP 
signalling, which is of central importance for the functioning of the central nervous 
system.  
Several lines of evidence suggest PDE4s as genetic and biological candidates for 
mental illness. The PDE4B gene is disrupted by a chromosomal translocation found 
in one schizophrenia patient and a cousin with psychosis (Millar et al, 2005b), and 
multiple independent studies have found association between SNPs in this gene and 




reported (Bradshaw & Porteous, 2012). There is also some genetic evidence 
involving PDE4D in schizophrenia in the Finnish population, suggesting a wider 
implication of PDE4s in mental illness (Tomppo et al, 2009). In Drosophila 
melanogaster, the PDE4 othologue dunce plays an important role in neuronal 
function, synaptic plasticity and memory through the regulation of cAMP hydrolysis 
in neurons, and it is also involved in axonal growth cone motility (Davis, 1996; 
Delgado et al, 1998; Kim & Wu, 1996; Zhao & Wu, 1997). Several PDE4 inhibitors, 
including the selective inhibitor rolipram, influence memory and cognition via 
modulation of the NMDA receptor activity (Mackie et al, 2007), and rolipram has an 
antidepressant and antipsychotic-like effect in rodent models (Kanes et al, 2007; 
Maxwell et al, 2004; O'Donnell & Zhang, 2004). Consistently, mice with genetic 
deletion of PDE4B or PDE4D display the same behaviour as wild-type mice treated 
with antidepressants (O'Donnell & Zhang, 2004; Zhang et al, 2002).  
PDE4 isoforms are classified as long, short or super-short depending on their 
upstream conserved region (UCR) regulatory domains, which control access of the 
substrate to the catalytic domain (Houslay & Adams, 2003) (Figure 1.4, taken from 
Millar et al, 2005b). The UCR1 domain is exclusively found in the long isoforms, 
and PKA phosphorylation at this site determines a conformational change that 
increases the catalytic activity of the enzymes, triggering a feed-back mechanism that 
restores basal cAMP levels (Houslay & Adams, 2003).  
 
 
Figure 1.4 Schematic representation of long, short and super-short PDE4 isoforms, 
adapted from Millar et al, 2005b. All PDE4 isoforms possess a unique N-terminus, 
which mediates their differential subcellular targeting, and a conserved catalytic 




possess both the UCR1 and UCR2 regulatory domains. Short and super-short 
isoforms contain a complete or partial UCR2 domain, respectively.  
 
Exogenously expressed full-length 100 kDa DISC1 is able to bind all four isoforms 
(A-D) of PDE4 through their UCR2 domain, and the interaction sites on both 
proteins have been mapped using deletion constructs and peptide arrays (Millar et al, 
2005b; Murdoch et al, 2007). There are three PDE4B-specific interaction sites, 
located in the N-terminal region of DISC1 (amino acids 31-65, 101-135 and 266-
290), and two general PDE4 binding sites; one in the N-terminal region (amino acids 
190-230) and one in the C-terminal region (amino acids 611-650) (Murdoch et al, 
2007). Interaction between endogenous 71 and 100 kDa DISC1 isoforms has also 
been detected by co-immunoprecipitation in human neuronal SH-SY5Y cells 
(Bradshaw et al, 2008; Millar et al, 2005b).  
Millar and colleagues originally reported that the interaction between DISC1 and 
PDE4B is dynamically regulated by intracellular cAMP levels through the action of 
PKA (Millar et al, 2005b). Upon cell treatment with the adenylyl cyclase inhibitor 
forskolin and the general PDE inhibitor IBMX, which results in intracellular 
accumulation of cAMP, the interaction between endogenous 71 kDa DISC1 and 
PDE4B is markedly reduced, as evidenced by decreased co-immunoprecipitation, 
and the catalytic activity of PDE4B is increased (Millar et al, 2005b). This effect can 
be prevented by concomitant treatment with the PKA-specific inhibitor H89 (Millar 
et al, 2005b). These observations suggested a model whereby DISC1 binding 
maintains PDE4B in a state of low catalytic activity until cAMP-PKA signalling is 
activated, releasing PDE4B from DISC1 and boosting its catalytic activity (Millar et 
al, 2005b). A later study added more facets to this model by showing that the cAMP-
dependent release of PDE4 from DISC1 is isoform-specific (Murdoch et al, 2007). In 
co-immunoprecipitation assays performed with exogenously expressed proteins, 
increased cAMP levels reduce the interaction between full-length 100 kDa DISC1 
and both long and short PDE4 isoforms D and C, but not B and A (Murdoch et al, 
2007). Additionally, this study showed that the cAMP-dependent release of PDE4D3 




PDE4D3 or DISC1 (Murdoch et al, 2007). This complicates the initial observations 
made by Millar and colleagues, and shows that the DISC1-PDE4 interaction is 
affected by isoform variability in both proteins (Murdoch et al, 2007). Since a N-
terminally truncated form of DISC1 that lacks the three PDE4B-specific binding sites 
fails to retain interaction with PDE4B upon increased cAMP levels, Murdoch and 
colleagues proposed that deletion of DISC1 N-terminus might mimic the 71 kDa 
isoform described by Millar and colleagues (Murdoch et al, 2007). However, the 
mechanisms mediating cAMP-dependent release of PDE4D and C from DISC1 
remain unclear (Murdoch et al, 2007).  
Recent studies suggested that interactions between PDE4, DISC1 and GSK3 may be 
finely interregulated, and that perturbations of this complex may lead to psychiatric 
illness. PKA is both an activator of PDE4 (MacKenzie et al, 2002) and a substrate of 
GSK3 (Hemmings et al, 1982), and in turn cAMP signalling has been shown to 
affect the activity of GSK3  (Goessling et al, 2009), suggesting the possible 
existence of complex feed-back control mechanisms. This is substantiated by studies 
in vivo and in vitro. For example, a  Disc1 mouse model characterised by the L100P 
missense mutation, which will be described in more detail in the next section, 
presents behavioural abnormalities mimicking certain characteristics of 
schizophrenia that can be partially rescued by combined inhibition of PDE4 and 
GSK3, but not of either enzyme individually (Lipina et al, 2011a; Lipina et al, 
2011b). In SH-SY5Y cells, both DISC1 overexpression and GSK3  inhibition 
attenuate the increase of PDE4 activity in response to increased cAMP levels 
(Carlyle et al, 2011). Additionally, GSK3  inhibition reduces the activity of PDE4 at 
basal cAMP levels, indicating that GSK3  has a tonic activating effect on the 
enzyme (Carlyle et al, 2011).  
1.2.3.7 Disc1 mouse models 
Although it is obviously not possible to accurately model complex human diseases 
such as schizophrenia or depression in a much simpler organism like a mouse, some 
of the clinical features of these illnesses have measurable behavioural, cognitive and 




pharmacologic manipulations (Arguello & Gogos, 2006). Under this premise, several 
mouse models have been generated to investigate the effect of Disc1 mutations or 
altered Disc1 expression levels on brain development, behaviour and cognition, and 
shed light on their molecular consequences.  
The first Disc1 mouse model was inspired by the serendipitous observation that all 
129 mouse strains carry a frame-shift mutation in Disc1 exon 6 that is predicted to 
result in the production of a truncated protein (Clapcote & Roder, 2006; Koike et al, 
2006). Koike and colleagues introduced this novel mutation in the C57BL/6J 
background, along with two premature stop codons (one in exon 7 and one in exon 8) 
and a premature polyadenylation site in intron 8. Interestingly, the resulting Disc1 
mutant line presented working memory defects and neurodevelopmental and brain 
structural abnormalities (Koike et al, 2006; Kvajo et al, 2008).  
Using N-nitroso-N-ethylurea (ENU) mutagenesis, a method that can be used to 
introduce a single point mutation at a random locus, Clapcote and colleagues 
generated two mutant mouse lines carrying distinct missense mutations in Disc1 
exon 2, resulting in amino acid substitutions Q31L and L100P, respectively 
(Clapcote et al, 2007). Similarly to the Disc1 mutation mentioned above, the Q31L 
and L100P amino acid substitutions resulted in working memory deficits, a 
commonly observed clinical feature of schizophrenia patients (Clapcote et al, 2007). 
The two ENU-induced Disc1 mutant mouse lines displayed additional behavioural 
abnormalities that had not been observed in the previously described deletion mutant 
mice. Similarly to psychotic patients, both the Q31L and L100P mutants had 
prepulse inhibition (PPI) and latent inhibition (LI) deficits, which reflect abnormal 
sensory information processing (Clapcote et al, 2007). Interestingly, these deficits 
could be rescued by typical and atypical antipsychotics (haloperidol and clozapine, 
respectively) or by the PDE4 inhibitor rolipram in L100P but not in Q31L mutants, 
whereas the antidepressant bupropion normalised the PPI deficits in Q31L mice only 
(Clapcote et al, 2007). This suggested that the information processing deficits 
observed in the two Disc1 mutant lines originated through distinct mechanisms. 
Further behavioural testing highlighted a net distinction between the two mutant 




test as well as reduced sociability and reward responsiveness, which all together 
delineate a depression-like phenotype (Clapcote et al, 2007). Consistently, the 
antidepressant bupropion, but not the PDE4 inhibitor rolipram, significantly reduced 
the immobility of Q31L mice in the forced swim test (Clapcote et al, 2007). The 
distinct behavioural and pharmacological profiles of Q31L and L100P Disc1 mutants 
led to the conceptualisation of the first as a model of depression and the second as a 
model of schizophrenia (Clapcote et al, 2007). Of interest, neuroanatomical 
abnormalities consistent with those observed in patients with schizophrenia, bipolar 
disorder or depression were documented in both Q31L and L100P mice, which 
display reduced brain volume and contraction of the cortex, thalamus and 
cerebellum, as well as defective neuronal proliferation, distribution and maturation in 
the cerebral cortex and hippocampus (Clapcote et al, 2007; Lee et al, 2011). In a 
recent study, Shoji and colleagues performed a battery of behavioural tests on 
homozygous Disc1 Q31L and L100P mice that had been backcrossed to the 
C57BL/6JJcl strain (the same strain utilised in the study by Clapcote and colleagues 
(Clapcote et al, 2007)) for two more generations (Shoji et al, 2012). The results of 
the behavioural analyses conducted by Shoji and colleagues on these two Disc1 
mutant lines (Shoji et al, 2012) show gross inconsistencies with those previously 
reported by Clapcote and colleagues (Clapcote et al, 2007). Indeed, except for 
increased locomotor activity in L100P Disc1 mutants, which had also been reported 
by Clapcote and colleagues (Clapcote et al, 2007), neither the Q31L nor the L100P 
mutants performed differently from wild-type controls in the study conducted by 
Shoji and colleagues (Shoji et al, 2012). These discrepancies might reflect 
differences in genetic background between the Disc1 mutants analysed in the two 
studies, but might also be due to differences in the housing/laboratory environment 
and/or testing conditions (Shoji et al, 2012).  
Several groups have generated Disc1 mouse models expressing a N- or C-terminally 
truncated protein in an attempt to mimic the functional consequences of the t(1;11) 
translocation disrupting DISC1 in the original Scottish family. In regard to this, it is 
important to emphasise that although the production of a C-terminally truncated form 
of DISC1 in carriers of the t(1;11) translocation is theoretically possible, no evidence 




et al, 2005b). Nevertheless, Disc1 mouse models mimicking the t(1;11) translocation 
have provided valuable information on the role of Disc1 in neurodevelopment and 
neurosignalling. Slightly different approaches have been taken in the generation of 
mouse lines expressing truncated DISC1, and a vast spectrum of neuroanatomical 
and behavioural abnormalities have been observed in these mouse models, with some 
recurring features. Several models used a N- or C-terminally truncated DISC1 cDNA 
expressed constitutively or inducibly under control of the promoter for αCaMKII, 
which is expressed in forebrain regions only (Ayhan et al, 2011; Hikida et al, 2007; 
Li et al, 2007a; Pletnikov et al, 2008a; Pletnikov et al, 2008b). An alternative 
approach was adopted by Shen and colleagues, who used a bacterial artificial 
chromosome (BAC) vector containing Disc1 exons 1-9 and its entire upstream 
promoter sequence to generate mice that constitutively express truncated and 
endogenous full-length Disc1 at comparable levels (Shen et al, 2008). The observed 
phenotypes include macroscopic brain structural changes that have also been 
reported in schizophrenia patients, such as enlargement of the lateral ventricles and 
decreased thickness of the cerebral cortex (Ayhan et al, 2011; Hikida et al, 2007; 
Pletnikov et al, 2008b; Shen et al, 2008). Microscopic neuroarchitectural 
abnormalities have also been commonly observed in mice expressing truncated 
DISC1. These include decreased dendritic complexity (Li et al, 2007a; Pletnikov et 
al, 2008a; Shen et al, 2008), decreased neurite outgrowth (Pletnikov et al, 2008a; 
Shen et al, 2008) and reduced number of parvalbumin-positive cells in the prefrontal 
cortex (Ayhan et al, 2011; Hikida et al, 2007; Shen et al, 2008), the latter being a 
strongly replicated observation in post-mortem analyses of schizophrenic brains 
(Lewis et al, 2005). At the cognitive and behavioural level, expression of truncated 
DISC1 was found to correlate with reduced sociability (Li et al, 2007a; Pletnikov et 
al, 2008a), working memory deficits (Li et al, 2007a), defects of LI or PPI (Li et al, 
2007a; Shen et al, 2008) and increased immobility in depression-related tests (Ayhan 
et al, 2011; Hikida et al, 2007; Li et al, 2007a; Shen et al, 2008). Only some of the 
histological and behavioural findings are consistent across the different mouse 
models expressing truncated DISC1, a discrepancy that could result from differences 
in the temporal and spatial expression of mutant DISC1. Indeed, a recent study 




dependent on the stage at which transgene expression is switched on (Ayhan et al, 
2011).  
Other models are based on electroporation- or retroviral-mediated delivery of Disc1-
targeting short hairpin RNAs (shRNAs) to knock-down endogenous Disc1 
expression in the mouse brain. Knock-down of Disc1 expression by in utero 
electroporation results in delayed neuronal migration and aberrant dendritic 
arborisation in the cerebral cortex (Kamiya et al, 2005).  Using a similar approach in 
adult animals, Duan and colleagues demonstrated that Disc1 suppression in neural 
progenitors of the dentate gyrus of the hippocampus results in overextended 
migration, accelerated integration and misfiring of these cells (Duan et al, 2007). A 
separate study showed that Disc1 knock-down in the embryonic brain inhibits the 
proliferation and promotes the premature differentiation of neural progenitors in the 
cortex, and that this arises from aberrant Wnt-GSK3 - -catenin signalling (Mao et 
al, 2009). Similar defects to those reported by Duan, Kamiya and Mao were 
observed after transient knock-down of Disc1 in the PFC during early development, 
and resulted in defective maturation of dopaminergic neurons and behavioural 
alterations in adulthood (Niwa et al, 2010).  
Due to its transcriptional complexity, complete knock-out of Disc1 expression has 
proven particularly difficult to achieve (Chubb et al, 2008). Recently, the generation 
of a novel mouse line lacking Disc1 exons 2 and 3 (Disc1 2-3) has been reported 
(Kuroda et al, 2011). These mice do not express full-length Disc1, but transcripts 
containing Disc1 exons 7-9 were detected in mice homozygous for the 2-3 
mutation, indicating that shorter Disc1 isoforms lacking exons 2 and 3 may still be 
produced (Kuroda et al, 2011). Surprisingly, no structural or histological brain 
abnormalities were observed in these mice (Kuroda et al, 2011). Despite having a 
higher threshold for long term potentiation (LTP) induction, Disc1 2-3 mice did not 
display any deficits in various learning and memory-related tests (Kuroda et al, 
2011). Further behavioural testing revealed increased impulsivity, reduced PPI and 
increased responsiveness to the dopaminergic agonist methamphetamine in Disc1 
2-3 mice. The Disc1 mutants also spent a significantly longer time in the open arms 




normalised by the administration of the antipsychotic clozapine (Kuroda et al, 2011). 
The discrepancy between the neuroanatomical abnormalities seen in the studies that 
used transient Disc1 knock-down and the normal brain morphology in Disc1 2-3 
mice may arise from compensatory mechanisms induced by chronic Disc1 depletion, 
and might be resolved by the study of mice with conditional knock-out of full-length 
Disc1 (Kuroda et al, 2011).  
Recent studies have investigated the impact of maternal immune activation on 
behavioural and neuroanatomical outcomes in mice expressing C-terminally 
truncated DISC1. Epidemiological studies have found a consistent association 
between maternal infection by various infective agents during gestation and 
increased risk of schizophrenia in the offspring (Brown & Derkits, 2010). Gestational 
infections are thought to interfere with foetal brain development through the 
activation of the maternal immune system and consequent production of pro-
inflammatory cytokines, some of which cross the placenta (Brown, 2011). The 
double-stranded RNA synthetic analogue Polyribosinic-polyribocytidilic acid 
(PolyI:C) is commonly used to mimic infection in rodents as it induces the release of 
pro-inflammatory cytokines through the activation of Toll-like receptors in mammals 
(Nagai et al, 2011a). Administration of PolyI:C to pregnant dams or neonate mice 
has often been used as a model to study the cognitive, behavioural and anatomical 
consequences of infection during development (Nagai et al, 2011a). Despite the 
important limitations arising from the difficulty of matching pregnancy stages in 
humans and rodents, PolyI:C models have been useful in showing how maternal or 
neonatal immune activation can impact on a wide spectrum of cognitive and 
behavioural phenotypes that correlate with schizophrenia (Nagai et al, 2011a).  
A recent study investigated the effects of neonatal administration of PolyI:C to mice 
expressing C-terminally truncated dominant-negative DISC1 (DN-DISC1) on 
cognitive and behavioural correlates of schizophrenia assessed during adolescence 
(Ibi et al, 2010). This study found synergistic detrimental effects of PolyI:C 
treatment and DN-DISC1 expression on short-term, object recognition and fear 
memory during adolescence (Ibi et al, 2010). Additionally, PolyI:C-treated DN-




NMDA receptor antagonist MK-801, which is commonly used to model psychosis 
(Ibi et al, 2010). A significant treatment x genotype interaction was also observed in 
relation to the number of parvalbumin-positive interneurons in the PFC, with 
PolyI:C-treated DN-DISC1 mice showing the most marked decrease when compared 
to both treated and untreated wild-type littermates and untreated mutants (Ibi et al, 
2010). The recorded phenotypes in PolyI:C-treated DN-DISC1 mice could be 
differentially rescued by the antipsychotics clozapine and haloperidol, with the 
memory deficits responding to clozapine only, the exacerbated response to MK-801 
responding to both drugs, and the social impairments responding to neither (Nagai et 
al, 2011b).  
A separate study focused on the interaction between DN-DISC1 expression and 
PolyI:C treatment during gestation, a model considered more relevant to human 
psychopathology, based on epidemiological studies (Abazyan et al, 2011). Prenatal 
interaction produced markedly increased anxiety and depression-like behaviours, as 
well as altered social interaction, but had no effect on cognitive measures (Abazyan 
et al, 2011). These behavioural abnormalities were accompanied by reduced 
reactivity of the hypothalamus-pituitary-adrenal (HPA) axis, reduced serotonin 
neurotransmission and altered brain morphology (Abazyan et al, 2011). 
Collectively, these studies support PolyI:C treatment in DN-DISC1 mice as a 
valuable tool to study the interaction between two well established genetic and 
environmental susceptibility factors for schizophrenia, and highlight important 
differences between the cognitive and behavoiral consequences of pre- and post-natal 
immune activation.  
1.3 The interaction of DISC1 with ATF4  
1.3.1 The identification of ATF4 as a DISC1 binding partner 
Activating Transcription Factor 4 (ATF4), also known as cAMP Response Element 
Binding Protein 2 (CREB2), was first identified as a DISC1 binding protein in two of 
the three yeast-two-hybrid (Y2H) screens that shortly followed the discovery of 




foetal and adult human brain (Millar et al, 2003; Morris et al, 2003) and heart 
(Morris et al, 2003) cDNA libraries with full-length DISC1, identified several 
positive clones for ATF4 in the brain, but none in the heart. In the screen performed 
by Millar and colleagues, ATF4 was the only DISC1 interacting protein identified in 
both foetal and adult brain libraries (Millar et al, 2003). ATF4 is not the only nuclear 
protein identified in Y2H for DISC1 interactors, as the highly related Activating 
Transcription Factor 5 (ATF5) and the chromatin remodelling protein SWI/SNF 
related matrix associated actin dependent regulator of chromatin (SMARCE1) were 
also positive hits (Millar et al, 2003; Morris et al, 2003). DISC1 binding to ATF4 
was first confirmed by mammalian-two-hybrid (M2H) assays (Morris et al, 2003) 
and later by co-immunoprecipitation (co-IP) of both endogenous (Bradshaw et al, 
2008) and exogenous (Sawamura et al, 2008) proteins. The identification of ATF4 
and other nuclear interactors provided the first clue on the potential functions of 
nuclear DISC1. However, to date only one study, which will be described in detail 
later in this thesis, has focused on the functional implications of the DISC1-ATF4 
interaction in the nucleus, and how this may relate to psychiatric illness (Sawamura 
et al, 2008). 
Limited evidence from linkage and association studies implicates ATF4 in 
schizophrenia, but not bipolar disorder. ATF4 is one of the genes located in the 
schizophrenia-linked chromosomal region 22q13, and has thus been suggested as a 
positional candidate gene for schizophrenia (Lewis et al, 2003; Mowry et al, 2004; 
Williams et al, 2003). A single study found association of two SNPs within ATF4 
with schizophrenia in male patients from the Han Chinese population (Qu et al, 
2008). However, no association between ATF4 and bipolar disorder was found in a 
Japanese population (Kakiuchi et al, 2007). No firm conclusions can be drawn from 
the genetic data collected so far, and further studies are needed to elucidate the 
potential role of ATF4 as a candidate gene for psychiatric illness.  
1.3.2 ATF4 is a ubiquitous and multifunctional protein 
ATF4 belongs to the ATF/CREB family of basic region-leucine zipper (bZIP) 
transcription factors, which share the ability to bind to the cAMP response element 




gene (Karpinski et al, 1992; Vallejo et al, 1993) involved in a plethora of 
developmental and homeostatic processes, but its best characterised functions, which 
will be described in detail later in this chapter, are the control of the cellular response 
to stress and the modulation of long-term potentiation and long-term memory (Ameri 
& Harris, 2008). Consistent with its prominent role in memory formation, ATF4 
expression has been detected in the mouse hippocampal regions CA1-3 and dentate 
gyrus, as well as other brain regions, including the amygdala, caudate nucleus, 
corpus callosum, thalamus, subthalamic nuclei and substantia nigra (Yukawa et al, 
1999). 
Several ATF4 knock-out (KO) mice have been independently generated and 
characterised (Hettmann et al, 2000; Masuoka & Townes, 2002; Tanaka et al, 1998). 
These are generally viable, but present with multiple severe defects that highlight the 
importance of ATF4 in the development of different tissues (Ameri & Harris, 2008). 
For example, ATF4 inactivation results in defective lens development, leading to 
severe microphthalmia and blindness in the adult animals (Hettmann et al, 2000; 
Tanaka et al, 1998). Other phenotypes observed in ATF4 KO mice include severe 
foetal anaemia, delayed growth and smaller size, reduced fibroblast proliferation, 
subfertility, lower fat mass and glucose levels, and defective skeletal development 
(Fischer et al, 2004; Masuoka & Townes, 2002; Muir et al, 2008; Dobreva et al, 
2006; Yang et al, 2004; Yoshizawa et al, 2009). Consistent with a role of ATF4 in 
development, mutations in the Drosophila melanogaster ATF4 homolog 
cryptocephal result in larval moulting and metamorphosis defects (Hewes et al, 
2000).  
A recent study demonstrated for the first time that ATF4 is also involved in 
neurodevelopment through its role in cell cycle control (Frank et al, 2010). 
Experiments in cultured cells demonstrated that ATF4 protein levels normally 
oscillate during the cell cycle, and that proteasome-dependent ATF4 degradation is 
necessary for correct cell cycle progression (Frank et al, 2010). Analysis of the 
developing mouse brain by in-situ hybridization and western blotting revealed that 
ATF4 expression is highest at the early stages of brain development, when progenitor 




then reactivated in mature neurons (Frank et al, 2010). Electroporation of a 
proteasome-resistant mutant form of ATF4 in the embryonic mouse brain  caused 
accumulation of neural progenitors in the ventricular zone due to cell cycle arrest in 
early G1, indicating that correctly timed ATF4 degradation is necessary for 
neurogenesis in vivo (Frank et al, 2010).  
Further studies that focused on the role of ATF4 in bone morphogenesis revealed that 
it is essential for the maturation of osteoblasts, the cells responsible for bone 
formation (Hartmann, 2009). In these cells, selective accumulation of ATF4, which 
is otherwise present at very low levels, occurs through the inhibition of its 
proteasomal degradation (Hartmann, 2009). The transcriptional activity of ATF4 in 
osteoblasts is further activated through phosphorylation by ribosomal S6 protein 
kinase 2 (RSK2), and it has been proposed that the lack of ATF4 phosphorylation by 
RSK2 may contribute to the skeletal displasia that characterises Coffin-Lowry 
syndrome (Yang et al, 2004). Through its expression in osteoblasts, ATF4 also 
regulates the differentiation of osteoclasts, the cells responsible for bone resorption 
(Elefteriou et al, 2005). In osteoblasts, ATF4 activates the expression of the receptor 
activator of nuclear factor-KappaB ligand (RankL) gene, which encodes a secreted 
factor that promotes osteoclast differentiation (Elefteriou et al, 2005). Accordingly, 
ATF4 KO mice have decreased osteoclast numbers due to reduced RankL expression 
(Cao et al, 2010). 
Expression of ATF4 in osteoblasts has also been demonstrated to be responsible for 
the endocrine function of these cells, and in particular for their role in the control of 
glucose metabolism (Yoshizawa et al, 2009). Indeed, osteoblast-expressed ATF4 
negatively regulates insulin secretion and reduces the insulin sensitivity of liver, 
muscle and fat tissue (Yoshizawa et al, 2009). As discussed later, ATF4 promotes 
the expression of genes involved in amino acid uptake and protein synthesis, and this 
particular function contributes to the anabolic and catabolic actions of insulin and 
glucocorticoids, respectively (Adams, 2007). Under anabolic conditions, when 
nutrients are abundant, insulin induces ATF4 expression through activation of 
mammalian target of rapamycin complex 1 (mTORC1), whereas under catabolic 




ATF4 is also involved in the regulation of thermogenesis and lipid metabolism, as 
demonstrated by the observation that ATF4 KO mice are leaner, they have increased 
energy expenditure, increased lipolysis, reduced fat accumulation and increased 
resistance to diabetes under high-feeding conditions (Seo et al, 2009; Wang et al, 
2010a). Its multiple functions in the regulation of lipid and glucose metabolism, 
energy homeostasis, insulin secretion, and sensitivity, suggest that ATF4 is a central 
regulator of metabolism. 
Tumour biology is an additional area of research in which much attention has been 
devoted to ATF4, by virtue of its role as a mediator of the cellular stress responses 
(Rzymski et al, 2009). Expanding solid tumours have to adapt to the adverse 
conditions generated by the lack of efficient vascularisation, namely the defective 
supply of oxygen and nutrients and the accumulation of toxic waste products. To 
cope with these stressful conditions, the cells activate the integrated stress response 
(ISR), a coordinated program of gene expression whose primary purpose is to restore 
homeostasis through the upregulation of pro-survival genes, but that can ultimately 
divert towards apoptosis if the cell damage is too advanced (Harding et al, 2003; 
Haynes et al, 2004). ATF4 is the master regulator of the ISR, and fibroblasts lacking 
ATF4 show a markedly increased sensitivity to hypoxia, nutrient deprivation and 
oxidative stress, which are the typical conditions present in the tumour 
microenvironment (Harding et al, 2003). By contrast, ATF4 overexpression is often 
detected in tumour cells (Bi et al, 2005), especially in the regions of more severe 
hypoxia (Ameri et al, 2004; Bi et al, 2005), and has been positively correlated with 
the degree of tumour aggressiveness (Ameri et al, 2010; Daibata et al, 2004) and 
with resistance to anti-cancer drugs (Rzymski et al, 2009). For these reasons, it has 
been suggested that ATF4 overexpression represents a key adaptive mechanism that 
promotes tumour progression and malignancy, and that hinders the effectiveness of 
current chemotherapeutic approaches (Rzymski et al, 2009). As a consequence, 
innovative anti-cancer strategies based on ATF4 inhibition are currently under 





1.3.3 ATF4 protein structure, dimerisation partners and DNA binding 
properties 
The human ATF4 protein is 351 amino acids long, and is organised in several 
domains that mediate its homo and heterodimerisation, DNA binding, transcriptional 
activation and protein degradation (Ameri & Harris, 2008) (Figure 1.5, taken from 
Ameri et al, 2008). ATF4 is ubiquitously expressed at the mRNA level, but, with the 
exception of osteoblasts, ATF4 protein levels are very low under basal (non-stressed) 
conditions due to its inefficient translation and short half-life (Rzymski et al, 2009). 
As described later in this chapter, several mechanisms contribute to the regulation of 
ATF4 protein levels in response to stress, one of these being its proteasomal 
degradation (Ameri & Harris, 2008). Three domains in ATF4 are involved in the 
regulation of the protein stability:  the histone acetyltransferase (HAT) P300-binding 
domain at amino acids (1-85), the oxygen-dependent degradation domain (ODDD) at 
amino acids (154-181), and the TrCP recognition motif at amino acids (218-224) 
(Koditz et al, 2007; Lassot et al, 2005; Lassot et al, 2001) (Figure 1.5). Binding of 
HAT P300 stabilises ATF4 by inhibiting its ubiquitination (Lassot et al, 2005). The 
ODDD is recognised by the oxygen sensor prolyl-4-hydroxylase 3 (PHD3), which 
mediates the proteasomal degradation of ATF4 under normoxic conditions (Koditz et 
al, 2007). Finally, the TrCP recognition motif mediates the phosphorylation-
dependent degradation of ATF4 through its binding to the SCF
TrCP 
E3 ubiquitin 






Figure 1.5 Adapted from Ameri et al, 2008. Schematic representation of ATF4 
protein structure and modulatory domains. The position of the P300 interaction site 
and modulatory acetylation site (Lassot et al, 2005) are indicated, along with the 
PHD3 binding domain and ODDD. The TrCP binding site and C-terminal bZip 
domain are also shown. 
The initial characterisation of the protein upon cloning of its cDNA revealed the 
presence of a basic leucine-zipper motif and adjacent basic region in the C-terminus 
of ATF4, between amino acids (280-334) (Karpinski et al, 1992) (Figure 1.5). This 
motif, which is commonly referred to as the bZip motif, is shared by a variety of 
transcription factors, including CREB, CREM, FOS and JUN, which are thus 
collectively called bZip transcription factors, and is essential for their function 
(Vinson et al, 2002). Within the bZip domain, the leucine zipper mediates the homo 
or heterodimerisation of these transcription factors, whereas the basic region is 
necessary for their binding to DNA (Karpinski et al, 1992). ATF4 is evolutionary 
conserved, with the human and mouse proteins sharing 80% similarity overall, and 
the sequence conservation is particularly high in the bZIP region, which is 98.6% 
identical between human and mouse, denoting its functional importance (Mielnicki 
& Pruitt, 1991).  
ATF4 possesses an additional conserved leucine zipper (zipper II) spanning amino 
acids (91-126) (Liang & Hai, 1997). Zipper II mediates the interaction of ATF4 with 
regulatory proteins such as PHD3 and neuronal cell death-inducible putative kinase 
(NIPK), and is thus involved in the control of ATF4 protein stability and 
transcriptional activity (Koditz et al, 2007; Ord & Ord, 2003).  
ATF4 was originally isolated based on its ability to bind to the palindromic 
ATF/CRE consensus site (TGAGCTCA) (Hai et al, 1989). The study of the 
dimerisation partners of ATF4 revealed that not only can it form homodimers, but it 
can also heterodimerise with members of the AP-1 family of bZip transcription 
factors, which preferentially bind to the AP-1 consensus site (TGACTCA) (Hai & 
Curran, 1991), and with other bZip transcription factors belonging to the 
CCAAT/enhancer-binding protein (C/EBP) family (Gombart et al, 2007; Vallejo et 




has not been reported to heterodimerise with other ATF/CRE transcription factors 
(Hai & Hartman, 2001; Vinson et al, 2002). While ATF4 homodimers preferentially 
bind to the ATF4/CRE site, the DNA binding affinity of ATF4 heterodimers is 
dependent on the heterodimerisation partner, and in some cases it differs from that of 
each parental homodimer (Hai & Curran, 1991; Vallejo et al, 1993; Vinson et al, 
1993). For example, ATF4-C/EBP  heterodimers bind to a subclass of asymmetric 
CREs that are not recognised by either parental homodimer (Vallejo et al, 1993). 
Thus, the relative abundance of the different ATF4-binding transcription factors in a 
particular system and at a particular time is likely to be one of the factors controlling 
its transcriptional activity (Vallejo et al, 1993).  
The N-terminus and, albeit more weakly, the C-terminal bZip domain of ATF4 have 
been reported to function as transactivator domains in transcriptional reporter assays 
(Liang & Hai, 1997; Schoch et al, 2001), whereas no transferrable repressor domains 
have been identified within the ATF4 protein sequence (Schoch et al, 2001). 
However, ATF4 has been initially described to act as a transcriptional repressor 
(Cibelli et al, 1996; Jungling et al, 1994; Karpinski et al, 1992), and this observation 
is at the basis of its proposed role as a repressor of long-term memory formation 
(Bartsch et al, 1995). A possible explanation for this apparent discrepancy may be 
provided by the reported ability of ATF4 to bind the transcriptional co-activator 
CREB-binding protein (CBP), as well as several components of the basic 
transcriptional machinery, including TATA binding protein (TBP) and transcription 
factors IIB (TFIIB) and IIF (TFIIF) (Liang & Hai, 1997). It has been suggested that, 
by binding to these factors and sequestering them away from the promoter, 
overexpressed ATF4 may compete with other transcription factors (Hai & Hartman, 
2001; Liang & Hai, 1997; Schoch et al, 2001). This hypothesis is supported by 
titration experiments with exogenous ATF4, which showed that the protein inhibits 
its own transcriptional activity when expressed at high concentrations (Liang & Hai, 
1997). 
ATF4 has several additional interacting proteins, the variety of which reflects its 
multifunctionality (Ameri & Harris, 2008). A non exhaustive list of ATF4 binding 




mitosin/CENPF (Zhou et al, 2005), the centrosomal protein CEP290 (Sayer et al, 
2006), the bZip protein Zhangfei, which potentiates ATF4 transcriptional activity on 
CRE-containing promoters (Hogan et al, 2006), the C/EBP homologous protein 
CHOP (Gachon et al, 2001), the transcription factor Nrf2, which regulates the 
expression of antioxidant genes (He et al, 2001), and the two subunits of the 
metabotropic GABAB receptor (Nehring et al, 2000; Ritter et al, 2004; Vernon et al, 
2001; White et al, 2000). The last of these is a particularly intriguing interaction, 
given the proposed role for dysfunctional GABA signalling in schizophrenia (Coyle, 
2004) and the recently reported interplay between DISC1 and GABA signalling in 
the regulation of neurogenesis (Kim et al, 2012), but it has not been investigated 
beyond the initial reports that proposed a functional link between GABAB receptor 
signalling and ATF4 transcriptional activity in neurons (Vernon et al, 2001; White et 
al, 2000).   
Consistent with its role in transcriptional control, ATF4 is highly enriched in the 
nucleus, although its presence has been reported in other subcellular compartments 
(Lai et al, 2008; Nehring et al, 2000; White et al, 2000). Nuclear targeting of ATF4 
is mediated by a signal sequence located within its C-terminal basic region, at amino 
acids (280-300). Single point mutations of basic amino acids within this region 
identified the sequence 280-KKLKK-284 as necessary for ATF4 nuclear targeting 
(Cibelli et al, 1999).  
1.3.4 Regulation of ATF4 transcriptional activity 
In most cell types, the main function of ATF4 is to orchestrate the transcriptional 
response to a range of damaging external stimuli, including oxygen deprivation, 
amino acid limitation, oxidative stress, viral infections and endoplasmic reticulum 
stress  (Ameri & Harris, 2008). Consistently, ATF4 protein levels are normally very 
low, and often undetetectable, in the majority of non-stressed cells (Ameri & Harris, 
2008). The transcriptional activation of ATF4 in response to stress is necessary to 
induce the expression of genes that allow the cell to successfully cope with the 
stressful stimulus and hence adapt and survive (Harding et al, 2003). However, 
ATF4 target genes also include pro-apoptotic factors such as CHOP, and protracted 




Rutkowski et al, 2006). For these reasons, several regulatory mechanisms are 
normally in place to keep ATF4 transcriptional activity under strict control. As 
detailed below, these include the regulation of ATF4 protein dosage at the 
transcriptional, translational and post-translational level, as well as the direct 
modulation of ATF4 transcriptional activity by its interaction with partner proteins 
(Ameri & Harris, 2008).  
1.3.4.1 Transcriptional regulation of ATF4 
As described below, the main mechanism responsible for the increase in ATF4 
protein levels in response to stress is the selective enhancement of its translation. 
However, some studies have reported changes in ATF4 mRNA levels in response to 
certain types of stress, although the specific factors responsible for this stress-
dependent transcriptional control of ATF4 are still unknown (Dey et al, 2010). Like 
the ATF4 protein, ATF4 mRNA is short-lived, with a half-life of only 3 hours, 
which allows for rapid regulation of its levels (Dey et al, 2010). The changes in 
ATF4 mRNA levels in response to stress do not seem to be mediated by regulation of 
its stability, but instead involve activation or repression of mRNA synthesis (Dey et 
al, 2010). Most, but not all studies reported increased ATF4 mRNA synthesis in 
response to stress. For example, in primary rat fibroblasts, anoxia was reported to 
increase ATF4 mRNA expression (Estes et al, 1995), but hypoxia had no effect on 
ATF4 mRNA levels in HeLa cells (Blais et al, 2004). This may suggest that the 
induction of ATF4 transcription only occurs under conditions of severe oxygen 
deprivation. Additionally, ATF4 mRNA is induced by amino acid and glucose 
deprivation (Siu et al, 2002), endoplasmic reticulum stress (Adachi et al, 2008; 
Harding et al, 2000; Lu et al, 2004) and by oxidative stress (Lange et al, 2008). A 
recent study based on reporter constructs confirmed that ATF4 transcription is 
activated in response to endoplasmic reticulum stress, and also found that it is 
inhibited by UV irradiation (Dey et al, 2010). Given the reportedly detrimental effect 
of ATF4 activation in response to some stressors, including UV irradiation, it has 
been proposed that the differential regulation of ATF4 expression depending on the 




1.3.4.2 Translational regulation of ATF4 
In mammalian cells, multiple stress-responsive pathways converge on the 
phosphorylation of the eukaryotic initiation factor 2α (eIF2α) at serine 51. In turn, 
this results in the inhibition of general translation, which allows the cell to save 
resources while reconfiguring gene expression to adapt to the new conditions (Wek 
et al, 2006). There are four known eIF2α kinases, each preferentially responding to a 
different type of stress: RNA-dependent protein kinase-like endoplasmic reticulum 
kinase (PERK) is activated by endoplasmic reticulum (ER) stress, which is 
determined by the saturation of the protein folding capacity of the ER; protein kinase 
RNA-activated (PKR) responds to double-stranded RNA and is involved in the 
antiviral response; general control nonrepressed 2 (GCN2) is activated by uncharged 
tRNAs, which accumulate in the cell when the availability of amino acids is reduced, 
and finally, heme-regulated eIF2α kinase (HRI), which is predominantly expressed in 
erythroid cells and responds to decreased availability of heme, as well as oxidative 
stress and heat-shock (Dever, 2002).  
In unstressed cells, dephosphorylated GTP-bound eIF2α binds to the initiator Met-
tRNAi
Met 
and transfers it to the 40S ribosomal subunit, forming the 43S pre-initiation 
complex. This complex binds the 5' end of the capped mRNA chain and scans it in 
the 5'-3' direction until it recognises the start codon. This induces eIF2α to hydrolyse 
its GTP-bound molecule and dissociate from the pre-initiation complex, thus 
allowing the 60S ribosomal subunit to join the complex and form the 80S initiation 
complex (Dever, 2002). Phosphorylation of serine 51 of eIF2α by one of the four 
stress-responsive kinases prevents the exchange of its GDP-bound molecule with 
GTP, thus inhibiting the formation of the pre-initiation complex and suppressing 
general translation (Dever, 2002). By contrast, under these circumstances the 
efficiency of ATF4 mRNA translation is greatly enhanced, thus inducing a rapid 
increase of its protein levels. The preferential translation of ATF4 mRNA under 
stress conditions is due to the particular sequence of it 5' untranslated region (UTR), 
which includes two short upstream open reading frames (uORF). The 5' proximal 
and positive-acting uORF1 consists of a strong start codon surrounded by a Kozak 




inhibitory uORF2, which possesses a weaker start codon and overlaps with the first 
83 nucleotides of the ATF4 ORF, but produces a polypeptide of only 59 amino acids. 
Under non-stressed conditions, the scanning ribosome initiates translation at uORF1, 
and retains the ability to rapidly re-initiate at the inhibitory uORF2, thus preventing 
translation of the ATF4 ORF. Under stressed conditions, the lack of eIF2α-GTP 
means that the time necessary for the 40S ribosomal subunit to acquire the Met-
tRNAi
Met 
is increased, allowing it to scan through uORF2 and initiate translation at 
the ATF4 start codon (Harding et al, 2000; Lu et al, 2004; Vattem & Wek, 2004).  
1.3.4.3 Regulation of ATF4 protein stability 
Besides being subjected to translational inhibition, ATF4 protein is also selectively 
targeted to the proteasome for degradation under normal conditions. As a result, 
ATF4 is a very unstable protein, with a half-life of only 30 minutes (Lassot et al, 
2001). The proteasomal degradation of ATF4 is dependent on its interaction with a 
specific subtype of Skp1/cullin/F-box protein (SCF) E3 ubiquitin ligase complex in 
which the F-box protein is beta-transducin repeat-containing protein ( TrCP) (Lassot 
et al, 2001). The function of TrCP is to recognise the target protein (in this case 
ATF4) and anchor it to the SCF complex. SCF-bound ATF4 is then recognised by 
the E2 ubiquitin conjugating enzyme, which mediates its polyubiquitination. 
Deletion and single amino acid mutation analyses established that the degron motif 
218-DSGICMS-224 on ATF4 mediates TrCP binding, and that this requires 
phosphorylation of serine 219 located within thin motif (Lassot et al, 2001; Pons et 
al, 2007) (Figure 1.5). A recent study demonstrated that ATF4 interaction with 
TrCP, and hence its stability, is additionally modulated by a gradient of 
phosphorylation at five other sites (T212, S223, S230, S234 and S247) located 
outside the originally identified degron (Frank et al, 2010). The degree of serine 219 
phosphorylation and TrCP binding depends on which and how many of these 
additional sites are phosphorylated, allowing for fine-tuning of ATF4 protein 
stability (Frank et al, 2010). The identity of the serine 219 kinase(s) is still under 
investigation. Frank and colleagues showed that exogenous ATF4 is stabilised by the 
inhibition of casein kinase 1 (CK1), and that this coincides with reduced S219 




colleagues demonstrated that ribosomal protein L41 (RPL41) is a strong activator of 
ATF4 proteasomal degradation, and that mutation of ATF4 S219 confers resistance 
to RPL41-induced degradation, but the effect of RPL41 is not blocked by CK1 
inhibition, suggesting that alternative and yet unidentified kinases may be recruited 
on ATF4 through the action of RPL41 (Wang et al, 2011). Unlike RPL41, binding of 
the acetyltransferase P300 to the N-terminus of ATF4, at amino acids (1-85), protects 
it from proteasomal degradation and favours its accumulation in the cell (Lassot et 
al, 2005). P300 acetylates ATF4 in its bZIP domain, but this modification is not 
responsible for the P300-dependent stabilisation of ATF4, and might be instead 
involved in the regulation of its transcriptional activity (Lassot et al, 2005).  
A specific mechanism of ATF4 protein control in response to hypoxia has been 
described to involve binding of the hypoxia-induced oxygen sensor PHD3 to its 
ODDD (Koditz et al, 2007). PHD3 binding to the ODDD on ATF4 promotes its 
degradation via the proteasome under normoxic conditions (Koditz et al, 2007). 
During hypoxia, both proteins are upregulated, and PHD3 binding accelerates the 
degradation of ATF4 once the oxygen levels have normalised (Koditz et al, 2007). 
This mechanism assures that ATF4 induction by hypoxia is transient and rapidly 
counteracted as soon as the stressful stimulus is removed.  
1.3.4.4 Regulation of ATF4 by protein-protein interactions 
Several proteins are able to bind ATF4 and regulate its transcriptional activity 
without interfering with the protein stability, thus providing an additional level of 
control. Among these, DISC1 was shown to strengthen the ATF4-mediated 
inhibition of the CRE at elevated intracellular cAMP levels (Sawamura et al, 2008). 
By contrast, dimerisation of ATF4 with the bZIP transcription factor Zhangfei 
markedly enhances its transactivation potential on CRE/ATF4-containing promoters 
in response to activation of the mitogen-activated protein kinase (MAPK) pathway 
(Hogan et al, 2006). Other examples of binding partners that potentiate ATF4 
transcriptional transactivation include the nuclear matrix protein SATB2, whose 
activating effect on ATF4 promotes normal skeletal development (Dobreva et al, 
2006) and the CREB-binding protein CBP, a transcriptional co-activator implicated 




Several interacting proteins that inhibit the transcriptional activity of ATF4 have also 
been described, including the anti-apoptotic factor NIPK, which is also known as 
tribbles homolog 3 (TRB3) (Jousse et al, 2007; Ohoka et al, 2005; Ord et al, 2007; 
Ord & Ord, 2003), the pro-apoptotic transcription factor CHOP (Gachon et al, 2001), 
and the nuclear matrix protein mitosin/CENP-F, which is involved in the regulation 
of cell proliferation (Zhou et al, 2005). 
1.3.5 ATF4 as a memory suppressor gene 
While short-term memory only requires covalent modifications of pre-existing 
proteins, the establishment of long-term memory, an essential component of 
cognition, is dependent on new protein synthesis (Kandel, 2001). At the cellular 
level, the process of memory consolidation is modelled by a stable increase in 
synaptic strength termed long-term potentiation (LTP) in vertebrates and long-term 
facilitation (LTF) in invertebrates, which is coupled to the establishment of new 
synaptic connections (Kandel, 2001). In both invertebrates and vertebrates, the 
transition from short- to long-term memory requires the activation of the Ca
+2 
and 
cAMP-responsive transcription factor CREB via phosphorylation, which in turn 
drives the expression of several target genes necessary for the establishment of LTP 
by binding to the CRE in their promoter (Kandel, 2001). Early experiments carried 
out in the sea snail Aplysia and in cultured mammalian cells revealed that ATF4 and 
its Aplysia paralog ApCREB2 inhibit the transcriptional activity of CREB (or its 
Aplysia paralog ApCREB1) on the CRE, and that the selective inhibition of 
ApCREB2 in neurons lowers the number of serotonin pulses required for the 
establishment of LTF and the growth of new synaptic connections (Bartsch et al, 
1995; Karpinski et al, 1992; Lee et al, 2003). This led to the suggestion that 
ApCREB2 inhibits LTF though its repressive effect on CREB-dependent 
transcription, implying that LTF requires both the activation of ApCREB1 and the 
release of ApCREB2-mediated inhibition (Bartsch et al, 1995).  
A later study provided evidence for a similar role of ATF4 in mammalian neurons 
(Chen et al, 2003). Following on from previous work that suggested a role of C/EBP 
transcription factors in LTP and memory storage (Alberini et al, 1994; Sterneck et al, 




and colleagues expressed a broad dominant-negative inhibitor of C/EBPs (termed 
AZIP) in the mouse forebrain to elucidate the function of these proteins in synaptic 
plasticity (Chen et al, 2003). AZIP was shown to preferentially interact with and 
inhibit several repressive isoforms of C/EBP as well as ATF4, and to result in the 
specific downregulation of ATF4 protein, but not mRNA levels. Importantly, AZIP 
transgenic mice had enhanced hippocampal-based spatial memory and LTP, and this 
was due to enhanced cAMP/PKA dependent transcription and translation (Chen et al, 
2003). These findings are in line with those of previous studies conducted in the 
invertebrate Aplysia (Bartsch et al, 1995), and strongly suggest that the repressive 
role of ATF4 in long-term memory formation is conserved in mammals.  
Two further studies collectively provided compelling evidence for the translational 
control of ATF4 acting as a key molecular switch that regulates the transition from 
short- to long-term memory (Costa-Mattioli et al, 2007; Costa-Mattioli & Sonenberg, 
2006). The first study focused on the electrophysiological and behavioural 
characterisation of mice with a homozygous deletion of GCN2, encoding one of the 
four eIF2α kinases. Consistent with the decreased phosphorylation of eIF2α, ATF4 
expression was reduced in the hippocampus of GCN2 KO animals, and this was 
paralleled by increased CREB activity. In GCN2 KO hippocampal slices, a short 
electrical stimulation was sufficient to elicit LTP, whereas sustained electrical 
stimulation or treatment with the cAMP-enhancing drug forskolin, which activates 
CREB, induced LTP in wild-type but not in GCN2 KO slices. The anomalous 
response of GCN2 KO neurons to LTP-inducing stimuli was reflected in the 
performance of the animals in the Morris water maze test, which is used to assess 
spatial memory. In this test, GCN2 KO mice performed better than wild-types after 
short training, but worse after prolonged training. GCN2 was thus suggested to 
modulate synaptic plasticity via translational control of ATF4 protein levels (Costa-
Mattioli & Sonenberg, 2006). A follow-up study from the same laboratory examined 
mice with a heterozygous S51A mutation in eIF2α, which prevents phosphorylation 
of the protein by all four eIF2α kinases. As expected, this mutation was found to 
result in decreased ATF4 protein levels, and this corresponded with a lower threshold 
for LTP induction, consistent with what previously seen in GCN2 KO mice. 




including the Morris water maze, where they needed fewer trials than wild-types to 
achieve the same degree of learning. Again, this suggested that although the 
magnitude of long-term memory was unchanged in eIF2α S51A animals, they could 
achieve it more readily than wild-types. Consistently, the pharmacological inhibition 
of eIF2α dephosphorylation, which represents a reciprocal model of the eIF2α S51A 
mutation, inhibited the acquisition of long-term memory in wild-type animals. In 
addition, it increased the translation of ATF4 and blocked the induction of LTP in 
wild-type hippocampal slices, but strikingly it did not affect LTP induction in ATF4 
KO hippocampal slices (Costa-Mattioli et al, 2007). This strongly suggests that the 
blockage of LTP induction by eIF2α dephosphorylation inhibitors is specifically 
mediated by increased ATF4 translation and provides further confirmation of the role 
of ATF4 as a memory suppressor.  
In light of its prominent regulatory role in learning and memory, it is tempting to 
speculate that ATF4 may be directly involved in the biological alterations underlying 
the cognitive and behavioural abnormalities that characterise schizophrenia. A recent 
study by Trinh and colleagues provided intriguing preliminary evidence supporting 
this hypothesis (Trinh et al, 2012). In mice, forebrain-specific KO of the eIF2α 
kinase PERK determines decresed levels of eIF2α phosphorylation and reduced 
ATF4 expression in the prefrontal cortex (PFC) (Trinh et al, 2012). These changes 
are associated with reduced prepulse inhibition, reduced behavioural flexibility, 
increased behavioural perseveration and reduced fear extincton, which are consistent 
with the alterations commonly observed in schizophrenia (Trinh et al, 2012). Chronic 
treatment with SSR504734, a glycine transporter inhibitor that is known to improve 
behavioural flexibility by enhancing the function of the N-Methyl D-Aspartate 
Receptor (NMDAR), rescues the cognitive impairment in PERK KO mice, and 
normalises the expression of phosphorylated eIF2α and ATF4 in the PFC (Trinh et 
al, 2012). Additionally, and in agreement with the cognitive and behavioural effects 
of PERK KO in mice, expression levels of PERK and ATF4 are reduced in the PFC 
of post-mortem brains from schizophrenia patients, suggesting that these alterations 




1.3.6 ATF4 as a mediator of the cellular stress response  
While the induction of ATF4 in response to a variety of stressors has been 
consistently reported in numerous studies based on both in vitro and in vivo models, 
the observed effects of ATF4 activation are more variable, and seem to be dependent 
on the cell type and the particular experimental conditions. Perhaps this is not 
surprising, given the extensive variety of regulatory mechanisms that converge on 
ATF4, some of which are likely to be cell type- and/or stressor-specific. For 
example, as mentioned earlier, the elevated and protracted expression of ATF4 in 
cancer cells is thought to contribute to their survival and resistance to anti-cancer 
drugs through the induction of genes that confer protection from hypoxia, oxidative 
stress and apoptosis while promoting autophagy (Rzymski et al, 2009). On the other 
hand, most but not all studies based in neurons established a clear connection 
between ATF4 induction after stress exposure and increased apoptosis. Here, I will 
provide an overview of the studies that investigated the function of ATF4 in neurons 
or in pathways relevant for neuronal biology. 
ER stress and impairment of ER function has been implicated in the pathogenesis of 
many neurological and neurodegenerative diseases, including stroke and 
Alzheimer’s, Parkinson’s and Huntington’s diseases (Yang & Paschen, 2009). 
Activation of PERK and increased phosphorylation of eIF2α have been observed in 
stroke, Alzheimer’s, Parkinson’s and amyotrophic lateral sclerosis (Yang & Paschen, 
2009). Given that ATF4 is a direct mediator of the ER stress response, several 
studies have investigated the effect of ATF4 induction in animal and cell models of 
the above neurological disorders. In a recent study, Kim and colleagues mimicked 
the characteristic pathological alterations of Alzheimer’s disease by treating cultured 
neurons with the protein phosphatase-2A (PP2A) inhibitor okadaic acid (OA), which 
induces tau phosphorylation and deposition of amyloid-  (A ), resulting in cell death 
(Kim et al, 2010). In neurons treated with OA, phosphorylation of eIF2α was 
increased, and this resulted in ATF4 accumulation in neurites first and its migration 
to the nucleus later, suggesting that activation of ATF4-mediated transcription may 




Besides ER stress, defective autophagy has also been suggested to play a role in the 
pathogenesis of Alzheimer’s and other neurodegenerative diseases, but the mediating 
mechanisms are still unclear (Hara et al, 2006; Komatsu et al, 2006; Pickford et al, 
2008; Tsuzuki et al, 1994). Intriguingly, ATF4 has been reported to directly 
upregulate the expression of presenilin-1 (PS1) (a component of the -secretase 
enzyme responsible for the generation of A ) in response to reduced autophagic 
activity, amino acid depletion, and ER stress (Mitsuda et al, 2007; Ohta et al, 2011; 
Ohta et al, 2010). Accordingly, the ATF4-dependent upregulation of PS1 expression 
results in increased -secretase activity and secretion of A , thus suggesting that the 
increased expression of ATF4 in Alzheimer’s may actively contribute to the 
progression of the disease (Mitsuda et al, 2007; Ohta et al, 2011; Ohta et al, 2010).  
While investigating the mechanisms of ER stress-induced cell death, Galehdar and 
colleagues found that ATF4 overexpression increases the sensitivity of neurons to 
ER stress-induced apoptosis, while ATF4 suppression has the opposite effect 
(Galehdar et al, 2010). They went on to show that ER stress-induced neuronal 
apoptosis is mediated by the activation of p53-upregulated modulator of apoptosis 
(Puma), but this activation occurs independently of p53 expression. On the other 
hand, ATF4 was found to be necessary for the induction of Puma in response to ER 
stress, although it did not do so directly, but through the intermediate action of its 
target gene CHOP, a pro-apoptotic transcription factor (Galehdar et al, 2010). 
Prolonged, but not short-term ATF4 overexpression was also reported to induce 
apoptosis in the absence of stressful stimuli in postmitotic neuronally differentiated 
PC12 cells, an effect that was blocked by co-expression of the ATF4 inhibitor NIPK 
(TRIB3) (Ord et al, 2007). This latter experiment highlights the relevance of timing 
in ATF4-dependent cellular events. As discussed earlier, transient ATF4 induction is 
necessary to promote adaptation to stress, but prolonged stress and/or persistently 
elevated levels of ATF4 activate the expression of pro-apoptotic genes (Rutkowski et 
al, 2006).  
Other studies investigated the role of ATF4 in the cellular response to hypoxia and/or 
oxidative stress, two paradigms commonly used to model cerebral ischemia and 




relation to neurodegeneration, because oxidative stress has been implicated in the 
initiation or propagation of neuronal damage in several neurodegenerative diseases 
(Beal, 2000; Lin & Beal, 2006). Cultured cortical neurons from ATF4 KO mice 
displayed increased resistance to oxidative stress compared to wild-type neurons 
(Lange et al, 2008). This effect was not caused by long-term compensatory 
mechanisms established in consequence of chronic ATF4 depletion, because 
expression of a dominant-negative mutant version of ATF4 in wild-type neurons also 
conferred resistance to oxidative stress. Consistently, ATF4 overexpression restored 
sensitivity to oxidative stress in ATF4 KO neurons and conferred increased 
sensitivity to oxidative stress in wild-type neurons. In addition, and consistent with 
previous findings in PC12 cells (Ord et al, 2007), ATF4 overexpression in wild-type 
neurons was able to induce apoptosis on its own (Lange et al, 2008). Transcriptional 
profiling of ATF4 KO and wild-type neurons that had been exposed or not to 
oxidative stress revealed that ATF4 is normally induced by oxidative stress, and that 
in turn it is responsible for the expression of a large number of oxidative stress-
responsive genes, including those involved in glutathione metabolism (Lange et al, 
2008). However, two independent studies reported a negative effect of ATF4 on the 
intracellular concentration of glutathione in neurons (Lange et al, 2008; Ord et al, 
2007). Importantly, the pro-death effect of ATF4 under conditions of oxidative stress 
was not limited to cultured neurons, but could also be detected in vivo, as ATF4 KO 
animals were found to be more resistant to neuronal loss after cerebral ischemia 
(Lange et al, 2008). A separate study used cultured mouse neurons to study the 
temporal patterning of gene expression after exposure to hypoxia. As expected, 
hypoxia determined increased eIF2α phosphorylation and ATF4 expression. The 
number of neurons expressing high levels of ATF4 gradually increased with 
prolonged exposure to hypoxia, and in the majority of neurons ATF4 expression 
overlapped with markers of apoptosis (Halterman et al, 2010). Consistent with this, 
induction of ATF4 was determined to coincide with the switch from adaptive to pro-
apoptotic signalling in response to hypoxia (Halterman et al, 2008).  
In contrast with the above studies, which generally observed a positive correlation 
between ATF4 expression and susceptibility to oxidative stress or hypoxia, ATF4 




several stressors, including oxidative stress (Harding et al, 2003). Accordingly, 
elevated ATF4 expression determined the upregulation of the cysteine/glutamate 
antiporter system Xc
- 
, which is essential for the maintenance of normal glutathione 
levels in the cell, and resulted in increased resistance to oxidative stress, an effect 
that could be observed in different cell lines as well as in immature primary cortical 
neurons (Lewerenz & Maher, 2009; Lewerenz et al, 2012). Moreover, this study 
reported activation of eIF2α/ATF4 signalling in the brains of Alzheimer’s patients 
(Lewerenz & Maher, 2009).  The latter, which had been previously observed and 
interpreted as a sign of neurodegeneration (Chang et al, 2002; Kim et al, 2007; Page 
et al, 2006; Unterberger et al, 2006), was instead proposed to be an adaptive pro-
survival response in the light of the above findings (Lewerenz & Maher, 2009; 
Lewerenz et al, 2012).  
The reasons for the discrepancy between the studies that described ATF4 as a pro-
death or pro-survival factor in response to oxidative stress are not clear, but may be 
related to the proliferative and/or maturation status of the tested cell model. Indeed, 
ATF4 expression appears to be detrimental in postmitotic and differentiated cells 
(Halterman et al, 2008; Halterman et al, 2010; Lange et al, 2008; Ord et al, 2007), 
but protective in proliferating cell lines and immature neurons (Harding et al, 2003; 
Lange et al, 2008; Lewerenz & Maher, 2009; Lewerenz et al, 2012). Given that 
oscillating ATF4 expression in proliferating non-stressed cells is involved in the 
regulation of cell cycle progression and neurogenesis (Frank et al, 2010), it is likely 
that additional control mechanisms are in place in these cells to prevent the activation 
of apoptotic genes when ATF4 protein levels peak. Further studies are needed to 
clarify the multiple implications of changes in ATF4 expression levels in stressed 
and non-stressed cells.  
1.4 Aims of this PhD 
A wealth of genetic and biological evidence has firmly established DISC1 as one of 
the most promising tools to dissect the molecular pathogenesis of psychiatric illness 
and identify new therapeutic targets. It is now clear that DISC1 is involved in the 




development and functioning of the brain. The next task will then be to understand if 
and how the deregulation of each of these DISC1-modulated pathways and processes 
can lead to psychiatric illness. This refinement process can be greatly aided by the 
study of the structural and functional impact of DISC1 mutations or variants that are 
known to increase the risk of mental illness. Besides the original t(1;11) 
translocation, whose impact on the nature and relative abundance of DISC1 protein 
isoforms is still uncertain, several DISC1 missense variants have been associated 
with increased risk of psychiatric illness and altered brain structure or cognition in 
healthy subjects, but the underlying mechanisms are still largely unknown. 
Thus, the first aim of this PhD is to investigate the potential effect of a selected 
subset of these variants on the subcellular distribution of DISC1, the disruption of 
which is likely to impact on its molecular interactions and ultimately interfere with 
its normal function. In particular, I will focus on two subcellular compartments in 
which DISC1 normally resides: the nucleus and the centrosome. Many of the 
neurodevelopmental functions of DISC1 depend on its ability to establish 
interactions with key centrosomal partners, and any mutation that prevents its correct 
targeting to the centrosome is likely to have negative consequences for brain 
development. On the other hand, nuclear DISC1 has been involved in the regulation 
of sleep homeostasis and CRE-dependent transcription, and the nuclear distribution 
of DISC1 is altered in schizophrenic brains, suggesting that mutations that disturb the 
targeting and/or function of nuclear DISC1 may contribute to psychopathogenesis.  
The interaction of DISC1 with the transcription factor ATF4 has been reported by 
several groups but has scarcely been investigated, yet it is of potential relevance for 
our understanding of mental illness, since ATF4 is a key regulator of cognition, 
which is severely impaired in schizophrenia, and a master controller of stress 
responses to environmental insults that increase the risk of schizophrenia.   
Thus, the second aim of this PhD is to better characterise the functional implications 
of the DISC1-ATF4 interaction at the molecular level, with a particular focus on the 
role of DISC1 as a regulator of ATF4-mediated transcription and on the functional 




related to stress. The potential impact of risk-conferring DISC1 amino acid 




2 Materials and Methods 
2.1 Bioinformatics  
2.1.1 DNA sequence analysis 
All the reporter plasmids and expression plasmids used in this study were validated 
by direct sequencing. Plasmid DNA sequences were obtained using the method 
described in 2.6.4 and aligned to the reference sequences using the Standard 
Nucleotide BLAST algorithm: 
http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastn&BLAST_PROGRAMS=
megaBlast&PAGE_TYPE=BlastSearch&DATABASE=wgs 
2.2 Reagents  
The chemical reagents used in this thesis, along with the name of their supplier and, 
where appropriate, the vehicle in which they were dissolved, are listed below. 
 
10x TGS (BioRad), diluted with dH2O 
30% Acrylamide/Bis solution (BioRad) 
Acetic acid (Fischer) 
Agar (BD Bioscience) 
Agarose (Invitrogen), made up in TAE buffer  
Ammonium persulphate (Sigma), made up in dH2O 
Ampicillin (Sigma), made up in dH2O 
ATP solution, PCR grade (Sigma) 
Boric acid (Sigma) 
Bromophenol blue (Sigma) 






DAPI (Sigma), made up in mowiol mounting solution 
DMSO (Sigma) 
D-PBS (Invitrogen) 
DTT (Sigma), made up in dH2O 
EDTA (Sigma), made up in dH2O 
Ethanol (Fischer), diluted with dH2O where appropriate 




GTP solution, PCR grade (Sigma) 
H2O2 (Sigma) 
Hydrochloric acid (Fischer) 
IBMX (Sigma), made up in absolute ethanol 
Instant milk powder (Marvel), made up in PBS  
IPTG (Melford) in dH2O 
Isobutanol (Fischer) 
Isopropanol (Fischer)  








Paraformaldehyde (Sigma), made up in PBS 
PBS (Sigma), made up in dH2O often as a 10x solution 
PFA (Sigma) 
Phenol/chlorophorm/isoamyl alcohol (Invitrogen) 
Phosphatase inhibitor cocktail II (Calbiochem) 
Poly-D-lysine (Sigma) 
Ponceau S (Sigma) 
Protease inhibitor cocktail (Roche) 
Rolipram (Sigma) 
SDS (Fischer) made up in dH2O 
Sodium acetate (BDH Laboratory Supplies), made up in dH2O and pH adjusted using 
hydrochloric acid and/or sodium hydroxide 
Sodium chloride (Fischer), made up in dH2O 
Sodium deoxycholate (Fischer), made up in dH2O 
Sodium hydroxide (Fischer), made up in dH2O 
TEMED (Sigma) 
Thapsigargin (Sigma) 
Tris (Fischer), made up in dH2O and pH adjusted using hydrochloric acid and/or 
sodium hydroxide 
Tris-HCl (Fischer), made up in dH2O and pH adjusted using hydrochloric acid and/or 
sodium hydroxide 
Triton X-100 (Sigma), made up in dH2O 





2.3 Solutions and buffers 
The recipes of the solutions and buffers used in this thesis are listed below. 
1% Triton lysis buffer 
0.5 ml Triton X-100 
Up to 50 ml with PBS 
1 tablet Complete Protease Inhibitor Cocktail (Roche) 
Stored at -20 C 
2x (0.3M) Borate buffer 
9.2745 g Boric acid 
Up to 500 ml with dH2O 
Adjust pH to 8.5 with 1M Sodium Hydroxide. 
4% PFA 
Used to fix cultured mammalian cells. 
2 g PFA  
Up to 50 ml with PBS 
Heat to 50 C 
Add 1M Sodium Hydroxide dropwise and mix until PFA is completely 
dissolved. 
Dissection buffer 
Used to dissect foetal mouse brains for primary neuron production. All the 
reagents are from Invitrogen. 
500 ml HBSS with CaCl2 and MgCl2 
5 ml 200 mM L-Glutamate 
3.5 ml 1M HEPES (cell culture standard, pH 7.3-7.5) 
DNA loading buffer (6x) 
Used to load DNA on agarose gels 
4.5 ml glycerol  
1.875 ml 2% Xylene Cyanol FF  





An equal mix of PCR-grade ATP, CTP, GTP and TTP diluted appropriately 
in dH2O. Stored at -20°C. 
Freezing medium 
Used to freeze mammalian cells for long-term storage in liquid N2. 
5 ml DMSO 
45 ml FBS (Invitrogen) 
Stored in 15 ml aliquots at -20 C. 
L Agar/ampicillin 
50 g Tryptone 
25 g Yeast Extract 
50 g Sodium chloride 
Up to 5 litres with dH2O 
Adjust pH to 7.2. Pour into a bottle and add 1.5 g Agar per 100 ml medium. 
Stored at 4°C. Before use, melt in a microwave and then stand at room 
temperature until cool enough to touch with gloved hands and add ampicillin 
to a final concentration of 100 ng/ml. Used immediately. 
L Broth/ampicillin 
50 g Tryptone 
25 g Yeast Extract 
25 g Sodium chloride 
Up to 5 litres with dH2O 
Adjust pH to 7.2. Solution stored at 4°C. Before use add ampicillin to a final 
concentration of 50 ng/ml. 
Membrane blocking buffer 
Used for pre-stain blocking of PDVF membranes. 
2.5 g Instant milk powder 




100 μl TWEEN-20 
Up to 50 ml dH2O 
Solution was made up immediately before use. 
Membrane probing buffer 
Used to incubate PDVF membrane with antibodies. 
0.5 g Instant milk powder 
5 ml 10x PBS 
100 l Tween-20 
Up to 50 ml dH2O 
Membrane washing buffer 
            Used to wash PDVF membranes after incubation with antibodies. 
100 ml 10x PBS 
20 ml TWEEN-20 
Up to 1 litre with dH2O 
Stored at room temperature. 
Mowiol mounting solution 
7.5 g Mowiol 
10 ml Glycerol 
25 ml dH2O 
Solution was then incubated overnight at room temperature 
50 ml 0.2 M Tris-HCl (pH 8.5) 
Solution was then heated at 100°C for 20 minutes and allowed to cool 
1.75 g DABCO 
Solution was stored at -20°C, with working aliquots stored at 4°C. 
Poly-D-lysine solution 




25 ml 2x Borate buffer 
2.5 ml 500 g/ml Poly-D-Lysine 
Up to 50 ml with dH2O. 
Ponceau S stain 
1 g Ponceau S 
4 ml Acetic acid 
Up to 200 ml dH2O 
Solution was stored at room temperature and was recovered after each stain 
for reuse. 
 
Protein sample buffer 
1 ml 1M Tris pH 6.8 
2 ml Glycerol 
2 ml 20% SDS 
2 ml 1M DTT 
2 ml dH2O 
1ml 0.1% Bromophenol blue 
Solution was stored at -20 C. 
RIPA buffer 
2.5 ml 1M Tris-HCl pH 7.5 
1.5 ml 5M Sodium chloride 
0.5 ml NP-40 
2.5 ml 10% Sodium deoxycholate 
250 μl 20% SDS 
Up to 50ml dH2O 
1 tablet Protease inhibitor cocktail 





24.2 g Tris 
5.71 ml Acetic acid 
10 ml 0.5 M EDTA 
Make up to 5 litres with dH2O 
Buffer was stored at room temperature. 
TE buffer 
10 ml 1M Tris-HCl pH 7.5 
2 ml 500mM EDTA 
Make up to 1 litre with dH2O 
The pH of the buffer was adjusted using hydrochloric acid and/or sodium 
hydroxide. 
Buffer was stored at room temperature. 
Transfer buffer  
Used to transfer protein from acrylamide gels to PDVF membranes with the 
BioRad system. 
2.9 g Glycine 
5.8 g Tris base 
0.37 g SDS 
200 ml methanol 
Up to 1 litre with dH2O 
Trypsinisation buffer 
Used to dissociate brain tissue for primary neuron preparation. 
20 ml TrypLE Express (Invitrogen) 




2.4 Cell culture 
2.4.1 Maintenance of cell lines 
The cell lines used in this thesis, along with their source, are listed in table 2.1. Cells 
were grown in T25, T75, or T175 CellStar flasks (Greiner Bio-one) and maintained 
in a Galaxy 170 incubator (Scientific Laboratory Supplies) at 37 C in a humidified 
atmosphere containing 5% CO2. Unless otherwise specified, all the buffers and 
media used for cell culture were from Gibco, Invitrogen. Live cells were manipulated 
aseptically in an Envair Bio2+ Class II Safety Cabinet under containment level 1. 
Cells were grown in DMEM (catalogue number 41965) supplemented with 10% FBS 
(DMEM/FBS) until they had reached the desired confluence. To harvest the cells, the 
culture medium was replaced with the minimum volume of Tryple Express that 
completely and evenly covered the cells. After incubation at 37 C for 2-5 minutes, 
the flask was gently tapped or rocked to aid detachment of the cells from the plastic 
surface, then 5 volumes of DMEM/FBS were added and the cell suspension was 
repeatedly pipetted to insure dissociation of cell clusters. The cell suspension was 
then transferred to a 50 ml Falcon tube and centrifuged at 1000 RPM in a 5804R 
centrifuge (Eppendorf) for 5 minutes. After centrifugation, the supernatant was 
discarded and the cell pellet resuspended in an adequate volume of DMEM/FBS, 
which was adjusted depending on the size of the pellet. If necessary for subsequent 
applications, the cell concentration of the resulting cell suspension was determined as 
described in 2.4.2. If the cells were to be maintained for future use, they were 
passaged by diluting the cell suspension 1:2 or more in a new flask containing fresh 
DMEM/FBS, then transferred back to the incubator.  
 
Cell line Source 
COS7 ECACC 
HEK293 Mark Bradley, Bradley research group, University of Edinburgh 
HeLa ECACC 




NSC-34 Cathy Abbott, Abbott research group, University of Edinburgh 
SH-SY5Y Organon and ECACC 
 
Table 2.1 List of cell lines used in this thesis. ECACC is the European Collection of 
Cell Culture.  
2.4.1.1 Preparation of the cell culture medium used in the amino acid 
deprivation experiments 
The cell culture media used in the amino acid deprivation experiments described in 
section 4.5.1 of this thesis ware prepared as follows. 7.4 g of HAM’s F12 medium 
powder (Sigma D9785) were dissolved in deionised H2O to a final volume of 50 ml 
to generate a 10X stock medium solution, which was sterilised by filtration through a 
0.22 µm filter and stored at 4 C until further use. In a sterile 50 ml tube, 4 ml of 10X 
HAM’s F12 medium were supplemented with 50 µl each of the following salt 
solutions, which had been previously sterilised by filtration through a 0.22 µm filter: 
MgSO4 (Sigma M2643) (48.84 g/l, final concentration 0.04884 g/l); MgCl2 x 6H2O 
(Sigma M2393) (61.2 g/l, final concentration 0.0612 g/l); CaCl2 x 2H2O (Sigma 
C2536) (154.5 g/l, final concentration 0.1545 g/l), plus 640 µl of a 7.5% solution of 
Sodium Bicarbonate (Gibco 25080)(final concentration 0.12%). The medium was 
then supplemented with the following amino acid solutions: 400 µL of GlutaMAX-1 
(200 mM; final concentration 2 mM); 40 µL of L-lysine monochloryde (Sigma 
L8662) (450 mM; final concentration 450 µM); 40 µl of L-methionine (Sigma 
M5308) (115.549 mM; final concentration 115,549 µM); 400 µl of L-leucine (Sigma 
L8912) (45 mM; final concentration 450 µM). To induce amino-acid starvation, the 
medium was prepared as above, but without adding leucine and lysine. After adding 
the amino acids, the medium was supplemented with 160 µl of a 250X solution of 
Phenol red, then 30 ml of deionised H2O was added, and the pH adjusted to 7.4 using 
a 0.5M solution of NaOH. Finally, the volume was adjusted to 40 ml by adding 
deionised H2O, and the medium was supplemented with 4 ml of dialised foetal 




2.4.2 Cell counting 
If the cells were to be plated for subsequent applications, they were harvested as 
described in 2.4.1, then the concentration of the cell suspension was measured using 
an Improved Neubauer haemocytometer. First, the haemocytometer and coverslip 
were washed in tap water, rinsed with 70% ethanol and wiped dry with a paper 
tissue, then the coverslip was humidified and applied to the haemocytometer. The 
cell suspension was mixed gently using a thin bore plastic Pastette, and a small 
amount of cell suspension was loaded on one of the two chambers of the 
haemocytometer.  The same process was repeated to fill the second chamber of the 
haemocytometer. The cells were counted in a 0.1 mm
3
 area in each chamber, then the 
average cell count was calculated from readings made in the two chambers and 
multiplied by 10
4
 to obtain the cell concentration in the original cell suspension, 
expressed in cells/ml. 
2.4.3 Cell plating 
If the cells were to be transfected and/or subjected to drug treatments, they were 
seeded in sterile cell dishes (Iwaki) or multi-well plates (Corning) of different sizes, 
depending on the particular downstream application. The cells were first harvested 
and counted as described in 2.4.1 and 2.4.2, respectively. For plating in 6, 12, 24 or 
96 well plates, cells were first diluted to the desired final concentration and then 
equal volumes of cell suspension were dispensed in each well. For plating in 6 or 10 
cm dishes, a fixed volume of cell suspension corresponding to the desired cell 
number was dispensed in each dish, and, if necessary, the total volume of medium 
was adjusted by adding DMEM/FBS. If the cells were to be analysed by 
immunocytochemistry (see 2.5.7) they were plated on dry heat sterilised glass 
coverslips in 12 well plates. In the case of primary neurons, the coverslips were 
treated with ethanol before sterilisation (see 2.4.5). Cells were plated 16 hours 
before transfection/treatment, and the cell density was adjusted so that would reach at 




2.4.4 Freezing and recovery of cell lines 
To generate stocks for long-term storage in liquid N2, the cells were grown in T75 
flasks until they had reached 70-80% confluence, then they were harvested as 
described in 2.4.1. The cell pellet obtained from each T75 flask was resuspended in 3 
ml of freezing medium (see section 2.3), then 1 ml aliquots were dispensed in 
individual cryovials (Nunc) that had been previously labelled with cell line name and 
passage number and the date. The cryovials were then placed in a “Mr. Frosty” 
(Nalgene) pre-filled with isopropanol at room temperature and transferred to -70 C 
for at least 16 hours. This procedure guarantees a steady cooling rate of -1 C/minute, 
allowing successful cryopreservation and efficient recovery. Once frozen, the cells 
were rapidly transferred from the “Mr. Frosty” to storage boxes in a liquid N2 tank. 
To recover cryopreserved cells, the desired cryovials were rapidly transferred from 
liquid N2 to dry ice and transported to the laboratory. The vials were sprayed with 
70% ethanol and transferred to a safety cabinet, where the lid was slightly unscrewed 
to release any residues of N2 that could have remained trapped inside the tube, so to 
prevent explosion of the vial during the subsequent heating stage. Next, the vial was 
held upright in a 37 C water bath until only one small ice crystal was left in the cell 
suspension, using particular care to insure that the water level was constantly below 
the lid, so to avoid contamination by microorganisms. Once thawed, the cells were 
transferred to a T25 flask pre-filled with DMEM/FBS and grown to confluence, then 
harvested as described in 2.4.1. After harvesting, the cell pellett was resuspended in 
fresh DMEM/FBS, the entire cell suspension was transferred to a T75 flask and the 
cells were allowed to grow to confluence, then passaged as described in 2.4.1.  
2.4.5 Establishment and maintenance of cultures of primary neurons 
Primary neurons were seeded on glass coverslips to allow for subsequent analysis by 
immunocytochemistry. The coverslips were incubated overnight (O/N) in methanol 
at 4 C with end-over-end agitation, washed twice with fresh methanol to remove any 
debris and dry heat sterilised.  To allow neurons to adhere, the coverslips were 
coated with Poly-D-Lysine as described below. One day before use, individual sterile 




l of Poly-D-Lysine solution, and incubated O/N at 37 C. Immediately before use, 
the coverslips were washed 4 times with sterile distilled water (Gibco, Invitrogen).  
All the buffers, media and supplements used for the establishment and culture of 
primary neurons were from Gibco, Invitrogen. Eighteen days post fertilisation (DPF), 
pregnant CD1 mice were sacrificed by a schedule 1 procedure performed by 
experienced animal facility technicians, then handed to me for dissection. Embryonic 
day 18 (E18) foetuses were extracted from the mother’s uterus and immediately 
placed in tissue culture grade ice-cold PBS. Using sterile surgical tools, the brains 
were removed from the embryos, transferred to ice-cold dissection buffer and 
dissected under a Leica MZ6 microscope with a Fiber-Lite MI-150 high intensity 
illuminator. After removal of the meninges, the cortices and hippocampi were 
isolated and stored separately in ice-cold dissection buffer until all the brains had 
been dissected, then they were finely triturated with a sterile scalpel and processed as 
described below. 
2.4.5.1 Hippocampal neurons 
The triturated hippocampal tissue obtained from an individual litter (10-13 foetuses) 
was placed in a 15 ml Falcon tube with 10 ml of tripsinisation buffer and incubated 
at 37 C for 45 minutes, manually inverting the tube every 15 minutes. After 
tripsinisation, the tissue was centrifuged for 5 minutes at 1500 revolutions per minute 
(RPM) in a MSE Mistral 1000 centrifuge and the supernatant carefully removed with 
a thin bore pastette. The pellet was then resuspended in 10 ml DMEM/FBS by 
repeatedly pipetting with a wide bore pastette, and centrifuged as before. The pellet 
was thoroughly resuspended in 5 ml DMEM/FBS using a P1000 Gilson pipette set at 
1 ml, then 5 ml DMEM/FBS were added, and the sample was centrifuged as above. 
The pellet was resuspended in 2 ml DMEM/FBS as before, then 8 ml DMEM/FBS 
were added.  
2.4.5.2 Cortical neurons 
The triturated cortical tissue obtained from an individual litter was placed in a 50 ml 




then passed through a wide bore Pastette 10-15 times. The resulting suspension was 
centrifuged as described in 2.4.5.1, resuspended in 20 ml DMEM/FBS and passed 
through a wide bore pastette 10-15 times. After a second centrifugation, the pellet 
was resuspended in 10 ml DMEM/FBS by 20 passages through a wide bore Pastette 
followed by 10 passages through a thin bore Pastette, then centrifuged again and 
resuspended in 20 ml DMEM/FBS.  
The resulting cell suspention of hippocampal or cortical neurons was passed through 
a 40 m cell strainer, collected in a 50 ml Falcon tube and counted as described in 
2.4.2, then centrifuged as before. The cell pellet was resuspended in Neurobasal 
medium supplemented with 200 mM GlutaMAX-1, 100 g/ml of penicillin and 
streptomycin and 20% (vol/vol) of B-27 supplement, and plated in 12 well plates at a 
final concentration of 2x10
5
 cells/well and in a total volume of 2 ml. Primary neurons 
were maintained at 37 C in a humidified atmosphere containing 5% CO2 in a Galaxy 
170 incubator.  
After 7 days in vitro, and every 7 days thereafter, 1 ml of the culture medium was 
replaced with fresh medium. Neurons were maintained in vitro for up to 24 days.  
2.4.6 Transfection of cell lines and primary neurons 
Different transfection methods were used to express one or more exogenous proteins, 
luciferase reporter constructs or small interfering RNAs (siRNAs) in cell lines and 
primary neurons. The pre-existing protein expression constructs and luciferase 





Plasmid name Encoded protein Tag Source 
CREB1α Human CREB1α none Richard Killick
1 
p5HuSH-GFP GFP Turbo none Origene 
pCDNA3.1(+) Empty vector none Invitrogen 
pcDNA3.1-Myc DISC1-WT Human DISC1 N-terminal Myc Fumiaki Ogawa
2 
pcDNA3.1-Myc DISC1-37A Human DISC1 N-terminal Myc Fumiaki Ogawa
2 
pcDNA3.1-Myc DISC1-37W Human DISC1 N-terminal Myc Fumiaki Ogawa
2 
pcDNA3-PDE4D3 PDE4D3 none Miles Houslay
3
 (Bolger et al, 1997) 
pcDNA4/TO Empty vector none Invitrogen 
pcDNA4/TO-Flag DISC1 Human DISC1 N-terminal Flag Shaun Mackie
2
 
pcDNA6/myc-HIS B Empty vector C-terminal Myc Invitrogen 
pCG-ATF4 Human ATF4 none Adrian Harris
4
 (Liang & Hai, 1997) 
pDEST53-ATF4 Human ATF4 N-terminal GFP Kirsty Millar and Sheila Christie
2
 (Bradshaw et al, 2009) 
pEE7-PDE4B1 PDE4B1 none Miles Houslay
3
 (Huston et al, 1997) 
pGL4.23[luc2/minP] Firefly Luciferae none Promega 
pGL4.29[luc2P/CRE/Hygro] Firefly Luciferase none Promega, donated by Richard Killick
1 
PKIα-mCherry PKIα mCherry Jin Zhang
5




pRK5-HA Disc1 100P Mouse Disc1-100P mutant N-terminal HA Akira Sawa
5 
pRK5-HA Disc1 31L Mouse Disc1-31L mutant N-terminal HA Shaun Mackie
2 
pRK5-HA Disc1 WT Mouse Disc1-wild type N-terminal HA Shaun Mackie
2
 
pRK7 Empty vector none Pamela Maher
6
 (Lewerenz & Maher, 2009) 
pRK7-ATF4 Mouse ATF4 none Pamela Maher
6
 (Lewerenz & Maher, 2009) 
SomCRE-Luc Firefly Luciferase none Stratagene, donated by Richard Killick
1 
TK-Renilla Renilla Luciferase none Richard Killick
1 
SV40-Renilla Renilla Luciferase none Richard Killick
1 
 
Table 2.2 Pre-existing protein expression constructs and luciferase reporters used in this study. 1King’s College, London, UK. 2University 
of Edinburgh, UK. 3University of Glasgow, UK. 4University of Oxford, UK. 5Johns Hopkins University, MA. 6Salk Institute for Biological 




2.4.6.1 Lipofectamine 2000 
Transfection with the liposome-based reagent Lipofectamine 2000 (Invitrogen) was 
used to express exogenous proteins and/or luciferase reporter vectors in primary 
neurons, HEK293, COS7 and MO3.13 cells, and to deliver siRNAs to HEK293 and 
MO3.13 cells. For transfection of cell lines, on the evening of the day before 
transfection, cells were plated in dishes or multi-well plates of different sizes as 
described in 2.4.3, and the cell density was adjusted so that cells would be 70-80% 
confluent the following morning.  For luciferase assays, HEK293 and MO3.13 cells 





/well, respectively, in a total volume of 100 l DMEM/FBS. Cells were 
transfected the following morning using Lipofectamine:DNA complexes formed in 
warm OptiMEM (Gibco, Invitrogen), according to the manufacturer’s instructions. 
The cell plating volume, amount of Lipofectamine 2000 and DNA, and volume of 
transfection mix were adjusted to the dish/plate format as suggested by the 
manufacturer. Primary neurons were transfected after 21 DIV, and the 
Lipofectamine:DNA complexes were assembled in 200 l of warm Neurobasal 
medium supplemented with GlutaMAX-1, using 4 l of Lipofectamine 2000 and 3-4 
g of DNA. Not sooner than 1 hour before transfection, the old medium was 
removed from the wells and replaced with 1 ml of fresh Neurobasal supplemented 
with GlutaMAX-1. Neurons were transfected for 3-4 hours, then the transfection 
medium was removed and replaced with the old preconditioned medium.  
2.4.6.2 Fugene HD 
Fugene HD Tranfection Reagent (Roche) was used to express exogenous proteins in 
SH-SY5Y cells, and to transfect HEK293, NSC-34 and MO3.13 for luciferase 
reporter assays. Cells were plated on the evening before transfection so that they 
could reach 90-100% confluence by the following morning, when they were 
transfected. Fugene HD:DNA complexes were formed in warm OptiMEM following 
the manufactures’s directions. SH-SY5Y cells were transfected in 6 or 10 cm dishes, 















DNA ( g) 
6 1.5x10
5 
5 30 300 7.5 
10 3.5x10
6 
11.6 58 580 11.6 
 
Table 2.3 Summary of SH-SY5Y transfection conditions with Fugene HD 
 
For luciferase reporter assays, HEK293 and MO3.13 cells were plated in black-







respectively, in a total volume of 100 l of medium. Fugene HD:DNA complexes 
were assembled as follows: 4 l of Fugene HD were mixed with 300 ng of Firefly 
luciferase reporter vector, 30 ng of Thymidine Kinase (TK) Renilla Luciferase 
reporter vector, and up to 670 ng of the relevant expression plasmids. If necessary, 
the total amount of DNA was brought to 1 g by adding an appropriate empty vector.  
The total volume of transfection mix was adjusted to 40 l by varying the volume of 
OptiMEM. Cells were transfected with 12 l/well of transfection mix for 48 hours. 
The day after transfection, 200 l/well of fresh DMEM/FBS were added to the cells.  
2.4.6.3 Nucleofection 
Nucleofection was used to transfect SH-SY5Y cells for luciferase reporter assays, 
and was performed with the Amaxa Nucleofector device (Lonza) according to the 
manufacturer’s instructions, which are summarised below. Cells were grown to 
80% confluence in a T75 flask. The medium was removed from the flask, and the 
cells were washed twice with 3 ml of Tryple Express, leaving 200 l of solution in 
the flask after the second wash, and then incubated at 37 C without tapping or 
rocking until the cells had completely detached. After adding 4 ml DMEM/FBS, the 
cell suspension was pipetted several times to break most cell clusters then transferred 




volume of cell suspension corresponding to 2x10
6
 cells was transferred to a 1.5 ml 
tube and centrifuged at 2000 rpm for 10 minutes at RT in a table top microcentrifuge 
(Heraeus). During the centrifugation step, 100 l of RT Nucleofector solution V 
(Amaxa) were mixed in a 1.5 ml tube with 3 g of DNA containing the luciferase 
reporters (900 ng of Firefly luciferase reporter and 90 ng of TK-Renilla luciferase 
reporter) and the appropriate expression constructs or empty vector. The dried cell 
pellet was thoroughly resuspended in the Nucleofector solution V:DNA mix before 
being transferred to a Nucleofector cuvette. The cuvette was placed in the 
Nucleofector device and a built-in program optimised for SH-SY5Y transfection (A-
023) was applied. After nucleofection, the cell mix was rapidly transferred from the 
cuvette to a 1.5 ml tube pre-filled with 900 l of warm DMEM/FBS, then 250 l of 
this suspension ( 5x10
5 
cells) were plated in each well of a black walled 96 well 
plate.  
2.4.6.4 Assessment of transfection efficiency  
When new tranfection protocols were tested, their efficacy was assessed by replacing 
the luciferase reporters or protein expression constructs with the GFP Turbo 
expressing vector P5HuSH. At regular time intervals after transfection (typically 24, 
48, 72 hours), live cells were examined under an inverted microscope equipped with 
a Mercury lamp and the appropriate light filter for GPF excitation ( 480 nm). Both 
cell viability and transfection rate (proportion of GFP-expressing cells) were 
estimated by visual examination of cells transfected in parallel using different 
transfection protocols.  
2.4.7 Drug treatments 
2.4.7.1 Mitotracker Red 
Mitotracker Red (Molecular Probes, Invitrogen), is a cell-permeant red-fluorescent 
probe that accumulates in active mitochondria, where it is retained after cell fixation, 
allowing the visualisation of mitochondria by fluorescent or confocal microscopy. 
Mitotracker Red was used to label mitochondria in cells that had been transfected 




transfection, the cells were exposed to fresh DMEM/FBS containing 50 nM 
Mitotracker Red for 30 minutes at 37 C and 5% CO2 in a humidified incubator. 
Next, the cells were washed twice with warm PBS before being processed for 
immunocytochemistry as described in 2.5.7. 
2.4.7.2 Other drug treatments 
Forskolin treatment was used to increase the intracellular cAMP concentration by 
stimulating adenylyl cyclase, and Rolipram was used to specifically inhibit the 
activity of endogenous PDE4s. To induce the expression of endogenous ATF4 
trough the activation of stress-responsive pathways, the cells were exposed to the 
endoplasmic reticulum (ER) stress-inducer Thapsigargin or to the oxidative stress 
inducers H2O2 or DL-Homocysteine. All the above drugs were sourced from Sigma 
except for DL-Homocysteine, which was purchased from Santa Cruz Biotechnology. 
Unless otherwise specified, the drugs or an equal volume of the respective vehicles 
were diluted in warm DMEM/FBS and administered to the cells as detailed in table 
2.4. When DMSO (Sigma) was used as vehicle, its final concentration in the medium 
was 0.1% or lower, and it did not affect cell viability or morphology. 
 
Drug Final concentration ( M) vehicle Treatment time 
(hours) 
Forskolin 10 or 1 DMSO 4 
Rolipram 10 DMSO 4 
Thapsigargin 1 DMSO 16 or 24 
H2O2 200 H2O 16 or 24 
DL-Homocysteine 500 H2O 24 
 





2.5 Protein biochemistry 
2.5.1 Preparation of cell lysates 
Cell lysates were produced for subsequent protein analysis by western blotting (WB) 
or immunoprecipitation (IP). Unless otherwise specified, cell lysates were prepared 
in RIPA buffer for western blotting and in PBS 1% Triton X-100 for IP. After 
removal of the culture medium the cells were rinsed once in ice-cold PBS, then lysed 
in the appropriate volume of ice-cold lysis buffer, which was adjusted to the size of 
the tissue culture plate or well.  For 10 cm dishes, the volume of lysis buffer was 
600-700 l, with slight adjustments made depending on the cell density. For 6, 24 
and 96 well plates, the volume of lysis buffer was 200, 100 and 30 l/well, 
respectively. Immediately after addition of the lysis buffer, the cell dish or plate was 
placed on ice, and the cell lysates were harvested with the aid of a cell scraper or, in 
the case of 24 and 96 well plates, by pipetting repeatedly. For cells grown in 96 well 
plates, the lysates obtained from 6 wells that had received identical treatment were 
pooled to give a final volume of 180 l. The crude lysates were transferred to 
appropriately labelled pre-chilled 1.5 ml tubes and incubated for one hour at 4 C on 
a rotary wheel before being centrifuged for 30 minutes at 13,000 RPM in a table-top 
microcentrifuge (Heraeus) to sediment the cell debris. The resulting cleared 
supernatant was transferred to a clean pre-labelled 1.5 ml tube. If they were not 
processed immediately, cell lysates were stored at -70 C until use.  
2.5.2 Measurement of protein concentration 
The protein concentration in cell lysate to be analysed by western blotting and in 
subcellular protein extracts was measured using the DC Protein Assay (Biorad). The 
DC Protein Assay is a colorimetric assay based on a two-step chemical reaction. 
First, proteins react with Copper tartrate in an alkaline solution, then Folin is reduced 
by the Copper-treated proteins, resulting in the production of coloured products that 
turn the solution blue. The assay was performed in 96 well flat-bottomed clear 
microtiter plates following the manufacturer’s instructions. Briefly, Bovine Serum 
Albumin (BSA) protein standards with concentrations ranging between 0 and 2 




Alternatively, commercially available pre-diluted BSA protein standards were used 
(Biorad). Cell lysates were diluted 4 times in H2O, then 5 l/well of each BSA 
standard and protein sample were loaded in the microtiter plate, in triplicate. Reagent 
A' was prepared by mixing reagents A and S, and 25 l were added to each well, 
followed by 200 l of reagent B. After incubation at room temperature for 10 
minutes, the absorbance was read at 750 nm using a Synergy HT Multi-detection 
Microplate Reader and bespoke Gen 5 software (Bio Tek). The Prism GraphPad 
software was used to calculate the equation of the regression line from the plotted 
mean absorbance values of the BSA standards, and the concentration of the protein 
samples was then calculated by interpolation from this regression line.    
2.5.3 Subcellular protein fractionation 
Subcellular protein fractionation was used to analyse the distribution of exogenous 
and endogenous DISC1 and ATF4 in different cell compartments in HEK293 and 
SH-SY5Y cells. HEK293 and SH-SY5Y cells were tranfected for 24 and 72 hours, 
respectively, then harvested in Tryple Express and diluted in fresh DMEM/FBS in a 
15 ml Falcon tube. The cell suspension was pelleted by centrifugation at 500 g for 5 
minutes in an Eppendorf 5804 R centrifuge, then resuspended in 0.5-1 ml of ice-cold 
PBS and transferred to a pre-chilled 1.5 ml tube. If subcellular fractions were to be 
prepared from transfected cells, a small proportion of this cell suspension ( 50 l) 
was transferred to a new 1.5 ml tube, then both tubes were centrifuged at 500 g for 3 
minutes at 4 C in a table-top microcentrifuge (Heraeus), and the supernatant was 
carefully removed. The larger cell pellet was used to produce subcellular fractions, 
while the smaller cell pellet was lysed in 50 l of RIPA buffer to produce a whole 
cell lysate. Subcellular fractions were generated using two different commercial kits 
from Pierce. The Subcellular Protein Fractionation kit was used to extract 
cytoplasmic, membrane-bound, soluble nuclear, cytoskeletal and chromatin-bound 
proteins from SH-SH5Y cells. The NE-PER Nuclear and Cytoplasmic Extraction 
Reagents were used to isolate nuclear and cytoplasmic proteins from SH-SY5Y and 
HEK293 cells. The protein concentration of each subcellular extract was measured as 




2.5.4 Antibodies  
Details of the antibodies used in this thesis for protein immunoprecipitation or 
immunodetection, along with the conditions at which they were used, can be found in 






















1:250 0.5 g 
(Ogawa et al, 2005) 
Raised against the 669-832 fragment of Lv DISC1. 
Used for WB at 1:10,000 and 1:1,000 to detect the 
exogenous and endogenous protein, respectively 
-actin -actin Mouse Sigma 1:50,000 _ _  
-tubulin M -tubulin Mouse Sigma (T6557) _ 1:3,000 _  
-tubulin R -tubulin Rabbit AbCam (ab11317) _ 1:2000 _  
ATF4 MMC ATF4 Mouse Sigma 
(WH0000468M1) 
1:1,000 3 hours 
1:2,500 
1:100 
1 g Used for ICC at 1:2,500 or 1:100 to detect the 
exogenous and endogenous protein, respectively  
ATF4 RPC ATF4 Rabbit Santa Cruz (sc-
200) 
1:1000 3 hours 
1:100 
1:4000 
1 g Unless otherwise stated, this ATF4 antibody was 
used  
Calreticulin Calreticulin Mouse AbCam (ab22683) 1:100,000 1 hour _ _  
c-myc c-myc tag Mouse Santa Cruz (sc-40) 1:1000 1 hour 1:500   
Flag MMC Flag tag Mouse Sigma (F3165) 1:10,000 O/N 1:10,000 1 g 
Unless otherwise stated, this Flag antibody was used 
for WB 
Flag RPC Flag tag Rabbit Sigma (F7425) 1:10,000 O/N 1:2000  
Unless otherwise stated, this Flag antibody was used 
for ICC 
GAPDH GAPDH Mouse Chemicon 
(MAB347) 
1:100,000 1 hour _ _  




HA Y-11 HA tag Rabbit Santa Cruz (sc-
805) 
_ 1:2000 _  
HA.11 HA tag Mouse Covance MMS-
101P 
_ 1:3,000 _  
HSP90 HSP90 Mouse AbCam (ab13492) 1:100,000 1 hour _ _  
N-16 DISC1 Goat Santa Cruz (sc-
47990) 
_ 1:100  Requires PFA fixation 
p84 p84 Mouse AbCam (ab487) 1:100,000 1 hour _ _  
PSD95 PSD95 Mouse ABR (MAI-046)  1:1000 _  
Synaptophysin Synaptophysin Mouse Sigma (S5758) 1:5,000 O/N 1:50,000 _  
V5 V5 tag Mouse Invitrogen 
(R96025) 
1:1,000 1 hour 1:5,000  
 
Vimentin Vimentin Mouse AbCam (ab8978) 1:100,000 1 hour _ _  
Goat anti 
rabbit 
Rabbit IgG Goat Dako (P0448) 
1:2,000 30 
minutes 
_ _ HRP-conjugated secondary antibody 
Goat anti 
mouse 
Mouse IgG Goat Dako (P0447) 
1:1,000 30 
minutes 
_ _ HRP-conjugated secondary antibody 
Goat anti 
rabbit 
Rabbit IgG Goat Invitrogen 
(A11008) 
_ 1:1,000 _ Fluorescent secondary antibody (488 nm) 
Goat anti 
rabbit 
Rabbit IgG Goat Invitrogen 
(A11012) 
_ 1:1,000 _ Fluorescent secondary antibody (594 nm) 
Goat anti 
mouse 
Mouse IgG Goat Invitrogen 
(A11029) 
_ 1:1,000 _ Fluorescent secondary antibody (488 nm) 
Goat anti 
mouse 
Mouse IgG Goat Invitrogen 
(A11005) 




Table 2.5 Details of the antibodies used in this study, and the conditions at which 
they were used for western blotting (WB), immunocytochemistry (ICC) and 
immunoprecipitation (IP) in 600 l of cell lysate. All the antibodies detect human 
antigens. Species refers to the species in which the antibody was raised. O/N 
indicates overnight incubation at 4 C on a horizontal shaker. The probing conditions 
reported in the table refer to typical experiments, and may have been adjusted 
depending on the particular nature of the experiment. 1Laboratory of Molecular and 
Genetic Information, University of Tokyo, Japan. 
 
2.5.5 Immunoprecipitation  
Immunoprecipitation allows to concentrate a target protein from a cell lysate or a 
similar protein mixture by exploiting a specific antibody. In this study, 
immunoprecipitation was used to compare the ability of the target protein to complex 
with different interactors that were present in the original cell lysates. This was done 
by semiquantitative detection of the different interactors that had co-
immunoprecipitated with the target protein. Cells were grown in 10 cm tissue culture 
dishes (Iwaki) and either transfected for 24 hours as described in 2.4.6.1 or left 
untransfected. Cell lysates were prepared as detailed in 2.5.1 and processed 
immediately, without freezing. Unless otherwise stated, cell lysates were prepared in 
PBS 1% Triton X-100. The precipitating antibody was added to 600-700 l of lysate 
in a 1.5 ml tube at the concentration detailed in table 2.5, and incubated for 1 hour at 
4 C on a rotary wheel. This step allows the antibody to complex with its target 
protein, if this is present in the lysate. The protein concentration was measured in the 
remaining lysate (100-200 l) as detailed in 2.5.2, and this was subsequently stored 
at -70 C until further use. At the end of the first hour of incubation with the 
precipitating antibody, 50 l of protein G-coated Sepharose beads diluted in PBS 
(Sigma) were added to the lysate, and incubated as above for 2 hours. This allows the 
establishment of a stable interaction between protein G and the immunoglobulins 
present in the lysate. At the end of this stage, thus, the antigen-antibody complexes 




transferred to the column of a spin cup equipped with a paper filter (Pierce) and 
rapidly centrifuged in a table-top microcentrifuge set at 4 C until the speed of 
10,000 RPM had been reached. This allows the G Separose-bound antigen-antibody 
complexes to sediment on the paper filter, while the unbound proteins are collected 
in the collection tube below, along with the rest of the lysate, which was discarded. 
The beads were washed by adding 500 l of the same buffer used to produce the 
lysate to the column, followed by incubation for 5 minutes at 4 C on a rotary wheel. 
The spin cups were then centrifuged as before, the flow-through was discarded and 
the process was reapeated 3 more times.  After the final wash, the collection tube was 
carefully dried, the column placed back in the collection tube and 50 l of protein 
sample buffer were added to the bead slurry in the column to elute the antigen-
antibody complexes from the beads. The spin cups were then heated to either 40 C 
for 10 minutes or 100 C for 5 minutes, depending on the downstream application, 
then quickly centrifuged as above to transfer the eluate to the collection tube. The 
column was discarded, and the protein eluate was either processed immediately for 
western blotting or stored at -70 C until use.   
2.5.6 SDS-PAGE and western blotting 
2.5.6.1 Sample preparation 
The protein concentration of cell lysates and subcellular protein fractions was 
measured as described in 2.5.2, and used to calculate the volume of protein sample 
corresponding to the desired total amount of protein to be analysed by western 
blotting (WB). This volume of protein sample was transferred to a clean 1.5 ml tube 
and mixed with an equal volume of protein sample buffer, then heated at 100 C to 
denature the proteins and disrupt protein complexes. Protein samples obtained by 
immunoprecipitation were prepared as detailed in 2.5.5, and 10 l/sample were 




2.5.6.2 BioRad system 
The BioRad system was used when it was necessary to achieve satisfactory 
resolution of proteins of similar molecular weight. High density resolving gels 
containing 12% acrylamide were prepared following the recipe detailed below. 
 
2.672 ml                  dH2O 
3.2 ml                      30% acrylamide/bisacrylamide solution 
2 ml                         1.5M Tris pH 8.8 
40 l                        20% SDS 
80 l                        10% APS 
8 l                          TEMED 
8 ml                         Total volume 
 
Once mixed, the gel solution was poured between two glass plates separated by a 1 
mm spacer, to produce a gel with a thickness of 1 mm, and an empty space of about 
2 cm was left at the top. This empty space was filled with isobutanol, and the gel 
was allowed to polymerise for 1 hour, after which the isobutanol was replaced with 
a 4% stacking gel prepared as described below. 
 
3.0 ml                      dH2O 
670 l                      30% acrylamide/bisacrylamide solution 
1.25 ml                    1.5M Tris pH 8.8 
50 l                        20% SDS 
50 l                        10% APS 
5 l                          TEMED 
5 ml                         Total volume 
 
A 1 mm-thick comb was placed inside the stacking gel to produce either 10 or 15 
wells, and the gel was allowed to polymerise for 1 hour. Once polymerisation was 




(BioRad), which was then filled with enough 1 x TGS buffer to completely cover the 
gel. After removing the comb, the wells were gently flushed with 1 x TGS buffer, 
and the protein samples that had been prepared as detailed in 2.5.6.1 were loaded in 
the wells using a thin bore gel loading tip (Fisher). A prestained protein size marker 
(BioRad All Blue Precision Plus Protein Standard) was loaded next to the protein 
samples. The gel tank was connected to a Power Pac 3000 (BioRad) and a 150V 
current was applied for 60-90 minutes to achieve separation of the proteins by 
molecular weight.  Once the desired degree of protein resolution had been achieved, 
as judged by the spacing between the protein marker bands, the current was switched 
off, and the proteins were transferred to a PDVF membrane as follows.  
A 6 cm by 8 cm rectangle was cut out from a sheet of Hybond-P PDVF membrane 
(Amersham) and briefly soaked in methanol, then rinsed in dH2O and equilibrated in 
transfer buffer for at least 5 minutes. Meanwhile, 2 rectangles of 6 cm by 8 cm were 
cut out from a sheet of blotting paper (Whatman) and briefly soaked in transfer 
buffer. The protein gel was carefully removed from the glass plates and laid flat on 
one of the 2 pre-wetted rectangles of blotting paper. The PDVF membrane was then 
placed on top of the gel, making sure that no air bubbles were trapped between the 
gel and the membrane, and covered with the second rectangle of blotting paper. Once 
stacked as described, the gel, membrane and blotting paper were placed in a 
TransBlot Gel Holder Cassette (BioRad), between 2 fibre pads soaked in transfer 
buffer. A TransBlot modular electrode (BioRad) was placed in a TransBlot Cell pre-
filled with transfer buffer, and the Gel Holder Cassette was then inserted in the 
TransBlot electrode. Finally, a current of 30V was applied for 90-120 minutes to 
induce the transfer of the proteins, including the pre-stained marker, from the gel to 
the PDVF membrane. Once the transfer was complete, the PDVF membrane was 
rinsed once in PBS, and stored in PBS at 4 C until staining.  
2.5.6.3 Invitrogen system 
The Invitrogen protein electrophoresis system (Novex NuPAGE SDS-PAGE Gel 
System) was used in combination with NuPAGE 7% Tris-Acetate or NuPAGE 4-
12% Bis-Tris precast gels (Invitrogen). One or two gels were removed from their 




SureLock Mini-Cell) (Invitrogen). The gel tank was filled with the appropriate 1x 
running buffer (NuPAGE Tris-Acetate SDS Running Buffer for Tris-Acetate gels, or 
NuPAGE MES SDS Running Buffer for Bis-Tris gels), then the gel(s) was loaded as 
described in 2.5.6.2 and electrophoresis was performed on a Power Pac 3000 
(BioRad) at 150V for 60-90 minutes at 4 C to separate the proteins by molecular 
weight. Meanwhile, one or two Invitrolon PDVF membranes (Invitrogen) were 
briefly soaked in methanol, then rinsed in dH2O and equilibrated for at least 5 
minutes in the transfer buffer (1x NuPAGE Transfer Buffer containing 20% 
methanol). Once electrophoresis was complete, the gel(s) were removed from the gel 
tank and laid flat on the 3 MM filter paper supplied with the Invitrolon PDVF 
membrane, which had been quickly soaked in transfer buffer. The Invitrolon PDVF 
membrane(s) was then placed on the gel(s), and covered with a second sheet of pre-
soaked 3 MM paper. Maintaining the same orientation, the gel, membrane and paper 
stack was placed inside an XCell II Blot Module, between two layers of sponges 
soaked in transfer buffer. If two gels were transferred simultaneously, a soaked 
sponge was placed between them. The blotting module was then filled with transfer 
buffer and a 30V current was applied for 2 hours to allow the protein to transfer from 
the gel(s) to the PDVF membrane(s). Once the transfer was complete, the 
membrane(s) was extracted from the blotting module, washed once in PBS and 
stored in PBS at 4 C until staining.  
2.5.6.4 Staining of protein blots 
Staining of total protein on PDVF membranes was used to confirm efficient protein 
transfer after western blotting and, in some instances, to verify equal protein loading 
between samples. Three different total protein staining methods were employed to 
visualise proteins on PDVF membranes after western blotting and before 
immunostaining, as detailed below. 
2.5.6.4.1 Ponceau-S 
Ponceau-S is a reversible red-coloured protein dye. Proteins on PDVF membranes 
were stained by incubation in Ponceau-S for 5 minutes at room temperature with 




as red bands on the PDVF membrane, and the dye was recycled for future use. The 
dye was subsequently removed from the membrane by washing repeatedly with 
dH2O.  
2.5.6.4.2 SimplyBlue 
SimplyBlue SafeStain is a Coomassie-based reversible protein dye with a higher 
sensitivity than Ponceau-S. Dry PDVF membranes were soaked in SimplyBlue for 2 
minutes with gentle shaking, then the dye was discarded and the membrane washed 3 
times for 1 minute in dH2O to remove the background staining. After the washes, 
proteins were visualised by eye as blue bands on the PDVF membrane. De-staining 
of PDVF membranes was achieved by repeated washes with dH2O. 
2.5.6.4.3 SYPRO Ruby 
SYPRO Ruby Protein Blot Stain (Invitrogen) is a sensitive orange/red-fluorescent 
protein dye that can be visualised using UV illumination. All the staining steps were 
performed at room temperature with gentle agitation. Dry PDVF membranes were 
floated face-down in a solution containing 7% acetic acid and 10% methanol for 15 
minutes, then rinsed 4 times for 5 minutes in dH2O before being floated face-down 
on SYPRO Ruby for 15 minutes. The membranes were then washed 3 times for 1 
minute in dH2O to remove the excess dye, after which they were ready to visualise. 
Protein bands stained with SYPRO Ruby were visualised and photographed under 
UV illumination using a Gene Genius Bioimaging System (Syngene).  
2.5.6.5 Immunostaining of protein blots 
To block non-specific binding of the antibodies, PDVF membranes were incubated 
in blocking buffer for 30 minutes. The primary antibody was diluted in 10 ml of 
probing buffer as detailed in Table 2.5, then incubated with the PDVF membrane for 
the appropriate time. After incubation with the primary antibody, the membrane was 
washed 3 times for 5 minutes with washing buffer, then incubated with the 
appropriate HRP-conjugated secondary antibody diluted in probing buffer (see Table 
2.5). The membrane was then washed as before and transferred to PBS. All the steps 




To visualise the protein bands, the membranes were incubated with SuperSignal 
West Dura Extended Duration Substrate (Pierce), a highly sensitive 
chemiluminescent substrate for HRP detection on western blots. The 
chemiluminescent signal was detected using a CCD camera (GeneGnome Imaging 
System, Syngene), and the exposure time was adjusted depending on the intensity of 
the signal in order to obtain the best signal/noise ratio.  
Alternatively, the membranes were incubated with ECL Plus solution (Amesham) for 
5 minutes, then the excess substrate was removed from the membrane by holding it 
upright and touching a piece of blotting paper with the bottom edge of the 
membrane. The drained membrane was tightly wrapped in a single layer of cling 
film, then exposed to photographic film (Scientific Laboratory Supplies) for a 
between 1 second and 16 hours. To visualise the protein bands, the film was 
developed using an Amersham Hyperprocessor.  
2.5.6.6 Band densitometry 
For relative quantification of protein band intensities on western blots, images 
acquired with the GeneGnome Imaging System, as detailed in 2.5.6.5, were analysed 
with the GeneTools software (Syngene). To quantify the signal intensity of bands on 
photographic film, a digital image of the film was acquired using an office scanner, 
then analysed with the software ImageJ, downloaded from    
http://rsbweb.nih.gov/ij/download. Band density measurements obtained from 
different samples were then analysed and compared statistically. 
2.5.6.7 Stripping PDVF membranes 
In some cases, PDVF membranes had to be probed for immunodetection of two 
distinct proteins of the same or very similar size, or probed for the same protein 
using two different antibodies. In these cases, the membranes were probed with the 
first set of antibodies and imaged as described in 2.5.6.5, then the antibodies were 
removed chemically from the membrane and the second set of antibodies was 
applied. Removal of the antibodies bound to proteins on a PDVF membrane (or 




between 1 hour and 16 hours in Restore Western Blot Stripping Buffer (Perbio 
Science) at room temperature with constant agitation. The incubation time varied 
depending on the intensity of the signal recorded after probing with the first set of 
antibodies, with stronger signals requiring longer incubation times. After stripping, 
the membrane was washed 3 or 4 times with PBS to completely remove the stripping 
buffer. To verify complete removal of both the primary and secondary antibodies, the 
membrane was blocked and re-probed with the same secondary antibody as 
described in 2.5.6.5. If no chemiluminescent signal was detected at this stage, the 
membrane was washed in PBS, then probed with the second set of antibodies (see 
2.5.6.5).  
2.5.7 Immunocytochemistry 
Immunocytochemistry allows the detection of one or multiple proteins in structurally 
intact cells, and can be used to analyse the subcellular expression pattern of the 
protein(s) and investigate protein-protein interactions. This technique requires 
adherent cells to be grown as a monolayer on the surface of glass coverslips. Cells 
(either transfected or untransfected) are then fixed and the protein(s) of interest are 
detected by sequentially incubating the cells with one or more protein-specific 
antibodies, followed by fluorescently labelled secondary antibodies. Stained cells can 
then be visualised using a light microscope equipped with the necessary excitation an 
emission filters.  
2.5.7.1 Cell fixation and permeabilisation 
By rapidly stopping the activity of any biomolecule, chemical fixation kills the cells 
while preserving their structure and preventing decay due to autolysis. Membrane 
permeabilisation can be achieved by treating the cells with solvents or detergents, 
and is necessary for immunodetection of antigens that are not exposed on the cell 
surface. Two different methods were used to fix and permeabilise cells in this study. 
For the first method, the cells were washed once with warm PBS, then PBS was 
replaced with 500 l/well of -20 C methanol and the cells were incubated at -20 C 




gently washed 3 times with ice-cold PBS. Since methanol simultaneously fixes and 
permabilises the cells, no further permeabilisation steps were necessary.  
For the second method, cells were washed once with warm PBS, then PBS was 
replaced with 500 l/well of room temperature 4% PFA, and the cells were 
incubated at room temperature for 10 minutes. After removal of 4% PFA, the cells 
were washed 4 times with ice-cold PBS. For membrane permabilisation, the PFA-
fixed cells were incubated in PBS containing 0.1% Triton X-100 for 5 minutes at 
room temperature, then washed 4 times with room temperature PBS to remove the 
detergent. This method of permabilisation was used whenever the cell nuclei were to 
be counterstained with TO-PRO-3 (Invitrogen). 
Fixed and permeabilised cells were either immunostained immediately or wrapped in 
tin foil and stored in PBS at 4 C for up to 2 days before immunostaining.  
2.5.7.2 Immunostaining  
Immunostaining was performed at room temperature. To block non-specific binding 
sites, the cells were incubated in 300 l/well of PBS containing 3% BSA (w/v) 
(blocking buffer). Meanwhile, the primary antibody was diluted in blocking buffer as 
detailed in Table 2.5. If the cells were to be probed with 2 or more primary 
antibodies, these had to be raised in different species, and they were diluted together 
in blocking buffer. After blocking, the blocking buffer was removed from the wells 
and replaced with the primary antibody dilution, and the cells were incubated for 2 
hours with gentle agitation. Cells were then subjected to 2 quick washes followed by 
3 x 5 minute washes with PBS containing 0.02% BSA (w/v) (washing buffer). 
Meanwhile, the appropriate fluorescently labelled secondary antibody was diluted in 
blocking buffer (see Table 2.5). If two or more proteins were to be detected 
simultaneously, secondary antibodies with well resolved excitation and emission 
peaks were selected so that they could be visualised separately. Whenever possible, 
if two or more secondary antibodies were to be used together, antibodies raised in the 
same species were chosen so to avoid any artefact due to cross-reaction between 
secondary antibodies. Cells were incubated with the secondary antibody for 1 hour. 




times and added to the cells along with the secondary antibody. Once the secondary 
antibody had been added, the cells were protected from light at all times to prevent 
photobleaching of the fluorophores. After incubation with the secondary antibody, 
the cells were washed as before, then mounted on glass slides using mowiol 
mounting medium supplemented with 2 mg/ml of DAPI to counterstain the nuclei. 
The slides were wrapped in tin foil and kept at 4 C for at least 16 hours after 
mounting to allow the mounting medium to set completely.  
2.5.7.3 Confocal microscopy 
Laser scanning confocal microscopy allows the generation of images representing a 
thin horizontal optical section of a fluorescently stained cell or tissue, with minimal 
contamination from light deriving from adjacent planes. This is achieved through the 
utilisation of high-intensity monochromatic laser beams that can be precisely focused 
to excite a defined focal plane, in combination with a photomultiplier detector with a 
pinhole aperture that excludes the out-of-focus light. These technical characteristic 
render confocal microscopy the method of choice to detect co-localisation of 
fluorescent signals in a biological specimen, as it can be assumed that two sources of 
light (i.e. two fluorescently labelled proteins or structures) will generate overlapping 
signals only if they are located on the same plane. A further advantage of using 
confocal microscopy consists in the possibility of minimising colocalisation artefacts 
caused by spectral bleed-through. This occurs when two fluorophores with partially 
overlapping spectral profiles are used to stain a sample and consists in the emission 
of one fluorophore being detected in the photomultiplier channel or through the filter 
combination reserved for the second fluorophore. Bleed-through can be minimised 
by sequentially scanning the sample with individual lasers to excite the different 
fluorophores and carefully setting the width of the photomultiplier slit so that only 
the light emitted by one fluorophore can be detected. Sequential scanning was used 
in this study whenever more than one fluorophore had to be imaged in the same cell.  
Confocal images were acquired using either a Zeiss LSM510 or a Nikon A1R 
confocal microscope, each used in combination with its bespoke software. Since the 




cell nuclei were counterstained with TO-PRO-3 (Invitrogen) when using this 
microscope.  
2.5.7.3.1 Analysis of DISC1 centrosomal distribution 
For the analysis of the centrosomal distribution of DISC1 variants in transfected 
COS7 cells, confocal images were acquired with the Zeiss LSM510 microscope. This 
analysis was based on measurement of the co-localisation of exogenous DISC1 and 
the endogenous centrosomal protein -tubulin.  Initially, fluorescent TetraSpeck 
beads (Invitrogen) were used to check the registration of the confocal microscope, 
i.e. the microscope’s ability to resolve and co-localise two objects fluorescing at 
different wavelengths on the same focal plane. This was a necessary control step to 
verify that the microscope could correctly detect co-localisation between DISC1 
puncta and the centrosome. Since the size of the centrosome varies between 0.8 and 
1.5 m, blue, red and green-fluorescing TetraSpeck microspheres with a diameter of 
0.5 m were used. A 5 l droplet of bead suspension was spotted on a glass slide and 
allowed to dry, after which 5 l of glycerol were applied on the beads and a coverslip 
was mounted and secured to the slide by applying nail polish along its edges. 
Multichannel confocal images of the fluorescent beads were acquired and inspected 
visually to verify perfect overlap between images of the same sphere in different 
channels and absence of overlap between images of adjacent spheres.  
Given the relatively small size of the centrosome, particular care was taken to 
guarantee that the maximum possible image resolution was achieved. Image 
resolution is determined by two factors: the optics of the microscope and the 
sampling interval or pixel size. To achieve the ideal image resolution it is necessary 
to adjust the sampling interval (pixel size) so that it is equal or smaller than the 
optical resolution capacity of the microscope. The optical parameters of the 
microscope were entered in the Nyquist Calculator (www.svi.nl/NyquistCalculator) 
to compute the minimal sampling interval necessary to capture in the image all the 
information generated by the microscope. The image resolution, digital zoom level 
and thickness of the optical z plane of the microscope were adjusted to achieve the 
calculated pixel size. A dual channel z-stack of images (one channel for DISC1 




selected microscope fields. Up to 7 z-sections were acquired for each cell, each with 
a sampling interval of 0.04 x 0.04 x 0.3 m, to cover a total surface area of 73.1 x 
73.1 m, with a thickness of up to 2.8 m. For comparability, all the cells were 
imaged using the same confocal settings.  
Image analysis was performed using a bespoke IPLab script developed in 
collaboration with Paul Perry at the MRC HGU in Edinburgh. For each dual channel 
image, the script generates a maximum pixel projection of the -tubulin channel 
stack and the operator is asked to indicate, using the paintbrush tool, which area is to 
be analysed.  The image data within this region of interest (ROI) is auto-segmented 
to select the actual centrosomal signal and exclude the background noise. The term 
“segmentation” used here refers to the selection of all pixels in the image whose 
intensity is above an arbitrarily set background value. A three-dimensional sequence 
plot is then calculated for this small ROI for all z planes.  The z plane with the 
maximum average centrosomal pixel value is taken to be the plane of best 
centrosomal focus and the rest of the analysis relates to this plane only. The operator 
is prompted to paint an encircling ring around the cell in the contrast enhanced 
DISC1 channel.  The outer rim of this ring delimits the ROI for the analysis.  The 
pixels in this channel are segmented using an arbitrary pixel intensity threshold 
value, which is the same for all images, and detailed information on the segmented 
pixels is recorded. Segment analysis is similarly performed on the region of the 
DISC1 channel corresponding to the previously selected centrosomal ROI, and all 
the data is recorded in an automatically-generated table.  
2.5.7.3.2 Analysis of DISC1 nuclear distribution 
For the analysis of the nuclear distribution of DISC1 variants in transfected COS7 
cells, images were acquired using the Zeiss LSM510 microscope. Until completion 
of the analysis, the operator was blinded to which DISC1 variant had been 
transfected in each set of cells. Cells were stained to detect exogenous DISC1 and the 
nucleus, as detailed in 2.5.7.2, then dual-channel single plane images of individual 
cells in randomly selected fields were acquired, with a pixel size of 0.14 x 0.14 m. 
To insure comparability of the results, all the cells in the same experiment were 




Image analysis was performed using an IPLab script developed in collaboration with 
Paul Perry, at MRC HGU in Edinburgh. For each dual channel image, where one 
channel corresponds to DISC1 signal and the other channel corresponds to the 
nuclear signal, the script prompts the operator to encircle the cell perimeter using the 
paintbrush tool on the DISC1 channel. The outer rim of this circle defines the 
boundaries of the region of interest (ROI) to be analysed. Within this ROI, all the 
DISC1 pixels whose intensity is above an arbitrarily defined background threshold, 
which is the same for all images, are selected. This processed is defined as pixel 
segmentation. The script then records detailed information on the segmented pixels 
in the DISC1 channel. The image corresponding to the nuclear channel is then auto-
segmented to select the actual nuclear ROI and exclude the background noise. The 
nuclear ROI is then transferred to the DISC1 channel, and detailed information on 
the pixels within this ROI is recorded. At the end of the analysis of each cell, a table 
containing all the measured image parameters is automatically generated.   
2.6 Molecular biology methods 
A complete list of primers used in this thesis is shown in Tables 2.6, 2.7 and 2.8. 






Name Sequence (5'-3') Purpose 
DISC1 Q264R F
1 
GACCCGCGATGTCTCTCTAGACCCTTCAGTCTCTTGGCTACA Replace Q with R at position 264 in 
human DISC1. Introduces an XbaI 






DISC1 R37W F GCGTGCTTTCGGAGGTGGCGGCTGGCACGGAGGC 
Replace R with W at position 37 in 
human DISC1 DISC1 R37W R GCCTCCGTGCCAGCCGC ACCTCCGAAAGCACGC 
DISC1 T603I F GGAAACCATTTCTGGATGGCTAAAGACCTCACCG 
Replace T with I at position 603 in 
human DISC1 DISC1 T603I R CGGTGAGGTCTTTAGCCATCCAGAAATGGTTTCC 
DISC1 C704S F GGAAGCATGTCGATTGCTTATCCAGAGCCTACAGCTCCAGG Replace C with S at position 704 in 
human DISC1. Removes a HindIII 
restriction site DISC1 C704S R CCTGGAGCTGTAGGCTCTGGATAAGCAATCGACATGCTTCC 
DISC1 T847A F GCTTCCTGCATGACAGCTGGTGTCCACGAAGCACAAGCCTGA 
Replace T with A at position 847 in 
human DISC1 DISC1 T847A R TCAGGCTTGTGCTTCGTGGACACCAGCTGTCATGCAGGAAGC 
DISC1 P432L F GGAGATGACACCCACACCCTACTGAGAATGGAGCC 
Replace P with L at position 432 in 




Replace L with F at position 607 in 
human DISC1 DISC1 L607F R
1 
TCTAATCTCCTCGGTGAAGTCTTTAGCCGTCCAGA   
CHOPAARE F CGCTAGCCTCGAGGAAACATTGCATCATCCCCGCAACATTGCATCATCCCCGCATCTGGCCTCG 
Introduce the CHOP AARE  in the 
pGL4.23 luciferase reporter CHOPAARE R CCGAGGCCAGATGCGGGGATGATGCAATGTTGCGGGGATGATGCAATGTTTCCTCGAGGCTAGG 




mutCHOPAARE R CCGAGGCCAGATGCGGGGATGATGCATTGTTGCGGGGATGATGCATTGTTTCCTCGAGGCTAG 
the pGL4.23 luciferase reporter 
pcDNA4TO Flag to 
myc F 
GGAATTCGCCGCCATGGAACAAAAGCTAATATCAGAAGAAGACCTACCAGGCGGGGGTCC Replace the Flag tag with the Myc tag in 
pcDNA4/TO-Flag DISC1 
pcDNA4TO Flag to 
myc R 
GGACCCCCGCCTGGTAGGTCTTCTTCTGATATTAGCTTTTGTTCCATGGCGGCGAATTCC Replace the Flag tag with the Myc tag in 
pcDNA4/TO-Flag DISC1 
ATF4 RK F GCAAAACAAGACAGCAGCCACTGGTTACCTGGAAGCAGCGGCCGCGGAGCAGGAGGC 
Mutate the DNA binding domain of 
human ATF4 to generate ATF4 RK 
ATF4 RK R GCCTCCTGCTCCGCGGCCGCTGCTTCCAGGTAACCAGTGGCTGCTGTCTTGTTTTGC 
hDISC1 LZ9 F GGACGGCTAAAGACTTGGTGTTGAGTTCC Remove the predicted Leucine zipper in 
exon 9 of human DISC1 to generate 
DISC1 LZ9 hDISC1 LZ9 R GGAACTCAACACCAAGTCTTTAGCCGTCC 
 
Table 2.6 Details of the mutagenic primers used in this study. 1Primers designed and supplied by Shaun Mackie. 
 
Name Sequence (5'-3') Purpose 
BGH R TAGAAGGCACAGTCGAGG Reverse sequencing of plasmids from the BGH polyadenylation signal 
CMV F CGCAAATGGGCGGTAGGCGTG Forward sequencing of plasmids from the CMV promoter 
Firefly R1 ATGTGCATCTGTAAAACG Reverse sequencing of firefly luciferase in the Som-CRE-Luc reporter 
Firefly R2 AACCGAACGGACATTTCG Reverse sequencing of firefly luciferase in the Som-CRE-Luc reporter 




Promega Luc2 R ATGTGCGTCGGTAAAGGC Reverse sequencing of firefly luciferase in the pGL4.23 reporter 
S1
1 
GTGAGCCACCGCGCAG Forward sequencing of human DISC1 cDNA 
S2
1 
CACTTTGGGATTCAGCTC Forward sequencing of human DISC1 cDNA 
S3
1 
ATTCGGCTCTCGCTTGGC Forward sequencing of human DISC1 cDNA 
S4
1 
GATGCCCACTCTTGGGAC Forward sequencing of human DISC1 cDNA 
S5
1 
GCCACTCAGCAGGCCAGC Forward sequencing of human DISC1 cDNA 
S6
1 
CTGGGTCAGCTGCAGGAG Forward sequencing of human DISC1 cDNA 
S7
1 
CTGGAGGGACTCCTCAGC Forward sequencing of human DISC1 cDNA 
S8
1 
GAGAGGCAGATGGATGAC Forward sequencing of human DISC1 cDNA 
SP6 F ATTTAGGTGACACTATAG Forward sequencing of mouse DISC1 cDNA in pRK5 vector 
T7 F TAATACGACTCACTATAGGG Forward sequencing of plasmids from the T7 promoter 
 
Table 2.7 Details of the sequencing primers used in this study. 1Primers designed and provided by Fumiaki Ogawa. 
 
Name Sequence (5'-3') Purpose 
ATF4 F GATCGAATTCCCACCATGACCGAAATGAGCTTCCTGAGC 
ATF4 sub-cloning 




CRE mut F TCGAGAGCCTGACGTCAGAGAGCCTGACGTCAGAGAGCCTGACGTCAGAGAGCCTGACGTCAGAGA Insertion of 4 copies of the 
Somatostation CRE in 
pGL4.23 CRE mut R AGCTTCTCTGACGTCAGGCTCTCTGACGTCAGGCTCTCTGACGTCAGGCTCTCTGACGTCAGGCTC 
Mouse Disc1 HA F GATCGAATTCACCATGGGCTACCCC 
Sub-cloning of mouse Disc1 
from pRK5 to pcDNA4/TO 
Mouse Disc1 R CTTAGCGGCCGCTCAGGCCTCGG 
Mouse Disc1 mut F AATTCGCCGCCATGGATTACAAGGATGACGACGATGACAAGCAGGGCGGGG Replacing the HA tag with the 
Flag tag in pcDNA4/TO-HA 
mouse Disc1 Mouse Disc1 mut R GACCCCCGCCCTGCTTGTCATCGTCGTCATCCTTGTAATCCATGGCGGCG 
pDEST53 ATF4 F1 GATCGAATTCACCGAAATGAGCTTCCTGAGC ATF4 sub-cloning from 
pDEST53 to pcDNA3.1 
 pDEST53 ATF4 R2 GATCCTCGAGTTAATTCGCGGGGACCCTTTTCTTCC 
 









PCR was used was used to introduce point mutations in DISC1 coding sequence 
(cds) cloned in pcDNA4/TO, as well as insert or remove segments of DNA from 
other plasmids. PCR was also used to amplify mouse DISC1 and ATF4 coding 
sequences from their original vectors (pRK5 and pDEST53, respectively) and insert 
them into a different vector. Finally, PCR was used to screen bacterial colonies after 
transformation with a ligation product and, in a variant form, to generate DNA 
fragments for automated sequencing. All PCR reactions were carried out using a 
PTC-225 Peltier Thermal Cycler (MJ Reasearch). Unless otherwise specified, the 
PCR reactions were assembled in 0.2 ml thin walled Thermowell PCR tubes 
(Costar). 
2.6.1.1 Basic PCR reaction 
The basic PCR reaction was used to amplify cDNAs from a vector for sub-cloning. 
To minimise the chance of introducing unwanted base changes in the original cDNA, 
a high-fidelity DNA polymerase was used. The reaction was set up as follows, and 
the individual components were added in the order in which they are listed: 
 
37 l                            dH2O 
5 l                              10x reaction buffer 
1 l                              5 ng/ l plasmid DNA template  
2.5 l                           20 pmol/ l forward primer 
2.5 l                           20 pmol/ l reverse primer 
1.25 l                         10 mM dNTPs 
0.75 l                         Pfu Ultra Fusion Polymerase (Stratagene) 
 
Reaction conditions were as follows: 




2.    95 C 30 seconds 
3.    60 C for 30 seconds 
4.    72 C for 15 seconds/kb of plasmid length 
5.    Repeat steps 2-4 for an additional 29 times 
6.    72 C for 10 minutes 
7.   4 C Holding temperature 
 
2.6.1.2 Site-directed mutagenesis PCR 
Site-directed mutagenesis was used to introduce point mutations, deletions or 
insertions in ATF4 or DISC1 coding sequences, as well as the pGL4.23 luciferase 
reporter vector. Site-directed mutagenesis was performed with the QuikChange II 
Site-Directed Mutagenesis Kit or the QuikChange Lightning Site-Directed 
Mutagenesis Kit, both from Stratagene. The PCR recipe shown below refers to the 
QuikChange II kit, when additional/different reagents or volumes were used for the 
QuikChange Lightning kit, these are shown in parenthesis. The reaction components 
were added in the order in which they are listed. 
 
39.5 l                         dH2O     (38 l) 
5 l                              10x Reaction buffer 
1 l                              25 or 100 ng/ l plasmid DNA template  
1.25 l                         125 ng/ l forward primer 
1.25 l                         125 ng/ l reverse primer 
1 l                              10 mM dNTPs 
(1.5 l                          QuikSolution Reagent) 
1 l                              2.5 U/ l Pfu Ultra HF DNA polymerase  





Reaction conditions were as follows: 
QuikChange II 
1. 95 C 30 seconds 
2. 95 C 30 seconds 
3. 60 C 1 minute 
4. 68 C 1 minute/kb of DNA 
5. Repeat steps 2-4 for an additional 17 times      
6. 4 C Holding temperature 
QuikChange Lightning 
1. 95 C 2 minutes 
2. 95 C 20 seconds 
3. 60 C 10 seconds 
4. 68 C 30 seconds/kb of plasmid DNA 
5. Repeat steps 2-4 for an additional 17 times 
6. 68 C 5 minutes 
7. 4 C Holding temperature          
         
2.6.1.3 Pre-sequencing PCR                     
Pre-sequencing PCR was used to generate DNA templates for automated sequencing 
and was performed in 96 well PCR plates (Sarstedt), using the Big Dye Terminator 
Ready Reaction Mix v3.1 system (Applied Biosystems). Reactions were assembled 
as follows: 
 
5.5 l                           dH2O 
1 l                              300 ng/ l plasmid DNA template 




1.5 l                           5x Sequencing Reaction Dilution Buffer 
1 l                              Big Dye v3.1 enzyme 
 
Reaction conditions were as follows: 
1. 96 C 1 minute 
2. 96 C 10 seconds 
3. 50 C 5 seconds 
4. 60 C 4 minutes 
5. Repeat steps 2-4 an additional 24 times 
6. 4 C Holding temperature 
2.6.1.4 Colony PCR 
To screen colonies of E.coli transformed with DNA ligation products, the following 
protocol was used. Fifty microliters of dH2O were added to the wells of a 96 well 
PCR plate. Individual bacterial colonies were numbered and picked with a sterile 
toothpick, which was then used to inoculate the dH2O in individual wells of the 96 
well plate. Once all the desired colonies had been picked, the plate was sealed with 
adhesive PCR film (Thermo Scientific) and heated at 95 C for 5 minutes in a PTC-
225 Peltier Thermal Cycler (MJ Reasearch). The resulting bacterial lysate was used 
as substrate in the following PCR reaction, assembled in a 96 well PCR plate 
(Sarstedt): 
 
10.75 l                       H2O 
1.5 l                           10x PCR reaction buffer (Sigma) 
0.9 l                           25 mM Magnesium Chloride 
0.75 l                         20 M forward primer 
0.75 l                         20 M reverse primer 




0.2 l                           in-house produced Taq DNA polymerase 
The reaction conditions were as detailed in 2.6.1.1. 
2.6.2 DNA sequencing 
Sequencing was used to verify all the new protein expression and luciferase reporter 
plasmids generated in this study, as well as plasmids that had been received as gifts 
from researchers from other laboratories. The plasmid to be sequenced was used as 
template in a pre-sequencing PCR assembled in a 96 well PCR plate, as detailed in 
2.6.1.3. At completion of the PCR, the plate was briefly centrifuged in a Jouan 
CR422 centrifuge to remove any condensation from the lid, which was then carefully 
removed. 2.5 l of 125 mM EDTA (Sigma) were added to each sample in the plate, 
followed by 30 l of 100% ethanol (Fisher). The plate was sealed with a Hybaid 
rubber sealing mat and inverted 4 times to mix the samples, then incubated at room 
temperature for 15 minutes. Immediately after this, the plate was centrifuged at 3000 
RPM for 30 minutes at 8 C to precipitate DNA. After spinning, the sealing mat was 
removed and the plate was inverted over a paper towel, gently tapped and quickly 
centrifuged up to 1000 RPM to completely dry the DNA pellet. After adding 30 
l/sample of 70% ethanol to wash the DNA pellet, the plate was centrifuged again at 
3000 RPM for 15 minutes at 8 C, then the ethanol was completely removed as 
before. Next, the plate was sealed with a sheet of adhesive PCR film (Thermo 
Scientific), appropriately labelled and stored at -20 C until analysis.  
The DNA sequence was determined by the technical staff at the DNA Sequencing 
Facility of the MRC HGU in Edinburgh, who then forwarded the results to me for 
analysis. DNA sequences were viewed and analysed using FinchTV version 1.4.0 
(Geospiza).  
2.6.3 DNA electrophoresis 
DNA electrophoresis was used to assess the size of DNA fragments generated by 
PCR, verify the effectiveness of DNA restriction reactions and isolate DNA 




2.6.3.1 Preparation and running of agarose gels 
To prepare agarose gels for DNA electrophoresis, agarose (Invitrogen) was added to 
room temperature TAE buffer to a final concentration of 1%. This suspension was 
heated in a microwave to completely dissolve the agarose, after which SYBR Safe 
DNA Gel Stain (Invitrogen) was added to a final concentration of 0.02% v/v. The 
melted agarose solution was then gently poured in a plastic gel mould of the 
appropriate size (Bioscience Service), which had been previously prepared by 
inserting one or more combs to create wells in the gel. The agarose solution was 
allowed to cool and solidify into a gel. Once set, the gel was placed in an 
electrophoresis tank (Bioscience Service) filled with TAE buffer and completely 
submerged, then the comb was carefully removed. The DNA samples and DNA 
marker (1 Kb DNA Ladder, Invitrogen) were diluted 5 times in DNA loading buffer, 
then loaded into the wells of the gel. To run the DNA gel, a current of 90V was 
applied to the electrodes of the tank for the time necessary to achieve good resolution 
of the DNA fragments of interest. The DNA fragments in the gel were visualised by 
UV light illumination using an Uvidoc Lightbox (Uvitec) and photographed with the 
built-in camera.    
2.6.3.2 Purification of DNA fragments from agarose gels 
To isolate DNA fragments after restriction digest, the DNA samples were ran on an 
agarose gel as described in 2.6.3.1. The gel was then placed on a Safe Imager Box 
UV transilluminator (Invitrogen) to visualise the DNA bands. Next, using a sterile 
scalpel, the gel was cut around the DNA band of interest, then the fragment of gel 
containig the DNA was excised from the rest of the gel and placed in a sterile 1.5 ml 
tube. The DNA fragment was then extracted from the gel and purified using the 
QIAquick Gel Extraction Kit (QIAGEN), following the manufacturer’s protocol.  
2.6.4 Isolation, amplification and purification of plasmids 
DNA plasmids carrying one or more genes conferring resistance to antibiotics were 
isolated and amplified by transformation of different strains of the bacterium 




appropriate antibiotic and expansion of the transformant clones. The plasmids were 
then extracted and purified from the transformed bacterial cells.  
2.6.4.1 Transformation and expansion of E.coli 
Strains of E.coli with different transformation efficiencies were used in this thesis. 
DH5α Competent Cells (Invitrogen) were used to amplify existing purified plasmids 
and to isolate new plasmids generated by cloning. XL1-Blue and XL10-Gold 
Ultracompetent Cells (Statagene) were used to isolate new plasmids generated by 
site-directed mutagenesis using the QuikChange II and QuikChange Lightning 
Mutagenesis Kits, respectively. The general transformation protocol is described 
below, and the specific conditions applied to each strain of E.coli are detailed in 
Table 2.9.  
After thawing on ice, an aliquot of cell suspension was transferred to a pre-chilled 
sterile tube and kept on ice. 1-5 l of plasmid DNA was added to the cells and gently 
stirred by swirling the pipette tip. The cells were incubated on ice for 30 minutes 
before being heat shocked by incubation at 42 C followed by 2 minutes on ice. 
S.O.C. medium (Invitrogen) preheated at 37 C was added to the cells, which were 
then incubated for 1-2 hours at 37 C with shaking at 250 RPM in an Innova 4300 
incubator shaker (New Brunswick Scientific).  After this, 50-200 l of bacterial 
culture was evenly spread on LB Agar supplemented with the appropriate antibiotic 
in a Petri dish and incubated at 37 C in a Plus II incubator (Gallencamp) until 
bacterial colonies were visible (typically 16-22 hours). To expand the clones of 
transformants, individual colonies were picked from the plate using a sterile 
toothpick or loop and used to inoculate either 5 ml or 200 ml of LB Broth 
supplemented with the appropriate antibiotic. The cultures were then incubated at 













50 l 20 seconds  






15 ml Falcon 45 l 30 seconds 
2 l of -mercaptoethanol were 
added to the cells before the heat 
shock 
 
Table 2.9 Conditions used to transform the different strains of E.coli used in this 
thesis. 
2.6.4.2 Purification of plasmids from E.coli 
Plasmids were extracted and purified from expanded clones of transformed E.coli 
using commercial kits supplied by QIAGEN. These kits are based on the alkaline 
lysis of bacterial cells followed by binding of DNA to a resin under appropriate salt 
conditions. Once all the unwanted cell components have been washed off the resin 
under low-salt conditions, DNA is eluted using a high-salt solution, then desalted and 
concentrated by isopropanol precipitation. If plasmid DNA was to be used to 
transfect particularly delicate cells, like primary neurons, it was purified from 
bacterial endotoxin using the EndoFree Maxi Prep kit. 
Bacterial cultures grown in 5 ml of LB broth were centrifuged in 1.5 ml tubes. 1.5 ml 
of culture was transferred to the tube and spun at 13,000 RPM for 1 minute at room 
temperature in a table-top microcentrifuge (Eppendorf). The supernatant was 
discarded by tipping the tube, then 1.5 ml of culture was added to the tube and 
centrifuged again as before. The supernatant was carefully removed using a pipette to 
completely dry the cell pellet. Plasmid DNA was purified from the cell pellet using 
the Spin Miniprep Kit (QIAGEN), according to the manufacturer’s directions. To 
produce larger amounts of Plasmid DNA, bacterial cultures grown in 200 ml of L 
Broth were centrifuged at 6,000 RPM for 15 minutes at 4 C in an Avanti J-201 
centrifuge (Beckman Coulter). The supernatant was discarded and the plasmid DNA 
was extracted and purified from the cells using a standard or EndoFree Plasmid 




2.6.5 Measurement of DNA concentration 
The DNA concentration of purified plasmid solutions was determined using the 
Nanodrop 2000 spectrophotometer (Thermo Scientific). After cleaning the pedestal 
of the instrument with dH2O, 1.5 l of undiluted DNA solution was placed on the 
pedestal and the absorbance measured at 230, 260 and 280 nm. The instrument 
automatically calculates the concentration of the DNA solution based on its 
absorbance, and also returns the 260/280 nm and 260/230 nm absorbance ratios. 
These are good indicators of potential contamination of the DNA solution with 
proteins or carbohydrates, respectively. The purity of the DNA solution was 
considered satisfactory when the 260/280 nm ratio was above 1.8 and the 260/230 
ratio was above 2.2.  
2.6.6 Cloning methods 
2.6.6.1 Site-directed mutagenesis 
Site-directed mutagenesis was used to introduce specific mutations such as single 
amino acid substitutions or larger amino acid insertions and deletions in ATF4 and 
DISC1 expression constructs, as well as to insert the appropriate Response Element 
in the promoter region of the pGL4.23 luciferase reporter. Site-directed mutagenesis 
was performed using the QuikChange II or QuikChange Lightning Site-Directed 
Mutagenesis kit (Stratagene). 
The DNA plasmid to be modified by site-directed mutagenesis was used as template 
in a PCR reaction carried out as described in 2.6.1.2, using appropriate mutagenic 
primers designed to introduce the desired mutation (see Table 2.6). The PCR product 
was treated with DpnI to digest the parental methylated and hemimethylated DNA. 
Treatment conditions were 1 l of enzyme for 1 hour (QuikChange II kit) or 2 l of 
enzyme for 5 minutes (QuikChange Lightning kit) at 37 C. After DpnI treatment the 
PCR product was used to transform ultracompetent bacterial cells as detailed in 
2.6.4.1. The transformant colonies were expanded in 5 ml of LB broth (2.6.4.1) and 




sequencing (2.6.1.3 and 2.6.2) to confirm that only the desired mutation had been 
inserted. 
2.6.6.2 Purification of PCR products 
PCR products obtained with the method described in 2.6.1.1 were purified using the 
QIAquick PCR purification kit (QIAGEN), according to the manufacturer’s 
instructions. Briefly, DNA is absorbed on a silica column under high-salt condition, 
and all impurities are washed off the column and discarded. After this, the purified 
DNA is eluted from the column using a low-salt buffer like Tris, or dH2O.  
2.6.6.3 Restriction digests 
Restriction digests were used to cleave DNA fragments generated by PCR, along 
with the desired destination vectors, to generate compatible overhangs. In turn, this 
allowed DNA fragments to be easily inserted in the destination vectors in the desired 
orientation. Restriction digests were also used to analyse plasmid DNA obtained 
from bacteria transformed with ligation products after sub-cloning reactions.  Prior to 
restriction, PCR products were purified as described in 2.6.6.2 and eluted in 35 l of 
dH2O. 30 l of purified PCR product or 3 g of vector DNA were mixed with 5 l of 
the appropriate 10x restriction buffer and 1 l of each restriction enzyme, and the 
final volume of the mix was brought to 50 l by adding dH2O. The reactions were 
incubated at 37 C for 2-16 hours. The restriction products were then analysed by 
electrophoresis on agarose gel (2.6.3.1). When a relatively large fragment was 
removed from a DNA vector by restriction digest, the linearised vector was 
subsequently purified as described in 2.6.3.2. Table 2.10 shows the restriction 
enzymes used in this thesis, along with their corresponding buffers. 
 
 
Enzyme Target site (5'-3') Buffer Source 
EcoRI G
>
AATT<C H Roche 
XhoI C
>






GWC<CY 4 New England Biolabs 
HindIII A
>
AGCT<T B Roche 
NotI G
>
CGGCCG<C H Roche 
 
Table 2.10 Details of the restriction enzymes used in this thesis. The position of the 
cleavage sites on the top (>) and bottom (<) strand are shown. R: A or G; W: A or T; 
Y: C or T. 
2.6.6.4 Purification of DNA fragments 
DNA fragments generated by restriction digest were purified by phenol-chlorophorm 
extraction followed by ethanol precipitation before being used in ligation reactions.  
The volume of the DNA solution to be purified was brought to 100 l by adding the 
appropriate volume of TE buffer, then 100 l of phenol/clorophorm/isoamyl alcohol 
mix (Sigma) was added. The sample was vortexed for 10 seconds, then centrifuged at 
13,000 RPM for 2 minutes at 4 C in a table-top microcentrifuge (Heareus) to 
separate the phases. 75 l of the aqueous (top) phase, containing the DNA, was 
transferred to a fresh tube and 50 l of TE was added to the remaining mixture, 
which was then vortexed and spun again as before. A further 70-80 l was removed 
from the aqueous phase and pooled with the 50 l extracted before, and the rest of 
the tube contents were discarded. 1 l of a 2 mg/ml glycogen solution (Sigma) was 
added to the extracted DNA, along with a volume of 3 M pH 5.2 Sodium Acetate 
solution corresponding to one tenth of the DNA solution. After this, a volume of 
100% ethanol (Sigma) corresponding to the original volume of the DNA solution 
was added, the mix was vortexed and incubated at -20 C for 15 minutes to facilitate 
DNA precipitation. DNA was then pelleted by centrifugation at 13,000 RPM for 30 
minutes at 4 C, the supernatant discarded and an equal volume of 80% ethanol was 
added to wash the pellet. After spinning as before for 5 minutes, the ethanol was 
removed thoroughly and the pellet was allowed to air dry before being resuspended 




2.6.6.5 SAP phosphatase treatment 
Shrimp Alkaline Phosphatase (SAP) treatment was performed on linearised DNA 
vectors after purification (2.6.6.5) and before ligation with the appropriate inserts.  
By dephosphorylating DNA ends, this step prevents religation of vector DNA, thus 
favouring the ligation of insert and vector. 10 l of purified DNA vector was mixed 
with 8.5 l of SAP buffer and 1.5 l of SAP enzyme, both from USB. The reaction 
mix was incubated at 37 C for 1 hour, then heated at 65 C for 15 minutes to 
inactivate the enzyme 
2.6.6.6 DNA ligation 
DNA ligation was used to insert either purified DNA fragments generated by PCR or 
chemically synthesised oligonucleotydes (see Table 2.8), in purified linearised 
vectors with complementary ends. DNA ligation was performed using the Rapid 
DNA Ligation Kit (Roche). A reaction mix was assembled containing 2 l DNA 
dilution buffer, 2-5 l of insert, 1 l of vector and dH2O to a final volume of 10 l. 
10  of T4 DNA ligation buffer was added to the mix, followed by 1 l of T4 DNA 
ligase. The reaction was gently mixed and incubated at room temperature for 5 
minutes or longer, then transformed into competent DH5α cells as described in 
2.6.4.1.  
2.6.7 Gene silencing by RNA interference 
Small interfering RNA oligonucleotides (siRNAs) were used in this study to knock-
down the expression of endogenous DISC1 and ATF4 in human cell lines. Detailed 
information on the siRNA oligonucleotides used in this thesis is shown in table 2.11. 
siRNAs were transfected into cells using Lipofectamine 2000 (Invitrogen) as 
described in 2.4.6.1, and cells were lysed 48 hours after transfection. Ambion and 
Qiagen siRNAs were used at the final concentration of 6 nM and 5 nM, respectively. 
Unless otherwise specified, when drug treatments were performed on cells 
transfected with siRNAs, these were started 34 hours after transfection and lasted 
16 hours. At the end of the drug treatments, the cells were either lysed (2.5.1), 






Full name Target Source Sequence (5'-3') Notes 
DISC1 
#2 
Silencer Select siRNA 
DISC1_2 





Pre-designed, HPLC purified and 
annealed by the supplier. 
DISC1 
#5 
Silencer Select siRNa 
DISC1_5 





Pre-designed, HPLC purified and 









Pre-designed and annealed by the 
supplier. The siRNA sequence is 
proprietary. 
A ATF4 
Silencer Select siRNA 
ATF4 





HPLC purified and annealed by the 
supplier. The siRNA sequence was 




None in mammalian 
transcriptome. 
Qiagen 
Proprietary, not disclosed by the 
supplier. 




Negative Control #1 
siRNA 
None in human, mouse 
and rat transcriptome. 
Ambion 
Proprietary, not disclosed by the 
supplier. 
Pre-designed by Ambion. HPLC purified 





Table 2.11 Details of the siRNA oligonucleotides used in this study. All siRNAs target human genes. UTR: untranslated region. The final 




2.7 Functional assays 
2.7.1 Luciferase reporter assays 
Luciferase reporter assays were used to measure the effect of ATF4 and DISC1 on 
transcription driven by the cyclic AMP Response Element (CRE) or the C/EBP 
homologous protein (CHOP) Amino Acid Response Element (AARE). Luciferase 
activity was measured in transiently transfected cells using the Dual-Glo Luciferase 
Assay System (Promega), as directed by the manufacturer. This system is based on 
the use of two reagents that are added step-wise to the cells to be analysed. First, the 
Dual-Glo Luciferase Reagent induces cell lysis and provides the substrate for Firefly 
luciferase. Next, the Dual-Glo Stop & Glow Reagent quenches the Firefly 
luminescence and provides the substrate for Renilla luciferase. In the present study, 
transcription of Firefly luciferase was driven by the CRE or CHOP AARE regulatory 
elements, while transcription of Renilla luciferase was driven by the constitutively 
active Thymidine Kinase (TK) promoter, and served as an internal control to correct 
for differences in transfection efficiency between samples. 
To minimise signal interference between adjacent well, cells were plated and assayed 
in black-walled 96 well plates (Corning). HEK293 and MO3.13 cells were 
transfected with Fugene HD (2.4.6.2), whereas SH-SY5Y cells were transfected by 
Nucleofection (2.4.6.3). In each experiment, cells transfected with an appropriate 
empty vector were used to measure the background luminescence. Each transfection 
was performed in triplicate. 
If drug treatments were to be performed, these were started 48 hours after 
transfection. Unless otherwise specified, the appropriate drugs and vehicles were 
diluted in 37 C DMEM/FBS (2.4.7.2 and Table 2.4), then the transfection medium 
was carefully aspirated from the wells and replaced with either 50 l/well (for 
treatments that lasted up to 8 hours) or 200 l/well (for treatments that lasted longer 
than 8 hours) of drug dilution.   
If the volume of DMEM/FBS in each well was higher than 50 l, this was adjusted 




completely aspirated and replaced with 50 l/well of fresh DMEM/FBS at 37 C, and 
the plate was allowed to equilibrate at room temperature for 5-10 minutes. After 
adding 50 l/well of room temperature Dual-Glo Luciferase Reagent, the plate was 
incubated at room temperature for 10 minutes and gently tapped to facilitate cell 
lysis. Firefly luminescence was then measured using a Synergy HT Multi-detection 
Microplate Reader with bespoke Gen 5 software (Bio Tek). Next, 50 l/well of room 
temperature Dual-Glo Stop & Glo Reagent was added and the plate was incubated as 
above before reading Renilla luminescence.  
For each sample, the mean Firefly and Renilla luminescence was calculated from the 
3 technical replicates. Next, the mean background luminescence was subtracted from 
these values, and the ratio between Firefly and Renilla luminescence was calculated. 
Measurements obtained from a minimum of 3 independent experiments were then 
analysed and compared statistically.  
2.7.2 Cell viability assay 
The cell viability assay described below was used to assess the effect of ATF4 or 
DISC1 knock-down and overexpression on survival of MO3.13 oligodendrocytes 
after exposure to environmental stress. Cell viability was measured using the 
CellTiter-Glo Luminescent Cell Viability Assay (Promega), according to the 
manufacturer’s directions. This assay exploits a bioluminescent reaction to quantify 
the amount of ATP present in each well, which is in turn directly proportional to the 
number of metabolically active cells.  
Cells were plated in black-walled 96 well plates (Corning) in a total volume of 100 
l of DMEM/FBS/well (2.4.3). Cell density was 1x10
4
/well for siRNA transfections 
and 2x10
4
/well for DNA transfections. Cells were transfected with Lipofectamine 
2000 (2.4.6.1), using 50 l/well of transfection mix containing 0.5 l Lipofectamine 
2000, 15 nM or 18 nM of Qiagen or Ambion siRNA, respectively, or 200 ng of the 
appropriate protein expression plasmid. Each transfection was performed in 
duplicate. 24 hours after transfection, the medium was replaced with 200 l/well of 
DMEM/FBS containing the appropriate drug/vehicle, and the cells were incubated 




replaced with 50 l/well of fresh 37 C DMEM/FBS, and the plate was allowed to 
equilibrate at room temperature for 10 minutes. After adding 50 l/well of room 
temperature CellTiter-Glo Reagent, the plate was incubated for 10 minutes at room 
temperature on an orbital shaker to induce cell lysis, then luminescence was recorded 
from individual wells using a Synergy HT Multi-detection Microplate Reader with 
bespoke Gen 5 software (Bio Tek). For each sample, the mean luminescence was 
calculated from the 2 technical replicates. Mean readings obtained from 3 




3 The effect of missense variants on the subcellular 
distribution of DISC1 
3.1 Introduction 
Besides the originally described t(1;11) translocation, several common and rare 
DISC1 missense point mutations are associated with increased risk of psychiatric 
illness and/or brain and cognitive abnormalities in healthy carriers (Chubb et al, 
2008; Soares et al, 2011). The three common polymorphisms resulting in amino acid 
substitutions R264Q, L607F and S704C appear to increase the risk of psychiatric 
illness in at least some studies and are associated with brain structural and cognitive 
defects, as detailed in the introduction of this thesis (Chubb et al, 2008; Soares et al, 
2011). In addition, several rare or ultra-rare amino acid substitutions are associated 
with schizophrenia or schizoaffective spectrum disorders (G14A, R37W, S90L, 
T603I and P758R), bipolar disorder (S209L, R338Q and T754S) or both (R418H) 
(Green et al, 2011; Song et al, 2008; Song et al, 2010).  
In vitro studies have provided biological evidence suggesting that amino acid 
substitutions R264Q, L607F and S704C negatively impact on specific functions of 
DISC1 at the cellular and molecular level. In particular, L607F and S704C are 
associated with specific alterations in DISC1 expression profiles observed in 
schizophrenia patients (Nakata et al, 2009), and both have been shown to interfere 
with the recruitment of PCM1 to the centrosome in neuronal cells and glia (Eastwood 
et al, 2009; Eastwood et al, 2010). L607F additionally interferes with 
neurotransmitter release from cultured neuronal cells (Eastwood et al, 2009) and 
induces mitochondrial trafficking defects when expressed in neurons (Atkin et al, 
2011). Both R264Q and L607F dampen the inhibitory effect of DISC1 on GSK3 , 
resulting in defects in Wnt signalling, neural progenitor proliferation and brain 
development (Singh et al, 2011). Finally, S704C reduces the kinase activity of 
Extracellular signal-regulated kinase 1 (ERK1) and Akt1 (Takahashi et al, 2009), 
alters DISC1 binding affinity to NDE1 and NDEL1 (Burdick et al, 2008; Kamiya et 
al, 2006), interferes with DISC1 oligomerisation (Leliveld et al, 2009) and impairs 




consistent with the evidence from association and imaging studies, and support the 
hypothesis that R264Q, L607F and S704C may be functional variants that increase 
the risk of psychiatric illness by impacting on multiple aspects of DISC1 biology. On 
the other hand, no biological effects have been reported to date for any of the rare 
DISC1 missense mutations associated with psychiatric illness, but ongoing research 
indicates that R37W enhances the mitochondrial localisation of DISC1 and induces 
perinuclear mitochondrial clustering when expressed in cell lines (Ogawa F., 
unpublished data) (Brandon et al, 2009). Despite the growing biological evidence 
supporting a functional role of risk-conferring DISC1 amino acid substitutions, the 
mechanisms linking them to the observed clinical phenotypes still need to be 
elucidated.  
Predictions based on sequence conservation across species, location within protein 
structural motifs and likelihood of introducing detrimental structural changes in the 
protein suggest that human DISC1 amino acid substitutions R37W, R264Q, P432L, 
T603I, L607F and S704C are likely to affect the protein function ((Soares et al, 
2011) and Soares D., unpublished observations) (Table 3.1 and Figure 3.1, adapted 
from Soares et al, 2011). Mouse DISC1 mutations Q31L and L100P, which are 
associated with abnormal cognitive and behavioural phenotypes in mice, are 
similarly predicted to negatively impact on the protein structure and function 
(Clapcote et al, 2007; Soares et al, 2011) (Table 3.2 and Figure 3.1).  As a 
consequence of their potential for structural disruption, any of the above amino acid 
substitutions might interfere with the correct subcellular targeting of DISC1, which is 
inextricably linked with its function. Thus, to better elucidate their biological effects, 
I tested their ability to disrupt the subcellular distribution of the protein using in vitro 
models. Any such effect may provide valuable insight on the particular DISC1 
functions and/or protein-protein interactions that could be affected by these amino 
acid substitutions. In particular, I focused on two subcellular compartments in which 
DISC1 is normally enriched and where it is thought to play important roles for brain 








and location on 
structure 
Notes, motifs and potential effects on 
structure and function 
Human common variants 
R264Q (Q264 minor 
allele frequency 
0.2599) 
R in hs, pt, ma; Not well 
conserved, Q not seen in 
any ortholog; loop 
Lies close to peptide region in DISC1 
266-290 mapped as PDE4B1 binding. 
Loss or gain of charge alters-interaction 
propensity? 
L607F  (F607 minor 
allele frequency 
0.0986) 
hs, pt, ma, bt, cf, rn, mm, 
tr, dr; strictly conserved; 
coiled coil helix 
Located directly within a leucine zipper 
motif, within a heptad repeat at position 
‘d’. Change to Phe could alter the 
intricate Leu-Leu packing between 
adjacent helices. The presence of 
repeating leucine residues at position ‘d’ 
in leucine zippers is critical for 
modulating coiled-coil stability, 
maintaining oligomeric state, partner 
selection, and orientation of coiled coil 
helices. L607F is likely to impact on the 
structure of the protein. 
S704C (C704 minor 
allele frequency  
0.2472) 
hs, pt, ma, bt, rn, mm; 
largely conserved amino 
acid position: G in cf, tr, 
dr; alpha-helix 
S704C lies close (context amino acid) to 
a predicted nuclear export signal 
(NES4). The context around the leucine 
residues in the nuclear export signal 
has been suggested to play an 
important role (la Cour et al, 2004). 
Human rare and ultra-rare mutations 
R37W  
hs, pt, ma, cf, rn, mm, tr, 
dr; strictly conserved; 
alpha-helix 
Proximal residue in mouse Q31L 
mutation (equivalent human residue 
R35) causes reduced binding to 
PDE4B1. Hence, R37W might also 
affect PDE4B binding (since it lies within 
binding peptide mapped to 31-65). It 
also lies close to Kal-7 binding site (41-
100). R37W lies within tetra-arginine 






hs, rn, mm; low 
conservation; loop 
Could alter DISC1 
structure/conformation. May impact on 
DISC1 oligomerisation as it is located 
within a self-association domain (region 
403-504). Located within a potential 
proline-directed kinase recognition site 
(T431-P432-L433-A434). 
T603I 
hs, pt, ma, bt, cf, rn, mo; 
highly conserved (S in tr, 
dr); coiled coil helix 
Potential to disrupt a predicted 
phosphorylation site. Also close to ATF4 
binding region 606-628 and near PDE4 
(general) binding region 611-650. 
Mouse missense mutations 
Q31L  
mm, rn; Q31 is not 
conserved; in humans the 
equivalent amino acid is 
R35; boundary of loop 
and α-helix 
Part of peptide region in DISC1 31-65 
mapped as important for PDE4B1 
binding. However, outside known 
GSK3β-binding regions. These have 
however been incompletely mapped. 
Clapcote and colleagues (Clapcote et 
al, 2007) suggested likely effects of the 
mouse mutations based upon the 
physicochemical properties of amino 
acids; that is, glutamine is hydrophilic 
and would normally be found surface 
exposed. This is probably true in the 
case of Q31, as it is immediately 
adjacent to the nuclear localization 
signal NES1. Q31 replaced by leucine, 
a hydrophobic amino acid, would be 
unfavourable at this position. 
L100P  
mm, rn; L100P is not 
conserved; in humans the 
equivalent amino acid is 
S100; loop 
Adjacent to the peptide region 101-135 
shown to bind PDE4B. However, 
outside known GSK3β binding regions. 
As mentioned above, these have been 
incompletely mapped. However, a 
change from a Leu to a Pro could have 
structural consequences, since Pro is a 
conformationally important amino acid. 
 
Table 3.1 Sequence conservation and predicted structural effects of DISC1 




troglodytes, ma: Macaca mulatta, bt: Bos taurus, cf: Canis familiaris, rn: Rattus 
norvegicus, mm: Mus musculus, tr: Takifugu rubripes, dr: Danio rerio.  
 
 
Figure 3.1 Position of DISC1 sequence variants in relation to the predicted 




(A) Predicted secondary structure of DISC1 and position of sequence variants. The 
vertical rectangles represent regular or ambiguous α-helices (pink and light green, 
respectively, and coiled-coils (green). The horizontal yellow lines represent 
disordered regions. The position of the nuclear localisation signal (NLS) and SF-rich 
region is also indicated, along with that of the phosphorylation sites (brown 
triangles). The vertical dashed line marks the position of the t(1;11) translocation 
breakpoint, corresponding to amino acid 597. Common and rare/ultra rare human 
amino acid substitutions are indicated in black and red, respectively, whereas 
mouse mutations are in turquoise. (B) DISC1 regions that are known to be involved 
in self-association or protein binding. Regions that are sufficient for protein binding 
are in green; if two or more regions are sufficient for binding, the overlapping 
sections are indicated with a solid line and the rest with a dotted line. Regions that 
are essential for binding are in red. The bolts indicate short stretches of amino acids 
that abolish binding when mutated. 
 
In actively dividing animal cells, microtubules nucleate from the centrosome, which 
functions as the main microtubule-organising center (MTOC) (Nigg & Raff, 2009). 
The centrosome consists of a pair of microtubule-based structures, the centrioles, 
embedded in an amorphous protein matrix, the pericentriolar matrix (PCM) (Nigg & 
Raff, 2009). As well as being essential for the process of cell division, it is well 
established that the centrosome plays important roles throughout neurodevelopment. 
In proliferating neural progenitors, the centrosome regulates asymmetrical 
distribution of cell fate factors to daughter cells, thus determining whether they will 
continue dividing, or begin differentiating (Higginbotham & Gleeson, 2007). 
Moreover, correct positioning of the centrosome is necessary for the establishment of 
cell polarity in newborn neurons, and for the correct migration of developing neurons 
to their final destinations in the brain (Kuijpers & Hoogenraad, 2011). As discussed 
in the introduction of this thesis, the correct centrosomal function of DISC1 is known 
to be important for proper brain development in animal models. Indeed, centrosomal 
DISC1 is involved in the recruitment of several proteins, including kendrin, dynein, 
dynactin, LIS1, NDEL1 and PCM1 to the centrosome (Soares et al, 2011) and in the 




outgrowth (Kamiya et al, 2005; Kamiya et al, 2008; Miyoshi et al, 2004; Shimizu et 
al, 2008). Thus, DISC1 variants that prevent the correct positioning of DISC1 at the 
centrosome may have detrimental effects on brain structure and function.  
Although the nuclear function of DISC1 has not been investigated as extensively as 
its roles at the centrosome, some studies provided intriguing clues suggesting that 
nuclear DISC1 may also be important for correct brain functioning. A particular 
example is represented by a study conducted on autopsied brains, which revealed 
aberrant nuclear distribution of DISC1 in psychiatric patients. In particular, a 75-85 
kDa DISC1 protein isoform was found to be specifically enriched in nuclear extracts 
obtained from the orbitofrontal cortex of patients with schizophrenia and major 
depression. While this effect was correlated with drug abuse in patients with major 
depression, none of the common brain-associated confounding factors explained the 
nuclear enrichment of DISC1 in schizophrenic brains, suggesting aberrant DISC1 
nuclear targeting as a potential pathogenetic mechanism (Sawamura et al, 2005). 
Another study examined the effects of brain-specific human DISC1 overexpression 
in the fruit fly Drosophyla melanogaster (Sawamura et al, 2008). In transgenic flies, 
expression of full-length DISC1 was limited to the nucleus, where the protein formed 
distinct puncta or speckles, whereas C-terminally truncated DISC1 ((DISC1(1-597)) 
assumed a diffuse distribution in both the nucleus and cytoplasm. Intriguingly, in 
male flies only, expression of full-length but not truncated DISC1 induced 
disturbances of sleep homeostasis, suggesting a potential role for nuclear DISC1 in 
the regulation of sleep/wake cycles (Sawamura et al, 2008). However, it is important 
to point out that invertebrates are not known to express endogenous DISC1 (Chubb 
et al, 2008). This represents a major limitation of this study, whose results should 
therefore be interpreted with caution. Nevertheless, the findings of Sawamura and 
colleagues are of particular relevance as they highlight the potential involvement of 
DISC1 in the regulation of sleep homeostasis, a process that is often disturbed in 
psychiatric patients (Schulz & Steimer, 2009; Wulff et al, 2009) and that is partly 
regulated by cAMP signalling (Zimmerman et al, 2008), a pathway in which DISC1 
is involved by virtue of its modulatory interaction with PDE4 (Millar et al, 2005b; 




DISC1 targeting to the nucleus is mediated by well-conserved cis-acting elements in 
the protein (Soares et al, 2011). The high degree of conservation of these nuclear 
targeting elements suggests that DISC1 may have important functions in the nucleus. 
In silico analyses originally identified two putative nuclear localisation signals (NLS) 
within DISC1 protein sequence (Brandon et al, 2005; Ma et al, 2002a; Taylor et al, 
2003). The first is a classical tetra-arginine NLS motif (Kalderon et al, 1984; Nakai 
& Horton, 1999) at positions 35-RRRR-38 (NLS1), and the second is a bipartite 
motif (Nakai & Horton, 1999; Robbins et al, 1991) at positions 331-
RKWEPVLRDCLLRNRRQ-347 (NLS2).  Additionally, two putative nuclear export 
signals (NES) were identified at positions 504-513 (NES1) and 621-631 (NES2) 
(Brandon et al, 2005).  
Two studies, whose results are detailed in the text below and summarised in Table 
3.2, investigated the NLSs and NESs within DISC1 (Brandon et al, 2005; Sawamura 
et al, 2008). To better assess the role of the putative NLSs and NESs in DISC1, 
Brandon and colleagues expressed different mutant forms of GFP-tagged DISC1 in 
HeLa cells, and analysed their subcellular distribution by immunofluorescence 
(Brandon et al, 2005). Deletion of the tetra-arginine motif within NLS1 did not affect 
DISC1 localisation, nor did amino acid substitutions in NLS2, NES1 and NES2 that 
had previously been shown to block the function of similar motifs in other proteins, 




Details of the mutation 







NONE (Brandon et al, 2005) 
NLS1 Deletion of amino acids 1-45 
Impaired 
(not quantified) 































Deletion of amino acids 598-854 
Impaired 
by 50% 





targeting of DISC1 
(1-597) 
(Sawamura et al, 2008) 
 
Table 3.2 Summary of the mutation analyses conducted on the putative NLSs and 
NESs in DISC1. The asterisks indicate deletion of the corresponding amino acids. 
The mutated amino acids are underlined.  
The putative NLSs and NESs in DISC1 were further analysed in a subsequent study 
that adopted a similar strategy, but used the HA epitope instead of GFP to tag DISC1 
(Sawamura et al, 2008). A DISC1 (46-854) deletion construct lacking NES1 
displayed defective nuclear targeting, and so did a mutant DISC1 form in which the 
tetra-arginine motif within NES1 had been replaced by a stretch of four alanines 
(Sawamura et al, 2008). Consistently, an eGPF-NLS1 chimera was efficiently 
targeted to the nucleus, whereas its counterpart containing a mutated NLS1 was not 
(Sawamura et al, 2008). This is in contrast with the findings of Brandon and 
colleagues, who saw no effect of deletion or mutation of NES1 (Brandon et al, 
2005). This discrepancy is likely caused by technical differences between the studies, 
and in particular by the use of different DISC1 tagging epitopes. Indeed, GFP 
tagging is known to interfere with DISC1 subcellular targeting (Kirsty Millar, 
personal communication), and might have masked the effect of NLS1 mutation in the 
experiments described by Brandon and colleagues (Brandon et al, 2005). By 
contrast, and in agreement with the findings of Brandon and colleagues, an eGFP-




is an active NLS within DISC1 (Sawamura et al, 2008). Sawamura and collegues 
also identified an additional putative NES at DISC1 positions 546-555 (NES3), and 
showed that a leucine to serine substitution at position 553 within NES3 results in 
redistribution of DISC1 (1-597) from the cytoplasm to the nucleus, while an eGFP-
NES3 chimera was localised entirely to the nucleus (Sawamura et al, 2008). This led 
the authors to conclude that NES3 is a functional NES, although reservations based 
on the structural conformation of this region were raised recently (Soares et al, 
2011). Finally, Sawamura and colleagues reported that the introduction of leucine to 
proline substitutions at positions 614 and 621, within the putative leucine zipper 
spanning residues 607-628, results in cytoplasmic distribution of DISC1 (Sawamura 
et al, 2008). Consistently, DISC1 (1-597) showed defective nuclear localisation 
(Sawamura et al, 2008). A more recent bioinformatic investigation led to the 
identification of a further putative NES (NES4) within DISC1, at positions 607-709, 
which has not been experimentally investigated yet (Soares et al, 2011). 
3.2 Generation of DISC1 expression constructs 
3.2.1 Human DISC1 expression constructs 
The construct pcDNA4/TO-Flag DISC1 (Table 2.2), encoding N-terminally Flag-
tagged full-length human DISC1 (isoform L) was used as template in a series of site-
directed mutagenesis reactions to generate a selected panel of DISC1 amino acid 
variants. The resulting expression constructs (n=20) carried either a rare or ultra-rare 
DISC1 mutation (37W, 432L or 603I) or the common variant 607F in all possible 
combinations with the common polymorphisms R264Q and S704C (Figure 3.2). 
With the exception of R264Q and P432L, all of the above DISC1 variants are at 
highly conserved amino acid positions, and all have the potential to influence the 
subcellular distribution of DISC1, either because they are predicted to disrupt critical 
structural motifs, or because they occur in regions of DISC1 that mediate binding to 
key partner proteins (Soares et al, 2011) (Table 3.1 and Figure 3.1). Variant P432L is 
predicted to impact on the structure/function of DISC1 but does not increase the risk 
of schizophrenia (Song et al, 2008), thus it might provide useful information on the 




common and rare DISC1 amino acid substitutions, the expression constructs 
generated here offer the possibility to test for potential functional interactions 
between distinct risk-conferring DISC1 missense variants.  
The expression constructs encoding N-terminally Myc-tagged wild-type, 37W or 
607F DISC1 as well as the DISC1 LZ9 mutant, which lacks the leucine zipper 
spanning amino acids 607-628 in exon 9, were all generated from the corresponding 
pcDNA4/TO-Flag DISC1 constructs by site-directed mutagenesis.  
Partially overlapping sequences spanning the entire DISC1 coding sequence were 
obtained for each construct to verify that only the desired nucleotide substitutions 
had been introduced. The details of the mutagenic and sequencing primers used to 
generate the human DISC1 expression constructs used in this thesis are reported in 






Figure 3.2 Generation of human DISC1 expression constructs by site-directed 
mutagenesis. The diagram represents the mutagenic reactions used to generate the 
human DISC1 variant expression constructs used in this thesis. DISC1 constructs 
are named according to the amino acid substitution(s) carried by the respective 
encoded protein. The constructs carrying common variants only are in black, 
whereas the ones carrying rare or ultra-rare mutations are in red. The arrows 
represent individual mutagenic reactions, and the resulting amino acid substitution is 





3.2.2 Mouse Disc1 expression constructs 
The constructs pcDNA4/TO-Flag mDisc1, encoding N-terminally tagged wild-type, 
31L or 100P mouse Disc1 were generated from the corresponding pRK5-HA Disc1 
plasmids (Table 2.2). The Disc1 coding sequences in pRK5 were amplified by PCR 
using primers Mouse Disc1 HA F and Mouse Disc1 R (Table 2.8) and sub-cloned 
between the EcoRI and NotI sites of pcDNA4/TO (Table 2.2). After sub-cloning in 
pcDNA4/TO, the HA tag was replaced with the Flag tag by restriction with EcoRI 
and PpuMI followed by religation with the chemically synthesised oligonucleotides 
Mouse Disc1 mut F and Mouse Disc1 mut R (Table 2.8). The resulting expression 
constructs were verified by direct sequencing using primers SP6 F and BGH R 
(Table 2.7).  
3.3 Analysis of the subcellular distribution of DISC1 variants by 
immunocytochemistry 
3.3.1 Human DISC1 variants 
3.3.1.1 Analysis of the centrosomal abundance of DISC1 variants 
To determine the relative abundance of human DISC1 variants at the centrosome, 
COS7 cells were transfected with equal amounts of the 20 Flag-DISC1 expression 
constructs individually and subsequently double-stained with an anti-Flag and an 
anti- -tubulin antibody (Table 2.5) to detect exogenous DISC1 and the centrosome, 






Figure 3.3 Confocal image of a representative COS7 cell expressing exogenous 
Flag-DISC1 and stained with the Flag RPC and the -tubulin M antibodies. The 
arrowheads indicate the centrosome. 
 
Confocal images of at least 20 transfected cells for each DISC1 variant were 
acquired and analysed as described in detail in the methods chapter of this thesis 
(paragraphs 2.5.7.3 and 2.5.7.3.1). For each DISC1 variant analysed, the proportion 
of exogenous DISC1 localising at the centrosome was calculated as the ratio between 
the total pixel intensity of DISC1 staining at the centrosome and the total pixel 
intensity of DISC1 staining in the whole cell, and was used as an estimate of the 
efficiency of DISC1 centrosomal targeting (Figure 3.4). The common variant of 
DISC1, or wild-type DISC1, was the reference against which all other variants were 
compared. No statistically significant difference between the variants was detected 
using two-way ANOVA, probably due to the high variability of the centrosomal 
distribution observed for some DISC1 variants. However, it is interesting to note that 
although neither of the common amino acid substitutions 264R and 704C alone 
seems to produce any effect on DISC1 centrosomal targeting, the centrosomal 
abundance of both mutants 432L and 603I appears to be influenced by the 
concomitant presence of the 704C substitution, albeit with opposing effects (Figure 
3.4). Similarly, while the common 607F variant is efficiently targeted to the 
centrosome, its combination with either 264Q or 704C appears to be detrimental for 
DISC1 centrosomal abundance, which is particularly decreased when all three 
variants are present together (Figure 3.4). Although no firm conclusions can be 




acid substitutions may have substantially different effects on the centrosomal 
localisation of DISC1. In particular, two neutral substitutions may become 
detrimental when combined and, on the other hand, the effects of a deleterious 
substitution may be rescued by the simultaneous presence of a second substitution. 
Further analyses will be needed to accept or reject these preliminary observations.  
 
 
Figure 3.4 Centrosomal distribution of DISC1 variants. Relative centrosomal 
abundance of exogenous DISC1 in transfected COS7 cells. The arrow indicates the 
reference wild-type DISC1 variant, to which all other variants were compared. The 
bars represent the average of 20 cells/variant analysed in a single experiment.  
 
3.3.1.2 Analysis of the nuclear abundance of DISC1 variants 
To assess the potential effect of common and rare DISC1 amino acid substitutions on 




the 20 Flag-DISC1 expression constructs and subsequently stained with an anti-Flag 
antibody and the nuclear dye TO-PRO-3. Single-plane confocal images of individual 
transfected cells were then acquired and analysed as detailed in paragraphs 2.5.7.3 
and 2.5.7.3.2.  As for the centrosome, the relative nuclear abundance of each DISC1 
variant was calculated as the ratio between the total pixel intensity of DISC1 staining 
in the nucleus and the total pixel intensity of DISC1 staining in the whole cell. A 
pilot experiment in which at least 20 cells/variant were analysed demonstrated that 
sequence changes at positions 264, 432, 603 or 704 do not interfere with the nuclear 
targeting of DISC1 (Figures 3.5 and 3.6), nor do they grossly alter the overall 
subcellular distribution of DISC1 (Figure 3.6). However, it cannot be excluded that 
these variants might have subtle and/or cell type-specific effects on DISC1 targeting, 
whose detection requires more sensitive and specific methods. On the other hand, the 
R to W, and L to F substitutions at positions 37 and 607, respectively, result in partial 
depletion of exogenous DISC1 from the nucleus (Figures 3.5 and 3.6). Additional 
variation at positions 264 and 704 does not modify the effect of 37W or 607F on the 






Figure 3.5 Nuclear distribution of DISC1 variants. Relative abundance of DISC1 
variants in the nucleus of transfected COS7 cells, calculated as the ratio between 
the total pixel intensity of DISC1 staining in the nucleus and the total pixel intensity 
of DISC1 staining in the whole cell. The bars represent mean measurements of 20 
cells/variant carried out in a single experiment. The arrow indicates the common 







Figure 3.6 Subcellular distribution of DISC1 variants. Representative COS7 cells 
expressing the indicated DISC1 variants and stained with the Flag RPC antibody to 
detect the exogenous protein. Nuclei were counterstained with TO-PRO-3. Scale 
bars are 20 µm.  
 
These preliminary observations on the effect of 37W and 607F on the nuclear 
distribution of DISC1 were confirmed by further immunocytochemistry experiments 
in which a larger sample of cells was analysed (Figures 3.7). Both sequence variants 
reduce the nuclear expression of DISC1 by approximately 50% (P<0.01).  
 
 
Figure 3.7 Nuclear distribution of DISC1 variants. Relative abundance of DISC1 
variants in the nucleus of transfected COS7 cells calculated as the ratio between the 
total pixel intensity of DISC1 staining in the nucleus and the total pixel intensity of 
DISC1 staining in the whole cell. The bars represent the mean values measured in 3 
independent experiments in which 50 cells/variant were analysed, for a total of 150 
cells/variant. Data were analysed by one-way ANOVA followed by Dunnett’s Multiple 





The observed decrease in nuclear expression of DISC1-37W or DISC1-607F is not 
due to decreased overall expression of these DISC1 variants (Figure 3.8), which 
confirms that DISC1 carrying R or L at positions 37 and 607, respectively, is 
targeted to the nucleus more efficiently.  
 
 
Figure 3.8 Scatterplot and regression lines of total pixel intensity of DISC1 staining 
in the whole cell (x-axis, independent variable) vs. nucleus (y-axis, dependent 
variable) in individual COS7 cells transfected with wild-type DISC1, DISC1-37W or 
DISC1-607F. The graph was generated by pooling measurements obtained from 50 
cells/variant in 3 independent experiments (150 cells/variant in total). Pearson r 
(95% confidence interval) = 0.3337, P<0.0001 (wild-type DISC1); 0.5648, P<0.0001 
(DISC1-37W); 0.5760, P<0.0001 (DISC1-607F).  
 
Since there is no evidence for an effect of amino acid variation at positions 264 and 
704 on the subcellular distribution of DISC1, all the subsequent experiments were 
performed using DISC1 constructs encoding the common variants at these positions 
(264R and 704S). The common DISC1 variant, to which all other variants analysed 
here are compared, will henceforth be referred to in the text as “wild-type (WT) 
DISC1” 
The defective nuclear targeting of DISC1-37W and DISC1-607F is not limited to 
COS7 cells, as the same effect can be observed upon expression of these variants in 




primary mouse hippocampal neurons, DISC1-WT, but not DISC1-37W is efficiently 
targeted to the nucleus (Figure 3.10).  
 
 
Figure 3.9 Subcellular distribution of DISC1 variants in COS7 and SH-SY5Y cells. 
Confocal images of representative COS7 and SH-SY5Y cells expressing DISC1-
WT, DISC1-37W or DISC1-607F and stained with the Flag RPC antibody (green). 
Nuclei (blue) are counterstained with DAPI. Scale bars are 20 µm (COS7 cells) and 






Figure 3.10 Distribution of DISC1 variants in hippocampal neurons. Primary mouse 
hippocampal neurons were transfected with pcDNA4/TO-FLAG DISC1-wild-type or 
pcDNA4/TO-Flag DISC1-37W after 21 days in vitro and stained with the Flag RPC 
antibody to detect exogenous DISC1 (green). Confocal images of individual 
transfected neurons were acquired focusing on the nucleus (left hand panels) or on 
the neurites (far-right panels). Nuclei (blue) are counterstained with DAPI. Scale 
bars are 10µm.  
 
When expressed in cell lines, DISC1-37W is recruited to the mitochondria, and it 
induces the formation of perinuclear mitochondrial clusters (Figures 3.6 and 3.9), 
which is the subject of a separate study (Ogawa F., unpublished data). To establish 
whether the defective nuclear targeting of DISC1-37W is related to its increased 
recruitment to mitochondria, COS7 cells were transfected with a construct expressing 
the mutant DISC1-37A, which was kindly provided by Fumiaki Ogawa. Independent 
investigations have established that like 37W, the artificial mutation 37A elevates 
DISC1 mitochondrial targeting and induces mitochondrial aggregation, but it does so 
to a much lesser extent than 37W (Ogawa F., unpublished data). Thus, if the 
defective nuclear targeting of DISC1-37W is related to its aberrant recruitment to the 





However, when expressed in COS7 cells, the nuclear distribution of DISC1-37A is 
indistinguishable from that of DISC1-37W, indicating that both mutants are equally 
excluded from the nucleus (Figure 3.11). This suggests that the defective nuclear 
targeting of DISC1-37W is likely a direct consequence of the disruption of NSL1 by 




Figure 3.11 Subcellular distribution of DISC1-37A. Representative COS7 cells 
transfected with either pcDNA3.1-Myc DISC1-WT, pcDNA3.1-Myc DISC1-37W or 




Exogenous DISC1 was detected with the c-myc antibody (Table 2.5). Nuclei (blue) 
are stained with DAPI. Scale bars are 20 µm.  
 
Leucine 607 is part of a predicted leucine zipper located in DISC1 exon 9 
(DISC1LZ9), spanning amino acids 607-628. This putative leucine zipper is thought 
to be important for the correct nuclear targeting of DISC1, as alanine substitutions at 
positions 614 and 621 result in exclusion of DISC1 from the nucleus (Sawamura et 
al, 2008) (Table 3.2). To confirm that DISC1LZ9 is indeed an important cis-acting 
element that controls the nuclear distribution of DISC1, the subcellular distribution 
of a mutant form of DISC1 lacking LZ9 (DISC1 LZ9) was analysed in transfected 
COS7 cells. As expected, deletion of LZ9 prevents the nuclear accumulation of 
DISC1, suggesting that the defective nuclear targeting of DISC1-607F may arise 
from its disruption of this important structural motif (Figure 3.12).  
 
 
Figure 3.12 Subcellular distribution of DISC1 LZ9. Confocal images of a 
representative COS7 cell expressing DISC1 LZ9 and stained with the Flag RPC 
antibody (green). Nuclei (blue) are stained with DAPI. The scale bar is 20 µm.  
 
Interestingly, besides interfering with the nuclear targeting of DISC1, 607F 




fewer large punctate cytoplasmic structures evidenced by immunocytochemistry  
(Figure 3.13).  
 
 
Figure 3.13 Subcellular distribution of DISC1-607F. Confocal images of 
representative COS7 cells expressing either DISC1-WT or DISC1-607F and stained 
with the Flag RPC antibody (green). Nuclei (blue) are stained with DAPI. The 
cytoplasmic regions delimited by the white squares are magnified in the panels on 
the right. Scale bars are 20 m. 
 
Due to the propensity of DISC1 to oligomerise (Leliveld et al, 2008; Leliveld et al, 
2009; Narayanan et al, 2011; Ottis et al, 2011), I hypothesised that risk-conferring 
DISC1 variants 37W and 607F might affect the nuclear targeting of wild-type DISC1 
in a dominant-negative fashion. To further examine this, DISC1-37W or DISC1-
607F were co-expressed with wild-type DISC1 in COS7 and SH-SY5Y cells and the 
subcellular distribution of each variant was analysed by immunocytochemistry, using 
cells transfected with wild-type DISC1 only as a control.  As expected, when wild-
type DISC1 is expressed alone it translocates to the nucleus, where it is detectable as 
numerous bright puncta on a more diffuse background (Figure 3.14).  As predicted, 
both DISC1-37W and DISC1-607F reduce the formation of wild-type DISC1 puncta 
in the nucleus and, as observed in a separate study (Ogawa F., unpublished data), 
DISC1-37W recruits wild-type DISC1 to large perinuclear mitochondrial aggregates 





Figure 3.14 Dominant-negative effect of DISC1-37W and DISC1-607F. Subcellular 
distribution of Flag-DISC1 (green) and Myc-DISC1 (red) in representative COS7 (A) 




with an equal amount of either pcDNA4/TO-Myc DISC1-WT (top), pcDNA4/TO-Myc 
DISC1-37W (middle) or pcDNA4/TO-Myc DISC1-607F (bottom). Flag-DISC1 and 
Myc-DISC1 were detected using the Flag RPC and c-myc antibodies, respectively. 
Magnifications of the nuclei are shown in the far-right panels in (A). Nuclei (blue) are 
stained with DAPI. Scale bars are 20µm (A) and 10µm (B).  
 
3.3.1.3 Analysis of the mitochondrial distribution of DISC1 variants  
A pool of DISC1 normally localises to mitochondria and is involved in 
mitochondrial function (Atkin et al, 2011; Brandon et al, 2005; James et al, 2004; 
Millar et al, 2005a; Ozeki et al, 2003; Park et al, 2010). Given that 37W has been 
shown to both enhance the recruitment of DISC1 to this organelle and induce 
mitochondrial clustering in the perinuclear region (Ogawa F. unpublished data), the 
potential effect of other DISC1 amino acid substitutions on the mitochondrial 
targeting of the protein and/or mitochondrial morphology was examined by 
immunocytochemistry. As shown in figure 3.15, amino acid substitutions 264Q, 
432L, 603I, 607F and 704C do not appear to interfere with DISC1 mitochondrial 
targeting, nor do they grossly alter mitochondrial morphology. However, since a 
precise quantification of the mitochondrial pool of DISC1 was not carried out in this 
thesis, it is not possible to exclude that the above variants may have more subtle 





Figure 3.15 Mitochondrial distribution of DISC1 variants. COS7 cells expressing the 




the fluorescent mitochondrial dye Mitotracker (red) and analysed by confocal 
microscopy. Nuclei (blue) are stained with DAPI. Scale bars are 20 µm.  
 
3.3.2 Mouse Disc1 variants 
The ENU-induced amino acid substitutions Q31L and L100P determine depression-
like and schizophrenia-like behavioural phenotypes in mice, respectively (Clapcote 
et al, 2007). Both mutations reduce Disc1 interaction with PDE4B and GSK3  
(Clapcote et al, 2007; Lipina et al, 2011a; Lipina et al, 2011b). Additionally, 31L 
inhibits the activity of PDE4 and enhances that of GSK3 , while 100P affects 
dopamine function (Clapcote et al, 2007; Lipina et al, 2011a; Lipina et al, 2010; 
Lipina et al, 2011b). Amino acid positions 31 and 100 are not conserved between 
human and mouse, and nor 31L or 100P correspond to known clinical mutations 
(Table 3.1, Figure 3.1) (Soares et al, 2011). However, since they both occur in the 
proximity of functional domains or protein binding regions within Disc1 and they 
both have the potential to introduce deleterious structural changes, these amino acid 
substitutions might affect the subcellular distribution of the protein, and could 
provide useful clues on the relation between altered DISC1 distribution and function 
(Table 3.1, Figure 3.1) (Soares et al, 2011). In particular, 31L may interfere with the 
nuclear targeting of Disc1 as it is located in close proximity to NLS1 (Table 3.1, 
Figure 3.1) (Soares et al, 2011). To test for possible effects of 31L and 100P on 
Disc1 localisation, the distribution of mDisc1-WT, 31L and 100P was analysed by 
immunocytochemistry in transfected COS7 cells (Figure 3.16). Overall, the 
distribution of mouse Disc1 is very similar to that of the human protein, the only 
exception being that the nuclear staining is slightly less prominent for the former 
(Figure 3.16).  Qualitative comparison of transfected cell images did not reveal any 
gross abnormalities in the subcellular distribution of Disc1 mutants 31L and 100P 
(Figure 3.16). In particular, the nuclear distribution of Disc1-31L was 
indistinguishable from that of the wild-type protein (Figure 3.16). However, these 
observations do not exclude the possibility that either Disc1 mutant may have more 






Figure 3.16 Subcellular distribution of Disc1 mutants 31L and 100P. Representative 
COS7 cells expressing mDisc1-WT, 31L or 100P and stained with the Flag RPC 





3.4 Analysis of the subcellular distribution of DISC1 variants by 
subcellular fractionation 
To further examine the impact of risk-conferring amino acid substitutions 37W and 
607F on the subcellular distribution of DISC1, whole cell lysates and subcellular 
protein fractions were prepared from transfected and untransfected SH-SY5Y cells as 
described in paragraph 2.5.3, and analysed by western blotting. Cellular proteins 
were fractionated into cytoplasmic extract (CE), membrane-bound extract (ME), 
soluble nuclear extract (SNE), chromatin-bound nuclear extract (CBNE) and 
cytoskeletal extract (CSKE). To verify the purity of the individual subcellular protein 
fractions, a mock-transfected cell sample was included in each fractionation 
experiment, and the resulting fractions were analysed in parallel by western blotting 
using specific antibodies to detect fraction-specific proteins, which were used as 
fraction markers (Figure 3.17). As expected, heat shock protein 90 (HSP90) was 
highly enriched in the CE, whereas the nuclear matrix protein p84 was 
predominantly found in the SNE (Figure 3.17). Similarly, the cytoskeletal protein 
Vimentin was enriched in the CSKE, and Calreticulin in the ME (Figure 3.17). On 
the other hand, chromatin-bound histone 3 (H3) was detected both in the CBNE and 
in the CSKE, indicating that the latter fraction is contaminated by chromatin-
associated proteins (Figure 3.17). A similar distribution profile of the above fraction 
markers was detected in all sets of fractions examined, which guarantees the 
comparability of the subcellular expression profiles of exogenous DISC1 observed in 






Figure 3.17 Purity control of subcellular protein fractions. Mock-transfected SH-
SY5Y cells were subjected to subcellular fractionation, and equal amounts of protein 
for each fraction were analysed in parallel by western blotting using antibodies to 
detect proteins that are known to be enriched in either one of the fractions. ME: 
membrane exctract, CE: cytoplasmic extract, CSKE: cytoskeletal extract, SNE: 
soluble nuclear extract, CBNE: chromatin-bound nuclear extract. The size (kDa) and 
position of the protein markers is indicated.  
 
3.4.1 Distribution of endogenous and exogenous DISC1 
To compare the subcellular distribution of endogenous and exogenous DISC1, 
subcellular fractions were prepared from SH-SY5Y cells that had been either 
transfected with pcDNA4/TO-Flag DISC1-WT or left untransfected (Figure 3.18). 
Both the exogenous and the endogenous full-length 100 kDa DISC1 isoform can be 
detected in the membrane-bound, cytoplasmic, soluble nuclear and cytoskeletal 
extracts, but not in the chromatin-bound nuclear extract (Figure 3.18). However, 
while exogenous DISC1 is predominantly enriched in the cytoskeletal fraction, 
which contains most of the protein, endogenous DISC1 mainly distributes to the 
cytoplasmic and membrane-bound fractions, and it is scarcely represented in the 
cytoskeletal extract (Figure 3.18). The absence of DISC1 from the chromatin-bound 
nuclear extract implies that the contamination of the cytoskeletal extract with 
proteins from this fraction does not prevent the accurate quantification of 




that of the endogenous protein except for the cytoskeletal fraction, where the vast 




Figure 3.18 Distribution of exogenous and endogenous DISC1 in subcellular 
fractions. Equal amounts of subcellular protein exctracts obtained from SH-SY5Y 
cells that were either transfected with pcDNA4/TO-Flag DISC1-WT (left) or 
untransfected (right) were analysed by western blotting to detect exogenous and 
endogenous DISC1, respectively. Exogenous DISC1 was detected with the Flag 
MMC antibody, whereas endogenous DISC1 was detected with and antibody raised 
against the C-terminus of the protein that specifically recognises the 100 kDa 
isoform of DISC1 (α-DISC1). ME: membrane exctract, CE: cytoplasmic extract, 
CSKE: cytoskeletal extract, SNE: soluble nuclear extract, CBNE: chromatin-bound 
nuclear extract. The position and size (kDa) of the protein marker is indicated.  
 
3.4.2 Distribution of DISC1 variants 37W and 607F 
To compare the subellular distribution of DISC1-WT, DISC-37W and DISC1-607F, 
SH-SY5Y cells were transfected with equal amounts of the respective pcDNA4/TO-
Flag DISC1 expression constructs before being subjected to subcellular fractionation. 
Before fractionation, a small aliquot of transfected cells were lysed in RIPA buffer, 
which contains particularly strong detergents, and the resulting whole cell lysate was 
later used to determine the total expression level of exogenous DISC1 (Figure 3.19). 
For each DISC1 variant, equal amounts of each subcellular protein extract were 
analysed in parallel by western blotting, and the respective DISC1 band intensities 
were corrected using appropriate loading controls (p84 for nuclear extracts, GAPDH 
for cytoplasmic extracts, Calreticulin for membrane-bound extracts and Vimentin for 




duplicate, and the mean relative DISC1 band density was taken as one technical 
replicate. To correct for variation in DISC1 total expression levels, the relative 
protein abundance of DISC1 variants in each fraction was divided by the respective 
GAPDH-corrected protein abundance in whole cell lysates.  
While the total expression levels of exogenous DISC1-WT, DISC1-37W and DISC1-
607F do not differ significantly, the relative nuclear abundance of DISC1-37W and 
DISC1-607F is decreased by 50% compared to DISC1-WT (P<0.01, Figure 3.19). 
This is equivalent to the reduction in nuclear expression of DISC-37W and DISC1-
607F observed in COS7 cells by immunocytochemistry (Figures 3.6 and 3.6). In 
addition, while the relative protein abundance of DISC1-WT, DISC1-37W and 
DISC1-607F is comparable in the cytoplasmic and membrane-associated fractions, 
DISC1-607F is strongly depleted from the cytoskeletal extract (P<0.01, Figure 3.19), 






Figure 3.19 Subcellular distribution of DISC1 variants 37W and 607F. Distribution of 




protein fractions obtained from transfected SH-SY5Y cells. The loading controls are 
proteins known to be preferentially enriched in either of the different subcellular 
fractions analysed. The bars represent the average of four independent 
experiments. All the densitometry data are normalised to the relative band intensity 
of DISC1-WT. The position and size (kDa) of the protein markers is indicated. Data 
were analysed by one-way ANOVA followed by Dunnett’s Multiple Comparisons 
Test.  
 
3.4.3 Dominant-negative effect of DISC1 variants 37W and 607F 
To further test if DISC1-37W and DISC1-607F can disrupt the nuclear targeting of 
DISC1-WT in a dominant-negative fashion, whole cell lysates and nuclear protein 
extracts from SH-SY5Y cells expressing wild-type DISC1 alone or in combination 
with either DISC1-37W or DISC1-607F were analysed by western blotting. The 
different DISC1 expression constructs used in this experiment achieved comparable 
levels of protein expression, as confirmed by western blotting analysis of lysates 
from transfected SH-SY5Y cells (Figure 3.20).  
 
 
Figure 3.20 Testing of DISC1 expression constructs. Whole cell lysates were 
obtained from SH-SY5Y cells that were either mock transfected or transfected with 
equal amounts of the indicated pcDNA4/TO-DISC1 expression constructs, and 
analysed by western blotting. DISC1 expression was assessed using the α-DISC1 
antibody (Table 2.5) to ensure that comparable total exogenous DISC1 expression 
was achieved, and the antibody concentration was adjusted so that only exogenous 





As shown in Figure 3.21, co-expression of DISC1-37W or DISC1-607F results in a 
significant decrease in nuclear abundance of wild-type DISC1 (P<0.01), with this 
effect being particularly pronounced for the 37W variant when compared to 607F 
(P<0.05). This finding is in agreement with the impaired nuclear localisation of 
DISC1-WT upon co-expression of DISC1-37W or DISC1-607F observed by 
immunocytochemistry in both COS7 and SH-SY5Y cells (Figure 3.14). Collectively, 
the results obtained by immunocytochemistry and subcellular fractionation predict 
that 37W or 607F carriers may have reduced nuclear DISC1 expression, and that 
607F homozygotes may be similar to 607F heterozygotes in this particular respect. 
 
 
Figure 3.21 SH-SY5Y cells were transfected with Flag-WT DISC1 and an equal 
amount of either Myc-DISC1-WT, Myc-DISC1-37W or Myc-DISC1-607F. The 
relative abundance of Flag-WT DISC1 was then quantified by western blotting in 
whole cell lysates and nuclear extracts (NE) prepared from the transfected cells. 
The bars represent the average of 3 independent experiments. The data are 
normalised to the relative band density of Flag-DISC1 in samples expressing WT 
DISC1 only and were analysed by one-way ANOVA followed by Dunnett’s multiple 
comparison test, except where indicated. **P<0.01; # paired two-tailed student’s t-
test.  
3.5 Discussion 
Growing evidence indicates that by establishing dynamic interactions with multiple 
binding partners, DISC1 functions as a hub protein whose principal role is to 
modulate various cellular processes in a space- and time-regulated manner. Sequence 




interactions are therefore likely to have functional consequences, and may highlight 
biological processes involved in psychopathology. 
In this chapter, I have demonstrated that both the ultra-rare, putatively causal 
mutation 37W, observed in a patient diagnosed with schizophrenia and not in 10.000 
control alleles (Song et al, 2008), and the common polymorphism 607F induce a 
50% depletion of the nuclear pool of DISC1, and perturb the nuclear targeting of 
wild-type DISC1 in a dominant-negative fashion. 
The 37W mutation disrupts a highly conserved tetra-arginine nuclear localisation 
signal, which I have previously referred to as NLS1, in the otherwise poorly 
conserved head region of DISC1 (Sawamura et al, 2008). There is contrasting 
evidence regarding the importance of NLS1 for DISC1 nuclear targeting (Brandon et 
al, 2005; Sawamura et al, 2008) (Table 3.2), but the detrimental effect of 37W 
suggests that the integrity of NLS1 is indeed necessary for the correct nuclear 
localisation of DISC1. However, 37W additionally dramatically increases the 
recruitment of DISC1 to perinuclear mitochondrial aggregates (Ogawa F., 
unpublished data), an effect that may in itself obstruct DISC1 translocation to the 
nucleus. Here, I have provided evidence that the defective nuclear targeting of 
DISC1-37W and its increased recruitment to the mitochondria are likely two 
independent consequences of the 37W mutation. Thus, although additional 
mechanisms cannot be excluded, my results strongly suggest that 37W impairs 
DISC1 nuclear targeting by directly disrupting NSL1, providing further confirmation 
that this is a functional NLS within DISC1.  
The common polymorphism 607F is located in a conserved predicted leucine zipper 
(DISC1LZ9) which was previously shown to contribute to DISC1 nuclear targeting 
(Sawamura et al, 2008) (Table 3.2). Here, I confirmed that DISC1LZ9 in indeed 
essential for the correct nuclear localisation of DISC1. Thus, the predicted disruption 
of this leucine zipper structural feature by 607F (Soares et al, 2011) likely explains 
the reduced DISC1 nuclear targeting induced by this amino acid substitution.  
Depending on the construct tested, DISC1 is capable of forming dimers, octamers 
and other oligomers and multimers (Brandon et al, 2004; Kamiya et al, 2005; 




transfected cells expressing wild-type and variant DISC1, hetero/oligomerisation will 
likely occur, accounting for the dominant-negative effects reported here. Indeed, 
DISC1-37W recruits wild-type DISC1 to perinuclear mitochondrial aggregates 
(Ogawa F., unpublished data).  It is therefore possible that the dominant-negative 
effect exerted by DISC1-37W on the nuclear targeting of wild-type DISC1 results 
from redistribution of wild-type DISC1 to mitochondria. I have observed a 
significant, but milder reduction in nuclear abundance of wild-type DISC1 upon co-
expression of DISC1-607F. 607F is located close to a region of DISC1 (668-747) 
identified as essential for oligomerisation (Leliveld et al, 2009), and it resides within 
a predicted leucine zipper, a structural motif generally known to promote protein 
oligomerisation (Soares et al, 2011). Thus, the dominant-negative effect of DISC1-
607F may be related to the potentially altered oligomerisation propensity of this 
variant form of DISC1, which may interfere with the normal oligomerisation of wild-
type DISC1 by establishing partial interactions with it. Formal testing of this 
hypothesis will only be possible once the structural effects of 607F have been 
established experimentally. Collectively, these observations indicate that nuclear 
expression of wild-type and variant DISC1 will likely be reduced in 37W or 607F 
carriers, with consequent impairment of the nuclear function of DISC1. In this 
respect, it is important to remark that the average population frequency of 607L/607F 
heterozygotes and 607F/607F homozygotes is 23% and 2.2%, respectively, implying 
that, on average, 25% of the population carries at least one 607F allele 
(http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs6675281). Hence, while the 
data presented here suggest that the 607F allele might profoundly affect DISC1 
nuclear localisation, this variant is not strongly associated with schizophrenia or 
other major mental disorders. This suggests that, consistent with the complex 
aetiology of these diseases, the penetrance of the 607F allele likely depends on the 
individual’s genetic and environmental context.  
Here, I showed that exogenously expressed full-length DISC1 is highly enriched in 
the cytoskeletal protein fraction, which is consistent with its prominent role in the 
regulation of cytoskeleton-dependent processes (Wang et al, 2010a), and that variant 
607F markedly reduces the relative abundance of DISC1 in this fraction. This effect 




immunocytochemistry, and is consistent with the predicted deleterious consequences 
of 607F on DISC1 structure and oligomerisation propensity (Soares et al, 2011). It is 
possible that the abnormal cytoskeletal fractionation and cytoplasmic distribution of 
DISC1-607F may arise from its impaired ability to assemble into functional 
complexes and establish proper connections with cytoskeleton-associated partners. 
Interestingly, 607F has been associated with impaired centrosomal recruitment of 
PCM1 and reduced neurotransmitter release (Eastwood et al, 2009; Eastwood et al, 
2010), as well as defective mitochondrial trafficking in neurons (Atkin et al, 2011). It 
is intriguing to speculate that these reported effects of 607F may be related to its 
reduced association with the cytoskeleton.   
Despite its aberrant cytoskeletal and cytoplasmic distribution, DISC1-607F appears 
to normally distribute to the centrosome. Since the analysis of the centrosomal 
distribution of DISC1 variants was carried out on a relatively small cell sample, it is 
not possible to confidently speculate on the results. However, it appears that DISC1 
centrosomal targeting might be differentially perturbed by distinct amino acid 
substitutions, and that 607F might become deleterious only when present in 
combination with 264Q or 704C. If confirmed, this observation would be consistent 
with the reported cumulative effect of 607F and 704C on the centrosomal 
immunoreactivity of PCM1 in glial cells in post-mortem human brains (Eastwood et 
al, 2010). Here, PCM1 immunoreactity is lower in 704C carriers that are also 607F 
homozygotes compared to 704C carriers that are 607F heterozygotes or 607L 
homozygotes (Eastwood et al, 2010).  
Finally, since 37W is known to profoundly impact on DISC1 mitochondrial 
recruitment and morphology, which may contribute to its putative pathogenic role 
(Ogawa F., unpublished data), I tested whether any of DISC1 variants 264Q, 432L, 
603I, 607F and 704C produces a similar effect. My findings indicate that none of the 
above amino acids substitutions grossly disturb mitochondrial morphology and/or 
DISC1 recruitment to this organelle. It appears then that different DISC1 amino acid 
substitutions might increase the risk of psychiatric illness by impacting on distinct 




4 The effect of DISC1 on transcriptional regulation  
4.1 Introduction 
In the nucleus, DISC1 interacts with two members of the ATF4 sub-family of bZIP 
transcription factors: ATF4 and ATF5 (Millar et al, 2003; Morris et al, 2003; 
Sawamura et al, 2008).  Both ATF4 and ATF5 are stress-inducible transcription 
factors that are preferentially translated in response to many different cellular 
stressors, including amino acid limitation, endoplasmic reticulum stress and 
oxidative stress (Ameri & Harris, 2008; Watatani et al, 2008; Zhou et al, 2008a). By 
using reporter-based assays in human cell lines, Sawamura and colleagues 
demonstrated that DISC1 regulates the transcriptional activity of ATF4 (Sawamura 
et al, 2008). In particular, DISC1 co-expression significantly represses Gal4 
promoter transactivation by a Gal4-ATF4 chimera and strengthens the ATF4-
mediated repression of cAMP-induced CRE-dependent transcription (Sawamura et 
al, 2008). The same study also showed that DISC1 interaction with ATF4 is 
mediated by a putative leucine zipper motif located in DISC1 exon 9 (DISC1LZ9), 
between amino acids 607 and 628. Indeed, deletion of DISC1LZ9 completely 
abolishes ATF4 binding and, accordingly, it suppresses DISC1-dependent regulation 
of ATF4 transcriptional activity (Sawamura et al, 2008). Since a region in the C-
terminus of DISC1 also mediates binding to the nuclear receptor co-repressor N-
CoR, a transcriptional co-repressor that recruits histone deacetylase to the 
transcriptional machinery (Jepsen & Rosenfeld, 2002), it was hypothesised that 
DISC1 may act by recruiting this factor to the ATF4-containing complex (Sawamura 
et al, 2008).  
The transcriptional targets of ATF4 are not limited to CRE-containing genes. Indeed, 
ATF4 homo- or heterodimers are known to bind other response elements, including 
the composite C/EBP-ATF4 response elements (CARE), which mediate the ATF4-
dependent activation of several stress-responsive genes (Kilberg et al, 2009). ATF4-
responsive CARE-containing targets include, but are not limited to, genes involved 
in the response to amino acid limitation, such as asparagine synthetase (ASNS), 




aspartate/glutamate/cystine transporter (SLC7A11), and genes with pro- or 
antiapoptotic functions, such as C/EBP homology protein (CHOP) and Tribbles 3 
(TRB3) (Kilberg et al, 2009). In particular, ATF4 activates the transcription of 
CHOP by binding to a specific type of CARE in its promoter, known as the Amino 
Acid Response Element (AARE) (Fawcett et al, 1999; Ma et al, 2002b; Shan et al, 
2009). Although ATF4 is not the only transcription factor to be preferentially 
translated in response to cellular stress, ectopic expression of ATF4 alone is 
sufficient to induce transcriptional activation of CARE-containing genes in the 
absence of stress, but it does so at a relatively lower efficiency compared to stress-
induced endogenous ATF4 (Shan et al, 2009). This suggests that, although ATF4 is 
able to independently activate the stress response, other stress-responsive factors 
normally modulate its activity (Shan et al, 2009).  
In chapter 3 of this thesis I demonstrated that risk-conferring DISC1 amino acid 
substitutions 37W and 607F result in defective nuclear targeting of the protein in cell 
lines and primary neurons. This implies that both 37W and 607F may potentially 
impair the nuclear functions of DISC1, and that this mechanism may contribute to 
the increased risk of psychiatric illness associated with these variants. Thus, in this 
chapter I investigate the potential effects of these and other schizophrenia-associated 
variants on the ability of DISC1 to regulate ATF4-dependent transcription on CRE- 
and CARE-containing reporters.  
4.2 Generation of luciferase reporter constructs 
Most of the experiments described in this chapter were performed using the reporter 
vector SomCRE-Luc (Table 2.2), which drives the expression of Firefly luciferase 
under the control of four multimerised copies of the palindromic Somatostatin CRE 
5'-(AGCC[TGACGTCA]GAG)-3′ (CRE denoted in brackets) located immediately 
upstream of a minimal promoter (TATA box).  
The luciferase reporter vector pGL4.23-CRE was used to perform experiments in 
hard-to-transfect cells, since it carries a codon-optimised Firefly luciferase cDNA 
that guarantees very efficient protein expression in mammalian cells. The reporter 




F and CRE mut R (Table 2.8) between the XhoI and HindIII restriction sites of the 
vector pGL4.23[luc2/minP] (Table 2.2), which contains a minimal promoter (TATA 
box) upstream of the Firefly luciferase cDNA. To guarantee comparability between 
experiments carried out using the SomCRE-Luc and pGL4.23-CRE reporters, the 
sequence, number and spacing of the CREs in the resulting vector was identical to 
that of the SomCRE-luc reporter.  
The reporter vector pGL4.23-CHOP AARE and its mutant, non responsive version 
pGL4.23-mutCHOP AARE were generated by site-directed mutagenesis from 
pGL4.23[luc2/minP], using mutagenic primers CHOP AARE F and R and mutCHOP 
AARE F and R, respectively (Table 2.6). Mutagenic primers contained two copies of 
the core CHOP Amino Acid Response Element (AARE) (underlined) and its 
flanking regions: CHOP AARE, 5' AACATTGCATCATCCCCGC 3' and mut 
CHOP AARE, 5' AACAATGCATCATCCCCGC 3' (Bruhat et al, 2002), which only 
differed from each other by the base in bold. 
4.3 Design and optimisation of luciferase reporter assays 
Several preliminary experiments were carried out to determine the transfection 
conditions that achieved the best possible signal-to-noise ratio in luciferase reporter 
assays without producing cell toxicity.  Different transfection methods and 
conditions were tested and compared in SH-SY5Y, HEK293 and HeLa cells. 
4.3.1 SH-SY5Y cells 
For luciferase reporter assays, SH-SY5Y cells were initially transfected with Fugene 
HD transfection reagent, which is designed to achieve good transfection rates in 
hard-to-transfect cells forming a high-density monolayer. To determine the optimal 
cell density and Fugene HD:DNA ratio, cells were seeded in 12 well plates and 
transfected with the P5HuSH-GFP expression plasmid (Table 2.2) as detailed in 
Figure 4.1, then the transfection efficiency was visually assessed at 24 hour intervals 
using an inverted fluorescence microscope. The transfection rate gradually increased 
with the Fugene HD:DNA ratio, up to a maximum of 20-30%, and was not affected 




toxicity at lower cell densities. Higher numbers of transfected cells were obtained 
when cells were harvested 48 or 72 hours post-transfection compared to 24 hours 
post-transfection (not shown).  
In a second experiment, higher Fugene HD:DNA ratios were tested in the same way, 
but only on cells seeded at high density, as shown in Figure 4.2, and the transfection 
efficiency was assessed as before. This identified 4:0.8 as the optimal Fugene 
HD:DNA ratio, and 72  hours as the best incubation time post-transfection. These 
conditions achieved a transfection rate of 30-40% (not shown). 
Next, cells were seeded in 96 well plates, and the optimised cell density was 
proportionately scaled down to 2x10
4
/well. To determine the minimum amount of 
transfected reporter DNA/well necessary to achieve a good signal-to-noise ratio in 
luciferase assays, four transfection mixes containing reporter DNA and the empty 
vector pRK7 (Table 2.2) mixed in different proportions were assembled in OptiMEM 
as detailed in Table 4.1.  
 
 
Figure 4.1 SH-SY5Y transfection scheme. The three rectangles in A, B and C 
represent 12 well tissue culture plates, and are subdivided in 12 smaller rectangles, 
each representing an individual well. Each well is further divided in two triangles; the 
number in the upper triangle indicates the corresponding plating cell density 




(µl:µg) used to transfect cells in each well. To control for potential toxic effects of 
GFP overexpression, cells in plate 3, row 1, were transfected with the empty vector 




Figure 4.2 SH-SY5Y transfection scheme. The smaller rectangles represent 
individual wells of a 12 well plate. The corresponding Fugene HD:DNA ratios and 
plasmid DNA are indicated in the upper and lower triangles, respectively. The “X” 
indicates that cells in the corresponding well were not transfected.  
 
In 40 µl mix: 1 µg DNA, 4µl Fugene HD 
Mix SomCRE-Luc (ng) TK-Renilla (ng) pRK7 (ng) 
A 50 5 945 
B 100 10 890 
C 200 20 780 
D / / 1000 
 
Table 4.1 Transfection mixes for luciferase assay.  The indicated amounts of CRE 
(SomCRE-Luc) and internal control (TK-Renilla) reporter vectors were mixed with 
the empty vector pRK7, Fugene HD and OptiMEM to obtain a total volume of 
transfection mix of 40 µl. For ease of calculation, the Fugene HD:DNA ratio was 




Cells were transfected in triplicate with increasing volumes of each transfection mix, 
as shown in Figure 4.3. To activate CRE-dependent transcription, cells were treated 
for 4 hours with either 100 µM forskolin or vehicle (DMSO) starting from 24, 48 or 
72 hours after transfection, then the luciferase activity was measured as described in 
paragraph 2.7.1. None of the tested conditions produced luminescence readings 
significantly above the background value, which corresponded to the readings in 
cells transfected with the empty vector only (mix D) (not shown). 
 
 
Figure 4.3  SH-SY5Y transfection and assay scheme. The small squares delimited 
by dashed lines represent individual wells of a 96 well plate. The letters (A, B, C and 
D) indicate the transfection mix that was added to the cells in the respective wells, 
and the numbers indicate the volume of transfection mix that was added to the wells 
in the respective columns. In each plate, the wells in the top half were treated with 
forskolin (FSK) and the wells in the bottom half were treated with vehicle (DMSO).  
 
In an attempt to improve the transfection efficiency achieved with the selected 
protocol, cells seeded in 96 well plates were transfected with the P5HuSH-GFP 
vector and pRK7 mixed in different proportions, as shown in Table 4.2. The 
transfection mixes were incubated at room temperature for either 15 or 40 minutes, 
and then increasing volumes (4, 8, 12, 16 and 20 µl) of each mix were added to the 
cells. The best proportion of GPF-expressing cells ( 40-50%) with the least signs of 
cell toxicity were achieved with transfection mix D added to the cells at 12 µl/well 






40 µl mix 
Mix P5HuSH (ng) pRK7(ng) 
A (4:1) 50 950 
B (4:1) 100 900 
C (4:1) 200 800 
D (4:1) 400 600 
E (4:1.6) 400 1200 
F (12:8) 1600 6400 
G (16:4) 800 3200 
Mock (4:1) / 1000 
Mock (4:1.6) / 1600 
Mock (12:8) / 8000 
 
Table 4.2 SH-SY5Y transfection mixes for GFP expression test in 96 well plates. 
The indicated amounts of plasmids were mixed in OptiMEM, to achieve a total 
volume of 40 µl. The Fugene HD:DNA ratios used in each mix are in brackets.  
 
Next, the newly optimised transfection conditions were further tested in a luciferase 
reporter assay in 96 well plates. The transfection mixes were assembled as described 
in Table 4.3, and added to the cells at 12 µl/well. 48 hours after transfection, the cells 
were treated for 4 hours with 100 µM forskolin or DMSO, as described before, 
before being assayed for luciferase activity. However, even with the improved 
transfection conditions, the luminescence signal-to-noise ratio achieved was not 






In 40 µl mix: 1µg DNA, 4µl Fugene HD 
Mix SomCRE-Luc (ng) TK-Renilla (ng) pRK7 (ng) 
D 400 40 560 
D2 600 60 340 
D3 800 80 120 
Mock / / 1000 
 
Table 4.3  SH-SY5Y transfection mixes for luciferase assay.  
 
Next, nucleofection was tested as an alternative transfection method to perform 
luciferase reporter assays in SH-SY5Y cells (see paragraph 2.4.6.3). Cells were 
transfected with either pGL4.29[luc2P/CRE/Hygro] (Table 2.2), a commercially 
available CRE-luciferase reporter optimised to achieve high luciferase expression 
levels in mammalian cells, or SomCRE-Luc, as shown in Table 4.4. 24 hours after 
transfection, cells were treated with 10 µM forskolin for 4 hours before being 
assayed. The reporter pGL4.29[luc2P/CRE/Hygro], but not SomCRE-Luc, produced 
a good luminescence signal (not shown). However, the signal generated by Renilla 
luciferase was extremely low. This was resolved by replacing the TK-Renilla internal 
control with the SV40-Renilla reporter (Table 2.2), which expressed luciferase at 
higher levels in SH-SY5Y cells (not shown). 
 






A 600 / 60 1340 





Table 4.4 Amounts of DNA used to transfect SH-SY5Y cells by nucleofection. 
Detailed methods are described in paragraph 2.4.6.3.  
 
4.3.2 HEK293 cells 
Fugene HD was also tested in HEK293 cells, which normally achieve very high 
transfection rates. Cells were plated in 96 well plates in 100 µl/well of medium, at 
densities of 1, 2, 3, 4 or 5x10
4 
cells/well, and transfected with 4 µl/well of a mix 
containing either the pRK7 vector alone or in combination with P5HuSH-GFP (Table 
4.5). The following Fugene HD:DNA ratios were tested: 1.5:1, 2:1, 2.5:1, 3:1, 3.5:1 
and 4:1, and the proportion of GFP-expressing cells was assessed visually after 24 
and 48 hours. The highest transfection rate (70-80%) and lowest toxicity was 
achieved in cells seeded at 5x10
4 
cells/well and transfected for 48 hours with a mix 
containing Fugene HD and DNA in a 4:1 ratio (not shown). 
  
In 40 µl mix: 1 µg DNA and 1.5, 2, 2.5, 3, 3.5 or 4 µl Fugene HD 
Mix P5HuSH (ng) pRK7 (ng) 
A 300 700 
B / 1000 
 
Table 4.5 HEK293 transfection mixes for GFP expression test in 96 well plates.  
 
In a similar experiment, cells were transfected with increasing volumes of 
transfection mix to identify the volume that achieved the best transfection rate 
without inducing cell toxicity. As expected, higher volumes of mix achieved higher 
transfection rates, and volumes of 12 or 20 µl/well achieved similar results after 48 
hours, thus both these conditions were further tested in luciferase reporter assays. 




20 µl/well. 48 or 72 hours after transfection, the cells were treated with either 10 or 
100 µM forskolin, 1 mM 8-Br-cAMP or vehicle, and assayed for luciferase activity. 
Overall, the strongest relative luminescence signal was observed in cells that had 
been transfected with 20 µl of mix for 48 hours, and then treated with 10 µM 
forskolin (Figure 4.4). However, in this experiment transfection with 20 µl of mix 
produced evidence of apoptosis (i.e. cells appeared rounded and partially detached) 
(not shown). Therefore, in the following assays the cells were transfected with 12 µl 
of mix for 48 hours and treated with 10 µM forskolin.  
 
In 40 µl mix: 1 µg DNA, 4 µl Fugene HD 
Mix SomCRE-luc (ng) TK-Renilla (ng) pRK7 (ng) 
A 300 30 670 
B / / 1000 
 




Figure 4.4 Pilot luciferase assay in HEK293 cells. Cells were transfected with 12 or 
20 µl of the transfection mixes detailed in table 4.6 for either 48 or 72 hours, then 




4.3.3 HeLa cells 
Initially, cells seeded in 96 well plates at a cell density of 2 or 5x10
4
/well were 
transfected with mixes assembled as described in Table 4.5, using a Fugene 
HD:DNA ratio of 4:1. The mixes were added to the cells at 12, 16 or 20 µl/well and 
the proportion of GFP-expressing cells was visually assessed after 24 and 48 hours. 
The highest transfection rate (30-40%) and lowest toxicity was achieved in cells 
seeded at 5x10
4
/well and transfected with 12 µl/well of mix for 48 hours (not 
shown). Since the best transfection rate obtained with Fugene HD in HeLa cells was 
markedly lower that that achieved in HEK293 cells, a further optimisation 
experiment was performed in which the optimised Fugene HD transfection protocol 
was compared to Lipofectamine 2000 transfection.  The Lipofectamine 2000 
transfection mixes were assembled in OptiMEM using 1 µg of DNA (300 ng 
P5HuSH + 700 ng pRK7) and 2 (mix 1), 3 (mix 2) or 4 (mix 3) µl of Lipofectamine 
2000 in a total volume of 50 µl, and added to the cells at 50, 30 or 15 µl/well, as 
summarised in Table 4.7. Overall, Lipofectamine 2000 performed better than Fugene 
HD, and the highest transfection rate (50-60%) was observed after 48 hours in cells 
seeded at 2x10
4
/well and transfected with 15 µl/well of mix (not shown). Thus, these 
transfection conditions were tested in a luciferase reporter assay using mixes 
assembled as shown in Table 4.8. However, the luminescence signal observed after 4 
hour incubation with 10 µM forskolin was not significantly above background, 
leading to the conclusion that HeLa cells are not a suitable cell model for luciferase 
assays using the specified set of reporters.  
 
Mix # 
Volume of transfection mix (µl) 
added to 5x104 cells/well 
Volume of transfection mix (µl) 
added to 2x104 cells/well 
1 50 30 15 50 30 15 
2 50 30 15 50 30 15 
3 50 30 15 50 30 15 





Table 4.7 Transfection otimisation experiment in HeLa cells. The indicated volumes 
of transfection mixes containing Lipofectamine 2000 (1, 2 and 3) of Fugene HD (4) 
were added to cells seeded at 5 or 2x104/well. 
 
In 50 µl mix: 1µg DNA, 4 µl Lipofectamine 2000 
Mix SomCRE-Luc (ng) TK-Renilla (ng) pcDNA4/TO (ng) 
A 300 30 670 
B / / 1000 
 
Table 4.8 Pilot luciferase assay in HeLa cells. The composition of the mixes used to 
transfect the cells for a pilot luciferase assay is shown.  
 
4.4 The effect of DISC1 on ATF4-dependent transcription 
4.4.1 DISC1 inhibits ATF4-dependent transcription at basal cAMP 
levels 
Sawamura and colleagues (Sawamura et al, 2008) showed that co-expression of 
DISC1 suppresses Gal4-ATF4 mediated transcription and that it enhances the ATF4-
mediated inhibition of CRE-dependent transcription in response to increased 
intracellular cAMP levels. Since ATF4 has also been reported to activate CRE-
mediated transcription under basal (low cAMP) conditions (Koyanagi et al, 2011; 
Liang & Hai, 1997; Ord & Ord, 2003; Vallejo et al, 1993), I initially sought to 
confirm the findings of Sawamura and collegues, and test whether DISC1 regulates 
ATF4-mediated activation of the CRE at basal cAMP levels. 
HEK293 cells were initially chosen to perform luciferase reporter assays because in 
the optimisation tests they yielded a satisfactory transfection rate and luminescence 
signal-to-noise ratio (see paragraph 4.3). Furthermore, HEK293 cells are an 




et al, 2006; Shan et al, 2009; Zhou et al, 2005). Cells were transfected as described 
in paragraph 2.7.1, using the SomCRE-Luc reporter vector and the TK-Renilla 
internal control alone or in combination with different amounts of pRK7-ATF4 
(mouse ATF4, Table 2.2), pcDNA4/TO-Flag DISC1-WT (human DISC1) or both. 
As shown in Figure 4.5 A, at basal cAMP levels, ATF4 activates transcription from 
the CRE, as previously reported (Koyanagi et al, 2011; Liang & Hai, 1997; Ord & 
Ord, 2003; Vallejo et al, 1993), whereas DISC1 on its own has no effect. Consistent 
with the reported inhibition of Gal4-ATF4 by DISC1 (Sawamura et al, 2008), co-
expression of DISC1 significantly inhibits ATF4 transactivation of the CRE (Figure 
4.5 A). As previously observed (Karpinski et al, 1992; Sawamura et al, 2008), 
elevation of intracellular cAMP levels by forskolin treatment strongly activates CRE-
dependent transcription, and this effect is counteracted by ATF4 (Figure 4.5 A). 
DISC1 alone has no effect on the cAMP-dependent activation of CRE-driven 
transcription and, in contrast with the findings of Sawamura and colleagues 
(Sawamura et al, 2008), it does not strengthen ATF4-mediated inhibition (Figure 4.5 
A). Since at the concentrations shown in figure 4.5 A ATF4 inhibits CRE 
transcription very strongly and might have a saturating effect, the experiment was 
repeated using lower, non saturating concentrations of ATF4. This experiment 
confirmed that DISC1 does not modify the inhibitory effect of ATF4 on cAMP-
induced CRE-driven transcription, but it efficiently inhibits ATF4-mediated 






Figure 4.5 (A,B) HEK293 cells were transfected with the luciferase reporters only 
(CRE) or in combination with increasing amounts of pRK7-ATF4 (mouse ATF4), 
pcDNA4/TO-Flag DISC1-WT (human DISC1), or both. The transfected amounts of 
plasmid DNA are indicated in brackets as ng/well. Relative luciferase activity was 
measured after a 4 hour treatment with DMSO of 10 µM forskolin. The bars 
represent the average of at least 4 independent experiments. Data are normalised 
to the basal luciferase activity in DMSO-treated cells transfected with the reporters 
only. Data were analysed by one-way ANOVA and Dunnett’s post test. Pair-wise 
comparisons were performed using two-tailed paired student’s t-test.  
 
As expected, and similarly to mouse ATF4 (Figure 4.5), human ATF4 efficiently 
activates transcription from the CRE at basal cAMP levels, and human DISC1 
inhibits this effect in a dose-dependent manner, but does not modify the inhibitory 




specified, all subsequent experiments were carried out using human ATF4 and 
human DISC1 expression constructs. The discrepancy between these results and 
those reported by Sawamura and colleagues (Sawamura et al, 2008) may arise from 
experimental and/or analytical differences between the two studies such as, for 
example, the use of different cell types. Indeed, Sawamura and colleagues performed 
luciferase reporter assays in HeLa cells (Sawamura et al, 2008). However, this was 
not investigated further in this thesis because initial attempts to optimise the 
experimental conditions to perform luciferase assays in HeLa cells were not 
successful (Paragraph 4.3.3).  
 
 
Figure 4.6 Relative CRE-dependent luciferase activity in HEK293 cells transfected 
with a fixed amount of pCG-ATF4 (human ATF4, Table 2.2) and decreasing 
amounts of human DISC1-WT. Transfected cells were treated for 4 hours with 
DMSO or 10 µM forskolin before being assayed for luciferase activity. The numbers 
indicate the amount (ng/well) of plasmid DNA used for transfection. The bars 
represent the average of at least 5 independent experiments. Data are normalised 
to the basal luciferase activity in DMSO-treated cells transfected with the reporters 
only, and were analysed by one-way ANOVA and Dunnett’s post test. 
 
Attempts to replicate my findings were also carried out in SH-SY5Y cells, using two 




reporters have been codon-optimised to efficiently drive firefly luciferase expression 
in mammalian cells, and were chosen for these experiments because the non codon-
optimised SomCRE-Luc reporter did not produce a detectable signal in SH-SY5Y 
cells (see paragraph 4.2). Moreover, since the Fugene HD transfection protocol 
adopted for HEK293 cells did not achieve a satisfactory signal-to-noise ratio in 
luciferase assays performed in SH-SY5Y cells (see paragraph 4.3.1), these cells were 
transfected by nucleofection, as described in paragraph 2.4.6.3. As shown in Figure 
4.7 A, ATF4 does not significantly activate transcription from the 
pGL4.29[luc2P/CRE/Hygro] reporter in these cells, and it was therefore not possible 
to test for modifying effects of DISC1 using this reporter (Figure 4.7 A). On the 
other hand, ATF4 significantly activates transcription from the pGL4.23-CRE 
reporter in SH-SY5Y cells, and this effect is not modified by DISC1 co-expression 
(Figure 4.7 B).  Similar discrepancies between the effects of ATF4 on different CRE 
reporters have been observed before (Bartsch et al, 1995), and may be caused by 
differences in the number of CRE repeats and/or the nature of the flanking sequence. 
The lack of effect of DISC1 co-expression on ATF4 transactivation activity in SH-
SY5Y cells is in clear contrast with what was observed in HEK293 cells (Figure 4.6). 
However, this discrepancy may be explained by several important experimental 
differences. First, the two experiments were performed using different sets of 
reporter constructs (SomCRE-Luc and TK-Renilla for HEK293 and 
pGL4.29[luc2P/CRE/Hygro] or pGL4.23-CRE and SV40-Renilla in SH-SY5Y), and 
different transfection methods. Secondly, luminescence was assayed 48 hours after 
transfection in HEK293 cells and 24 hours after transfection in SH-SY5Y cells. A 
shorter transfection time was adopted in SH-SY5Y cells because the luminescence 
signal from the internal control (SV40 Renilla) drops below background 48 hours 
after transfection in these cells (not shown). The shorter incubation time post 
transfection may have significantly affected the expression levels of ATF4 and 
DISC1 in SH-SY5Y cells. Additionally, despite the improved luminescence signal 
achieved by nucleofection in SH-SY5Y cells, the luminescence generated by the 
internal control plasmid (SV40-Renilla luciferase) remains very low, and only 
slightly exceeds the background luminescence recorded in untransfected cells. All 




achieved in SH-SY5Y cells compared to HEK293 cells, question the validity of the 
results obtained in the former, and preclude any direct comparison between reporter 
assays carried out in the two cell lines.  
 
 
Figure 4.7 (A, B) SH-SY5Y cells were transfected by nucleofection with the 
reporters only (CRE) or in combination with the indicated amounts (ng) of human 
ATF4 and human DISC1. CRE reporters were pGL4.29[luc2P/CRE/Hygro (A) or 
pGL4.23-CRE (B). The internal control was SV40-Renilla. Relative luciferase activity 
was measured after treatment with DMSO or 10 µM forskolin for 4 hours. The 
indicated amounts of expression plasmid DNA were tested in one (no error bars) or 




luciferase activity in DMSO-treated cells transfected with the reporters only, and 
were analysed by one way ANOVA followed by Dunnett’s multiple comparisons test. 
To test for the specificity of the activating and repressive effects of ATF4 on 
SomCRE-Luc, the experiment was repeated using a dominant-negative mutant form 
of ATF4 (ATF4 RK), which lacks the DNA binding domain (He et al, 2001; Siu et 
al, 2002). The ATF4 RK expression plasmid pCG-ATF4 RK was obtained by 








) in pCG-ATF4 (Table 2.2) by site-directed mutagenesis, using 
mutagenic primers ATF4 RK F and R (Table 2.6). As expected, at basal cAMP 
levels ATF4, but not ATF4 RK, significantly activates transcription from SomCRE-
Luc in HEK293 cells, and DISC1 has no effect on ATF4 RK (Figure 4.8). At high 
cAMP levels, ATF4 RK still significantly inhibits activation of the CRE, albeit to a 
lesser extent compared to ATF4, and DISC1 does not modify this effect (Figure 4.8). 
The latter observation is consistent with the current hypothesis that at high cAMP 
levels ATF4 inhibits CRE-dependent transcription by competing with CREB for 
transcriptional co-factors such as CBP (Thiel et al, 2005), a mechanism that does not 
require DNA binding.  
 
 
Figure 4.8 HEK293 cells were transfected with the reporters only (CRE) or in 
combination with ATF4, ATF4 RK and DISC1, as indicated. Relative luciferase 
activity was measured after a 4 hour treatment with DMSO or 10 µM forskolin. The 




the basal luciferase activity in cells transfected with the reporters only, and were 
analysed by one-way ANOVA and Dunnett’s post test. 
 
4.4.2 The differential effect of DISC1 variants on ATF4-dependent 
transcription 
4.4.2.1 Effects on CRE-driven transcription 
In chapter 3 of this thesis I demonstrated that risk-conferring amino acid 
substitutions 37W and 607F, but not 264R, 432L, 603I and 704C, significantly 
reduce DISC1 nuclear expression, and might thus potentially interfere with the 
nuclear functions of the protein. Having observed that DISC1 represses the ATF4-
dependent activation of CRE-driven transcription at basal cAMP levels, an effect that 
might be conceivably mediated by nuclear DISC1, I next sought to test whether any 
of the above amino acid substitutions affect this particular DISC1 function. Initially, 
all 20 DISC1 variants were simultaneously compared for their ability to inhibit 
mouse ATF4, but no statistically significant effects were observed (Figure 4.9). As 
shown in Figure 4.9, this experiment produced highly variable results, probably 
reflecting technical inconsistencies due to the simultaneous handling of a large 
number of samples. Thus, the following analysis was focused on a selected subset of 
DISC1 variants, which were compared for their ability to inhibit human ATF4. All 
transfections were performed with 120 ng/well of pGC-ATF4, while the amount of 
transfected DISC1 DNA was either 81 (Figure 4.10 A, C) or 20.25 ng/well (Figure 
4.10, B). At basal cAMP levels, all the analysed DISC1 variants retain the ability to 
significantly inhibit ATF4 (P<0.05 for DISC1-704C, P<0.01 for all other variants, 
Figure 4.10 A and B), but the inhibitory effect of DISC1-37W and DISC1-607F is 
significantly weaker compared to DISC1-WT (P<0.05 for 37W, P<0.01 for 607F, 
Figure 4.10 A). As expected, overexpression of the PKA-dependent transcription 
factor CREB1α (Table 2.2), either alone or in combination with DISC1, has no effect 
at basal cAMP levels, when PKA activity is low (Figure 4.10 A).  In addition, at high 
cAMP levels, none of the analysed DISC1 variants significantly modifies the 




are consistent with the detrimental effect of 37W and 607F, but not 432L, 603I and 
704C, on DISC1 nuclear targeting described in chapter 3 of this thesis.  
 
 
Figure 4.9 Relative luciferase activity in HEK293 cells transfected with the reporters 
only (CRE) or in combination with mouse ATF4, with or without the indicated DISC1 
variants. Dots indicate the relative luminescence readings in individual experiments, 
and the mean value for each sample is indicated by a horizontal bar. Data are 
normalised to the basal luciferase activity in cells transfected with the reporters only, 
and were analysed by one-way ANOVA. 
 
 To further investigate the likely relationship between the decreased ability of DISC1 
variants 37W and 607F to inhibit the transcriptional activity of ATF4 and their 
defective nuclear targeting, I tested the effect of DISC1 LZ9, a mutant form of 
DISC1 that fails to accumulate in the nucleus (Figure 3.12). Consistent with its 
exclusion from the nucleus, DISC1 LZ9 does not significantly inhibit ATF4-
mediated activation of CRE-dependent transcription (P<0.05, paired student’s t-test, 
Figure 4.10 C). In contrast with my previous observations, in this particular 
experiment DISC1-WT, but not DISC1 LZ9, significantly dampened ATF4-






Figure 4.10 (A, B and C) HEK293 cells were transfected with the reporters only 
(CRE) or in combination with human ATF4 or CREB1α (A), with our without the 
indicated DISC1 variant. (A, C) Relative luciferase activity was measured after a 4 
hour treatment with DMSO or 10 µM forskolin. Transfected cells analysed in (B) 




Data are normalised to the basal luciferase activity in cells transfected with the 
reporters only, and were analysed by one-way ANOVA followed by Dunnett’s 
multiple comparisons test and paired student’s t-test.  
 
The differential effect of DISC1-WT, DISC1-37W and DISC1-607 on ATF4-
mediated transcription is not caused by differences in expression levels (Figure 4.11). 
Next, to test if the differential effect of DISC1 variants is limited to HEK293 cells, 
their inhibitory effect on ATF4-dependent transcription was compared in MO3.13 
human oligodendrocytes. In these cells, the SomCRE-Luc reporter does not respond 
to ATF4, and produces a very weak response to increased cAMP levels, probably 
due to lower transfection efficiency compared to HEK293 cells (Figure 4.12 A). To 
overcome this, the SomCRE-Luc reporter was replaced with the codon-optimised 
reporter pGL4.23-CRE, which is designed to efficiently drive luciferase expression 
in mammalian cells (see paragraph 4.2). As shown in figure 4.12 B, pGL4.23-CRE 
responds to ATF4 when transfected in MO3.13 cells, and this transcriptional 
activation is significantly inhibited by DISC1-WT, but not DISC1-37W or DISC1-
607F, replicating the findings in HEK293 cells. However, similarly to SomCRE-Luc, 
pGL4.23-CRE responds very weakly to forskolin treatment in MO3.13 cells (Figure 
4.12). The reasons for this are not clear, but it is possible that MO3.13 cells have a 
reduced sensitivity to forskolin, or that they respond differently to increased cAMP 
levels compared to HEK293 cells. Additionally, it cannot be excluded that the 
pGL4.23-CRE reporter has an intrinsically lower capacity to respond to cAMP, 




Figure 4.11 To compare the expression levels of DISC1-WT, DISC1-37W and 




equal amounts of the indicated pcDNA4/TO-Flag DISC1 expression constructs, and 
analysed by western blotting. The loading control is histone 3 (H3) (Table 2.5). The 
position and size (kDa) of the protein markers is shown.  
 
 
Figure 4.12 Relative luciferase activity in MO3.13 cells transfected with the 
reporters only (CRE) or in combination with ATF4 alone, with or without the 
indicated DISC1 variant. Cells were transfected with the SomCRE-Luc (A) or 
pGL4.23-CRE (B) luciferase reporter and treated for 4 hours with DMSO or 10 µM 
forskolin before being assayed for luciferase activity. The bars represent the 
average of one (A) or 3 (B) independent experiments. Data are normalised to the 
basal luciferase activity in DMSO-treated cells transfected with the reporters only, 





Next, I asked whether the ENU-induced mouse mutations Q31L and L100P, which 
are associated with depression- and schizophrenia-like behaviours in mice, 
respectively (Clapcote et al, 2007), affect Disc1’s inhibitory effect on ATF4. In 
HEK293 cells transfected with pRK7-ATF4, encoding mouse ATF4, and either 
pcDNA4/TO-Flag mouse Disc1-WT, 31L or 100P (paragraph 3.2), ATF4 weakly 
activates CRE-driven transcription at basal cAMP levels, although this effect does 
not reach statistical significance in this particular experiment, and DISC1 has no 
effect on ATF4 (Figure 4.13 A). Similarly, mouse Disc1 does not affect the 
magnitude of the ATF4-dependent inhibition of cAMP-induced CRE activity (Figure 
4.13 A). Although I have never compared them directly, I have noticed that mouse 
ATF4 has, on average, a weaker activating effect on the basal CRE activity in 
HEK293 cells compared to human ATF4, which may be explained by differential 
expression levels due to their different vector backbone (pRK7 and pCG, 
respectively, Table 2.2).  Alternatively, it is conceivable that the expression, stability 
and/or function of mouse ATF4 may be sub-optimal in human HEK293 cells. Thus, 
to better test their potential effect on ATF4-dependent transcription, mouse Disc1-
WT, 31L and 100P where co-expressed with human ATF4 in HEK293 cells. In this 
experiment, human ATF4 clearly activates CRE-dependent transcription, but mouse 
Disc1 does not inhibit this, nor does it interfere with the inhibitory effect of ATF4 at 
high cAMP levels (Figure 4.13 B).  
The lack of effect of mouse Disc1 on the transcriptional activity human ATF4 is in 
contrast with the strong inhibitory effect of human DISC1 on human ATF4 (Figure 
4.6). This discrepancy may reflect the substantial sequence differences between 
human and mouse Disc1 proteins (Taylor et al, 2003). To test this possibility, mouse 
ATF4 was co-expressed with either human DISC1 or mouse Disc1 in the mouse 
neuronal cell line NSC-34 (Cashman et al, 1992), and their transcriptional effects 
were tested in parallel on the pGL4.23-CRE reporter. NSC-34 cells were chosen for 
this particular experiment to rule out any potential detrimental effect of species 
context on the expression of exogenous ATF4 and DISC1. In NSC-34 cells, mouse 
ATF4 significantly activates transcription from the CRE at basal cAMP levels and 
human, but not mouse, DISC1 significantly inhibits this (Figure 4.13 C). 




Disc1-100P (Figure 4.13 C). As observed in MO3.13 cells (Figure 4.12 B), pGL4.23-
CRE responds very weakly to forskolin treatment in NSC-34 cells, reinforcing the 
possibility that this reporter might be intrinsically unable to respond to cAMP 
(Figure 4.13 C).  As confirmed by western blotting analysis, the differential effect of 
mouse and human DISC1 on ATF4-dependent transcription cannot be explained by 
different expression levels, at least in HEK293 cells, nor it is likely to arise from 
relatively weaker interaction between mouse ATF4 and mouse Disc1 (Figures 4.14 
and 4.15). In fact, in a co-immunoprecipitation assay performed in HEK293 cells, the 
relative amount of mouse ATF4 that co-precipitated with mouse Disc1 was higher 
compared to human DISC1 (Figure 4.15). Interestingly, the same assay also showed 
potentially reduced interaction of mouse ATF4 with Disc1-31L and Disc1-100P, 








Figure 4.13 HEK293 (A, B) or NSC-34 (C) cells were transfected with the reporters 
only (CRE) or in combination with human (h) or mouse (m) ATF4, with or without the 
indicated human or mouse Disc1 variant. Cells were transfected with the SomCRE-
Luc (A,B) or pGL4.23-CRE (C) luciferase reporter and treated for 4 hours with 




represent the average of one (B) or 4 (A, C) experiment(s). Data are normalised to 
the basal luciferase activity in cells transfected with the reporters only, and were 
analysed by one-way ANOVA followed by Dunnett’s post test.  
 
 
Figure 4.14 To compare the expression levels of the indicated variants of human (h) 
and mouse (m) DISC1, whole cell lysates were obtained from HEK293 cells 
transfected with equal amounts of the respective pcDNA4/TO-Flag DISC1 
expression constructs (see paragraph 3.2), and analysed by western blotting using 
the Flag MMC antibody (Table 2.5). The position and size (kDa) of the protein 
markers is shown.  
 
 
Figure 4.15 HEK293 cells were transfected with pRK7-ATF4 (encoding mouse 
ATF4) alone or in combination with the indicated human (h) or mouse (m) DISC1 
variants. Exogenous DISC1 was immunoprecipitated using the Flag MMC antibody 
and detected using the Flag RPC antibody. Co-precipitating ATF4 was detected with 
the ATF4 RPC antibody (sc-200) (Table 2.5). The position and size (kDa) of the 





When expressed in COS7 cells, mouse Disc1 appears to translocate to the nucleus 
less efficiently compared to human DISC1 (Figure 3.16). This effect might reflect 
sequence differences between human and mouse DISC1 in regions of the protein that 
are known to be important for nuclear localisation, such as NLS1 and LZ9 (Table 
3.2). Indeed, while the distribution of repeating leucines in LZ9 is highly conserved 
between human and mouse DISC1, suggesting that the structure and hence 
functionality of this motif is likely preserved, NLS1 shows a lower degree of 
conservation between the two species (Figure 4.16). The classic NLS motif is 
composed of four consecutive basic residues (Kalderon et al, 1984), and these are 
strictly conserved in NLS1 from human to dog in a multiple sequence alignment 
(Chubb et al, 2008). However, in mouse Disc1, NLS1 only has three consecutive 
basic residues (Figure 4.16). All DISC1 orthologues, including mouse Disc1, have a 
“loose” bipartite NLS motif (two clusters of basic amino acids separated by a short 
linker sequence) in the region spanning NLS1, which could also favour importin 
binding and nuclear translocation (Chubb et al, 2008; Robbins et al, 1991) (Figure 
4.16). However, the classic tetra-arginine NLS motif is likely to be the key driver of 
DISC1 nuclear import, implying that mouse Disc1 NLS1 might function less 
efficiently than human DISC1 NLS1 (Dinesh Soares, personal communication).  
Thus, it is conceivable that the lack of repressive activity of mouse Disc1 on ATF4 
may be related to its intrinsically reduced nuclear localisation compared to human 
DISC1, similarly to what observed for human DISC1 variants 37W and 607F.  
 
 
Figure 4.16 Sequence alignment of the NLS1 (A) and LZ9 (B) regions in human and 
mouse DISC1. (A) Basic residues are shown in red. (B) The leucine residues 
involved in the formation of the predicted leucine zipper are shown in bold.  
Hence, to test the hypothesis that the differential effect of human and mouse DISC1 




targeting efficiencies, nuclear and cytoplasmic fractions were obtained from NSC-34 
cells transfected with equal amounts of human or mouse Disc1, and analysed by 
western blotting. Contrary to what was seen in HEK293 cells (Figure 4.14), mouse 
Disc1 is expressed at higher levels than human DISC1 in NSC-34 cells (P<0.05, 
Figure 4.17). Accordingly, the relative nuclear abundance of mouse Disc1 is higher 
compared to human DISC1, although this does not reach statistical significance 
(Figure 4.17). Collectively, these data indicate that the differential ability of human 
and mouse Disc1 to repress the transcriptional activity of ATF4 cannot be explained 
by differences in nuclear targeting or ATF4 binding, and might thus reflect a 
functional divergence between the two proteins. Further experiments will be needed 
to test this possibility.  
 
 
Figure 4.17 The indicated subcellular protein extracts were obtained from NSC-34 
cells transfected with equal amounts of human (h) or mouse (m) Flag DISC1-WT in 
pcDNA4/TO and analysed by western blotting using the Flag MMC antibody to 
detect exogenous DISC1, followed by band densitometry. The loading controls (p84 
and GAPDH) are proteins known to be preferentially enriched in either of the 
different subcellular fractions analysed. The bars represent the average of 3 
independent experiments.  All the densitometry data are normalised to the relative 
band intensity of human DISC1. Data were analysed by one sample two-tailed 




4.4.3 Testing for a dominant-negative effect of DISC1 variants 37W and 
607F 
In chapter 3 of this thesis I demonstrated that DISC1 variants 37W and 607F disrupt 
the nuclear targeting of wild-type DISC1 in a dominant-negative fashion, and here I 
showed that these variants also significantly reduce the inhibitory effect of DISC1 on 
ATF4 transcriptional activity. Altogether, these observations suggest that the proper 
nuclear expression of DISC1 may be necessary for its regulation of ATF4 activity. If 
true, this would in turn imply that, by exerting a dominant-negative effect on the 
nuclear targeting of DISC1-WT, DISC1 variants 37W and 607F might also reduce its 
repressive activity on ATF4 in a dominant-negative fashion. Thus, I asked whether 
DISC1-37W and DISC1-607F affect the ability of DISC1-WT to inhibit the 
transcriptional activity of ATF4 on the CRE at basal cAMP levels. My previous 
experiments established that, in HEK293 cells, transfection of 81 ng/well of DISC1-
WT completely abolishes the transcriptional activation induced by 120 ng/well of 
ATF4 (Figures 4.5, 4.6 and 4.10 A and C). Thus, to produce partial inhibition of 
ATF4, HEK293 cells were transfected with 120 ng/well of ATF4 and 40.5 ng/well of 
DISC1-WT. As expected, this lower amount of DISC1-WT alone produces a milder 
( 65%) inhibition of ATF4 (P<0.01, Figure 4.18) and, consistent with my previous 
observations, the same amount of DISC1-37W or DISC1-607F alone inhibits ATF4 
to a lesser extent compared to DISC1-WT ( 47% and 45%, respectively) (P<0.05, 
Figure 4.18). Combining 40.5 ng/well of DISC1-WT with the same amount of either 
DISC1-37W or DISC1-607F produces an apparently stronger ( 85%) inhibition of 
ATF4 compared to 40.5 ng/well of DISC1-WT alone (Figure 4.18). However, the 
degree of inhibition produced by 40.5 ng/well of DISC1-WT plus 40.5 ng/well of 
DISC1/37W or DISC1-607F is not significantly different from the inhibitory effect 
produced by 40.5 ng/well of DISC1-WT alone (two tailed paired student’s t-test, 
Figure 4.18). These results suggest that DISC1’s potential to inhibit ATF4 may be 
reduced in subjects that are heterozygous for either 37W or 607F. However, due to 
the technical limitations of this reporter assay, it was not possible to determine 
whether these amino acid substitutions impair the inhibitory effect of DISC1-WT in 
a dominant-negative fashion. Indeed, although a previous experiment established that 




DNA (Figure 4.6), it was not possible to accurately determine the relationship 
between these two variables in the co-expression experiment (Figure 4.18). As a 
consequence, this experiment does not allow to accurately predict the degree of 
ATF4 inhibition based on the amount of transfected DISC1 DNA.  
 
 
Figure 4.18 Relative luciferase activity in HEK293 cells transfected with the 
reporters alone (CRE) or in combination with ATF4, with or without equal amounts 
(40.5 ng/well) of each of the indicated DISC1 variants. Bars represent the average 
of 3 independent experiments. Data are normalised to the basal luciferase activity in 
cells transfected with the reporters only, and were analysed by one-way ANOVA 
followed by Dunnett’s post test.  
 
4.4.4 Effect of DISC1 variants on AARE-driven transcription 
To test whether DISC1 is capable of modulating the transcriptional activity of other 
response elements regulated by ATF4, I generated a novel reporter that drives the 
expression of Firefly luciferase under control of two copies of the amino acid 
response element (AARE) found in the promoter of CHOP, one of ATF4 target 




AARE is a particular type of CARE that preferentially drives the transcriptional 
response to amino acid limitation (Bruhat et al, 2002; Kilberg et al, 2009), and ATF4 
overexpression alone is sufficient to activate the expression of CHOP and other 
CARE-containing genes (Shan et al, 2009). Accordingly, ectopic ATF4 activates 
transcription from the CHOP AARE, but not its mutant, non-responsive form 
(mutCHOP AARE), and this effect is not influenced by cAMP levels (Figure 4.19). 
As seen on the CRE promoter (Figure 4.5), DISC1-WT alone does not affect 
transcription from the CHOP AARE, but it significantly inhibits ATF4-mediated 
transactivation (P<0.05, Figure 4.19). However, DISC1-mediated inhibition of ATF4 
transcriptional activity on the CHOP AARE is not affected by 37W or 607F, as both 
DISC1-37W and DISC1-607F produce the same degree of inhibition as DISC1-WT 
(P<0.05 for 37W, P<0.01 for 607F, Figure 4.19). Interestingly, although the 
transactivation potential of ATF4 on the CHOP AARE remains unchanged at high 
cAMP levels, co-expression of either DISC1 variant has no effect on ATF4 under 
these conditions, suggesting that the interaction between the two proteins may be 
regulated by cAMP (Figure 4.19). Overall, these results indicate that the regulatory 
effect of DISC1 on ATF4 extends to the CHOP AARE, and may be influenced by 
cAMP levels. Additionally, they indicate that under the same experimental 
conditions, ATF4 has a markedly stronger transactivation activity on the CHOP 
AARE (10-11 fold activation) compared to the CRE (3-5 fold activation), and that 
the inhibitory effect of DISC1-WT is relatively milder on the CHOP AARE ( 20%) 
compared to the CRE (90-100%). Since for both 37W and 607F the loss of function 
observed on the CRE is partial ( 30% for 37W and 40% for 607F), the above 
observations may explain why no differential effects of DISC1-37W and DISC1-






Figure 4.19 HEK293 cells were transfected with the reporters only (CHOP AARE or 
mut CHOP AARE) or in combination with ATF4, DISC1-WT or both ATF4 and the 
indicated DISC1 variant. Luciferase activity was measured after a 4 hour treatment 
with DMSO or 10 µM forskolin. Bars represent the average of at least 4 independent 
experiments. Data are normalised to the basal luciferase activity in cells transfected 
with the reporters only, and were analysed by one-way ANOVA followed by 
Dunnett’s post test. *P<0.05; **P<0.001.  
 
Next, I hypothesised that, since the transactivation activity of ATF4 on the CHOP 
AARE is much stronger compared to the CRE, the amount of exogenous ATF4 that 
fully activates the CRE may over-saturate the CHOP AARE, thus partially masking 
the inhibitory effect of DISC1. As shown in figure 4.20, the CHOP AARE activation 
induced by 90 ng/well of ATF4 is the same as that previously seen with 120 ng/well 
of ATF4 (Figure 4.19), suggesting that the latter ATF4 concentration is indeed over-
saturating on this particular reporter. Consistently, the inhibitory effect of DISC1 is 
generally stronger (up to 40-50%) in the presence of lower concentrations of ATF4 





Figure 4.20 HEK293 cells were transfected with the reporters only (CHOP AARE) or 
in combination with different concentrations of ATF4, with or without a fixed amount 
of DISC1-WT (reported in brackets as ng/well of expression plasmid). 48 hours after 
transfection, the cells were lysed and assayed for luciferase activity. Bars represent 
mean luciferase activities measured in a single experiment. Data are normalised to 
the luciferase activity in cells transfected with the reporters only. 
 
In the next experiment, equal amounts of DISC1-WT, 37W or 607F (81 ng/well) 
were co-expressed with a non-saturating concentration of ATF4 that still produces a 
strong activation of CHOP AARE-driven transcription (15 ng/well) (Figure 4.20). 
These optimised experimental conditions revealed that DISC1-WT and DISC1 -607F 
significantly repress the ATF4-dependent transactivation of the CHOP AARE 
(P<0.01 for DISC1-WT and P<0.05 for DISC1-607F, Figure 4.21). On the other 
hand, DISC1-37W does not affect ATF4 transactivation of the CHOP AARE (Figure 
4.21). Importantly, and consistent with what I previously observed on the CRE 
(Figures 4.10 and 4.12), the inhibitory effect of both DISC1-37W and DISC1-607F is 






Figure 4.21 HEK293 cells were transfected with the reporters only (CHOP AARE) or 
in combination with ATF4 (15 ng/well), with or without the indicated DISC1 variants 
(81 ng/well). 48 hours after transfection, the cells were lysed and assayed for 
luciferase activity. Bars represent the average of at least 4 independent 
experiments. Data are normalised to the luciferase activity in cells transfected with 
the reporters only, and were analysed by one-way ANOVA followed by Dunnett’s 
post test. *P<0.05; **P<0.01.  
 
4.5 The effect of DISC1 variants on the transcriptional response to 
stress 
In the previous sections of this chapter I demonstrated that DISC1 inhibits the 
transcriptional activity of ectopically expressed ATF4, and that this effect is 
significantly impaired by amino acid substitutions 37W and 607F. Following on 
from these findings, I asked whether DISC1 similarly regulates the activity of 
endogenous stress-induced ATF4, and I investigated the effect of 37W and 607F on 
stress-related transcriptional events.   
4.5.1 Testing different stress paradigms to induce endogenous ATF4 
Preliminary experiments were designed to identify suitable experimental conditions 




reporter plasmids through induction of endogenous ATF4. The different stress 
paradigms tested in these experiments and the respective transcriptional responses 
they elicited are summarised in Figure 4.22. All the different drugs or treatments 
used here are known to induce expression of endogenous ATF4 by perturbing 
cellular homeostasis through different mechanisms. For example, the histidinyl 
tRNA synthetase inhibitor histidinol (HisOH) simulates amino acid deprivation and 
activates the amino acid deprivation response through the induction of ATF4 
(Hansen et al, 1972; Shan et al, 2009; Su & Kilberg, 2008), an effect that can also be 
induced by selective removal of leucine and/or lysine from the culture medium (Ohta 
et al, 2010). However, I could not detect activation of the CRE or CHOP AARE 
reporters upon treatment with 2 mM HisOH, nor after leucine and/or lysine 
deprivation (Figure 4.22) (for the composition of the media used in the leucine/lysine 
deprivation experiment, see section 2.4.1.1 of this thesis). Thapsigargin is a non-
competitive inhibitor of the sarco/endoplasmic reticulum Ca
2+
 ATPase and causes 
release of Ca
2+
 from the endoplasmic reticulum (ER) into the cytoplasm, whereas 
tunicamycin selectively inhibits N-linked glycosylation (Samali et al, 2010). Both 
drugs interfere with the normal function of the ER and induce accumulation of 
misfolded protein in the ER, triggering the unfolded protein response, which in turn 
results in the activation of ATF4 (Armstrong et al, 2010; Galehdar et al, 2010; 
Milani et al, 2009; Yamaguchi et al, 2008). At both concentrations (2 and 4 µg/ml) 
and incubation times (8 and 16 hours) tested, tunicamycin did not activate 
transcription from either reporter (Figure 4.22), possibly because it is highly toxic to 
the cells, many of which had become apoptotic during the treatment (data not 
shown). On the other hand, when used at the concentration of 1 µM for 16 hours, 
thapsigargin is well tolerated by the cells, and induces a 2-fold activation of CRE-
driven transcription but has no effect on the CHOP AARE reporter (Figure 4.22). As 
expected, the above thapsigargin treatment strongly induces endogenous ATF4 
expression in HEK293 cells (Figure 4.23). Importantly, the thapsigargin-induced 
activation of CRE-driven transcription is significantly inhibited by DISC1 (P<0.01, 
Figure 4.22). The selective activation of the CRE by thapsigargin is not surprising 
given that the CHOP AARE has been shown to preferentially respond to amino acid 




AARE reporter did not respond to amino acid starvation, as the same response 
element induces a five-fold reporter activation in leucine starved HeLa cells (Bruhat 
et al, 2002). As other studies used different reporters, it is possible that the context in 




Figure 4.22 HEK293 cells transfected with the indicated reporter plasmids alone or 
in combination with DISC1 were subjected to the indicated treatments before being 
assayed for luciferase activity. Where error bars are absent, bars represent the 
results of a single experiment. Where error bars are present, bars represent the 
average of 3 independent experiments. Data were analysed by two-tailed paired 






Figure 4.23 HEK293 cells were treated with 1 M thapsigargin (TG) for 16 hours. At 
the end of the drug treatment, nuclear protein extracts were prepared from the 
transfected cells and analysed by western blotting. Endogenous ATF4 was detected 
with the ATF4 RPC antibody. The position and size (kDa) of the protein markers is 
indicated. * Non specific band.  
 
4.5.2 DISC1 variants differentially affect the transcriptional response to 
endoplasmic reticulum stress 
In HEK293 cells, the thapsigargin-induced activation of the CRE is significantly 
inhibited by DISC1-WT, but not by DISC1-37W, DISC1-607F or DISC1 LZ9 
(P<0.01, Figure 4.24), consistent with their differential nuclear targeting and 
impaired ability to inhibit exogenous ATF4. However, these findings could not be 
confirmed in MO3.13 cells, since thapsigargin had no effect on CRE-driven 
transcription in these cells (Figure 4.24).  Due to time limitations, it was not possible 
to replicate this experiment in neuronal cells, such as SH-SY5Y and NSC-34.  
 
 
Figure 4.24 Relative luciferase activity in HEK293 (left) or MO3.13 cells (right) 
transfected for 32 hours with SomCRE-luc and pGL4.23-CRE, respectively, with or 




hours. Bars represent the average of at least 3 independent experiments. Data were 
analysed by one-way ANOVA followed by Dunnett’s post test.  
 
4.6 Discussion 
In this chapter, I demonstrated that DISC1 is capable of inhibiting the ATF4-
dependent transactivation of CRE- and CHOP AARE-driven transcription at basal 
cAMP levels in different neuronal and non-neuronal cell models. In addition, I 
showed that both risk-conferring amino acid substitutions 37W and 607F 
significantly reduce the inhibitory effect of DISC1 on the ATF4-dependent 
transactivation of the CRE and CHOP AARE. The partial loss of function induced by 
37W and 607F is likely related to the detrimental effect of these amino acid 
substitutions on the nuclear targeting of DISC1. Indeed, amino acid substitutions that 
do not affect the nuclear targeting of DISC1 also have no effect on its ability to 
inhibit ATF4 and, on the other hand, the mutant DISC1 LZ9, which is not properly 
targeted to the nucleus, has no effect on the transcriptional activity of ATF4. 
However, it is important to remark that the loss-of-function phenotype observed for 
DISC1-607F and DISC1 LZ9 may also be determined by partial or complete loss of 
ATF4 binding. Indeed, DISC1LZ9 was previously shown to be essential for DISC1 
interaction with ATF4 (Sawamura et al, 2008), and 607F has the potential to disrupt 
this ATF4 binding region by removing the first leucine in DISC1LZ9 and hence 
disrupting the leucine-leucine packing in this putative leucine zipper (Soares et al, 
2011). Since ATF4 mainly resides in the nucleus, the effects of DISC1 amino acid 
substitutions on DISC1 nuclear targeting, ATF4 binding and ATF4 repression are 
likely interconnected.   
As demonstrated in chapter 3 of this thesis, both DISC1-37W and DISC1-607F 
reduce the nuclear expression of DISC1-WT in a dominant-negative fashion, which 
potentially represents an additional mechanism of ATF4 deregulation by these 
variants.  Although it was not possible to produce conclusive evidence that DISC1-




DISC1-WT, co-expression of DISC1-37W or DISC1-607F does not significantly 
strengthen the inhibitory effect induced by a non-saturating dose of DISC1-WT 
alone. Put differently, one dose of DISC1-WT alone produces the same degree of 
ATF4 inhibition as one dose of DISC1-WT plus one dose of DISC1-37W or DISC1-
607F, and this degree of inhibition is lower than that achieved with two doses of 
DISC1-WT. This suggests that, overall, the ability of DISC1 to regulate ATF4 may 
be impaired in 37W and 607F carriers.  
As discussed in the introduction of this thesis, ATF4 transcriptional activity is 
modulated at multiple levels, including transcription and translation, post-
translational modification, regulation of protein stability and repression of its 
transcriptional activity through protein-protein interactions (Ameri & Harris, 2008; 
Dey et al, 2010; Elefteriou et al, 2005; Lassot et al, 2005; Lassot et al, 2001; Ord & 
Ord, 2003; Pons et al, 2007; Yang et al, 2004). The existence of multiple 
mechanisms controlling the production, persistence and activity of ATF4 indicates 
the critical importance of tight regulation of ATF4-mediated gene transcription. 
Given that I and others (Sawamura et al, 2008) have clearly demonstrated that 
DISC1 is capable of regulating the transcriptional activity of ATF4 in vitro, it is 
reasonable to speculate that DISC1 may be one of the many essential modulators of 
ATF4-mediated transcription in the brain. My observations suggest that the 
repressive activity of DISC1 on ATF4 may be weakened by sequence variants that 
influence the risk of mental illness, implying that the dysregulation of ATF4-
mediated transcription might be a contributing factor to the overall risk of disease.  
The activation of CRE-dependent transcription by CREB and the release of ATF4-
mediated transcriptional repression are essential for learning and memory 
consolidation in both invertebrates and mammals (Kandel, 2001). Therefore, through 
its modulatory effect on ATF4, DISC1 might be involved in the regulation of the 
transcriptional events that mediate synaptic plasticity. This in turn implies that 
DISC1 variants 37W and 607F may deregulate synaptic plasticity and cognitive 
processes through their defective modulation of ATF4 transcriptional activity. Since 
cognitive impairment is a core feature of schizophrenia, this is a potential route by 




A recent study demonstrated that ATF4 expression is controlled by key components 
of the circadian clock, and showed that its protein levels exhibit circadian oscillation 
in several mouse tissues, including the suprachiasmatic nucleus (SCN), the main 
controller of the mammalian circadian clock (Koyanagi et al, 2011). In the SCN, 
ATF4 is essential for the circadian expression of the Period2 gene, a central 
component of the circadian clock, and regulates its transcription by directly binding 
to the CRE in its promoter (Koyanagi et al, 2011). Thus, through its regulation of 
CRE-driven transcription, ATF4 is involved in the control of circadian pathways. 
That ATF4 is a direct target of Clock, a transcription factor that mediates the 
periodical expression of several genes controlling hormone release and sleep-wake 
cycles, constitutes further evidence for the importance of ATF4 in circadian control 
(Igarashi et al, 2007). Intriguingly, overexpression of human DISC1 in fruit flies 
induces alterations of sleep homeostasis, a process known to be regulated by CRE-
dependent transcription (Sawamura et al, 2008). If confirmed, the proposed role of 
DISC1 in sleep homeostasis would be of particular relevance to psychiatric illness, 
because sleep disturbances are common among psychiatric patients (Schulz & 
Steimer, 2009; Trbovic, 2010; Wulff et al, 2012; Wulff et al, 2009), and a recent 
study demonstrated that circadian rhythms are deregulated in a mouse model of 
schizophrenia (Oliver et al, 2012). Intriguingly, in Drosophyla melanogaster, 
mutation of the PDE4 orthologue dunce is associated with increased cAMP 
concentration and reduced sleep (Hendricks et al, 2001).  In light of these 
observations, it is intriguing to speculate that the effect of DISC1 on sleep 
homeostasis might be mediated by its concomitant regulation of ATF4 and PDE4, 
both of which converge on the modulation of CRE-driven transcription. If true, this 
would in turn imply that 37W and 607F might negatively impact on DISC1-mediated 
regulation of sleep homeostasis.  
Both DISC1 and ATF4 are implicated in the regulation of emotional behaviour in 
rodent models (Ayhan et al, 2011; Clapcote et al, 2007; Green et al, 2008; Hikida et 
al, 2007; Li et al, 2007a; Mao et al, 2009; Shen et al, 2008). Expression of 
endogenous ATF4 in the nucleus accumbens (NA), a key reward region in the brain, 
is induced by amphetamine administration or restraint stress, and ATF4 




amphetamine (Green et al, 2008). Like its related transcription factor CREB, ATF4 
attenuates emotional reactivity and induces depression-like behaviours when 
overexpressed in the NA, strongly suggesting that ATF4 functions as an activator of 
CRE-driven transcription in this brain area (Green et al, 2008). Like ATF4, DISC1 
modulates the behavioural responsiveness to amphetamine in rodent models (Ayhan 
et al, 2011; Lipina et al, 2010; Niwa et al, 2010), and both DISC1 mutations and 
altered DISC1 expression are associated with depression-like behaviours in several 
mouse models (Ayhan et al, 2011; Clapcote et al, 2007; Hikida et al, 2007; Li et al, 
2007a; Mao et al, 2009; Shen et al, 2008). Thus, it is tempting to speculate that 
DISC1 regulation of ATF4 transcriptional activity on the CRE might contribute to its 
effects on emotional behaviour. If true, this would imply that DISC1 variants that 
interfere with this particular function of DISC1, such as 37W and 607F, may directly 
impact on the regulation of emotional behaviour.  
ATF4 is also a key mediator of the Integrated Stress Response, and its transcription 
and translation are strongly upregulated in response to a range of stressors, including 
amino acid deprivation, oxidative stress, hypoxia, viral infections, endoplasmic 
reticulum stress and mitochondrial dysfunction (Badiola et al, 2011; Granberg et al, 
2006; Kilberg et al, 2009; Lange et al, 2008; Silva et al, 2009). Stress-induced ATF4 
can activate the transcription of target genes by binding to the CRE in their promoter. 
For example, ATF4 activates the expression of the anti-apoptotic gene Grp78 in 
response to endoplasmic reticulum stress by interacting with a CRE element in its 
promoter (Luo et al, 2003). However, induction of most of the stress-responsive 
ATF4 target genes that have been studied so far is mediated by CARE composite 
sites, of which the CHOP AARE is a very well characterised example (Bruhat et al, 
2002; Ma et al, 2002b; Oyadomari & Mori, 2004). In this chapter, I showed that, 
besides regulating the activity of ATF4 on the CRE, DISC1 is also capable of 
inhibiting the transactivation of the CHOP AARE by ATF4, and this effect is 
significantly weakened by amino acid substitutions 37W and 607F.  The contribution 
of damaging environmental exposures to the risk of developing schizophrenia is well 
established, but still mechanistically unclear. Maternal starvation, viral infections and 
perinatal hypoxia are among the best supported risk factors for schizophrenia 




responses mediated by ATF4. It is intriguing to speculate that, by modulating ATF4-
dependent stress-induced transcriptional events, DISC1 might contribute to the 
regulation of cellular responses to stress, tipping the balance towards adaptation or 
apoptosis. In this scenario, 37W and 607F substitutions in DISC1 could increase the 
risk of mental illness by rendering the brain more susceptible to stress (Figure 4.25).  
 
 
Figure 4.25 Hypothetical role of DISC1 in the regulation of ATF4-mediated stress 
responses. Several types of microenvironmental stress induce the expression of 
ATF4, which in turn regulates the transcription of target genes by binding to CRE or 
CARE elements in their promoters. ATF4 target genes can promote the cell’s 
adaptation to stress, but they also include pro-apoptotic factors, thus protracted 
ATF4 activation can result in cell death (Harding et al, 2003; Lange et al, 2008; Ord 
et al, 2007; Rutkowski & Kaufman, 2003). DISC1 might inhibit ATF4 transcriptional 
activity in response to stess, thus contributing to the regulation of the cell’s response 
to stress. Hence, by reducing DISC1’s ability to repress ATF4, amino acid 





5 Testing the effect of cAMP on DISC1-mediated 
regulation of ATF4 
5.1 Introduction  
Post-translational modification, and in particular phosphorylation, contributes to the 
regulation of ATF4 transcriptional activity (Elefteriou et al, 2005; Yang et al, 2004). 
As previously discussed, ATF4 possesses a strong and constitutively active 
transactivation domain, and unlike its related factor CREB, ATF4 activity does not 
depend on PKA-mediated phosphorylation (Schoch et al, 2001). However, both 
RSK2 and PKA protein kinases are known to modulate ATF4 transactivation 
capacity in bone cells by direct phosphorylation (Elefteriou et al, 2005; Yang et al, 
2004).  
DISC1 is known to bind to all four isoforms (A,B,C,D) of type 4 phosphodiesterases 
(PDE4s) in a cAMP-regulated fashion (Millar et al, 2005b; Murdoch et al, 2007) and 
to inhibit induction of PDE4 cAMP hydrolysis activity in response to elevated cAMP 
levels (Millar et al, 2005b; Murdoch et al, 2007). In turn, PDE4s contribute to the 
modulation of intracellular cAMP levels and PKA activity in a compartmentalised 
fashion (Houslay, 2010). Interestingly, through its interaction with PDE4, DISC1 has 
been shown to regulate PKA-dependent phosphorylation of its binding partner 
NDE1, which in turn controls its association with NDEL1 and LIS1 and regulates 
neurite extension (Bradshaw et al, 2009; Bradshaw et al, 2011). I therefore 
hypothesised that a similar mechanism might be in place to regulate the PKA-
mediated phosphorylation of ATF4, and that the inhibitory effect of DISC1 on 
ATF4-dependent transcription may occur, at least partially, through the regulation of 
PKA-dependent phosphorylation of ATF4 by DISC1-bound PDE4 (Figure 5.1). 
Thus, in this chapter I investigate the potential involvement of PKA and PDE4 in the 
regulation of ATF4 transcriptional activity on the CRE, and test whether these 





Figure 5.1 Hypothetical mechanism of DISC1-mediated inhibition of ATF4 
transcriptional activity. PKA phosphorylation of ATF4 might increase its 
transactivation activity on the CRE element. By linking PDE4 to the ATF4 complex, 
DISC1 might favour a localised reduction of cAMP levels, which would in turn inhibit 
PKA activity, thus inhibiting ATF4 phosphorylation.  
5.2 The effect of PKA inhibition on ATF4-dependent transcription 
First, to test for the potential involvement of PKA in the regulation of ATF4 
transactivation of the CRE, the luciferase reporter assay was performed in the 
presence of a selective PKA inhibitor. As detailed in the following sections, three 
different PKA inhibitors were tested. The results obtained with the first two, KT5720 
and mPKI, were largely inconclusive or negative under the tested experimental 
conditions, and are included only for completeness. More emphasis is placed on the 
findings obtained with PKIα, which yielded interesting results. 
5.2.1 KT5720 
KT5720 is a membrane-permeant selective and potent PKA inhibitor (IC50=56nM) 
that works by blocking the catalytic ATP sites on PKA (Cabell & Audesirk, 1993; 
Gadbois et al, 1992; Kase et al, 1987).  In the first pilot experiment, KT5720 (0.1, 5 
or 10 µM) was added to the cells 24 hours after transfection and incubated for 24 
hours before performing the luciferase assay. The tested concentrations correspond to 
the KT5720 concentration range commonly used in cell-based assays (Herbst et al, 
2009). When used at 0.1 or 10 µM, KT5720 partially inhibited the ATF4-induced 
activation of CRE-driven transcription, but surprisingly, it had the opposite effect at 




experiments to test whether KT5720 efficiently inhibits PKA under the tested 
experimental conditions.  
 
 
Figure 5.2 HEK293 cells were transfected with the reporters only (CRE) or in 
combination with ATF4 (ATF4). 24 hours later, the transfection medium was 
replaced with fresh medium supplemented with the indicated concentrations of 
KT5720, and the cells were incubated for further 24 hours before being assayed for 
luciferase activity. The bars represent the results of a single experiment. Data were 
normalised to the relative luciferase activity in DMSO-treated cells transfected with 
the reporters only.  
 
The adenylate cyclase activator forskolin is commonly used as a tool to raise 
intracellular cAMP levels (Insel & Ostrom, 2003). In turn, cAMP induces the 
phosphorylation of CREB at Serine 133, thus activating CRE-driven transcription 
(Delghandi et al, 2005). In cells treated with forskolin, the activation of CREB and 
CRE-driven transcription is largely mediated by the cAMP-dependent activation of 
PKA, the main CREB kinase (Delghandi et al, 2005). Indeed, the forskolin-induced 
activation of the CRE is almost entirely blocked by specific PKA inhibitors 
(Delghandi et al, 2005). Thus, to control for the ability of KT5720 to efficiently 
inhibit PKA activity under the tested conditions, transfected HEK293 cells were 
treated for 4 hours with KT5720 only (0.1, 5 or 10 µM) or in combination with 10 
µM forskolin before being assayed for CRE-driven luciferase expression.  In the 




CRE, but 0.1 µM KT5720 had no effect on ATF4 (Figure 5.3 A). In addition, under 
the same conditions, KT5720 did not prevent DISC1-mediated inhibition of ATF4 
trancriptional activity (Figure 5.3 A). Furthermore, KT5720 had virtually no effect 
on the ATF4-induced suppression of cAMP-dependent CRE activity, either in the 
presence or absence of DISC1 (Figure 5.3 A). Surprisingly, KT5720 not only did not 
prevent the forskolin-induced activation of CRE-driven transcription, but it had the 
opposite effect at all tested concentrations (Figure 5.3 A, B). This latter observation 
suggests that, under these particular experimental conditions, KT5720 might not 
effectively inhibit PKA activity. Thus, no conclusions can be drawn on the potential 
effect of PKA on ATF4 transactivation of the CRE from this particular experiment.  
 
 
Figure 5.3 (A) HEK293 cells were transfected with the reporters only (CRE) or in 
combination with ATF4, with or without DISC1. 48 hours later, cells were treated for 
4 hours with the indicated concentrations of KT5720 alone or in combination with 10 
µM forskolin, and then assayed for luciferase activity. Data are normalised to the 
luciferase activity in cells transfected with the reporters only and treated with vehicle 
(DMSO). (B) Effect of forskolin and KT5720 on cells transfected with the reporters 
only. The graphs in (A) and (B) were generated from the same experimental data 





The following experiment was designed to test the activity of KT5720 at different 
time points, as the apparent inactivity of the drug in the previous experiments might 
have been caused by gradual loss of activity with prolonged incubation times. To do 
this, HEK293 cells transfected with the SomCRE-Luc and TK-Renilla reporters were 
treated with either 10 µM KT5720, 10 µM forskolin or both drugs together for 30, 
60, 90, 120 and 240 minutes before being assayed for luciferase activity. As 
expected, the luminescence signal gradually increased over time in cells treated with 
forskolin alone, but this increase was only partially counteracted by co-treatment 
with KT5720 (Figure 5.4). Even at the earlier time points, when the activity of the 
drug should be intact, KT5720 only partially inhibited the accumulation of luciferase 
in HEK293 cells treated with forskolin (Figure 5.4). Again, this result suggests that 
KT5720 might not efficiently inhibit PKA activity in this particular test system. 
However, it is important to remark that in this particular set of experiments the 
activity of PKA was not measured directly, but was evinced indirectly from the 
activity of the CRE element. This was based on the assumption that the activation of 
CRE-driven transcription in response to increased cAMP levels is largely mediated 
by PKA-dependent phosphorylation of CREB, as demonstrated in other cell systems 
(Delghandi et al, 2005). However, based on the data presented here, it is not possible 
to formally exclude that in this particular test system the activation on CRE in 
response to increased cAMP levels might be mediated by PKA-independent 
mechanisms. Thus, the data shown here do not allow to conclusively establish 





Figure 5.4 HEK293 cells were transfected with the reporters only (SomCRE-Luc 
and TK-Renilla) for 48 hours, and then treated for the indicated times with 10 µM 
forskolin alone or in combination with 10 µM KT5720 before being assayed for 
luciferase activity. The bars represent the results of a single experiment. The 
numbers in brackets indicate the % inhibition of the forskolin-induced activation of 
the CRE by KT5720.  
 
5.2.2 mPKI 
Next, the PKA inhibitor mPKI was tested. This is a synthetic peptide corresponding 
to amino acids 14-22 of protein kinase inhibitor peptide (PKI) whose N-terminus is 
myristoylated to increase cell membrane permeability (Glass et al, 1989a; Glass et 
al, 1989b). PKI is a family of endogenous neuropeptides (PKIα,  and ) that inhibit 
PKA activity by binding to the free catalytic subunits of the enzyme and blocking the 
phosphorylation of its substrates (Dalton & Dewey, 2006). The effect of mPKI on 
ATF4-mediated activation of CRE-driven transcription was tested under two 
different experimental conditions, as shown in Figure 5.5. The tested mPKI 
concentrations are within the range commonly used in cell-based assays (Gong et al, 
2010; Nedvetsky et al, 2010). Under the tested conditions, mPKI did not inhibit the 
ATF4-induced activation of CRE-driven transcription at basal cAMP levels, nor did 




that it may not have a substantial inhibitory effect on PKA activity (Figure 5.5). 
Thus, like KT5720, in this particular test system mPKI may not be suitable to test the 
potential influence of PKA phosphorylation on ATF4 transactivation of the CRE. 
 
 
Figure 5.5 HEK293 cells were transfected with the reporters only (CRE) or in 
combination with ATF4. 24 (top) or 48 (bottom) hours later, cells were treated for the 
indicated times with mPKI alone or in combination with 10 µM forskolin, as shown, 
and then assayed for luciferase activity. The bars represent the results of a single 
experiment. Data were normalised to the relative luciferase activity in DMSO-treated 






Overexpression of the PKA inhibitor PKIα (see Paragraph 5.2.2 and Table 2.2) was 
tested as a possible alternative method to efficiently inhibit PKA activity in HEK293 
cells. Unlike other PKI isoforms, which inhibit both the cGMP-dependent protein 
kinase (PKG) and PKA, PKIα is a totally specific PKA inhibitor (Glass et al, 1986; 
Kumar & Walsh, 2002). At basal cAMP levels, PKIα expression does not affect the 
activity of the CRE, but it almost completely prevents the forskolin-induced 
activation of CRE-driven transcription (P<0.01, Figure 5.6). This result confirms 
that, as observed in other cell models (Delghandi et al, 2005), the forskolin-induced 
activation of the CRE in this particular test system is indeed mediated by PKA, and it 
indicates that PKIα, but not KT5720 or mPKI, is an effective inhibitor of PKA in 
these cells. Interestingly, PKIα co-expression partially inhibits the ATF4-induced 
transactivation of the CRE at basal cAMP levels (P<0.05, Figure 5.6). These results 
are consistent with the reported modulatory effect of direct PKA phosphorylation on 
the transcriptional activity of ATF4 (Elefteriou et al, 2005), and indicate that, in the 
tested cell model, ATF4 transactivation of the SomCRE-Luc reporter is positively 
regulated by PKA at basal cAMP levels (Figure 5.7). However, this experiment does 
not establish whether this modulatory effect involves direct phosphorylation of ATF4 
by PKA. PKIα additionally strengthens the inhibitory effect of ATF4 on the 
forskolin-induced activation of CRE-driven transcription (P<0.01, Figure 5.6). This 
might reflect a direct or indirect inhibitory effect of PKA on ATF4 at high cAMP 
levels, but it most likely arises from the concerted inhibition of CREB by ATF4 and 
PKIα, the former competing with CREB for Basic Transcription Factors (BTF), and 
the latter directly blocking PKA-dependent CREB phosphorylation (Figure 5.7). 






Figure 5.6 Relative luciferase activity in HEK293 cells transfected with the reporters 
only (CRE) or in combination with PKIα, ATF4 or both.  Transfected cells were 
treated for 4 hours with DMSO or 10 µM forskolin before being assayed for 
luciferase activity. Bars represent the average of 4 independent experiments. Data 
were normalised to the relative luciferase activity in DMSO-treated cells transfected 
with the reporters only and were analysed by one-way ANOVA and Dunnett’s 
multiple comparisons test, except for datasets “ATF4” and “ATF4 + PKI”, which were 
compared using two-tailed paired student’s t-test.  
 
 
Figure 5.7 Proposed molecular model of interaction between ATF4, PKA and 
CREB. At basal cAMP levels, PKA activity is low. ATF4 positively regulates CRE 
activity, and PKA-mediated phosphorylation directly or indirectly strengthens ATF4 
transactivation of the CRE. Consequently, by inhibiting PKA activity, PKIα weakens 
ATF4 transactivation of the CRE. Under these conditions, CREB is either completely 
unphosphorylated (and thus inactive) or has a low level of activity that is below the 
sensitivity limit of the detection system used here. At high cAMP levels, PKA is fully 




transcription. PKIα expression prevents the rise in CRE activity by inhibiting CREB 
phosphoryation by PKA. ATF4 strongly represses CRE activity, possibly by 
sequestering basic transcription factors (BTF) from CREB, and PKIα strengthens 
the inhibitory effect of ATF4 on the CRE. This latter effect may be due to the 
concomitant inhibition of CREB phosphorylation by PKIα and sequestration of BTF 
by ATF4. Alternatively, it is possible that PKA phosphorylation (direct or indirect) 
inhibits the repressive activity of ATF4 on the CRE.  
 
5.2.4 The effect of PDE4 overexpression and inhibition 
Having established that PKA enhances the transcriptional activity of ATF4 on the 
CRE at basal cAMP levels, I sought to test whether PDE4 activity, which regulates 
PKA by controlling intracellular cAMP concentration gradients (Houslay, 2010), is 
also implicated in the regulation of ATF4. A potential regulatory role of PDE4 on 
ATF4 is also supported by the fact that interaction between endogenous PDE4 and 
ATF4 has been detected by co-immunoprecipitation in SH-SY5Y cells (Bradshaw et 
al, 2008).  As shown in Figure 5.8, co-expression of two distinct PDE4 isoforms (B1 
and D3) inhibits ATF4 transactivation of the CRE at basal cAMP levels to a similar 
extent as PKIα co-expression (P<0.05 for PDE4B1 and P<0.01 for PDE4D3). On the 
other hand, PDE4 co-expression has no effect on ATF4-mediated inhibition of the 
forskolin-induced activation of the CRE (Figure 5.8). This indicates that, at basal 
cAMP levels, PDE4s might modulate CRE-dependent transcription via ATF4, 






Figure 5.8 HEK293 cells were transfected for 48 hours with the reporters only 
(CRE) or in combination with the indicated constructs, then subjected to a 4 hour 
treatment with either DMSO or 10 M forskolin before being assayed for luciferase 
activity. The bars represent the average of 3 independent experiments. Data were 
normalised to the relative luciferase activity in DMSO-treated cells transfected with 
the reporters only and were analysed by one-way ANOVA and Dunnett’s multiple 
comparisons test.  
Next, to test whether the inhibitory effect of DISC1 on ATF4-dependent 
transcription is partially mediated by PDE4, endogenous PDE4 activity was blocked 
using the specific PDE4 inhibitor rolipram. Rolipram treatment does not induce 
CRE-driven transcription from the SomCRE-luc reporter under basal cAMP levels 
(Figure 5.9 A and C), but significantly strengthens the forskolin-induced activation 
of the CRE (Figure 5.9 B and C), which confirms the effectiveness of the drug in this 
particular test system at the concentration used (10 µM), and is consistent with the 
previously established role of endogenous PDE4s in the regulation of CREB 
phosphorylation (Li et al, 2011; Li et al, 2009; MacKenzie & Houslay, 2000) and 
CRE-mediated transcription (Xia et al, 2009a; Xia et al, 2009b). At basal cAMP 
levels, the activity of ATF4 is not affected by rolipram treatment (Figure 5.9 A), 
which is in contrast with the inhibitory effect of PDE4 overexpression (Figure 5.8). 
The reasons for this discrepancy are not clear, but may arise from the fact that the 




focused on the endogenous proteins. As shown in Figure 5.9 A, the inhibitory effect 
of DISC1 on ATF4-mediated transcription at basal cAMP levels is entirely preserved 
in the presence of rolipram. Thus, while PDE4 appears to modulate ATF4-mediated 
transcription at basal, but not high cAMP levels (Figure 5.8), it is not required for the 
inhibitory effect of DISC1 at basal cAMP levels.  
 
 
Figure 5.9 HEK293 cells were transfected with the reporters only (CRE) (C) or in 
combination with the indicated constructs (A, B). 48 hours after transfection, the 
cells were simultaneously subjected to either one of the following drug treatments: 
vehicle (DMSO) or 10 M rolipram for 4 hours (A, C); 30 minute pre-treatment with 
DMSO followed by 3.5 hour treatment with 1 M forskolin; 30 minute pre-treatment 
with 10 M rolipram followed by 3.5 hour treatment with 1 M forskolin and 10 M 
rolipram (B, C). (C) Represents the same data from cells transfected with the 
reporters only plotted in (A) and (B). Relative CRE-dependent luciferase activity was 
measured at the end of the drug treatments. Data were normalised to the relative 
luciferase activity in vehicle-treated cells transfected with the reporters only, and 






As shown in figure 5.9 B, rolipram has virtually no effect on the ability of ATF4 to 
inhibit the forskolin-induced activation of the CRE ( 82% inhibition with 1 µM 
forskolin, 89% inhibition with 1 µM forkolin + 10 µM rolipram). This is consistent 
with the lack of effect of PDE4 co-expression on the ATF4-mediated repression of 
CRE-driven transcription at high cAMP levels (Figure 5.8). Furthermore, at high 
cAMP levels, the net CRE activity in cells transfected with ATF4 is higher in the 
presence of rolipram (P<0.001, Figure 5.9 B), which is consistent with the reduction 
of CRE activity seen in ATF4-epressing cells upon co-expression of PKIα (Figure 
5.6). Altogether, these data suggest that at high cAMP levels ATF4 is not directly 
regulated by PDE4, and that the opposing effects of PKIα and rolipram on the net 
CRE activity in ATF4-expressing cells most likely arise from their opposing effects 
on CREB. Similarly, and in line with my previous observations, the repressive 
activity of ATF4 at high cAMP levels is not influenced by DISC1 co-expression, 
either in the presence or absence of rolipram ( 78% inhibition with 1 µM forskolin, 
82% inhibition with 1 µM forkolin + 10 µM rolipram) (Figure 5.9 B).   
 
5.3 Discussion 
In osteoblasts, the Adrenergic beta-agonist isoproterenol increases ATF4 
transactivation activity on the Rankl promoter CRE by inducing its PKA-dependent 
phosphorylation at serine 254 (Elefteriou et al, 2005). Consistently, the inhibitory 
effect of PKIα on ATF4 observed here suggests that, under basal conditions, PKA 
contributes to the regulation of the transcriptional activity of ATF4 on the 
Somatostatin CRE element used in this study, either directly or indirectly. It is not 
known whether ATF4 is phosphorylated by PKA in response to forskolin treatment, 
but the ATF4-dependent repression of forskolin-induced activation of the CRE is 
thought to be mainly mediated by competition with CREB for access to basic 
transcription factors (BTF) (Thiel et al, 2005). Thus, as illustrated in the diagram in 
Figure 5.10, the stronger inhibition of cAMP-induced CRE activation observed in 
cells co-expressing ATF4 and PKIα compared to cells expressing ATF4 alone might 




inhibition of PKA-dependent CREB phosphorylation by PKIα. However, it cannot be 
excluded that PKA might inhibit the repressive activity of ATF4 at high cAMP levels 
by direct phosphorylation.  
 
 
Figure 5.10 Proposed model of interaction between PKA, PDE4, ATF4 and DISC1. 
(A) At basal cAMP levels, PKA and PDE4 are in a low-activity state. PDE4 inhibits 
the PKA-mediated phosphorylation of CREB, thus preventing its activation. Rolipram 
inhibition of PDE4 removes the PDE4-dependent repression of CREB, thus 
activating CRE-driven transcription (Li et al, 2011; Li et al, 2009; MacKenzie & 
Houslay, 2000; Xia et al, 2009a; Xia et al, 2009b). ATF4 might be present in both 
phosphorylated and unphosphorylated forms. Both forms of ATF4 are capable of 
binding to and activating the CRE, but phosphorylated ATF4 has a stronger 
transactivating effect on this promoter. ATF4 is inhibited by DISC1 via an unknown 
mechanism that does not appear to involve PDE4. PKA strengthens ATF4 
transactivation of the CRE, potentially via direct phosphorylation of ATF4, a 
mechanism that has been demonstrated in osteoblasts (Elefteriou et al, 2005). 




PKA-dependent phosphorylation. (B) At high cAMP levels, PKA is fully active, and 
can thus phosphorylate and activate CREB. PKA also activates PDE4 (MacKenzie 
et al, 2002), which in turn inhibits the PKA-dependent phosphorylation of CREB, 
providing a negative feedback mechanism. Rolipram inhibition of PDE4 removes the 
PDE4-dependent inhibition of CREB, thus resulting in higher CRE activity. DISC1 
might potentially have a similar, albeit milder, effect as rolipram, as it has been 
shown to attenuate the rise in PDE4 activity in response to increased cAMP levels 
(Carlyle et al, 2011). However, no evidence for a regulatory role of DISC1 on CRE 
activity at high cAMP levels has been found in this thesis. ATF4 overexpression 
inhibits the forskolin-induced activation of the CRE, probably by competing with 
endogenous CREB for interaction with basic transcription factors (BTF) (Hai & 
Hartman, 2001; Liang & Hai, 1997; Schoch et al, 2001), although a direct repressive 
effect of ATF4 on the CRE cannot be excluded. CRE-driven transcription is lower in 
cells co-expressing ATF4 and PKIα compared to cells expressing ATF4 alone, and it 
is higher in ATF4-expressing cells exposed to rolipram compared to vehicle-treated 
cells. This may suggest that, by phosphorylating ATF4, PKA might inhibit its 
repressive effect on the CRE, and PDE4 might counteract this. Alternatively (or 
additionally) it is possible that the effect of PKIα reflects a further inhibition of CREB 
due to blockage of its PKA-dependent phosphorylation. Similarly, the effect of 
rolipram may be due to removal of the PDE4-dependent inhibition of CREB 
phosphorylation. The overall conclusion is that the regulation of CRE-driven 
transcription is complex, context- and mutation/variant-dependent with DISC1, 
PDE4, ATF4, PKA and potentially other untested components interacting directly 
and/or indirectly to regulate cAMP signalling. 
 
The inhibitory effect of PDE4 co-expression on the ATF4 transactivation of the CRE 
is consistent with the observed inhibitory effect of PKIα, and suggests the 
involvement of PDE4-regulated pathways in the control of ATF4 transcription at 
basal cAMP levels (Figure 5.10). However, this is in contrast with the lack of effect 
of rolipram on the transactivating effect of ATF4 at basal cAMP levels. In this 
respect, it is important to notice that, when used at the concentration of 10 µM, 
rolipram does not induce a sufficient increase in cAMP levels to activate the 




study, rolipram determined a significant activation of a CRE- -lactamase reporter in 
CHO cells, with an EC50 of 200 nM (Xia et al, 2009b). This suggests that the 
SomCRE-Luc reporter used in this study might not be sensitive enough to reveal 
activation of the PKA-CREB pathway in response to rolipram treatment at basal 
cAMP levels. Moreover, at basal cAMP levels, PDE4 is in a low-activity state 
(Houslay & Adams, 2003), thus under these conditions, PDE4 inhibition is unlikely 
to produce a large rise in cAMP levels. On the other hand, the effect produced by 
PDE4 overexpression at basal cAMP levels may derive from cumulative 
contributions from a high number of low-activity molecules.  
At high cAMP levels, PDE4 is fully active and could potentially counteract the effect 
of forskolin on CRE-driven transcription (Houslay & Adams, 2003). However, 
unlike PKIα, PDE4 co-expression does not strengthen the repressive effect of ATF4 
on the forskolin-induced activation of the CRE. This apparent lack of effect of PDE4 
is likely due to experimental limitations. Although I have not performed a thorough 
titration experiment, forskolin is likely to induce saturation of the SomCRE-Luc 
reporter in my particular experimental system when used at a concentration of 10 
µM. Indeed, increasing the forskolin concentration to 100 µM does not produce a 
comparatively stronger activation of SomCRE-Luc in HEK293 cells (Figure 4.4). 
Thus, it is possible that the exogenous PDE4 expression levels achieved in this 
particular experiment are not sufficiently high to effectively counteract the strong 
activation of the CRE induced by 10 µM forskolin. My observation that rolipram 
strongly enhances CRE-driven transcription when used in combination with a non-
saturating dose of forskolin (1 µM) clearly indicates that PDE4 is indeed involved in 
the regulation of cAMP-induced CRE-driven transcription in the tested system 
(Figure 5.10). Thus, to better elucidate the role of different PDE4 isoforms in the 
regulation of cAMP-induced CRE-driven transcription, it would be necessary to test 
the effect of different amounts of PDE4s on the activity of the SomCRE-Luc reporter 
in the presence of non-saturating forskolin concentrations.  
Consistent with the effect of PKIα, the forskolin-stimulated activity of the SomCRE-
Luc reporter in cells expressing ATF4 is higher in the presence of rolipram. At first, 




activity of ATF4. However, the relative ability of ATF4 to repress the forskolin-
induced activation of the CRE is virtually unaffected by rolipram, suggesting that, at 
least in the tested system, PDE4 is not involved in the regulation of ATF4 at high 
cAMP levels. Thus, as for PKIα, the increase in forskolin-induced CRE activity 
observed in ATF4-transfected cells in the presence of rolipram likely results from the 
independent activating effect of rolipram on CREB activity (Figure 5.10).  
In conclusion, this limited set of experiments suggests that, although PDE4s are 
potentially involved in the regulation of ATF4 at basal cAMP levels, they do not 
mediate the repressive activity of DISC1 under the tested experimental conditions. 
Moreover, while PDE4s do not appear to influence the repressive activity of ATF4 at 
high cAMP levels, they are potentially involved in the regulation of CRE-driven 
transcription under these conditions. Further experiments will be needed to elucidate 
the mechanism by which DISC1 and PDE4s, either independently or in concert, 




6 Testing the effect of DISC1 on the cell’s response 
to oxidative stress 
6.1 Introduction 
There is increasing evidence supporting a role of oxidative stress in the pathogenesis 
of psychiatric conditions including depression, bipolar disorder and schizophrenia 
(Berk et al, 2011; Bitanihirwe & Woo, 2011; Do et al, 2009; Fendri et al, 2006; Ng 
et al, 2008; Wood et al, 2009b; Yao et al, 2001; Zhang et al, 2010). Oxidative stress 
results from the accumulation of reactive oxygen and nitrogen species (ROS and 
RNS, respectively) in the cell as a result of their increased production and/or 
defective elimination by the cells’ antioxidant defence system (Berg et al, 2004; 
Kohen & Nyska, 2002). ROS and RNS are highly toxic to the cell as they directly 
damage multiple essential cell components, including proteins, DNA and lipids 
(Avery, 2011; Lockwood, 2000; Stadtman & Levine, 2003). The brain is particularly 
susceptible to oxidative damage because of its high metabolic rate and high content 
of oxidisable molecules such as polyunsaturated fatty acids, coupled with its 
relatively low content of antioxidants (Bitanihirwe & Woo, 2011). Indeed, oxidative 
damage is implicated in the pathogenesis of several neurodegenerative diseases, 
including Alzheimer’s and Parkinson’s (Roberts et al, 2009). Several studies found 
that the expression of enzymes involved in ROS detoxification is reduced in 
schizophrenic and bipolar brains, including first-episode drug-naive patients, 
suggesting that this is not a side-effect of medication (Do et al, 2000; Gawryluk et al, 
2011; Yao et al, 2006). Accordingly, markers of oxidative stress are reportedly 
increased in the brain, blood and urine of schizophrenia and bipolar disorder patients, 
and their concentration correlates with the degree of psychotic symptoms (Dietrich-
Muszalska et al, 2009; Golse et al, 1978; Mico et al, 2011; Owe-Larsson et al, 2011; 
Wang et al, 2009; Yao et al, 2006; Yao et al, 1999; Zhang et al, 2009).  However, it 
is important to point out that, although the majority of studies observed an 
impairment of antioxidant defence in psychiatric patients, some reported the opposite 
(Boskovic et al, 2011). These discrepancies may be caused by multiple factors, 




(Boskovic et al, 2011). Intriguingly, a number of pre-clinical studies showed that 
perturbations of the antioxidant defence system result in cognitive deficits as well as 
behavioural and histological alterations relevant to schizophrenia (Cabungcal et al, 
2007; Dean et al, 2009; Steullet et al, 2010). Moreover, studies in humans and 
rodents demonstrated that many of the established environmental risk factors for 
schizophrenia, such as maternal malnutrition, obstetric complications, prenatal 
infection and psychosocial stress, increase ROS production and compromise the 
antioxidant defence system in the brain (Do et al, 2009). Despite the mounting 
evidence linking oxidative stress to psychopathogenesis, the role of the antioxidant 
defence system in the onset and progression of mental illness still needs to be 
elucidated (Bitanihirwe & Woo, 2011).  
Oxidative stress has been directly linked to two processes of central relevance for 
schizophrenia: NMDAR hypofunction and myelination defects (Do et al, 2009). 
Multiple lines of evidence suggest that NMDAR hypofunction likely contributes to 
the pathogenesis of schizophrenia (Coyle, 2006; Kantrowitz & Javitt, 2010; Olney et 
al, 1999). Administration of NMDAR antagonists exacerbates positive symptoms in 
schizophrenia patients, and in healthy individuals it induces disturbances typical of 
schizophrenia, such as psychosis and cognitive impairment (Coyle, 2006; Kantrowitz 
& Javitt, 2010; Olney et al, 1999). Additionally, post-mortem analysis of brains from 
schizophrenia, bipolar disorder and depression patients showed reduced expression 
of NMDAR subunits (Beneyto et al, 2007; Beneyto & Meador-Woodruff, 2008; 
Clinton et al, 2003; Gao et al, 2000; McCullumsmith et al, 2007; Meador-Woodruff 
et al, 2003; Nudmamud-Thanoi & Reynolds, 2004; Vrajova et al, 2010). By 
inhibiting the function of NMDARs, oxidative stress negatively impacts on the 
maintenance and function of parvalbumin (PV) interneurons, a cell population that 
plays a critical role in the synchronisation of brain activity, and that is reportedly 
depleted in schizophrenic brains (Do et al, 2009). Intriguingly, the environmental 
schizophrenia risk factors linked to increased oxidative stress in the brain were 
recently shown to decrease the number of PV interneurons in the hippocampus and 
prefrontal cortex in rodent models, and to induce behavioural and cognitive 
alterations compatible with schizophrenia (Powell et al, 2012). Thus, it has been 




during development (Behrens & Sejnowski, 2009; Powell et al, 2012). Of relevance, 
several DISC1 mouse models display reduced PV expression in the cortex, although 
a potential functional link with increased oxidative stress has not been investigated 
yet (Ayhan et al, 2011; Hikida et al, 2007; Shen et al, 2008).   
Growing evidence from imaging, gene expression and post-mortem studies indicates 
that oligodendrocyte function and myelination are impaired in schizophrenia and 
bipolar disorder (Davis et al, 2003; Dracheva et al, 2006; Haroutunian & Davis, 
2007; McIntosh et al, 2009; Sussmann et al, 2009; Takahashi et al, 2011; Tkachev et 
al, 2003; Uranova et al, 2004; Uranova et al, 2007). White matter (WM) volume 
reductions, reduced fractional anisotropy (a measure of WM integrity), reduced 
expression of oligodendrocyte-specific genes and oligodendrocyte abnormalities 
such as decreased cell density, altered morphology and increased apoptosis have all 
been observed in these diseases (Bernstein et al, 2009; Ellison-Wright & Bullmore, 
2009; Hof et al, 2003; Martins-de-Souza, 2010; Tkachev et al, 2003; Uranova et al, 
2001). The results of several studies that tested the effects of typical and atypical 
antipsychotics on oligodendrocyte viability, proliferation, differentiation and 
morphology in vitro or in vivo support the conclusion that the oligodendrocyte 
abnormalities associated with schizophrenia are not side-effects of antipsychotic 
medication, and may therefore be inherent to the pathogenetic mechanism (Garver et 
al, 2008; Hakak et al, 2001; Konopaske et al, 2008; Steiner et al, 2011; Wang et al, 
2010b; Xiao et al, 2008). According to the connectivity hypothesis, schizophrenia 
and bipolar disorder arise from defects in wiring and communication within and 
between different brain regions, which in turn lead to altered behaviour, perception 
and thought process (Harrison & Weinberger, 2005; Stewart & Davis, 2004). Since 
axon myelination is essential for the normal propagation of electric signals between 
neurons, it has been proposed that the WM abnormalities seen in schizophrenia and 
bipolar disorder may contribute to the aberrant connectivity characterising these 
disorders (Davis et al, 2003; Hulshoff Pol et al, 2004; Takahashi et al, 2011). 
Interestingly, the risk-conferring DISC1 polymorphism resulting in amino acid 
substitution S704C is associated with reduced fractional anisotropy (FA) in healthy 
carriers (Hashimoto et al, 2006; Sprooten et al, 2011). FA measures the directional 




fibres are associated with high FA values, because the structure and chemical 
composition of this tissue prevents water diffusion in any direction other than along 
the fibres, and decreasing FA is thought to reflect structural degeneration of WM 
tracts (Kochunov et al, 2007). Thus, the findings reported by Hashimoto and 
colleagues and Spooten and colleagues establish a direct link between genetic 
variation in DISC1 and WM abnormalities in humans (Hashimoto et al, 2006; 
Sprooten et al, 2011). Due to their high iron content and reduced antioxidant 
capacity, both mature oligodendrocytes and their progenitor cells are particularly 
sensitive to oxidative stress-induced cell damage (Bitanihirwe & Woo, 2011). 
Moreover, oxidative stress was shown to inhibit the proliferation and promote the 
differentiation of oligodendrocyte progenitors (Li et al, 2007b; Smith et al, 2000) 
and to cause direct damage to myelin sheaths (Halliwell, 1992),  providing a 
potential functional link between increased oxidative stress and defective 
myelination in schizophrenia (Bitanihirwe & Woo, 2011).  
ATF4 is activated by oxidative stress, and in turn regulates the expression of target 
genes involved in the regulation of redox metabolism (Fung et al, 2007; Harding et 
al, 2003; Igarashi et al, 2007; Jin et al, 2009a; Lange et al, 2008; Lewerenz & 
Maher, 2009; Lewerenz et al, 2012; Ogawa et al, 2008; Tagawa et al, 2011). 
Interestingly, aberrant ATF4 expression has been linked to the oligodendrocyte 
abnormalities that characterise Vanishing White Matter Disease (VWM) (Kantor et 
al, 2008; van der Voorn et al, 2005). VWM is caused by inactivating mutations of 
the ubiquitously expressed eukaryotic initiation factor 2B (EIF2B), which result in 
selective loss of oligodendrocytes and consequent loss of white matter and 
neurodegeneration (Bugiani et al, 2010). The progression of VWM is accelerated by 
physiological stresses such as fever, head trauma and fright (Bugiani et al, 2010). 
Intriguingly, cultured primary fibroblasts from VWM patients are hypersensitive to 
endoplasmic reticulum stress, as demonstrated by the hyperactivation of ATF4 in 
response to the ER stress inducer thapsigargin (Kantor et al, 2008). Consistently, 
immunohystochemical and biochemical analysis of post-mortem VWM brains 
revealed abnormal activation of ATF4 and its target gene CHOP in glial cells. Thus, 
it has been proposed that the increased stress response and ATF4 activation in 




der Voorn et al, 2005). It is therefore intriguing to speculate that excessive and/or 
prolonged ATF4 activation in response to oxidative stress may similarly contribute to 
oligodendrocyte loss in schizophrenia and bipolar disorder.  
Recent studies conducted in zebrafish and mouse provided evidence for the 
involvement of DISC1 in oligodendrocyte proliferation, differentiation and function 
in the developing brain, and suggested a potential functional interaction between 
DISC1 and Neuregulin 1 (NRG1), a gene of known importance for oligodendrocyte 
development and function (Katsel et al, 2011; Wood et al, 2009a). However, the 
mechanisms underlying the reported effects of DISC1 on oligodendrocyte 
physiology are currently unknown.  
In chapter 4 of this thesis I demonstrated that DISC1 inhibits the transcriptional 
activity of ATF4 and represses the thapsigargin-induced activation of CRE-driven 
transcription, suggesting that it may be involved in the regulation of the 
transcriptional response to cellular stress. Thus, in this chapter I test the hypothesis 
that, through its regulation of ATF4, DISC1 modulates the cell’s ability to adapt and 
survive to stressful stimuli that activate ATF4. I additionally test the hypothesis that 
DISC1 amino acid substitutions 37W and 607F, which negatively impact on the 
repressive activity of DISC1 on ATF4, may similarly perturb any potential effect of 
DISC1 on cell viability after stress exposure.  Given the proposed involvement of 
oxidative stress in the pathogenesis of schizophrenia, and the well-established role of 
ATF4 in the transcriptional response to oxidative stress, I chose this particular 
paradigm to investigate the putative effects of DISC1 on the cell’s adaptation to 
stress.  Since oxidative damage to oligodendrocytes has been suggested to underlie 
the WM abnormalities seen in schizophrenia (Bitanihirwe & Woo, 2011), I chose the 
MO3.13 human oligodendroglial cell line (McLaurin et al, 1995) as my experimental 
model. The MO3.13 cell line was established by McLaurin and colleagues 
(McLaurin et al, 1995) by fusing primary human oligodendrocytes with a human 
rhabdomyosarcoma cell line. MO3.13 cells express the glial cell markers myelin 
basic protein (MBP), glial fibrillary acidic protein (GFAP), galactosylceramide 
(GalC), myelin-associated glycoprotein (MAG) and proteolipid protein (PLP) 




oligodendrocytes (Buntinx et al, 2003), thus representing a suitable model to study 
oxidative stress-mediated injury in these cells.  
6.2 The effect of oxidative stress on endogenous DISC1 and ATF4 
expression 
To determine the optimal experimental conditions for the induction of endogenous 
ATF4 in response to oxidative stress, MO3.13 cells were incubated with increasing 
concentrations of hydrogen peroxide (H2O2) for 4, 8, 16 or 24 hours before being 
lysed and analysed by western blotting. The H2O2 concentrations tested here reflect 
the range of concentrations that have been previously used to induce oxidative stress 
in cell models (Papadia et al, 2008; Qin et al, 2008; Wei et al, 2003; Zhang et al, 
2005). As shown in Figure 6.1, H2O2 induces ATF4 expression when used at the 
concentration of 100 or 200 µM, whereas lower concentrations have no detectable 
effect. ATF4 induction appears stronger after 8 hours of treatment compared to 4 
hours, but does not increase further with prolonged incubation times (Figure 6.1).  
 
 
Figure 6.1 MO3.13 cells were treated with the indicated concentrations of H2O2 for 
4, 8, 16 or 24 hours. After treatment, the cells were lysed and analysed by western 
blotting to detect endogenous ATF4, using -actin as a loading control. ATF4 was 
detected with the ATF4 RPC antibody. The position and size (kDa) of the protein 





Next, to compare the effect of H2O2 on ATF4 and DISC1 nuclear expression, 
MO3.13 cells were treated with 100 or 200 µM H2O2 for 24 hours, then fractionated 
to obtain nuclear protein extracts, which were subsequently analysed by western 
blotting. ATF4 nuclear expression is strongly increased after treatment with 200, but 
not 100 µM H2O2 (Figure 6.2). On the other hand, H2O2 treatment reduces DISC1 
nuclear expression in a concentration-dependent manner, with 200 µM H2O2 having 
a stronger effect compared to 100 µM H2O2 (Figure 6.2).  
 
 
Figure 6.2 Western blotting analysis of nuclear extracts prepared from MO3.13 cells 
that had been treated for 24 hours with the indicated concentrations of H2O2. 
Endogenous DISC1 and ATF4 were detected using the α-DISC1 and ATF4 RPC 
antibodies, respectively, and the normalised relative DISC1 band densities are 
shown in the graph on the right. Nuclear matrix protein p84 was used as loading 
control. The position and size (kDa) of the protein markers is shown.  
 
To further investigate the effect of H2O2 treatment on DISC1 expression in MO3.13 
cells, nuclear and cytoplasmic extracts were prepared from cells treated with 200 µM 
H2O2 for 24 hours, and analysed by western blotting. As shown in Figure 6.3, DISC1 
protein levels are significantly reduced both in the nuclear and cytoplasmic fractions 
obtained from cells exposed to H2O2, confirming the initial observations reported in 
Figure 6.2. The differential effect of H2O2 treatment on the expression of endogenous 
DISC1 and ATF4 in MO3.13 cells was further confirmed by immunocytochemistry 





Figure 6.3 Western blotting analysis of nuclear and cytoplasmic extracts prepared 
from MO3.13 cells after a 24 hour treatment with either vehicle (H2O) or 200 µM 
H2O2. Endogenous DISC1 was detected with the α-DISC1 antibody. The relative 
abundance of DISC1 in the cytoplasmic extracts was measured using two distinct 
loading controls (GAPDH or HSP90), which produced comparable results. The 
position and size (kDa) of the protein markers is indicated. The bars represent the 
average of three independent experiments. Normalised data were analysed by two-





Figure 6.4 Endogenous ATF4 (top two rows) and DISC1 (bottom two rows) in 
MO3.13 cells treated for 24 hours with either 200 µM H2O2 or vehicle (H2O). ATF4 
and DISC1 were detected with the α-DISC1 and ATF4 MMC antibodies, 
respectively. For comparability, images of treated and untreated cells were acquired 





6.3 Testing the effect of ATF4 and DISC1 on MO3.13 cell viability in 
response to oxidative stress 
Initially, I verified that the expression of endogenous ATF4 and DISC1 can be 
successfully silenced using specific siRNA oligonucleotides in MO3.13 cells. The 
cells were transfected with siRNA oligonucleotydes for 48 hours, as detailed in 
paragraph 2.6.7, before being lysed and analysed by western blotting. As expected, 
DISC1 expression is efficiently knocked-down by two distinct DISC1-targeting 
siRNAs (DISC1 #2 and DISC1 #5, Table 2.11), but not by the negative control 
siRNA (A NC siRNA, Table 2.11) (Figure 6.5 A). Similarly, the ATF4 targeting 
siRNAs obtained from Qiagen (Q ATF4, Table 2.11) and Ambion (A ATF4, Table 
2.11), but not the respective negative controls (Q NC and A NC, Table 2.11), entirely 
prevented the H2O2-induced accumulation of ATF4 in the nucleus, confirming the 
efficiency of the siRNA transfection protocol in MO3.13 cells (Figure 6.5 B).  
 
 
Figure 6.5 (A) DISC1 expression in whole cell lysates from MO3.13 that were either 
left untransfected, mock transfected, or transfected for 48 hours with the indicated 




three independent experiments. DISC1 protein expression was not quantified in the 
two DISC1 siRNA samples as no bands were visible, even after a prolonged 
exposure time (>30 minutes). (B) MO3.13 cells were either mock transfected or 
transfected with Qiagen or Ambion ATF4-targeting siRNA or the respective negative 
controls. Starting from 32 hours after transfection, the cells were treated with 200 
µM H2O2 for 16 hours, then nuclear protein extracts were prepared and analysed by 
western blotting. DISC1 and ATF4 were detected using the α-DISC1 and ATF4 RPC 
antibodies, respectively. NC: negative control. The position and size (kDa) of the 
protein markers is indicated. * non-specific bands.  
 
To investigate the potential effects of ATF4 and DISC1 on MO3.13 survival under 
conditions of oxidative stress, the cells were treated for 24 hours with either 200 µM 
H2O2 or 5 mM DL-Homocysteine (HCY) after ATF4 or DISC1 knock-down or 
overexpression, as detailed in paragraph 2.7.2. HCY is a non-essential sulphur-
containing amino acid generated by demethylation from methionine (Bouaziz et al, 
2010). When HCY plasma levels are abnormally elevated, it can cause oxidative 
stress by increasing the generation of ROS (Heinecke et al, 1987; Yan et al, 2006), 
by inducing lipid peroxidation (Jones et al, 1994) and by inhibiting the synthesis of 
glutathione peroxidase (Handy et al, 2005; Pasca et al, 2006; Upchurch et al, 1997). 
Accordingly, HCY treatment induces ATF4 expression in cultured cells (Jin et al, 
2009b; Outinen et al, 1999; Roybal et al, 2004), and a number of studies suggest that 
increased HCY plasma levels may be a risk factor for schizophrenia (Applebaum et 
al, 2004; Bouaziz et al, 2010; Brown & Susser, 2005; Levine et al, 2002; Levine et 
al, 2006; Muntjewerff et al, 2005; Muntjewerff et al, 2006; Regland, 2005; Susser et 
al, 1998). Following on from my finding that the endoplasmic reticulum stress 
inducer thapsigargin (TG) elicits a CRE-driven transcriptional response that is 
differentially regulated by DISC1 variants 37W and 607F, I tested whether DISC1 
and its variants affect MO3.13 viability in response to TG treatment.  
Initially, for each different siRNA transfection, the cell viability at the end of each 
drug treatment was compared to the cell viability in untreated cells using paired 




by using a bioluminescent reaction to quantify the amount of ATP present in each 
well, which is in turn proportional to the number of metabolically active cells (see 
paragraph 2.7.2 for a detailed method description). As expected, all drug treatments 
significantly reduce MO3.13 cell viability in siRNA-transfected cells (Figure 6.6 A, 
B, C and D). HCY treatment (5mM) produces the strongest cell toxicity, and 
consistently reduces the number of viable cells by 60% (Figure 6.6 A, B, C and D). 
The effect of 200 µM H2O2 is comparable to that of HCY, whereas 1 µM TG 
determines a milder reduction of cell viability (30-40%) (Figure 6.6 A, B, C and D). 
Next, the same data were plotted differently for ease of comparison between different 
siRNA transfections (Figure 6.6 C and D). For each drug treatment, the viability of 
cells transfected with ATF4- or DISC1-targeting siRNAs was compared to the 
viability of cells transfected with the respective negative control siRNAs, using 
paired student’s t-tests. Surprisingly, when compared to the appropriate negative 
controls, ATF4-targeting siRNAs do not significantly affect MO3.13 cell viability 
after stress exposure (Figure 6.6 A and C).  On the other hand, ATF4 silencing 
mildly affects viability in untreated MO3.13 cells (Figure 6.6 E). However, since two 
distinct ATF4-targeting siRNAs produce opposing effects when compared to the 
respective negative controls, this observation is likely artifactual (Figure 6.6 E). Very 
similar results were obtained after DISC1 silencing: neither DISC1-targeting siRNA 
affects cell viability in stressed cells (Figure 6.6 B, D), but the two distinct DISC1 
siRNAs have opposing effects in untreated cells (Figure 6.6 F). Overall, then, these 
data indicate that transient knock-down of ATF4 or DISC1 has no effect upon 






Figure 6.6 MO3.13 cells were transfected with the indicated siRNAs for 24 hours 
before being subjected to the specified drug treatments for 24 hours, and then 
assayed for total cell viability. Figures A and B report the actual luminescence 
readings, which are directly proportional to the number of viable cells in each 
sample. In A and B, for each siRNA tested, the readings obtained after drug 
exposure were compared to the readings in non-drug-treated cells. The same data 
is plotted differently in C and D, to show the proportion of viable cells in each sample 
normalised to the viability of non-drug-treated cells, which was assumed to be 
100%.  In C and D, for each drug treatment condition, the readings obtained from 
cells transfected with ATF4 or DISC1-targeting siRNAs were compared to the 
readings from cells transfected with the respective negative control siRNA.  Figures 




E and F, the viability of cells transfected with ATF4- or DISC1-targeting siRNAs is 
normalised to the viability of the respective negative control-transfected cells, which 
was assumed to be 100%. The bars represent the average of 4 independent 
experiments. Data were analysed by two-tailed paired student’s t-test. *P<0.05; 
**P<0.01; ***P<0.001. Q ATF4 siRNA: Qiagen ATF4 siRNA; Q NC siRNA: Qiagen 
negative control siRNA; A ATF4 siRNA: Ambion ATF4 siRNA; A NC siRNA: Ambion 
NC siRNA.  
 
Next, the same analysis was applied to cells transfected with ATF4 or DISC1 
expression plasmids (Figure 6.7). Unlike siRNA-transfected cells, in ATF4-, 
ATF4 RK- or mock-transfected cells, HCY or H2O2 treatment only mildly, and non-
significantly, reduces cell viability ( 30% and 20% reduction, respectively), 
whereas TG has no effect (Figure 6.7 A and C). Overexpression of ATF4 or its 
dominant-negative mutant ATF4 RK produces no effect on cell viability when 
compared to mock-transfected cells, both under stressed and unstressed conditions 
(Figure 6.7 A, C and E). However, since in this particular experiment no significant 
effect of stress exposure could be detected in the control, mock-transfected cells 
(Figure 6.7 A), no firm conclusions can be drawn about the putative effect of ATF4 
overexpression on cell viability. In the absence of drug treatment, the viability of 
DISC1-transfected cells does not differ from that of mock-transfected cells (Figure 
6.7 F), indicating that DISC1 overexpression alone does not affect cell viability. 
Similarly to ATF4-transfected cells, DISC1- or mock-transfected cells are not 
significantly affected by H2O2 or TG treatment (Figure 6.7 B and D). On the other 
hand, HCY significantly reduces cell viability in wild-type DISC1- and mock-
transfected cells (P<0.05, Figure 6.7 A), but not in cells expressing DISC1-37W or 
DISC1-607F (Figure 6.7 A). This suggests that DISC1-37W- and DISC1-607F-, but 
not DISC1-WT expressing cells might be protected from cell death induced by HCY. 
However, this is in contrast with the observation that, when compared to mock-
transfected cells, cells expressing DISC1-WT show a small, but statistically 
significant increase in viability after exposure to HCY (P<0.05, Figure 6.7 D), 




from mock-transfected cells (Figure 6.7 D). The latter observation suggests that cells 
overexpressing DISC1-WT might be better protected from HCY-induced cell death 
compared to cells expressing DISC1-37W or DISC1-607F. The discrepancy between 
these two observations, which likely arises from the higher experimental error 
associated with viability measurements in cells expressing DISC1-WT or DISC1-
607F compared to cells expressing DISC1-WT and mock-transfected cells (Figure 
6.7 B and D), prevents any firm conclusions about the potential differential effect of 
DISC1 variants on MO3.13 cell survival after HCY exposure.  
As detailed in chapter 2 of this thesis, MO3.13 cells were plated at a cell density of 
1x10
4
/well for the silencing experiments and 2x10
4
/well for the overexpression 
experiments (Paragraph 2.7.2). This was done because while DNA transfection 
caused cell death at cell densities below 2x10
4
/well, siRNA transfection was well 
tolerated by cells seeded at 1x10
4
/well. The reason for this difference is not clear, as 
it does not depend on the transfection protocol, nor on the type of transfected DNA. 
Indeed, transfection of protein expression plasmids or empty vector produced similar 
degrees of cell toxicity (not shown).  A titration experiment carried out using HCY 
established that increased cell density increases cell survival after stress exposure 
(Figure 6.8). For this reason, and to achieve the strongest possible response to stress, 
each set of experiments was performed using the lowest cell density that allows 
transfection without toxicity (i.e. 1x10
4 
for siRNA transfection and 2x10
4 
for DNA 
transfection). Thus, the reduced cell toxicity of H2O2, HCY and TG in DNA-
transfected cells (Figure 6.7 A) compared to siRNA-transfected cells (Figure 6.6 A) 






Figure 6.7 MO3.13 cells were transfected with the indicated expression plasmids 
before being subjected to the specified drug treatments for 24 hours, and then 
assayed for total cell viability. Figures A and B report the actual luminescence 
readings, which are directly proportional to the number of viable cells in each 
sample. In A and B, for each DNA construct tested, the readings obtained after drug 
exposure were compared to the readings in untreated cells. The same data is 
plotted differently in C and D, to show the proportion of viable cells in each sample 
normalised to the viability of untreated cells, which was assumed to be 100%.  In C 
and D, for each treatment condition, the readings obtained from cells transfected 
with ATF4 or DISC1 expression plasmids were compared to the readings from 
mock-transfected cells.  Figures E and F show the proportion of viable cells in 
untreated samples, and each data set is normalised to the viability of mock-








Figure 6.8 MO3.13 cells seeded in 96 well plates at the indicated cell densities were 
either treated with 5 mM HCY for 24 hours or left untreated before being assayed for 
cell viability. The luminescence readings for each sample are directly proportional to 
the number of viable cells. The bars represent the readings obtained in a single 
experiment. The numbers above the bars indicate the reduction in cell viability, 
expressed as percentage.  
6.4 Discussion 
In this chapter, I investigated the effect of oxidative stress on ATF4 and DISC1 
protein expression in MO3.13 human oligodendrocytes, and tested for potential 
effects of both proteins on MO3.13 cell survival under conditions of oxidative and 
endoplasmic reticulum stress.  As previously observed in other cell types (Jin et al, 
2009a; Miyamoto et al, 2011), H2O2 treatment robustly induces ATF4 nuclear 
expression in MO3.13 cells. Interestingly, the same treatment produces the opposite 
effect on DISC1 protein levels. A recent study showed that exposure of primary 
mouse cortical neurons to H2O2 promotes the accumulation of endogenous DISC1 
aggregates (containing both full-length and 72 kDa isoforms) in the sarkosyl-
insoluble subcellular protein fraction (Atkin et al, 2012), an effect that may be 




nuclear and cytoplasmic fractions described here. However, in contrast with my 
findings, the above study found no evidence for a concomitant reduction of soluble 
DISC1 protein levels upon H2O2 treatment (Atkin et al, 2012). This discrepancy may 
be explained by experimental differences, as my experiments were performed using a 
10-fold higher H2O2 concentration (200 µM instead of 20 µM) and a significantly 
longer treatment time (16 hours instead of 2 hours).  The immunocytochemical 
analysis described in this chapter confirmed reduced DISC1 expression levels in 
MO3.13 cells exposed to 200 µM H2O2, but provided no evidence suggesting that 
this may result from the formation of insoluble endogenous DISC1 aggregates, the 
visualisation of which may require a higher resolution technique, such as electron 
microscopy. H2O2-induced insoluble DISC1 aggregation in neurons is enhanced by 
disruption of the autophagy pathway, indicating that these aggregates are normally 
degraded by autophagy (Atkin et al, 2012). Since stress-induced ATF4 is known to 
activate the autophagic pathway (Avivar-Valderas et al, 2011; Milani et al, 2009; 
Rouschop et al, 2010; Rzymski et al, 2010; Rzymski et al, 2009), it is intriguing to 
speculate that H2O2 concentrations that induce ATF4 expression may also promote 
the degradation of insoluble DISC1 aggregates by autophagocytosis. It would 
therefore be interesting to test whether inhibiting ATF4 expression promotes the 
accumulation of insoluble DISC1 aggregates in H2O2-treated cells. It is also possible 
that, besides promoting DISC1 aggregation, H2O2 treatment, and perhaps other 
cellular stressors, may control DISC1 expression by indirectly regulating its 
transcription and/or translation. Indeed, the recently characterised human DISC1 
promoter (Walker et al, 2012) contains one copy of the AP-1 consensus binding site 
(5' TGAGTCA 3') (Rosie Walker, personal communication). Consistently, ChIP-seq 
experiments performed as part of the ENCODE project 
(http://www.genome.gov/10005107) identified binding of AP-1 family members 
JunD and c-Jun to the DISC1 promoter region. The AP-1 family of transcription 
factors, which is composed by Fos, Jun and ATF homo- and heterodimers, is 
implicated in the transcriptional response to a variety of physiological and 
pathological stimuli, including stress signals (Hess et al, 2004). In the light of these 
observations, it would be particularly interesting to test for potential regulatory 




ATF4 has been shown to affect cell viability in response to oxidative stress in 
different cell models (Dickhout et al, 2012; Fung et al, 2007; Harding et al, 2003; 
Lange et al, 2008; Ogawa et al, 2008; Ord et al, 2007). It is therefore surprising that 
ATF4 silencing does not affect MO3.13 cell survival after exposure to toxic 
concentrations of H2O2 or HCY. The reasons for this discrepancy are not clear, but 
may be related to methodological problems. For example, all previous studies were 
performed in ATF4 KO cell lines or primary neurons, as opposed to cells in which 
ATF4 expression has been silenced by transient siRNA transfection, and may have 
reflected long-term changes arising from chronic ATF4 depletion. Moreover, in the 
present study both ATF4- and DISC1-targeting siRNAs were shown to efficiently 
knock-down protein expression 48 hours after transfection, but the drug treatments 
were started 24 hours after transfection. Thus, it cannot be excluded that ATF4 and 
DISC1 expression were only partially silenced at the start of the drug treatments, 
which may have affected the results. The choice of method used to evaluate cell 
viability may also have contributed to the discrepancy between my observations and 
what has previously been reported in the literature. Indeed, while in the present study 
cell viability was estimated on the basis of cellular ATP content, other studies used 
the 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay (Lange et al, 
2008). MTT assay can overestimate cell toxicity as it measures cellular NAD(P)H-
dependent reducing activity, which can be decreased by sub-toxic stress through a 
reduction of intracellular NAD(P)H levels (Bell et al, 2011).  Since knocking down 
ATF4, which is a key mediator of the cellular response to stress, does not show any 
effect upon MO3.13 cell survival to H2O2- and HCY-induced toxicity in this set of 
experiments, it is not surprising that DISC1 silencing also has no consequence on 
stress survival under the same conditions. Thus, based on this particular experimental 
model, it is not possible to draw any conclusions on the putative direct involvement 
of DISC1 in stress adaptation.  
The ATF4/DISC1 overexpression model described here is affected by a major 
technical limitation, as the minimal cell density that guarantees cell survival after 
transfection also protects the cells from death after exposure to the subsequent drug 
treatments. As a result of this, I could not detect a statistically significant decrease in 




cells exposed to HCY. Moreover, since transfection methods based on liposome 
DNA carriers, like the one used in this study, can induce cellular stress responses and 
thus alter the gene expression profile in transfected cells (Fiszer-Kierzkowska et al, 
2011), it is likely that stress-inducible pathways were already active in MO3.13 cells 
before the start of the drug treatments, which may have blunted the observed effects. 
Interestingly, cells expressing wild-type DISC1, but not 37W- or 607F-DISC1, show 
slightly but significantly improved stress survival compared to mock-transfected 
cells. However, given the very small size of this protective effect, coupled with the 
lack of effect of DISC1 silencing, this result must be interpreted with caution, and 
cannot be taken as direct evidence supporting a role of DISC1 in the regulation of the 
cell’s adaptation to stress. Nevertheless, this is a potentially relevant observation that 
would deserve further investigation, especially in the light of the differential effects 
of DISC1 variants on ATF4-dependent transcription reported in chapter four of this 
thesis.  Future experiments focused on alternative and more relevant cell models, 
such as primary oligodendrocytes or neurons, and exploiting efficient DNA delivery 
methods, such as adenoviral-mediated overexpression or gene silencing, may provide 
a better experimental approach to explore the potential role of DISC1 in the 




7 Molecular characterisation of the DISC1-ATF4 
interaction 
7.1 Introduction  
In the previous chapters of this thesis I demonstrated that amino acid substitutions 
37W and 607F significantly decrease the nuclear abundance of exogenously 
expressed full-length DISC1. I additionally demonstrated that at basal cAMP levels 
DISC1 inhibits the transcriptional activity of ATF4, and that this particular DISC1 
function is impaired by amino acid substitutions 37W and 607F. Since the partial 
loss of function phenotype observed for DISC1-37W and DISC1-607F in luciferease 
reporter assays is coupled with their reduced nuclear targeting, I hypothesised that a 
causal relationship might exist between these two observations, whereby reduced 
DISC1 nuclear expression results in, or contributes to its decreased ability to repress 
ATF4 activity. In support of this, as shown in chapters 3 and 4 of this thesis, the 
repressive effect of DISC1 on ATF4 function is not affected by the ultra-rare 
mutation 603I, which does not impair DISC1 nuclear expression. On the other hand, 
the artificial mutant DISC1 LZ9, which is not expressed in the nucleus, is unable to 
repress ATF4 transcriptional activity. I additionally postulated that amino acid 
substitutions 37W and 607F, both of which are predicted to introduce structural 
changes in DISC1 (Soares et al, 2011), might either directly or indirectly destabilise 
its physical interaction with ATF4, which in turn may contribute to their observed 
detrimental effect on the functional interaction between DISC1 and ATF4.  Thus, 
this chapter aims to investigate the mechanism(s) by which DISC1 represses ATF4 
transcriptional activity, and shed light on the molecular basis for the differential 
effects of DISC1 variants on the functional interaction with ATF4. In particular, I 
investigate the effect of amino acid substitutions 37W, 607F and 603I on DISC1’s 
ability to interact with ATF4 in intact cells, and ask if and how the impact of such 
DISC1 amino acid changes on ATF4 binding may relate to their differential effect on 
ATF4 regulation. In addition, having previously established that DISC1 represses 
ATF4-dependent transcription at basal cAMP levels, but has no effect on ATF4 




ATF4 and DISC1 subcellular distribution and binding. Finally, to test the hypothesis 
that the ATF4-DISC1 interaction may not be restricted to the cell nucleus, I analyse 
the subcellular distribution of both exogenous and endogenous ATF4 and DISC1 in 
two distinct human cell lines.  
7.2 Generation of novel ATF4 expression constructs 
To generate expression constructs pcDNA3.1-ATF4-Flag, coding for C-terminally 
Flag-tagged human ATF4, and pcDNA6-ATF4-Myc, coding for C-terminally Myc-
tagged human ATF4, the ATF4 coding sequence was amplified from construct 
pDEST53-ATF4 (Table 2.2), using primer couples ATF4 F plus ATF4 Flag R and 
pDEST ATF4 F1 plus pDEST ATF4 R2, respectively  (Table 2.8). The PCR 
reactions were performed as detailed in paragraph 2.6.1.1. The purified PCR 
products were ligated between the EcoRI and XhoI sites of destination vector 
pcDNA3.1(+) (Table 2.2), to generate pcDNA3.1-ATF4-Flag, or pcDNA6/myc-HIS 
B (Table 2.2), to generate pcDNA6-ATF4-Myc, according to the methods described 
in paragraphs 2.6.6.2 to 2.6.6.6. The new ATF4 expression constructs were validated 
by direct sequencing, using primers T7 F, CMV F and BGH R (Table 2.7).  
7.3 The effect of DISC1 on ATF4 expression and nuclear targeting 
In chapter 4 of this thesis I demonstrated that DISC1 co-expression inhibits the 
transactivation activity of ATF4 on the CRE and CHOP AARE promoters at basal 
cAMP levels. Interestingly, a previous study by Morris and colleagues showed that 
co-expression of full-length DISC1 inhibits the nuclear targeting of its interactor 
ATF5, a transcription factor that is both structurally and functionally related to ATF4 
(Morris et al, 2003). Thus, I sought to test whether DISC1 co-expression exerts a 
similar effect on the nuclear distribution and/or total protein expression levels of 
ATF4, which may contribute to its repressive effect on ATF4 transcriptional activity. 
Initially, COS7 cells were transfected using the same ATF4/DISC1 DNA ratio used 
in luciferase assays (i.e. 1/0.67) and analysed by immunocytochemistry to detect 
ATF4 and DISC1, using cells transfected with ATF4 only as controls. As shown in 




expression in COS7 cells. Interestingly, in transfected COS7 cells, ATF4 expression 
is not restricted to the nucleus, but can also be detected in the cytoplasm in a pattern 
closely resembling the typical morphology of mitochondria (Figure 7.1), an organelle 
where DISC1 is known to localise (James et al, 2004; Millar et al, 2005a; Park et al, 
2010). Notably, exogenous ATF4 and DISC1 partially co-localise both in the nucleus 
and cytoplasm, and particularly in the perinuclear region (Figure 7.1). To further test 
for potential effects of DISC1 on the overall protein expression and/or nuclear 
targeting of exogenous ATF4, whole cell lysates, nuclear extracts and cytoplasmic 
extracts were obtained from HEK293 cells expressing ATF4 alone or in combination 
with DISC1, and analysed by western blotting.  Consistent with what was observed 
by immunofluorescence in COS7 cells, DISC1 co-expression does not reduce ATF4 
expression in the nucleus or cytoplasm, nor does it reduce its total expression levels 
in HEK293 cells (Figure 7.2). Instead, and contrary to my expectations, DISC1 co-
expression appears to moderately increase ATF4 expression both in the nucleus and 
cytoplasm, although this effect is not statistically significant (Figure 7.2). Thus, on 
the basis of these results, the hypothesis that DISC1 may inhibit ATF4-mediated 






Figure 7.1 COS7 cells transfected with pCG-ATF4 and either the empty vector 
pcDNA4/TO (A) or pcDNA4/TO-Flag DISC1 WT (B) at a 1/0.67 ratio were double 
stained with the ATF4 RPC and Flag MMC antibodies to detect exogenous ATF4 
and DISC1, respectively, then analysed by confocal microscopy. The area delimited 
by a white rectangle is magnified in the inset. Nuclei are stained with DAPI (blue). 






Figure 7.2 HEK293 cells were transfected with pCG-ATF4 and either pcDNA4/TO-
Flag DISC1 WT or the empty vector pcDNA4/TO. The ATF4/DISC1 transfected DNA 
ratio was 1/0.67, reflecting the transfection conditions used for luciferase reporter 
assays. 24 hours after transfection, the cells were subjected to subcellular 
fractionation, and the resulting nuclear and cytoplamic extracts were analysed by 
western blotting, along with the corresponding whole cell lysates. Loading controls 
are histone 3 (H3) for whole cell lysates, nuclear matrix protein p84 for nuclear 
extracts and heat shock protein 90 (HSP90) for cytoplasmic extracts. Bars represent 
the average of 3 independent experiments. The position and size (kDa) of the 
protein markers is indicated. Data are normalised to ATF4 protein levels in cells 
transfected with ATF4 alone, and were analysed by one sample student’s t test.  
 
7.4 Distribution of DISC1 and ATF4 in human cell lines 
Although exogenous ATF4 is highly enriched in the nucleus, it is also expressed in 
the cytoplasm, in a pattern resembling the typical conformation of mitochondria 
(Figure 7.1). Hence, to better test whether exogenous ATF4 partially distributes to 
mitochondria, I used four different antibodies to detect the protein (both tagged and 
untagged) in transfected COS7 cells. In each case, I observed partial co-localisation 
of ATF4 with mitochondria, particularly in the perinuclear region (Figure 7.3). This 
confirms my previous observations, and suggests that ATF4 may potentially interact 






Figure 7.3 COS7 cells were transfected with pCG-ATF4 (top two rows), pcDNA3.1-
ATF4-Flag (third row) or pcDNA6-ATF4-Myc (bottom row). Exogenous ATF4 was 
detected using the following antibodies: ATF4 RPC (sc-200, top row), ATF4 MMC 
(WH000048M1, second row), Flag RPC (third row) or Myc MMC (bottom row). 
Mitochondria were stained with Mitotracker Red. The areas delimited by a white 
square are magnified in the insets.  
 
Next, I asked whether endogenous ATF4 also localises at mitochondria. As expected, 




both HEK293 and SH-SY5Y human cell lines (Figure 7.4 A and B, respectively). In 
addition, like the exogenous protein, endogenous ATF4 is also detectable in the 
cytoplasmic region, where it assumes a punctate distribution (Figure 7.4 A and B). 
Consistent with my previous observations, endogenous cytoplasmic ATF4 partially 
overlaps with mitochondria, and here its distribution is strikingly similar to that 
independently observed for endogenous mitochondrial DISC1 (Figure 7.4 A and B). 
These data indicate that both endogenous full-length DISC1 and ATF4 partially 
localise at mitochondria in HEK293 and SHSY5Y cells. However, due to technical 
limitations concerning the staining protocol, it was not possible to determine with 
confidence whether endogenous ATF4 and DISC1 co-localise at mitochondria in 
these cells. In the future, this could be tested by using triple staining to detect ATF4, 
DISC1 and mitochondria, or by combining mitotracker staining with Proximity 







Figure 7.4 Distribution of endogenous ATF4 and DISC1 in HEK293 (A) and SH-
SY5Y (B) cells analysed by confocal microscopy. ATF4 was detected with either the 
ATF4 MMC or ATF4 RPC antibody, whereas DISC1 was detected with the α-DISC1 
antibody. Mitochondria were stained with Mito Tracker Red. In cells stained with the 
α-DISC1 antibody, nuclei were visualised using DAPI (blue). The regions delimited 
by a white square are magnified in the far-right panels. The white arrowheads in (B) 
indicate juxtanuclear ATF4 speckles (see text). Scale bars are 10 µm.  
 
While analysing endogenous ATF4 distribution in cell lines, I noticed that ATF4 can 
often be seen in dense juxtanuclear speckles or puncta, which are particularly evident 
in cells stained with the ATF4 MMC antibody (Figure 7.4 B). Each cell typically 
shows one or two juxtanuclear ATF4 speckles (Figure 7.4 B). Intriguingly, the 
subcellular location of these ATF4 speckles is compatible with the position of the 




play important roles for neurite outgrowth and neuronal migration (Bradshaw et al, 
2009; Bradshaw et al, 2008; Kamiya et al, 2005; Kamiya et al, 2008; Miyoshi et al, 
2004; Morris et al, 2003; Shimizu et al, 2008). Indeed, centrosomal localisation of 
endogenous ATF4 in HEK293 cells has been observed before (Vaz Meirelles et al, 
2010). This prompted me to test whether endogenous ATF4 and DISC1 co-localise at 
the centrosome in human cells. As shown in Figure 7.5, in both HEK293 and SH-
SY5Y cells, ATF4 juxtanuclear puncta clearly co-localise with the centrosomal 
protein -tubulin, which is commonly used as a centrosomal marker (Bradshaw et al, 
2009; Bradshaw et al, 2008; Kamiya et al, 2005; Morris et al, 2003). Co-localisation 
of ATF4 with -tubulin is evidenced by two distinct anti-ATF4 antibodies in two 
different cell types (Figure 7.5 A and B), indicating that it is unlikely to be 
artefactual, and confirming previous findings (Vaz Meirelles et al, 2010). Thus, these 
data indicate that ATF4 juxtanuclear puncta correspond to the centrosomal pool of 
ATF4.  As expected, endogenous DISC1 also partially localises at the centrosome 
(Figure 7.5 A and B) and, intriguingly, ATF4 and DISC1 clearly co-localise in 
juxtanuclear puncta both in HEK293 and SH-SY5Y cells (Figure 7.5 A and B). Due 
to time limitations, it was not possible to confirm that the juxtanuclear puncta where 
DISC1 and ATF4 co-localise correspond to the centrosome. In the future, this could 
be achieved by using a triple staining protocol that employs anti-ATF4, anti-DISC1 
and anti- -tubulin antibodies raised in different species. Collectively, these data 
demonstrate that ATF4 expression is not restricted to the nucleus, but can also be 
observed at the mitochondria and centrosome, and suggest that DISC1 may be able 












Figure 7.5 Distribution of endogenous ATF4 and DISC1 in HEK293 (A) and SH-
SY5Y (B) cells analysed by confocal microscopy. ATF4 was detected with either the 
ATF4 MMC or ATF4 RPC antibody, whereas DISC1 was detected with the α-DISC1 




raised in mouse and rabbit, respectively. Nuclei were visualised using DAPI (blue). 
The white arrowheads indicate the position of the centrosomes. Scale bars are 10 
µm.  
7.5 Effect of DISC1 variants on the interaction with ATF4 
In chapters 3 and 4 of this thesis I demonstrated that amino acid substitutions 37W 
and 607F significantly reduce DISC1 distribution to the nucleus, and impair its 
ability to repress ATF4 transcriptional activity at basal cAMP levels. Since ATF4, 
both exogenous and endogenous, is predominantly expressed in the nucleus (Figures 
7.3, 7.4 and 7.5), these observations imply that amino acid substitutions 37W and 
607F may reduce the inhibitory effect of DISC1 on ATF4 by promoting the physical 
segregation of the two proteins inside the cell. Additionally, both 37W and 607F may 
introduce structural changes in DISC1 protein that destabilise its interaction with 
ATF4, either directly or indirectly. This is particularly likely for amino acid 
substitution 607F, as it occurs in a region of DISC1 that was previously shown to be 
important for ATF4 binding (Sawamura et al, 2008). Thus, to investigate the 
potential impact of DISC1 amino acid substitutions 37W and 607F on its ability to 
interact with ATF4, I carried out semi-quantitative co-immunoprecipitation assays 
(co-IP) in transfected HEK293 cells. These were performed as described in detail in 
paragraph 2.5.5. First, to determine the optimal conditions for co-IP of exogenous 
DISC1 and ATF4, the assay was performed in parallel using two different cell lysis 
buffers: Triton X-100 and RIPA. Triton X-100 is a relatively mild lysis buffer that 
contains a non-ionic detergent (Triton X-100). On the other hand, RIPA lysis buffer 
contains a mixture of non-ionic detergents and Sodium Dodecyl Sulphate (SDS), 
which is a strong anionic detergent. As shown in Figure 7.6, Flag-DISC1 is 
successfully immunoprecipitated both in the presence of Triton X-100 and RIPA, but 
while ATF4 does not co-precipitate with DISC1 in RIPA buffer, it clearly does in 
Triton X-100 buffer. Consequently, the following co-IP assay was performed using 
Triton X-100 lysis buffer.  In this assay, DISC1-WT was directly compared with 
DISC1-37W, DISC1-603I and DISC1-607F for its ability to co-precipitate ATF4. 




because it occurs in proximity to the ATF4 binding region in DISC1 (amino acids 




Figure 7.6 HEK293 cells were transfected with the empty vector pcDNA4/TO 
(mock) or with pCG-ATF4 (human ATF4) in combination with either pcDNA4/TO or 
pcDNA4/TO-Flag DISC1 WT. 24 hours after transfection the cells were lysed in 
Triton X-100 or RIPA lysis buffer, then Flag-DISC1 was immunoprecipitated using 
the Flag MMC antibody. The immunoprecipitates, along with the corresponding 
whole cell lysates, were then analysed by western blotting using the indicated 
antibodies. The asterisk indicates a non-specific band due to cross-reaction of the 
ATF4 RPC antibody with exogenous DISC1. The black arrowheads indicate non-
specific bands due to reaction of the secondary HRP-labelled antibody with the 
heavy chains of the precipitating anti-Flag antibody.  
 
Compared to DISC1-WT, ATF4 binding to DISC1-607F and DISC1-603I is reduced 
by 50% and 65%, respectively (P<0.01, Figure 7.7). By contrast, 37W does not 






Figure 7.7 HEK293 cells were transfected with pCG-ATF4 alone or in combination 
with the indicated human DISC1 variants. Exogenous DISC1 was 
immunoprecipitated using the Flag MMC antibody and detected using an anti-DISC1 
antibody (α-DISC1). Co-precipitating ATF4 was detected with the ATF4 RPC 
antibody. The bars represent the average of 3 independent experiments. Data are 
normalised to the average ATF4/DISC1 band intensity ratio measured for DISC1-
WT, and were analysed by one-way ANOVA and Dunnett’s multiple comparisons 
test. * Non-specific band. The position and size (kDa) of the protein markers is 
indicated 
 
As discussed earlier in this chapter, by virtue of their inhibitory effect on DISC1 
nuclear targeting, amino acid substitutions 37W and 607F might reduce DISC1 
binding to ATF4 by promoting a partial physical segregation of the two proteins in 
different cell compartments. However, there is an obvious discrepancy between the 
defective nuclear targeting of DISC1-37W (Figures 3.6 to 3.10) and its largely 
preserved interaction with ATF4 (Figure 7.7). This led me to hypothesise that 37W 
might favour DISC1 binding to ATF4 outside the nucleus, thus compensating for 
their reduced interaction in the nucleus. To test this, I co-expressed ATF4 with 
DISC1-WT, -37W, -607F or -603I in COS7 cells and analysed the subcellular 
distribution of the two proteins by immunocytochemistry. Interestingly, all DISC1 
variants analysed here showed partial co-localisation with ATF4 at mitochondria, 
providing further evidence in support of a possible interaction between the two 
proteins at this site (Figure 7.8). Of relevance, although the degree of mitochondrial 




appears strikingly higher for DISC1-37W compared to all other tested DISC1 
variants (Figure 7.8). The latter observation raises the possibility that amino acid 
substitution 37W might increase ATF4-DISC1 binding at mitochondria, providing a 






Figure 7.8 COS7 cells transfected with the indicated variants of DISC1 (green) and 
ATF4 (red). The right hand panels represent the corresponding merged images. The 





The observed inhibitory effect of amino acid substitution 603I on DISC1 binding to 
ATF4 (Figure 7.7) is in contrast with my previous observations that 603I does not 
perturb DISC1 nuclear targeting, and that the ability of DISC1-603I to inhibit the 
transcriptional activity of ATF4 is entirely preserved (Figure 4.10).  Thus, to better 
elucidate the relationship between the inhibitory effect of DISC1 on ATF4-mediated 
transcription and its interaction with ATF4, I exploited a mutant form of DISC1 
lacking the leucine zipper in exon 9 (DISC1 LZ9). This artificial DISC1 mutant, 
which was originally generated by Sawamura and colleagues to map ATF4 binding 
regions on DISC1, reportedly results in complete loss of ATF4 binding (Sawamura et 
al, 2008). On the basis of this finding, Sawamura and colleagues concluded that the 
leucine zipper in DISC1 exon 9 is essential for ATF4 binding (Sawamura et al, 
2008).  Accordingly, I demonstrated that DISC1 LZ9 does not significantly affect 
ATF4 transcriptional activity (Figure 4.10). In an initial attempt to partially replicate 
the experimental conditions described by Sawamura and collegues (Sawamura et al, 
2008), I transfected HEK293 cells with ATF4 and DISC1-WT or DISC1 LZ9, 
followed by immunoprecipitation of ATF4 with the ATF4 RPC antibody. The co-IP 
protocol adopted here does not accurately reflect the experimental conditions 
described by Sawamura and colleagues, who used a different cell line (HeLa) and 
different ATF4 and DISC1 expression constructs (Sawamura et al, 2008). However, 
the anti-ATF4 precipitating antibody (ATF4 RPC), and the co-IP buffer (RIPA) used 
in this thesis are the same used by Sawamura and colleagues (Sawamura et al, 2008). 
As shown in Figure 7.9 A, ATF4 is successfully immunoprecipitated by the ATF4 
RPC antibody. Surprisingly though, both DISC1-WT and DISC1 LZ9 co-precipitate 
with ATF4 (Figure 7.9 A). However, this experiment was invalidated by the fact that 
the ATF4 RPC antibody strongly cross-reacted with exogenous DISC1, as evidenced 
by the presence of DISC1 immunoreactivity in control samples transfected with 
DISC1 only (Figure 7.9 A). The same cross-reactivity problem was observed in a 
subsequent experiment that used a five-time lower concentration of ATF4 RPC 
antibody (0.2 µg instead of 1 µg per co-IP, Figure 7.9 B), leading to the conclusion 
that the low specificity of this antibody renders it unsuitable for use in this particular 






Figure 7.9 HEK293 cells were transfected with pCG-ATF4 alone or in combination 
with DISC1 WT (WT) or DISC1 LZ9 ( LZ9). Cells were lysed in Triton X-100 or 
RIPA lysis buffer, then ATF4 was immunoprecipitated using 1 µg (A) or 0.2 µg (B) of 
ATF4 RPC antibody. The resulting immunoprecipitates (IP), along with the 
corresponding whole cell lysates (Input) were analysed by western blotting, using 
the indicated antibodies.       
 
Next, I performed a similar co-IP assay using either the ATF4 MMC or the Flag 
MMC antibody to immunoprecipitate ATF4 or DISC1, respectively. Unlike the 
ATF4 RPC antibody, both these antibodies successfully and specifically precipitate 
their target proteins (Figure 7.10). The co-IP experiment performed with the Flag 
MMC antibody was thus replicated, and the results were quantified by band 
densitometry (Figure 7.10). Surprisingly, and in contrast with the findings of 
Sawamura and colleagues, this experiment indicates that DISC1-WT and 
DISC1 LZ9 do not significantly differ in their ability to bind ATF4. Collectively, 
these results suggest that the inhibitory effect of DISC1 on ATF4 transcriptional 







Figure 7.10 HEK293 cells transfected with ATF4 and DISC1, as indicated, were 
lysed in Triton X-100 lysis buffer, then subjected to immunoprecipitation (IP) using 
the ATF4 MMC or the Flag MMC antibody. The resulting immunoprecipitates (IP), 
along with the corresponding whole cell lysates (Input), were analysed by western 
blotting, using the indicated antibodies. The position and size (kDa) of the protein 
markers is indicated. The bars represent the average of 3 independent experiments. 
Data were normalised to the average ATF4/DISC1 band intensity measured for 
DISC1-WT, and were analysed by one-sample student’s t-test. WT: DISC1-WT; 
LZ9: DISC1 LZ9. 
7.6 Effect of high cAMP levels on the interaction and subcellular 
distribution of DISC1 and ATF4 
In chapter 4 of this thesis, I provided evidence suggesting that the functional 
interaction between DISC1 and ATF4 is regulated by cAMP levels. Indeed, while 
DISC1 efficiently inhibits ATF4 transactivation of the CRE and CHOP AARE 
promoters at basal cAMP levels, it has no effect on ATF4 function at high cAMP 
levels. On the basis of this observation, I hypothesised that cAMP levels might 
regulate DISC1 physical interaction with ATF4. The second messenger cAMP, either 
directly or indirectly, regulates the activity of several protein kinases, including PKA 
(Delghandi et al, 2005), which in turn is capable of phosphorylating both ATF4 
(Elefteriou et al, 2005) and DISC1 (Ishizuka et al, 2011). Thus, cAMP has the 
potential to regulate DISC1-ATF4 binding by controlling the phosphorylation status 




performed co-IP assays in transfected HEK293 cells after exposure to the adenylate 
cyclase activator forskolin, using DMSO-treated cells as controls. The drug treatment 
conditions adopted in this set of experiments reflect those used in the luciferase 
assays described in chapter 4 of this thesis. Given the potential relevance of ATF4 
and DISC1 phosphorylation status in this context, this particular set of co-IP 
experiments was performed using Triton X-100 lysis buffer supplemented with 
phosphatase inhibitors (Phosphatase inhibitor cocktail set II (Calbiochem), 10 µM -
glycerophosphate, 100 nM okadaic acid). As shown in Figure 7.11, forskolin 
treatment dramatically increases ATF4 protein levels in whole cell lysates (P<0.001, 
Figure 7.11), but has no significant effects on DISC1 total protein expression levels 
(Figure 7.11). As a result, the ATF4/DISC1 protein ratio is increased by almost 10-
fold in cells exposed to forskolin (P<0.01, Figure 7.11). In contrast with the lack of 
effect of DISC1 on ATF4 transcriptional activity at high cAMP levels observed in 
chapter 4 of this thesis, ATF4 binding to DISC1 is significantly increased by 
forskolin treatment (Figure 7.11).  
 
 
Figure 7.11 HEK293 cells were transfected with pCG-ATF4 (human ATF4) in 
combination with an equal amount of the empty vector pcDNA4/TO or pcDNA4/TO-




were treated for 4 hours with 10 µM forskolin or vehicle (DMSO), to reflect the 
treatment conditions used in luciferase reporter assays, then lysed in Triton X-100 
lysis buffer and subjected to immunoprecipitation using the Flag MMC antibody. The 
resulting immunoprecipitates (IP), along with the corresponding whole cell lysates 
(Input), were analysed by western blotting, using the indicated antibodies. The 
position and size (kDa) of the protein markers is indicated. The bars represent the 
average of 3 independent experiments. Data were analysed by one-sample 
student’s t test (IP) or paired two-tailed student’s t test (Input). ***P<0.001; **P<0.01.  
 
To further investigate the effect of increased cAMP levels on ATF4 and DISC1 
protein levels and subcellular distribution, I prepared whole cell lysates, nuclear 
extracts and cytoplasmic extracts from transfected and untransfected HEK293 cells 
treated with forskolin, and analysed them by western blotting. Consistent with my 
previous observations (Figure 7.11), forskolin treatment results in a marked increase 
in ATF4 protein levels in whole cell lysates (P<0.01, Figure 7.12). A similar increase 
in ATF4 protein levels ( 4 to 5-fold) is observed in nuclear and cytoplasmic extracts 
(P<0.01, Figure 7.12), indicating that forskolin does not promote the preferential 
accumulation of ATF4 in either of these subcellular compartments. In contrast with 
my previous findings (Figure 7.11), DISC1 protein expression is significantly 
increased in whole cell lysates and nuclear extracts, but not cytoplasmic extracts, 
prepared from forskolin-treated HEK293 cells (P<0.05, Figure 7.12).  Consequently, 
the ATF4/DISC1 protein ratio is not significantly increased by forskolin in this 
experiment (Figure 7.12). The reasons for the discrepancy between the lack of effect 
of forskolin on DISC1 protein levels seen in the co-IP experiment and the 
preferential increase in nuclear DISC1 expression observed by subcellular 
fractionation are not clear. However, this inconsistency may be related to the 
substantial technical differences between the two experimental approaches. For 
example, unlike the co-IP experiment, subcellular fractionation was performed using 
commercially available pre-made buffers that do not contain phosphatase inhibitors, 
which may have potentially affected DISC1 protein stability after cell lysis. In 




α-DISC1 for the co-IP experiment and Flag MMC in the subcellular fractionation 
experiment, which may have contributed to the observed discrepancy in DISC1 
protein levels.  
 
 
Figure 7.12 HEK293 cells co-transfected for 24 hours with equal amounts of pCG-
ATF4 (human ATF4) and pCDNA4/TO-Flag DISC1 WT (human DISC1) were 
treated for 4 hours with 10 µM forskolin (FSK) or vehicle (DMSO) before being 
subjected to subcellular fractionation. The resulting nuclear and cytoplasmic 
extracts, along with the corresponding whole cell lysates, were analysed by western 
blotting, using nuclear matrix protein p84, heat-shock protein HSP90 and -actin, 
respectively, as loading controls. ATF4 and DISC1 were detected using the ATF4 
RPC antibody and the Flag MMC antibody, respectively. The position and size (kDa) 
of the protein markers is indicated. The bars represent the average of 3 independent 






To test whether forskolin similarly affects expression of endogenous ATF4 and 
DISC1 proteins, the same subcellular fractionation experiment was carried out using 
untransfected HEK293 cells. Surprisingly, forskolin treatment significantly reduces 
total ATF4 protein expression levels (P<0.01, Figure 7.13), but does not affect the 
nuclear expression of endogenous ATF4 in these cells (Figure 7.13). In this set of 
experiments, endogenous ATF4 protein expression could not be quantified in the 
cytoplasmic extracts because it was below the antibody’s detection limit (data not 
shown). As observed for ATF4, the total expression level of endogenous 100 kDa 
DISC1 is mildly but significantly reduced by forskolin treatment (P<0.05, Figure 
7.13). Quantification of endogenous 100 kDa DISC1 protein levels is limited to 
whole cell lysates as the protein could not be detected in the nuclear and cytoplasmic 
extracts prepared from HEK293 cells (data not shown). Collectively, these results 
indicate that forkolin exerts distinct effects on the expression of exogenous and 
endogenous ATF4 and DISC1 in HEK293 cells.  
 
 
Figure 7.13 Untransfected HEK293 cells were subjected to subcellular fractionation 
after a 4 hour treatment with 10 µM forskolin (FSK) of vehicle (DMSO). The resulting 
nuclear extracts and the corresponding whole cell lysates were analysed by western 
blotting, using the nuclear matrix protein p84 and histone 3 (H3) as loading controls, 
respectively. Endogenous ATF4 and DISC1 were detected using the ATF4 RPC and 




markers is indicated. The bars represent the average of 3 independent experiments. 
Data were analysed by paired two-tailed student’s t test. **P<0.01, *P<0.05.  
7.7 Discussion 
Like most transcription factors, ATF4 is predominantly enriched in the cell nucleus. 
Consequently, amino acid substitutions that reduce DISC1 nuclear expression might 
prevent its interaction with ATF4, even if they do not directly impact on their 
binding potential. Under the above assumption, both amino acid substitutions 37W 
and 607F are predicted to reduce DISC1 binding to ATF4 in intact cells. However, in 
the co-IP assays described here, DISC1-607F, but not DISC1-37W, shows reduced 
binding to ATF4. This apparent contradiction may be resolved by the observed 
increased co-localisation between DISC1-37W and ATF4 at mitochondria. Based on 
this observation, it is plausible to speculate that the increased mitochondrial 
recruitment of DISC1-37W (Ogawa F., in preparation) may facilitate its interaction 
with mitochondrial ATF4, thereby compensating for the presumed reduced 
interaction between ATF4 and DISC1-37W in the nucleus. If true, this would in turn 
imply that the 37W mutation reduces DISC1’s ability to suppress ATF4 
transcriptional activity indirectly, by preventing DISC1 translocation to the nucleus, 
but has no direct effect on DISC1-ATF4 binding. On the other hand, amino acid 
substitution L607F reduces both DISC1 nuclear expression and ATF4 binding, but 
has no obvious effects on DISC1 co-localisation with ATF4 outside the nucleus.  
However, based on the currently available data, it is not possible to speculate 
whether 607F inhibits the DISC1-ATF4 interaction directly, by destabilising protein-
protein bonds, indirectly, by preventing DISC1 translocation to the nucleus, or both. 
Further experiments will be needed to test these possibilities.  
The conserved predicted leucine zipper located in DISC1 exon 9 (here referred to as 
DISC1LZ9) was previously shown to contribute to DISC1 nuclear targeting and to 
be essential for its interaction with ATF4 (Sawamura et al, 2008). Consistently, in 
chapter 4 of this thesis I demonstrated that the artificial mutant DISC1 LZ9, which 
lacks DISC1LZ9, is not expressed in the nucleus and does not inhibit ATF4 




here, which were initially designed to partially replicate the experimental conditions 
described by Sawamura and colleagues (Sawamura et al, 2008), DISC1 LZ9 does 
not differ from DISC1 WT in its ability to interact with ATF4. While the discrepancy 
between the results reported by Sawamura and colleagues (Sawamura et al, 2008) 
and the findings described here might be explained by experimental differences (e.g. 
different ATF4 and DISC1 expression constructs, different batch of 
immunoprecipitating ATF4 RPC antibody, different DISC1 tag, different cell line 
etc.), it is difficult to reconcile the lack of effect of DISC1 LZ9 on ATF4 
transcriptional activity and its exclusion from the nucleus with its intact ATF4 
binding capacity. Since the subcellular distribution of ATF4 and DISC1 LZ9 in co-
transfected cells was not analysed here, it cannot be excluded that, like 37W, LZ9 
might favour DISC1 interaction with ATF4 outside the nucleus. However, based on 
my previous observation that the subcellular distribution of DISC1 LZ9 is strikingly 
similar to that of DISC1-607F, which does not show increased interaction with 
cytoplasmic ATF4, this seems unlikely. The lack of effect of LZ9 on DISC1 
binding to ATF4 is also in contrast with the detrimental effect of 607F on the DISC1-
ATF4 interaction. Indeed, leucine 607 is located within DISC1LZ9, and the L607F 
amino acid substitution is predicted to disrupt the leucine packing within DISC1LZ9 
(Soares et al, 2011). In this respect, it is important to emphasise that, since DISC1 
protein structure has not yet been experimentally resolved, the available structural 
information is largely based on bioinformatic predictions, and hence may not be 
completely accurate. However, it is surprising that, while the disruption of a 
predicted DISC1 leucine zipper by 607F reduces ATF4 binding, its complete 
removal has no apparent effect on DISC1-ATF4 binding. Assuming that, as my 
results suggest, DISC1LZ9 is not directly involved in ATF4 binding, one might 
hypothesise that the effect of 607F on DISC1 binding to ATF4 arises indirectly, as a 
consequence of its detrimental effect upon DISC1 nuclear localisation. However, this 
hypothetical scenario is incongruent with the observed effect of LZ9, which, like 
607F, inhibits DISC1 nuclear expression. An alternative, albeit highly hypothetical 
possibility is that 607F, but not LZ9, might indirectly introduce deleterious 
structural changes in other yet unknown ATF4 binding sites on DISC1. Moreover, it 




may not accurately reflect the interactions taking place inside the cell. For example, 
it is possible that the results of the co-IP experiments described here reflect, at least 
in part, protein-protein interactions that are established after cell disruption and that 
were not present in the intact cells. Finally, one may speculate that the differential 
effects of DISC1-WT, -37W, -603I, -607F and - LZ9 on ATF4 transcriptional 
activity might be mediated by differential binding to other yet unknown regulatory 
proteins that might potentially be present in the ATF4/DISC1 complex.  
In contrast with the observed lack of effect of LZ9 on DISC1 binding to ATF4, the 
ultra-rare DISC1 mutation T603I significantly reduces interaction between the two 
proteins. Since 603I does not grossly affect DISC1 subcellular distribution, its effect 
on ATF4 binding might arise from direct or indirect disruption of an ATF4 binding 
site on DISC1. This suggests that additional contact sites may exist between DISC1 
and ATF4, besides the originally mapped DISC1LZ9, the evidence for which is now 
contrasting. Intriguingly, despite its detrimental effect on ATF4 binding, 603I does 
not impair DISC1-mediated repression of ATF4, as shown in chapter 4 of this thesis. 
This observation, in combination with the preserved ATF4 binding of DISC1 LZ9 
and DISC1-37W, indicates that DISC1 nuclear expression, but not its ability to co-
precipitate ATF4, is a good predictor of its ability to repress ATF4 activity. In turn, 
this suggests that nuclear DISC1 may inhibit ATF4 via an indirect mechanism that 
does not involve establishment of a direct protein-protein interaction with ATF4. For 
example, DISC1 may act by sequestering transcriptional co-factors and preventing 
their binding to ATF4. Collectively, this set of experiments suggests that DISC1LZ9 
may not be directly involved in ATF4 binding, which may be instead at least 
partially mediated by the DISC1 region spanning threonine 603. Further experiments 
will be needed to determine the mechanism by which nuclear DISC1 inhibits ATF4 
and, in particular, whether this functional interaction requires a physical interaction 
between the two proteins in the nucleus. Cell-free techniques such as in-vitro binding 
assays or surface plasmon resonance may be exploited to clarify the role of 
DISC1LZ9 on the interaction with ATF4 and further test the effect of amino acid 
substitutions 37W, 607F and 603I, eliminating their differential nuclear expression as 




In contrast with the findings of Sawamura and colleagues, and as detailed in chapter 
4 of this thesis, I detected no effect of DISC1 co-expression on the transcriptional 
activity of ATF4 on the CRE and CHOP AARE at high cAMP levels. This 
observation suggested that DISC1’s ability to bind to and regulate ATF4 
transcriptional activity might be reduced at high cAMP levels. However, the co-IP 
experiment described here indicates that the DISC1-ATF4 interaction is instead 
strengthened by cAMP. Once again, this observation indicates that DISC1’s ability to 
co-precipitate ATF4 does not directly correlate with its ability to regulate ATF4 
transcriptional activity, supporting the existence of indirect regulatory mechanisms.  
Nevertheless, the dramatic effect of forskolin on DISC1-ATF4 binding suggests that 
this interaction might be important in mediating some of the effects of increased 
cAMP levels. If the DISC1-ATF4 complex is indeed involved in transcriptional 
regulation in response to cAMP, it is possible that its effects may be context-, cell-
type- or target gene-dependent, and may not be evidenced by the reporter assays 
described in this thesis. Besides strengthening the DISC1-ATF4 interaction, forskolin 
increases ATF4 expression levels, both in the nucleus and cytoplasm, and might also 
regulate DISC1 protein levels, although different experimental approaches provided 
contradictory evidence in this particular respect. In particular, it is surprising that 
forskolin dramatically enhances expression of exogenous ATF4 while having the 
opposite effect on the endogenous protein expressed in the same cell type. Perhaps 
this could be an artefact due to the ATF4 expression vector used in these 
experiments, although no known cAMP-responsive elements are present in the pCG 
plasmid. Alternatively, it is possible that the effect of cAMP on ATF4 protein 
stability may be somehow dependent on ATF4 expression levels. The effects of 
cAMP on endogenous ATF4 expression levels have been previously investigated in a 
study by Yukawa and colleagues (Yukawa et al, 1999). In cultured mouse 
hippocampal neurons, forskolin treatment for 3-4 hours strongly induces ATF4 
protein expression in the nucleus, but has no effect on ATF4 mRNA levels (Yukawa 
et al, 1998). This is consistent with the enhancing effects of forskolin on exogenous 
ATF4 expression observed here, and indicates that cAMP regulates ATF4 protein 
abundance at the post-transcriptional level. Human ATF4 can be phosphorylated by 




the Rankl promoter CRE site (Elefteriou et al, 2005). It is therefore possible that 
cAMP-dependent phosphorylation of ATF4 serine 254 might increase ATF4 protein 
stability. Alternatively, cAMP might up-regulate ATF4 translation, although this 
latter possibility seems less likely, given that forskolin enhances ATF4 expression 
from the pCG-ATF4 construct, which does not contain the ATF4 mRNA 5' UTR 
regulatory region that is known to modulate ATF4 mRNA translation. Interestingly, 
DISC1 is also a PKA target (Ishizuka et al, 2011), and some of the experiments 
described here suggest that cAMP might regulate DISC1 expression levels, raising 
the possibility that PKA phosphorylation could similarly regulate DISC1 protein 
stability. Further experiments will be needed to test the potential effects of PKA-
dependent phosphorylation on ATF4 and DISC1 protein expression and functional 
interaction.  
Although ATF4 is predominantly expressed in the nucleus, it has been observed at 
other subcellular locations, including the cytoplasm and neuritis of mouse neurons, 
and the dendrites of Aplysia sensory neurons (Lai et al, 2008; Vernon et al, 2001; 
White et al, 2000). Here, I observed for the first time that ATF4 partially localises to 
the mitochondria in human cell lines, although the function of this mitochondrial 
pool of ATF4 remains to be elucidated. Of relevance, a previous study showed that 
in cultured human oligodendroglial cells, mitochondrial dysfunction induced by the 
respiratory chain Complex I inhibitor rotenone activates ATF4 protein expression 
(Silva et al, 2009). Interestingly, different studies showed that external stimuli can 
induce the translocation of ATF4 from the cytoplasm to the nucleus (Lai et al, 2008; 
White et al, 2000). In cultured mouse hippocampal neurons, LTD-, but not LTP-
inducing stimuli promote the retrograde translocation of ATF4 from distal neuritis to 
the nucleus (Lai et al, 2008) and, similarly, GABAB receptor activation in primary 
cortical neurons was shown to trigger the translocation of endogenous ATF4 from 
the cytoplasm to the nucleus (White et al, 2000). It is therefore tempting to speculate 
that mitochondrial ATF4 might be involved in retrograde signalling to the nucleus in 
response to mitochondrial dysfunction. Additionally, since I showed that endogenous 
full-length DISC1 also partially localises to mitochondria, it is possible that ATF4 




and test for potential functional implications of DISC1-ATF4 binding at 
mitochondria.  
In this chapter I showed that endogenous ATF4 partially localises at the centrosome 
in human cells. Since DISC1 is also expressed at the centrosome (Bradshaw et al, 
2009; Bradshaw et al, 2008; Kamiya et al, 2005; Kamiya et al, 2008; Miyoshi et al, 
2004; Morris et al, 2003; Shimizu et al, 2008), this observation suggests that the two 
proteins might interact at this additional location. Indeed, in a preliminary 
immunocytochemistry experiment, I detected co-localisation of endogenous ATF4 
and DISC1 in juxtanuclear puncta that are consistent with the morphology and 
location of the centrosome. However, due to time limitations, I could not confirm 
that these juxtanuclear puncta correspond to the centrosome. Interestingly, ATF4 
reportedly directly interacts with two structurally related centrosomal proteins, 
Nephronophthisis 6 (NPHP6, also known as CENP290) (Sayer et al, 2006) and 
Mitosin/CENP-F (Zhou et al, 2005). NPHP6 is implicated in the pathogenesis of 
Joubert syndrome, which is characterised by kidney failure, retinal degeneration, 
cerebellar aplasia and mental retardation, and of Senior-Loken syndrome, 
characterised by kidney dysfunction and retinal degeneration (Sayer et al, 2006). 
Consistently, NPHP6-targeting morpholinos cause defects in eye, kidney, and 
cerebellum development in zebrafish (Sayer et al, 2006). On the other hand, 
Mitosin/CENP-F is implicated in cell cycle progression and myoblast differentiation 
(Zhou et al, 2005). Like DISC1, both NPHP6 and Mitosin/CENP-F regulate ATF4 
transactivation of the CRE in luciferase reporter assays, the first acting as an 
activator and the second as a repressor (Sayer et al, 2006; Zhou et al, 2005). These 
findings suggest that the regulation of ATF4 transcriptional activity may be 
important for centrosomal function. Consistently, ATF4 KO mice exhibit severe 
growth and development defects, which may arise from underlying defects in cell 
division (Dobreva et al, 2006; Fischer et al, 2004; Hettmann et al, 2000; Masuoka & 
Townes, 2002; Muir et al, 2008; Tanaka et al, 1998; Yang et al, 2004; Yoshizawa et 
al, 2009).  The observed co-localisation of endogenous ATF4 and DISC1 at the 
centrosome is particularly intriguing, given that both proteins have been implicated 
in centrosome-dependent processes such as neuronal progenitor proliferation and 




2005; Kim et al, 2009; Mao et al, 2009; Meyer & Morris, 2009). Future experiments 
should aim to elucidate the function of centrosomal ATF4, and investigate the 
potential regulatory role of DISC1, as well as other centrosomal DISC1 binding 





Over ten years after its discovery, DISC1 remains one of the best supported genetic 
candidates for major psychiatric illness. In addition to the compelling genetic 
evidence implicating DISC1 in mental illness, a wealth of biological evidence has 
now firmly established DISC1 as a key player in processes such as 
neurodevelopment, plasticity and signalling (Brandon & Sawa, 2011; Chubb et al, 
2008; Porteous et al, 2011), the disturbance of which is thought to contribute to 
major psychiatric illness (Fatemi & Folsom, 2009; Insel, 2010). However, despite 
our greatly increased knowledge of the multiple biological functions of DISC1, the 
mechanisms linking impaired DISC1 function to increased risk of mental illness 
remain elusive.  
One widely used, and in many cases successful approach to dissect disease 
mechanism is to analyse the functional impact of causal genetic mutations by 
artificially introducing them in model organisms or in-vitro systems. In the case of 
DISC1, the only definitively causal mutation discovered to date is the t(1;11) 
translocation. However, the very complex nature of this mutation renders it 
particularly hard, if not impossible, to accurately reproduce in model systems.  On 
the other hand, risk-conferring SNPs and point mutations in DISC1 are 
comparatively easy to model, but their genetic contribution to disease is less well 
defined, and their biological effects are likely to be more subtle. Nevertheless, 
understanding the effects of multiple risk-conferring SNPs and point mutations can 
provide valuable clues as to which of the many DISC1 functions might be affected in 
the carriers, and help generate testable hypotheses about the mechanisms linking 
genetics and environment to clinical outcomes.  
In this thesis, the impact of a subset of common and rare risk-conferring DISC1 
amino acid substitutions was investigated. More specifically, two main objectives 
were set out in chapter one. The first was to analyse the potential effects of such risk-
conferring structural variants on the subcellular distribution of DISC1, with a 




characterise the functional implications of DISC1’s interaction with the transcription 
factor ATF4, and to analyse the potential impact of DISC1 amino acid substitutions 
on this particular interaction. Table 8.1 lists the DISC1 amino acid substitutions 
examined in this thesis, and summarises their observed effects in the limited set of 
assays described in the previous chapters. Figure 8.1 summarises the known 
regulators and biological functions of ATF4, and illustrates the potential influence of 
DISC1 on ATF4-regulated pathways. In the following sections I will recapitulate the 
experimental observations described in this thesis and their potential implications, 
discuss the outstanding questions and propose future experiments to address them.  
8.1 Effect of risk-conferring amino acid substitutions on the 
subcellular distribution of DISC1 
In chapter 3 of this thesis, I analysed the effect of a selected subset of human and 
mouse DISC1 amino acid substitutions on the subcellular distribution of the protein. 
This was done by overexpressing the selected DISC1 variants in different cell lines 
and primary neurons and quantifying their relative subcellular distribution by 
immunocytochemistry and subcellular fractionation. The main finding reported in 
this chapter is that human DISC1 amino acid substitutions 37W and 607F, but not 
264R, 432L, 603I and 704C, reduce the nuclear expression of the protein by 
approximately 50%, and also exert a dominant-negative effect on the nuclear 
distribution of exogenous wild-type DISC1. Additionally, 607F reduces DISC1 
association with the cytoskeleton by 75% and reduces the formation of DISC1 
cytoplasmic puncta. These observations suggest that DISC1 nuclear expression 
might be significantly reduced in 37W and 607F carriers, with potential detrimental 
effects on the nuclear functions of the protein. 607F might additionally impair the 
cytoskeletal functions of DISC1, with potential repercussions for neuronal 
development.  
8.2 Effect of DISC1 amino acid substitutions on the functional 
interaction with ATF4 
In chapter 4 of this thesis, to test the hypothesis that amino acid substitutions that 




designed luciferase reporter assays to investigate the potential impact of selected 
risk-conferring DISC1 missense mutations on the transcriptional activity of its 
interactor ATF4. These experiments, which were carried out in different transfected 
human and mouse cell lines, demonstrated that DISC1 represses ATF4 
transcriptional activity on CRE and AARE promoter elements at basal, but not 
elevated, cAMP levels.    
The luciferase reporter assays described in this thesis additionally showed that amino 
acid substitutions 37W and 607F, but not 432L, 603I and 704C significantly reduce 
DISC1’s ability to repress the transactivation activity of exogenously expressed 
ATF4. Accordingly, while wild-type DISC1 significantly inhibits the transcriptional 
activation of the CRE in response to the ATF4 inducer thapsigargin, DISC1-37W 
and DISC1-607F have no effect. Unexpectedly, despite being efficiently expressed in 
the nucleus in the tested cell model and being able to interact with ATF4, mouse 
Disc1 does not affect ATF4 activity in the particular CRE reporter assays described 
in this thesis. This suggests that mouse and human DISC1 might have functionally 
diverged in this particular respect, and that perhaps mouse Disc1 regulates ATF4 
activity on a different and/or more restricted set of promoters and/or cell types.  
Collectively, these observations support the hypothesis that amino acid substitutions 
37W and 607F might compromise the nuclear function of DISC1 by preventing its 
proper nuclear expression, implying that the former might be impaired in 37W and 
607F carriers, with potential repercussions on the regulation of ATF4 transcriptional 
activity. Since ATF4 is implicated in the regulation of several processes that have 
been linked to psychiatric illness, including stress responses (Ameri & Harris, 2008), 
emotional behaviour (Green et al, 2008), learning and memory consolidation (Chen 
et al, 2003; Costa-Mattioli et al, 2007; Costa-Mattioli & Sonenberg, 2006) and 
circadian rhythms (Koyanagi et al, 2011; Ushijima et al, 2012), it is conceivable that 
DISC1 amino acid substitutions 37W and 607F might impact on all of the above 
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264R  Punctate  (NQ) NT NT NT NT 
432L  Punctate  (NQ) 
 (tested on CRE 
only) 
NT NT NT 
603I  Punctate  (NQ) 
 (tested on CRE 
only) 
NT NT  ( 65%) 
607F  ( 50%) DN 
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 ( 50%) 
704C  Punctate  (NQ) 
 (tested on CRE 
only) 
NT NT NT 
LZ9  (NQ) Diffuse NT LOF LOF NT  
Mouse 
WT 
 (NQ) Punctate NT Null* NT NT  (NQ) 
Mouse 
31L 
 (NQ) Punctate NT Null* NT NT 
 (NQ); 






























 (NQ) Punctate NT Null* NT NT 
 (NQ); 
 compared to 
mouse Disc1 
WT (NQ) 
Table 8.1 Summary of the observed effects of DISC1 amino acid substitutions/mutations on the protein’s subcellular distribution and 
function. TG: thapsigargin; HCY: homocysteine; Co-IP: co-immunoprecipitation; : increased; : decreased; : not affected; NQ: Not 
Quantified; NT: Not Tested; LOF: Loss of Function; CSKE: cytoskeletal extract. The numbers in brackets indicate the percent change in 
the specified phenotype/function introduced by the DISC1 variant/mutation. DN indicates that the specified DISC1 variant affects DISC1-
WT in a dominant-negative fashion. 1Fumiaki Ogawa, unpublished data. #Average between the effects measured in HEK293 and MO3.13 










Figure 8.1 Regulators and biological functions of ATF4, and potential role of DISC1. 
Multiple mechanisms contribute to the regulation of ATF4 transcription, translation, 
protein stability and transcriptional activity. Microenvironmental stressors, including 
endoplasmic reticulum (ER) stress, oxidative stress, nutrient limitation, hypoxia and 
viral infections upregulate ATF4 transcription and translation (see section 1.3.4 of 
this thesis). ATF4 can also be regulated by direct phosphorylation by kinases that 
respond to various extracellular stimuli. Examples of kinases that can directly 
phosphorylate ATF4 in vitro include PKA (Elefteriou et al, 2005), RSK2 (Yang et al, 
2004), NEK6  (Vaz Meirelles et al, 2010) and MAPK (Bartsch et al, 1995). While 
PKA and RSK2 have been shown to positively regulate ATF4 activity (Elefteriou et 
al, 2005; Yang et al, 2004), the effects of NEK6- and MAPK-dependent 
phosphorylation on ATF4 transactivation activity have not been directly investigated 
yet. ATF4 expression is also controlled by circadian regulators, such as Clock 




transcriptional activity of ATF4 can also be modulated (either activated or repressed) 
by its interaction with several binding partners, some examples of which are listed in 
the figure (see section 1.3 of this thesis). By binding to CRE and CARE elements in 
the promoters of its target genes, ATF4 can activate a plethora of biological 
pathways involved in cell proliferation, cell survival and apoptosis. Additionally, 
through its repressive effect on CREB, ATF4 is involved in the regulation of Long-
Term Potentiation (LTP), the process underlying learning and memory, as well as 
emotional behaviour. DISC1 can bind to ATF4 and inhibit its activity on both CRE 
and CARE elements, and by doing so it could potentially impact on the function of 
all/any ATF4-regulated genes and pathways. Intriguingly, ATF4 and DISC1 
converge on the regulation of several biological processes of known relevance for 
psychiatric illness (highlighted in yellow), and it is conceivable that this functional 
convergence arises, at least in part, from their biological interaction. Under this 
assumption, DISC1 variants that modify its functional interaction with ATF4, like 
37W and 607F, might impact on multiple transcriptional events governing 
neurogenesis, stress responses, cognition, and circadian rhythms, all of which are 
implicated in psychiatric illness. DISC1 might additionally regulate ATF4 indirectly, 
by controlling its PKA-dependent phosphorylation through the establishment of 
dynamic interactions with PDE4. PKA: Protein kinase A; RSK2: Ribosomal protein 
S6 kinase, 90 kDa, polypeptide 3; NEK6: NIMA-related kinase 6; MAPK: Mitogen-
activated protein kinase; PDE4: Phosphodiesterase 4; RPL41: Ribosomal protein 
L41; PHD3: Prolyl-4-hydroxylase 3; SATB2: Special AT-rich sequence-binding 
homeobox 2; NIPK: Neuronal cell death-inducible putative kinase; CENP-F: 
Centromere protein F, 350/400 kDa; CEP290: Centrosomal protein, 290 kDa.  
8.3 Effect of cAMP on DISC1-mediated transcriptional regulation 
In chapter 5 of this thesis I used luciferase assays to investigate the potential 
involvement of cAMP, its regulator PDE4 and its effector PKA on DISC1-mediated 
regulation of ATF4 transactivation activity. At basal cAMP levels, ATF4 activity on 
the CRE is positively regulated by PKA, as demonstrated by the repressive effect of 
the specific PKA inhibitor PKIα. Since PKA phosphorylation of ATF4 at serine 254 
was previously shown to enhance its activity on the RankL promoter CRE site, it is 




phosphorylation of ATF4 by PKA. By contrast, at high cAMP levels, PKA inhibits 
the repressive effect of ATF4 on CRE-driven transcription. Again, this may be due to 
a direct inhibitory effect of PKA on ATF4, but it may also arise indirectly through 
the activation of endogenous CREB by PKA.  
At basal, but not at high cAMP levels, ATF4 activity on the CRE is inhibited by co-
expression of PDE4B and D. This suggests that PDE4 might be involved in the 
regulation of ATF4 activity at basal cAMP levels, perhaps via the control of local 
PKA activity. However, this is in contrast with the observed lack of effect of the 
PDE4 inhibitor rolipram on ATF4 activity at basal cAMP. As discussed in chapter 5 
of this thesis, this inconsistency might be related to the technical limitations of the 
particular reporter assay adopted here, and further experiments will be required to 
better elucidate the potential role of PDE4 and PKA in the regulation of ATF4. Some 
proposed experimental approaches will be described later in this chapter.  
Despite the potential regulatory role of PDE4 on ATF4 activity, the observed 
repressive effect of DISC1 on ATF4 does not appear to require the contribution of 
endogenous PDE4, as indicated by the fact that it is entirely preserved in the 
presence of a concentration of rolipram that efficiently inhibits PDE4 activity in the 
tested cell model. However, based on the limited experiments described here, it is not 
possible to rule out that PDE4 might contribute to the repressive effect of DISC1 on 
ATF4 on different promoters/cell types.  
8.4 The role of DISC1 in the cellular response to stress 
Given the well-established role of ATF4 in the regulation of the cellular response to 
stress, in chapter 6 of this thesis I hypothesised that DISC1 variants that impair its 
repressive effect on ATF4 might consequently impact on the cell’s ability to adapt 
and survive to stress. As expected, under conditions of oxidative stress induced by 
H2O2 treatment, endogenous ATF4 nuclear expression is greatly enhanced. On the 
other hand, the same experimental conditions determine a significant reduction of 
endogenous DISC1 expression in the particular tested cell line (MO3.13 human 
oligodendrocytes). Although highly preliminary, this observation suggests that 




tuning its repressive effect on ATF4. Alternatively, it is possible that the particular 
drug treatment adopted here destabilises DISC1 protein structure, hence promoting 
its misfolding, aggregation and consequent degradation in autophagosomes.  
The limited set of experiments performed in MO3.13 cells provided no conclusive 
evidence for a role of ATF4 or DISC1 in survival of these cells after exposure to 
oxidative or endoplasmic reticulum stress. This is in contrast with the well-
characterised function of ATF4 in the cell’s adaptation to stress. However, as 
discussed in chapter 6 of this thesis, the experimental approach adopted here is 
flawed by technical limitations that might explain these unexpected results. Potential 
alternative and improved experimental approaches that might be used to investigate 
the role of DISC1 in stress regulation are described later in this chapter.  
8.5 Characterisation of the molecular interaction between DISC1 and 
ATF4  
The final results chapter of this thesis investigates whether the factors that influence 
the functional interaction between DISC1 and ATF4 (i.e. DISC1 amino acid 
substitutions 37W and 607F and cAMP levels) also affect the physical interaction 
between the two proteins in the cell, which may potentially explain their functional 
impact. In addition, the distribution of endogenous and exogenous ATF4 and DISC1 
was analysed by immunocytochemistry in HEK293 and SHSY5Y cells. Interestingly, 
in these cells ATF4 is not confined to the nucleus but, like DISC1, it can also be 
detected at the mitochondria and centrosome, suggesting that ATF4 and DISC1 
might interact at these additional locations. If confirmed, this possibility would open 
new lines of enquiry about the potential role of the DISC1-ATF4 complex in the 
regulation of cell cycle progression and energy homeostasis.      
Consistent with its partial exclusion from the nucleus and decreased inhibitory effect 
on ATF4, DISC1-607F shows reduced interaction with ATF4. This effect may also 
arise from direct and/or indirect disruption of ATF4 binding sites on DISC1 by 607F. 
Unlike 607F, the artificial DISC1 mutation LZ9, which removes DISC1 amino 
acids 607-628 and ablates DISC1’s repressive effect on ATF4, has no apparent effect 




reduced inhibitory effect on ATF4, no effect upon ATF4 binding was detected for 
DISC1 mutation 37W. Finally, DISC1 mutation 603I significantly decreases ATF4 
binding despite having no effect upon DISC1’s inhibitory effect on ATF4 
transactivation. Although the lack of effect of 37W on DISC1-ATF4 binding might 
be partially explained by potentially increased interaction of DISC1-37W with 
mitochondrial ATF4, these results are largely incongruent. As discussed in chapter 7 
of this thesis, this incongruence may reflect experimental artefacts, and suggests a 
requirement for adoption of alternative experimental approaches to clarify the 
relationship between the physical and functional interaction between DISC1 and 
ATF4.  
Forskolin treatment dramatically enhances binding of exogenous ATF4 and DISC1, 
suggesting that this protein-protein interaction may be strengthened by cAMP, 
perhaps via PKA-dependent phosphorylation. Although this observation is in 
contrast with the lack of effect of DISC1 on ATF4 transactivation of the CRE and 
CHOP AARE at high cAMP levels observed here, it cannot be excluded that the 
effects of cAMP-dependent modulation of DISC1-ATF4 binding might be evident in 
different contexts (e.g. different cell types and/or different promoters).  In addition, 
the effect of forskolin on ATF4 and DISC1 protein levels was investigated, but this 
produced contrasting results. Indeed, while forskolin appears to increase ATF4 
protein levels in ATF4-overexpressing cells, it has the opposite effect in 
untransfected cells. Similarly, forskolin appears to increase DISC1 expression in 
some but not other experiments based on DISC1-overexpressing cells, but it reduces 
expression of endogenous DISC1 in untransfected cells. Although tantalising, these 
observations raise more questions than they answer about the potential regulatory 
role of cAMP on the physical and functional interaction between DISC1 and ATF4. 
Possible future experimental approaches to clarify the potential role of cAMP in the 
regulation of the DISC1-ATF4 interaction will be discussed in the next session.  
8.6 Future experiments 
The experiments described in this thesis provided intriguing preliminary evidence 




transcriptional activity at multiple promoters. In addition, they suggest that DISC1 
amino acid substitutions 37W and 607F may compromise DISC1 nuclear targeting 
and ATF4 regulation in brain cells, which in turn may contribute to their risk-
conferring effect, perhaps by introducing subtle changes in the way the brain 
responds to stressful and emotional stimuli, learns, and regulates its sleep/wake 
cycles. Although the present study was undoubtedly useful as it generated an array of 
interesting testable hypotheses, the fact that it is almost entirely based on 
overexpression of exogenous proteins represents an important limitation. This is a 
particularly relevant point especially in light of a recent study that proposed that, at 
least in the mouse brain, DISC1 expression levels are relatively low (Kuroda et al, 
2011). Thus, more work will be required to determine if and how endogenous DISC1 
regulates ATF4 transcriptional activity, and establish whether amino acid 
substitutions 37W and 607F impact on this particular DISC1 function in neurons.  
Below I propose some potential experimental approaches that might be adopted to 
expand and validate (or reject) the observations presented in this thesis. 
 It would be particularly important to establish whether amino acid 
substitutions 37W and 607F significantly impair the nuclear expression of 
endogenous DISC1 in neurons. This could be achieved by introducing these 
mutations in the DISC1 gene in a human neural cell line, such as SH-SY5Y. 
A more rigorous, albeit considerably more expensive and technically 
challenging approach, would be to analyse nuclear DISC1 expression in 
neurons derived from 607F and 37W carriers, and compare it with that of 
non-carriers. Such neurons could be differentiated from induced pluripontent 
stem cells (iPS cells) generated in vitro from skin biopsies. For the common 
607F substitution, it might also be possible to analyse DISC1 protein 
expression in post-mortem brains using immunohistochemistry and/or 
subcellular fractionation. Finally, since the t(1;11) translocation results in 
50% decreased DISC1 expression in patient-derived lymphoblastoid cell 
lines (Millar et al, 2005b), it would be particularly interesting to test whether 
nuclear DISC1 expression is decreased in iPS cell-derived neurons from 




 Several approaches of increasing complexity could be adopted to confirm that 
DISC1 regulates ATF4 transcriptional activity. Initially, this could be tested 
using overexpessed proteins in luciferase assays in which the entire 
promoters of selected well-characterised ATF4 target genes could be used, 
instead of isolated CRE or AARE elements. Examples of potential ATF4 
target promoters that could be tested in this way are Grp78 (containing a CRE 
element) and CHOP (containing an AARE element). This system could also 
be used to further examine the effect of increased cAMP levels on the 
regulatory effect of DISC1, and to test whether these ATF4-targeted 
promoters can be regulated by exogenous DISC1 when activated by stress.   
Another relatively simple way to further test DISC1’s potential to regulate 
ATF4 would be to test for co-localisation of both proteins with PML nuclear 
bodies, sites of active transcription in which exogenous DISC1 has been 
previously described to localise (Sawamura et al, 2008).  
Next, it would be important to determine whether DISC1 regulates ATF4 in 
neuronal cells. This experiment has been attempted in this thesis using SH-
SY5Y cells, but failed due to the insufficient transfection rate achieved in 
these cells, which are notoriously hard to transfect. Thus, to circumvent this 
problem it would be necessary to engineer a human neuronal cell line, such as 
SH-SY5Y, in which ATF4 and DISC1 can be induced either separately or 
together. Alternatively, one might use lentiviral transfection to express ATF4 
and/or DISC1 in cultured primary neurons. These cell models could be used 
to answer multiple questions. For example, one might quantify the expression 
of selected ATF4 target genes using Q-PCR before and after ATF4 
expression, and test whether this changes when DISC1 is co-expressed. In 
addition, it would be possible to use gene microarrays to analyse the 
transcriptional effect of ATF4 or DISC1 expression, and compare it to effects 
of ATF4-DISC1 co-expression. This might lead to the discovery of novel 
ATF4 and/or DISC1 regulated genes. These cells could also be exposed to 
cAMP-increasing drugs such as forskolin and/or IBMX before analysing gene 
expression to test whether any potential functional interaction between 




DISC1 modulates the transcription of ATF4-target genes in response to 
stress, as suggested by the thapsigargin experiment described in chapter 4 of 
this thesis, it would be possible to expose these cells to stress to induce 
endogenous ATF4, and then evaluate the effect of DISC1 co-expression on 
the mRNA levels of ATF4 target genes. These cells could also be engineered 
to express DISC1-37W or DISC1-607F instead of DISC1-WT, so to compare 
any potential transcriptional effects of these variants. Moreover, the 
transcriptional effects of ATF4 and DISC1 might be analysed and compared 
in undifferentiated/proliferating vs. differentiated/post-mitotic neural cells. 
Finally, to control for potential artefacts due to protein overexpression, one 
might perform complementary experiments in neuronal cells or primary 
neurons that express ATF4 and/or DISC1 short hairpin RNAs (shRNAs) to 
knock-down the endogenous proteins. If this approach leads to the 
identification of specific DISC1-regulated genes, it would then be possible to 
compare their expression in SH-SY5Y cells in which endogenous DISC1 has 
been mutated to encode the 607F or 37W variants, or, ideally, in iPS cells-
derived neurons from 37W, 607F and t(1;11) carriers.  
 Next, it would be interesting to understand how DISC1 regulates ATF4 
activity. In this thesis I showed that, at least in the tested system, DISC1-
mediated repression of ATF4 is not mediated by sequestration of ATF4 by 
DISC1 outside the nucleus, and that DISC1 does not act via PDE4. Again, 
different experimental approaches of increasing complexity could be used to 
test this. Initially, the Elecrophoretic Mobility Shift Assay (EMSA) could be 
employed to ask whether ATF4 and DISC1 bind together to promoter 
elements such as the CRE or AARE, or instead DISC1 prevents or inhibits 
ATF4 binding to its target DNA. If DISC1 and ATF4 bind DNA as a 
complex, the same experimental approach could also be used to test whether 
DISC1 prevents recruitment of basic transcription factors to the ATF4-DNA 
complex. If it were demonstrated that ATF4 and DISC1 bind DNA as a 
complex, it would also be interesting to identify the genes that are directly 




expression profiling studies proposed above. This could be done using neural 
cells with inducible ATF4/DISC1 expression, or neural/glial cells that have 
been exposed to stress to induce endogenous ATF4. A sequential chromatin 
immunoprecipitation (chIP) experiment (e.g. ATF4 chIP followed by DISC1 
chIP) could be performed to enrich for promoters that are bound by both 
proteins. These promoters could be subsequently identified by sequencing of 
the immunoprecipitated chromatin.    
 The results presented in chapter 5 of this thesis suggest that the activity of 
ATF4 on the CRE might be regulated by PDE4 and PKA. However, because 
of time limitations, it was not possible to investigate this further in this thesis. 
In the future, it would be interesting to test whether the activating effect of 
PKA on ATF4 transactivation of the CRE is mediated by direct PKA-
dependent phosphorylation of ATF4 at serine 254. This could be done by 
performing CRE-reporter assays with ATF4 serine 254 phospho-resistant and 
phospho-mimic mutants. Indeed, if PKA directly regulates ATF4 both at 
basal and elevated cAMP levels, the ATF4 serine 254 phospho-resistant 
mutant should be less active at basal cAMP levels and more active at high 
cAMP levels, whereas the serine 254 phospho-mimic mutant should have the 
opposite effect. However, if the repressive effect of PKA on ATF4 at high 
cAMP levels is not due to direct phosphorylation of ATF4, but to 
concomitant activation of CREB, mutating ATF4 serine 254 should not affect 
this.  As a complementary approach, it would also be interesting to test 
whether the phosphoryation status of ATF4 is affected by forskolin treatment 
and/or PDE4 overexpression, which could be done by mass spectrometry. 
Given the observed effect of PDE4 on ATF4 activity, the interaction between 
these two proteins, which was previously reported (Bradshaw et al, 2008), 
should be analysed further. For example, immunocytochemistry could be 
used to ask whether ATF4 and PDE4 co-localise in the nucleus and/or 
centrosome. In addition, the effect of PDE4 on CRE activity, both in the 
presence and absence of ATF4, should be tested after exposure to non-




 In the light of the intriguing preliminary findings described in chapter 6 of 
this thesis, the potential involvement of DISC1 in the regulation of the 
cellular response to stress should be investigated further. It would be of 
particular interest to establish whether DISC1 protein expression can be 
modulated by other types of cellular stressors besides H2O2 and in other cell 
types, and test whether this occurs at the transcriptional or post-
transcriptional level, or both. To test this, one may ask whether the effect of 
stress on DISC1 protein levels can be rescued by proteasome inhibitors, or 
inhibitors of autophagocytosis. Moreover, since the DISC1 promoter has 
already been cloned (Walker et al, 2012), luciferase reporter assays could be 
easily used to investigate the potential effect of various stressors on DISC1 
promoter activity in different cell types. Because of technical and time 
limitations, it was not possible to conclusively assess the role of ATF4 and 
DISC1 in MO3.13 cell survival after stress in this thesis. However, if the 
regulatory effect of DISC1 on ATF4-dependent transcription will be 
confirmed using the methods described above, the study of the potential 
effects of DISC1 on cellular stress survival would definitely be a line of 
enquiry worth pursuing. The neuronal cell models with inducible 
overexpression or silencing of ATF4 and DISC1 proposed above might be a 
more suited system in which to investigate this further. Additional stress 
paradigms relevant to schizophrenia (e.g. exposure to pro-inflammatory 
cytokines, nutrient deprivation, exposure to cortisol) should be tested in this 
model, and their effects on cell survival should be assessed both in 
undifferentiated and differentiated cells. Ultimately, it would be also 
necessary to analyse the stress response in DISC1-WT, -37W, -607F mutant 
cells and iPS cell-derived neurons. 
 In chapter 7 of this thesis, I showed that forskolin increases binding of 
exogenous ATF4 and DISC1. To confirm this observation, it would be useful 
to test the effect of forskolin on the interaction between the endogenous 
proteins. As an additional control, alternative methods could be used to raise 




additional cell types should be tested. To test the hypothesis that this effect is 
mediated by direct phosphorylation of ATF4 and/or DISC1 by PKA, co-IP 
experiments could be performed using phospho-mimic and phospho-resistant 
ATF4 and DISC1 mutants for each known PKA site.  In addition, the 
observed effects of forskolin on the expression levels and subcellular 
distribution of ATF4 and DISC1, both exogenous and endogenous, should be 
confirmed in other cell types, and complemented by immunocytochemistry.  
 The effects of DISC1 amino acid substitutions 37W, 607F and 603I and 
mutation LZ9 on ATF4 binding could be further investigated using in-vitro 
binding assays or surface plasmon resonance (SPR). Very briefly, SPR is 
based on the measurement of the angle by which incident light is reflected off 
a thin metal film. Such measure is influenced, among other things, by the 
presence of biomolecules (e.g. protein) on the metal film. Thus, once a bait 
protein (e.g. ATF4) is immobilised on a metal surface through a chemical 
linker, SPR can measure the change in refractive index that occurs when a 
solution containing the purified prey protein (e.g. DISC1) is allowed to flow 
on this surface. Since the degree of change in the SPR signal is proportional 
to the mass of protein bound to the metal surface, this methods allows to 
measure the stoichiometry of the interaction between the bait and prey 
proteins and compare different prey proteins (e.g. DISC1 variants) for their 
ability to bind to the immobilised bait.  
 Finally, it would be necessary to determine whether ATF4 and DISC1 
interact at the mitochondria and centrosome. This could be initially tested by 
developing a triple immunostaining technique to simultaneously detect ATF4, 
DISC1 and the mitochondria or centrosome. A more sensitive and specific 
follow-up experiment could be based on Proximity Ligation Assay (PLA) 
(Soderberg et al, 2006). This in-situ detection method exploits secondary 
antibodies bound to specific DNA strands. If the two secondary antibodies 
used to detect the two target proteins in the cell (ATF4 and DISC1, in this 




DNA strands linked to the antibodies will both anneal with subsequently 
added circle-forming DNA oligonucleotides. Next, a DNA polymerase is 
added to amplify these oligonucleotides in-situ via the formation of a rolling 
circle. Finally, addition of fluorescently labelled oligonucleotide probes 
allows the detection of the amplified DNA, which can be visualised as a 
bright spot under a fluorescence microscope. The potential presence of other 
DISC1 binding partners, such as PDE4, NDE1 and NDEL1, in mitochondrial 
and centrosomal ATF4-DISC1 complexes, should also be investigated. 
In conclusion, this thesis provided interesting insights on the potential role of 
nuclear DISC1, and proposed a novel mechanism by which amino acid 
substitutions 37W and 607F might contribute to the risk of mental illness, thus 
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Appendix – Relevant publications 
 
At the time of writing, one article relevant to this thesis has been published by 
Oxford Journals, who grants all authors the “right to include the article in full or in 
part in a thesis or dissertation, provided that this is not published commercially”.  
The details of this publication are as follows: 
“DISC1 variants 37W and 607F disrupt its nuclear targeting and regulatory role in 
ATF4-mediated transcription” 
Elise L.V. Malavasi, Fumiaki Ogawa, David J. Porteous and J. Kirsty Millar 
Hum. Mol. Genet. (2012) 21(12): 2779-2792 
This article contains work described in chapters 3, 4 and 7 of this thesis. I have 
designed and performed all the experimental work described in the article. The IPLab 
script used to analyse confocal images for DISC1 nuclear distribution measurements 
was developed in collaboration with Paul Perry, from the MRC HGU in Edinburgh. 
The article was written by me, with input from Kirsty Millar, David Porteous, Dinesh 
Soares and Fumiaki Ogawa. The graphics were prepared by me. The full version of 
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DISC1 variants 37W and 607F disrupt its nuclear
targeting and regulatory role in ATF4-mediated
transcription
Elise L.V. Malavasi, Fumiaki Ogawa, David J. Porteous and J. Kirsty Millar∗
The Centre for Molecular Medicine at the Medical Research Council Institute of Genetics and Molecular Medicine,
The University of Edinburgh, Crewe Road, Edinburgh EH4 2XU, UK
Received January 26, 2012; Revised and Accepted March 12, 2012
Disrupted-In-Schizophrenia 1 (DISC1), a strong genetic candidate for psychiatric illness, encodes a multicom-
partmentalized molecular scaffold that regulates interacting proteins with key roles in neurodevelopment and
plasticity. Missense DISC1 variants are associated with the risk of mental illness and with brain abnormalities
in healthy carriers, but the underlying mechanisms are unclear. We examined the effect of rare and common
DISC1 amino acid substitutions on subcellular targeting. We report that both the rare putatively causal vari-
ant 37W and the common variant 607F independently disrupt DISC1 nuclear targeting in a dominant-negative
fashion, predicting that DISC1 nuclear expression is impaired in 37W and 607F carriers. In the nucleus, DISC1
interacts with the transcription factor Activating Transcription Factor 4 (ATF4), which is involved in the regu-
lation of cellular stress responses, emotional behaviour and memory consolidation. At basal cAMP levels,
wild-type DISC1 inhibits the transcriptional activity of ATF4, an effect that is weakened by both 37W and
607F independently, most likely as a consequence of their defective nuclear targeting. The common variant
607F additionally reduces DISC1/ATF4 interaction, which likely contributes to its weakened inhibitory effect.
We also demonstrate that DISC1 modulates transcriptional responses to endoplasmic reticulum stress, and
that this modulatory effect is ablated by 37W and 607F. By showing that DISC1 amino acid substitutions asso-
ciated with psychiatric illness affect its regulatory function in ATF4-mediated transcription, our study high-
lights a potential mechanism by which these variants may impact on transcriptional events mediating
cognition, emotional reactivity and stress responses, all processes of direct relevance to psychiatric illness.
INTRODUCTION
Disrupted-In-Schizophrenia 1 (DISC1) is a risk factor for brain
disorders ranging from depression to schizophrenia (1). DISC1
encodes a multifunctional, multicompartmentalized scaffold
protein with well-established roles in several aspects of neur-
onal physiology, including neural progenitor proliferation, mi-
gration and differentiation, as well as neurotransmission (2).
In the nucleus, DISC1 partially co-localizes with promyelo-
cytic leukaemia nuclear bodies, which identify sites of active
transcription (3), suggesting that DISC1 might be involved
in transcriptional regulation. In support of this, DISC1 can
interact with two highly related stress-responsive transcription
factors, Activating Transcription Factor 4 (ATF4) and Activat-
ing Transcription Factor 5 (ATF5) (3–6), as well as the tran-
scriptional repressor nuclear receptor co-repressor (N-CoR)
(3). The first direct evidence for the involvement of nuclear
DISC1 in transcriptional regulation was provided in a study
by Sawamura et al. (3), who demonstrated that DISC1 can
modulate cAMP-dependent cAMP-response element (CRE)-
mediated transcription by interacting with ATF4.
ATF4 belongs to the activating transcription factor/CRE
binding protein (ATF/CREB) family of basic region-leucine
zipper (bZIP) transcription factors, which share the ability to
bind to the CRE (7). Under basal conditions, ATF4 is
expressed at very low levels, but its transcription and
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translation are rapidly upregulated in response to a range of
different stressors (8). ATF4 can function both as a transcrip-
tional activator and a transcriptional repressor (7). Genes
whose expression is activated by ATF4 include pro- and anti-
apoptotic factors (9,10), as well as genes involved in amino
acid metabolism, regulation of the cell’s redox balance and
mitochondrial function (11). Additionally, ATF4 regulates
emotional behaviour, synaptic plasticity and behavioural
learning (12,13). Indeed, because of its ability to repress the
CREB-mediated late phase of long-term potentiation (LTP)
and long-term memory (LTM) (13), ATF4 has been referred
to as a ‘memory suppressor gene’ (14,15). It is therefore pos-
sible that through its interaction with ATF4, DISC1 might
contribute to the regulation of the transcriptional response to
cellular stress as well as to emotional and LTP-inducing
stimuli.
A number of DISC1 missense variants have been associated
with the increased risk of psychiatric illness, altered brain
morphology or cognitive deficits (1,2), but the molecular
link between structural changes in DISC1 and clinical
outcome has yet to be established. Several risk-conferring mis-
sense variants within DISC1 have the potential to modify the
structure, biochemical properties and subcellular targeting of
the protein, lending support to their putative pathogenic role
(16). In this study, we examined the effect of a spectrum of
common and rare amino acid substitutions of DISC1 asso-
ciated with psychiatric illness on the nuclear targeting of
the protein. We found that both the rare putatively causal
variant 37W and the common 607F substitution impair
nuclear targeting of DISC1, exerting a dominant-negative
effect on the nuclear distribution of wild-type DISC1. Further-
more, the defective nuclear targeting of DISC1 variants 37W
and 607F is reflected in their decreased ability to inhibit
ATF4-dependent transcription. Recently, 607F was shown to
impact on neural development by abrogating DISC1-mediated
activation of wnt-dependent transcription (17). Our findings
add to the evidence for a functional role of 607F in transcrip-
tional regulation, and provide a direct link between risk-
conferring genetic variants and aberrant targeting and function
of nuclear DISC1.
RESULTS
Variants 37W and 607F decrease the nuclear abundance
of DISC1
Several non-synonymous DISC1 variants have been associated
with psychiatric illness and structural brain changes, and some
have been shown to impact on specific aspects of DISC1
biology (1,2,17). Because DISC1 is a multicompartmentalized
protein, we first assessed the impact of a panel of such
disease-associated amino acid substitutions upon its subcellu-
lar distribution. We generated expression constructs (n ¼ 20)
carrying 37W, 432L or 603I (rare/ultra rare) or 607F
(common) variants (1,2,18) in all possible combinations with
the common polymorphisms R264Q and S704C (1,2). With
the exception of R264Q and P432L, all of these DISC1 var-
iants are at highly conserved positions, and all have the poten-
tial to influence the subcellular distribution of DISC1, either
because they are predicted to disrupt critical structural
motifs, or because they occur in regions of DISC1 that
mediate binding to key partner proteins (16).
In a pilot experiment, we used immunocytochemistry to
quantify the relative nuclear abundance of exogenous DISC1
in COS7 cells transfected with either one of the 20 DISC1 ex-
pression constructs. We found no evidence for an effect of
substitutions at positions 264, 432, 603 or 704 on the
nuclear targeting of DISC1 (Supplementary Material,
Fig. S1), nor for gross alteration of the overall subcellular dis-
tribution of DISC1 (not shown). In contrast, both the R37W
and the L607F substitutions result in depletion of exogenous
DISC1 from the nucleus (Supplementary Material, Fig. S1).
Additional variation at positions 264 and 704 does not
modify the effect of 37W or 607F on the nuclear abundance
of DISC1 (Supplementary Material, Fig. S1). These prelimin-
ary observations were confirmed by further immunocytochem-
ical analysis on larger samples of cells (Fig. 1A and B). Both
sequence variants reduce nuclear expression of DISC1 by
50% (P , 0.01). The observed decrease in nuclear expres-
sion of DISC1-37W or DISC1-607F is not due to decreased
overall expression of these DISC1 variants (Supplementary
Material, Fig. S2), which confirms that DISC1 carrying R or
L at positions 37 and 607, respectively, is targeted to the
nucleus more efficiently. DISC1-37W also induces formation
of perinuclear mitochondrial clusters (Fig. 1B), which are
the subject of a separate study (F. Ogawa, unpublished
data). In addition, when compared with wild-type DISC1,
DISC1-607F assumes a more diffuse distribution in the cyto-
plasm (Fig. 1B and Supplementary Material, Fig. S3). Since
we found no evidence for an effect of amino acid variation
at positions 264 and 704 on the subcellular distribution of
DISC1, we performed all the subsequent experiments using
DISC1 constructs encoding the common variants at these posi-
tions (264R and 704S). The common full-length DISC1
variant, to which all other variants analysed here are com-
pared, will henceforth be referred to in the text as ‘wild-type
(WT) DISC1’.
To further examine the effect of DISC1 variants 37W and
607F on the subcellular distribution of the protein, we pre-
pared whole-cell lysates and subcellular protein fractions
from transfected and untransfected SH-SY5Y neuroblastoma
cells and analysed them by western blotting. While the total
protein levels of exogenous wild-type, DISC1-37W and
DISC1-607F were comparable, we detected a 50% decrease
in the relative nuclear abundance of DISC1-37W and
DISC1-607F (P , 0.01, Fig. 1C), and observed a similar
effect by immunocytochemistry (Supplementary Material,
Fig. S4). This reduction in nuclear expression in SH-SY5Y
cells is equivalent to that observed in COS7 cells. Besides
being clearly detectable in the soluble nuclear protein
extract, the full-length 100 kDa DISC1 isoform (both en-
dogenous and exogenous) is also present in the cytoplasmic,
membrane-bound and cytoskeletal extracts, but not in the
chromatin-bound protein fraction (Fig. 1D). While endogen-
ous DISC1 is predominantly enriched in the cytoplasmic and
membrane-associated fractions, the vast majority of exogen-
ous wild-type DISC1 is present in the cytoskeletal fraction
(Fig. 1D). Interestingly, the relative protein abundance
of DISC1-WT, DISC1-37W and DISC1-607F is comparable
in the cytoplasmic and membrane-associated fractions;
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Figure 1. Effect of DISC1 variants on its subcellular distribution. (A) Relative abundance of DISC1 variants in the nucleus of transfected COS7 cells calculated
as the ratio between the total pixel intensity of DISC1 staining in the nucleus and the total pixel intensity of DISC1 staining in the whole cell. The bars represent
the mean values measured in three independent experiments in which 50 cells/variant were analysed. (B) Representative confocal images of COS7 cells expres-
sing wild-type DISC1, DISC1-37W or DISC1-607F. DISC1 is in green, and the nuclei are stained with DAPI (blue). Scale bars are 20 mm. (C) Distribution of
wild-type DISC1, DISC1-37W or DISC1-607F in whole-cell lysates and soluble nuclear extracts (SNE) prepared from transfected SH-SY5Y cells. Each bar
represents the average of four independent experiments. (D) Equal amounts of sub-cellular protein extracts obtained from SH-SY5Y cells that were either
untransfected (bottom) or transfected with wild-type DISC1 (top) were analysed by western blotting using antibodies to detect endogenous or exogenous
DISC1, respectively. ME, membrane extract; CE, cytoplasmic extract; CSKE, cytoskeletal extract; CBNE, chromatin-bound nuclear extract. ∗Non-specific
band. (E) The indicated sub-cellular protein extracts were obtained from SH-SY5Y cells transfected with wild-type, 37W or 607F DISC1 and analysed by
western blotting to detect exogenous DISC1, followed by band densitometry. The loading controls are proteins known to be preferentially enriched in either
of the different subcellular fractions analysed. The bars represent the average of four independent experiments. All the densitometry data are normalized to
the relative band intensity of wild-type DISC1. The position and size (kDa) of the protein markers is indicated.
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however, variant 607F is strongly depleted from the cytoskel-
etal fraction (P , 0.01, Fig. 1E), consistent with its aberrant
cytoplasmic distribution (Fig. 1B and Supplementary Material,
Fig. S3).
Dominant-negative effect of 37W and 607F upon wild-type
DISC1 nuclear distribution
Next, due to the propensity of DISC1 to oligomerize (19–22),
we asked if risk-conferring DISC1 variants 37W and 607F act
in a dominant-negative fashion. Whole-cell lysates and
nuclear protein extracts from SH-SY5Y cells expressing wild-
type DISC1 alone or in combination with either DISC1-37W
or DISC1-607F were analysed by western blotting. We veri-
fied that the different DISC1 expression constructs used in
these experiments achieved comparable levels of protein
expression in SH-SY5Y cells (Supplementary Material,
Fig. S5). As shown in Figure 2A, co-expression of DISC1-
37W or DISC1-607F results in a significant decrease in
nuclear abundance of wild-type DISC1 (P , 0.01), with this
effect being particularly pronounced for the 37W variant
when compared with 607F (P , 0.05). To further examine
this, we co-expressed DISC1-37W or DISC1-607F with wild-
type DISC1 in COS7 and SH-SY5Y cells and analysed the
sub-cellular distribution of each variant by immunocytochem-
istry, using cells transfected with wild-type DISC1 only as a
control. As expected, when wild-type DISC1 is expressed
alone, it translocates to the nucleus, where it is detectable as
numerous bright puncta on a more diffuse background
(Fig. 2B and Supplementary Material, Fig. S6). Consistent
with the results of our subcellular protein fractionation experi-
ment, both DISC1-37W and DISC1-607F reduce the forma-
tion of wild-type DISC1 puncta in the nucleus (Fig. 2B and
Supplementary Material, Fig. S6). Furthermore, we noted
that the cytoplasmic distribution of wild-type DISC1 appears
more diffuse in the majority of cells co-expressing
DISC1-607F (Fig. 2B and Supplementary Material, Fig. S6).
Our results predict that 37W or 607F carriers will have sub-
stantially reduced nuclear DISC1 expression, and that 607F
homozygotes will be similar to 607F heterozygotes in this par-
ticular respect.
Differential effect of DISC1 variants 37W and 607F
on ATF4-mediated transcription
Sawamura et al. (3) showed that co-expression of DISC1
suppresses Gal4-ATF4-mediated transcription and that it
enhances the ATF4-mediated inhibition of CRE-dependent
transcription in response to increased intracellular cAMP
levels. Since ATF4 has also been reported to activate CRE-
mediated transcription under basal (low cAMP) conditions
(23–25), we asked whether DISC1 regulates ATF4-
mediated activation of the CRE at basal cAMP levels. As
expected, in luciferase reporter assays carried out in
HEK293 cells, we detected activation of CRE-driven tran-
scription upon overexpression of ATF4, but not its
dominant-negative mutant ATF4DRK, which lacks the
DNA-binding domain (26,27) (Supplementary Material,
Fig. S7). At basal cAMP levels, co-expression of DISC1
inhibits the ATF4-mediated transactivation of CRE-driven
transcription in a dose-dependent manner (P , 0.01,
Fig. 3A). Importantly, overexpression of DISC1 alone has
no effect on the basal activity of the Som-CRE-luc reporter
(Supplementary Material, Fig. S8), indicating that DISC1
acts via ATF4.
Next, we tested the effect of DISC1 variants 37W and 607F.
Both retain the ability to inhibit ATF4 transcriptional activity,
but their inhibitory effect is significantly weaker compared
with wild-type DISC1 (P , 0.05 for 37W, P , 0.01 for
607F, Fig. 3B). This is not caused by differences in expression
levels (Supplementary Material, Fig. S9) nor it is limited to
HEK293 cells, as we observed this same effect in MO3.13
human oligodendrocytes (P , 0.05 for both variants, Fig. 3C).
The transactivation activity of ATF4 is not limited to CRE-
containing promoters. In fact, several ATF4 target genes
involved in the response to cellular stresses such as amino
acid limitation, oxidative stress or endoplasmic reticulum
stress are activated through C/EBP-ATF Response Elements
(CARE) in their promoters (28). For example, ATF4 induces
expression of its target gene C/EBP homology protein
(CHOP) by binding to a particular type of CARE in its pro-
moter, the Amino Acid Response Element (AARE)
(9,29,30). Thus, we sought to test whether DISC1 modulates
the activity of ATF4 at the CHOP AARE. As expected,
ATF4 strongly activates transcription from a CHOP AARE-
luciferase reporter, but not from its mutant, non-responsive
counterpart (31) (Supplementary Material, Fig. S10). As
with the CRE, wild-type DISC1 significantly represses the
ATF4-dependent transactivation of the CHOP AARE (P ,
0.01, Fig. 3D). This inhibitory effect is reduced by
DISC1-607F (P , 0.05, Fig. 3D) and DISC1-37W (P ,
0.05, Fig. 3D).
To further investigate the likely relationship between the
decreased ability of DISC1 variants 37W and 607F to inhibit
the transcriptional activity of ATF4 and their defective
nuclear targeting, we tested a mutant form of DISC1 lacking
the predicted leucine zipper in exon 9 (DISC1DLZ9),
located between amino acids 607 and 628. Alanine substitu-
tions at positions 614 and 621 prevent translocation of
DISC1 to the nucleus (3), consistent with LZ9 being required
for nuclear targeting. As expected, when expressed in COS7
cells, DISC1DLZ9 fails to accumulate in the nucleus, and
assumes a diffuse distribution in the cytoplasm (Fig. 4A),
closely resembling that of DISC1-607F (Fig. 1B, Supplemen-
tary Material, Figs S3 and S4). The remarkably similar effects
of 607F and DISC1DLZ9 upon DISC1 nuclear localization are
likely related to the predicted structural disruption of LZ9 by
607F (16). Consistent with its exclusion from the nucleus,
DISC1DLZ9 does not significantly inhibit ATF4-mediated ac-
tivation of CRE-dependent transcription (P , 0.05, Fig. 4B).
ATF4 plays a central role in mediating the cellular response
to a range of damaging stimuli, including endoplasmic reticu-
lum stress (7). Following on from our finding that DISC1
represses the transcriptional activity of exogenous ATF4, we
examined the effect of DISC1 on the transcriptional activity
of endogenously induced ATF4 using the endoplasmic reticu-
lum stress inducer thapsigargin. In line with previously
reported observations (32), thapsigargin treatment induces ex-
pression of endogenous ATF4 (Supplementary Material,
Fig. S11) and determines a 2-fold activation of CRE-
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dependent transcription (Fig. 5). Overexpression of wild-type
DISC1, but not variants 37W and 607F or the mutant
DISC1DLZ9, significantly inhibits the thapsigargin-induced
activation of CRE-dependent transcription (Fig. 5).
Morris et al. (4) showed that co-expression of full-length
DISC1 inhibits accumulation of ATF5 in the cell nucleus.
Since ATF4 and ATF5 are structurally closely related (33),
we asked whether DISC1 impacts on the nuclear distribution
and/or protein levels of ATF4, which may contribute to the
observed transcriptional inhibition. Surprisingly, in cells trans-
fected using the same ATF4/DISC1 DNA ratio used in the
luciferase reporter assays, co-expression of DISC1 does not
decrease the overall protein expression or nuclear targeting
of exogenous ATF4, but instead seems to have the opposite
effect, although this does not reach statistical significance
(Fig. 6A and B). DISC1 therefore apparently does not
inhibit ATF4-mediated transcription by reducing nuclear
ATF4 expression.
Although exogenous ATF4 is highly enriched in the
nucleus, we noticed that it is also detectable in the perinuclear
region in a pattern closely resembling the typical morphology
of mitochondria (Fig. 6A), an organelle to which DISC1 is
known to localize (34–36). Cytoplasmic ATF4 partially
co-localizes with exogenous DISC1 in this location
(Fig. 6A). To better test for a potential mitochondrial localiza-
tion of exogenous ATF4, we used four different antibodies to
detect the protein (both tagged and untagged) in transfected
COS7 cells. In each case, we observed partial co-localization
Figure 2. Dominant-negative effect of 37W and 607F DISC1. (A) SH-SY5Y cells were transfected with Flag-WT DISC1 and an equal amount of either
Myc-DISC1-WT, Myc-DISC1-37W or Myc-DISC1-607F. The relative abundance of Flag-WT DISC1 was then quantified by western blotting in whole-cell
lysates and nuclear extracts (NE) prepared from the transfected cells. The bars represent the average of three independent experiments. The data are normalized
to the relative band density of Flag-DISC1 in samples expressing WT DISC1 only. (B) Sub-cellular distribution of Flag-DISC1 (green) and Myc-DISC1 (red) in
representative COS7 cells expressing Flag-WT DISC1 in combination with an equal amount of Myc-DISC1-WT (top), Myc-DISC1-607F (middle) or
Myc-DISC1-37W (bottom). Magnifications of the cell nuclei are shown in the far-right panels. ∗∗P , 0.01; #two-tailed paired Student’s t-test. Scale bars are
20 mm.
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of ATF4 with mitochondria, particularly in the perinuclear
region (Supplementary Material, Fig. S12).
DISC1 variants affect its interaction with ATF4
The L607F substitution is predicted to disrupt the Leucine
packing in DISC1 LZ9, a region identified as essential to
mediate binding to ATF4 (3), and could therefore directly
impair the DISC1–ATF4 interaction. In addition, by introdu-
cing a physical segregation between the two proteins, the defect-
ive nuclear localization of DISC1 variants 37W and 607F might
in itself impair their interaction with ATF4, the majority of
which is found in the nucleus. This mechanism could contribute
to their blunted inhibitory effect on ATF4-mediated transcrip-
tion. As expected, in co-immunoprecipitation assays performed
with exogenous proteins in HEK293 cells, DISC1-607F shows
significantly impaired binding to ATF4 (Fig. 7A). However,
the R37W substitution produces only a slight, non-significant
decrease in DISC1 binding to ATF4 (Fig. 7A).
The observed discrepancy between the defective nuclear
targeting of DISC1-37W and its largely preserved interaction
with ATF4 prompted us to analyse the sub-cellular distribution
of the two proteins in co-transfected cells. Interestingly, unlike
wild-type DISC1 and DISC1-607F, which exhibit limited
co-localization with ATF4 outside the nucleus, DISC1-37W
clearly co-distributes with ATF4 at mitochondria (Fig. 7B).
We therefore conclude that the reduced capacity of DISC1-
37W to inhibit ATF4-mediated transcription is due to its
exclusion from the nucleus, rather than to reduced interaction
with ATF4.
DISCUSSION
Growing evidence indicates that by establishing dynamic
interactions with multiple binding partners, DISC1 functions
as a hub protein whose principal role is to modulate various
cellular processes in a space- and time-regulated manner. Se-
quence changes in DISC1 that disrupt its normal compartmen-
talization and protein interactions are therefore likely to have
functional consequences, and may highlight biological pro-
cesses involved in psychopathology.
In this study, we demonstrated that the putatively causal
variant 37W and the common variant 607F both induce a
50% depletion of the nuclear pool of DISC1, and perturb
Figure 3. Differential effect of DISC1 variants on ATF4-mediated transcription. (A) Relative CRE-dependent luciferase activity in HEK293 cells transfected
with a fixed amount of pCG-ATF4 and decreasing amounts of wild-type DISC1. The numbers indicate the amount (ng/well) of plasmid DNA used for trans-
fection. (B and C) Relative CRE-driven luciferase activity in HEK293 (B) or human oligodendrocyte MO3.13 cells (C) transfected with ATF4 only or in com-
bination with the indicated DISC1 variants. (D) Relative CHOP AARE-driven luciferase activity in HEK293 cells transfected with ATF4 only or in combination
with the indicated DISC1 variants. All data are normalized to the relative luciferase activity in cells transfected with the reporters only (CRE or AARE). The bars
represent the average of at least three independent experiments. ∗P , 0.05, ∗∗P , 0.01.
2784 Human Molecular Genetics, 2012, Vol. 21, No. 12
 at E
dinburgh U







the nuclear targeting of wild-type DISC1 in a dominant-
negative fashion. In addition, both variants negatively
impact on the ability of DISC1 to regulate transcription in re-
sponse to exogenous ATF4 and endoplasmic reticulum stress.
37W was identified in a patient diagnosed with schizophrenia
and not in 10 000 control alleles (18), and is thus a rare,
putatively causal variant. In contrast, 607F is a common
variant, present in 10% of the population. The single nucleo-
tide polymorphism (SNP) determining variation at this pos-
ition, or haplotypes including this SNP, is associated with
schizophrenia, schizoaffective disorder, bipolar disorder and
depression and correlate with symptom severity in schizophre-
nia, the P300 waveform mental illness endophenotype and in-
fluence brain structure and function (37–46). Singh et al. (17)
recently assayed several DISC1 variants, including L607F and
two other common variants R264Q and S704C for their effect
on wnt signalling. Interestingly, they reported abnormal wnt
signalling for 264Q and 607F, but not 704C, while we
report abnormal nuclear localization and ATF4 binding for
607F, but not 264Q or 704C, consistent with a differential
effect of non-synonymous amino acid substitutions on the
varied and distinct functions of DISC1.
The 37W sequence change disrupts a highly conserved
tetra-arginine nuclear localization signal in the otherwise
poorly conserved head region of DISC1 (3), while the
common variant 607F is located in a conserved predicted
leucine zipper which was previously shown to contribute to
DISC1 nuclear targeting and to be essential for interaction
with ATF4 (3). The predicted disruption of this leucine
zipper structural feature by L607F (16) therefore likely
explains the reduced nuclear targeting and ATF4 binding of
DISC1-607F, two effects that may potentially be interrelated.
Figure 4. Effect of DISC1 LZ9 on nuclear distribution of DISC1 and transcriptional regulation of ATF4. (A) Confocal image of a representative COS7 cell
expressing DISC1DLZ9 (green). Nuclei are stained with DAPI (blue). (B) Relative luciferase activity in HEK293 cells transfected with the reporters only
(CRE) or in combination with ATF4 with or without wild-type DISC1 or DISC1DLZ9. The bars represent the average of four independent experiments. The
data are normalized to the relative luciferase activity in cells expressing the reporters only (CRE). ∗P , 0.05, two-tailed paired Student’s t-test. The scale
bar is 20 mm.
Figure 5. Effect of DISC1 on the CRE-mediated transcriptional response to
thapsigargin. HEK293 cells were transfected with the reporters only (CRE)
or in combination with the indicated expression constructs. Starting from
32 h post-transfection, the cells were exposed to thapsigargin or vehicle
(DMSO) for the indicated time before being assayed for luciferase activity.
The bars represent the average of at least three independent experiments.
∗∗P , 0.01.
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For both 37W and 607F sequence variants, the end result of
reduced nuclear DISC1 expression most likely explains their
decreased ability to repress ATF4 transcriptional activity.
Depending on the construct tested, DISC1 is capable of
forming dimers, octamers and other oligomers and multimers
(19,20,22,47,48). Thus, in heterozygous cells expressing wild-
type and variant DISC1, hetero/oligomerization will likely
occur, accounting for the dominant-negative effects reported
here. Indeed, we have recently observed that DISC1-37W
recruits wild-type DISC1 to perinuclear mitochondrial aggre-
gates (F. Ogawa, unpublished data). It is therefore possible
that the dominant-negative effect exerted by DISC1-37W on
the nuclear targeting of wild-type DISC1 results from redistri-
bution of wild-type DISC1 to mitochondria. We observed a
significant, but milder reduction in nuclear abundance of wild-
type DISC1 upon co-expression of 607F DISC1, and a change in
the cytoplasmic distribution of wild-type DISC1 from punctate
to diffuse. 607F is located close to a region of DISC1 (668–747)
identified as essential for oligomerization (20) and it resides
within a predicted oligomerization-promoting leucine zipper
(16). Thus, the dominant-negative effect of DISC1-607F on
the nuclear and cytoplasmic distribution of wild-type DISC1
may be related to the potentially altered oligomerization pro-
pensity of this variant form of DISC1. These observations indi-
cate that nuclear expression of wild-type and variant DISC1 will
likely be reduced in 37W or 607F carriers, with consequent
effects for the role of DISC1 in transcription.
ATF4 transcriptional activity is modulated at multiple
levels, including transcription and translation, post-
translational modification and repression of its transcriptional
activity through protein interactions (7,8,23,49–51).
Mammalian cells respond to different types of environmental
stressors by activating distinct stress-responsive kinases, all
converging on phosphorylation of the a subunit of eukaryotic
initiation factor 2 a (eIF2-a) (52). Phosphorylation of eIF2-a
inhibits general protein synthesis while favouring the preferen-
tial translation of ATF4 (11,53,54). The regulation of ATF4
expression in response to stress also occurs at the transcrip-
tional level, with different environmental stressors either acti-
vating or suppressing ATF4 mRNA synthesis (8). At the
post-translational level, ATF4 is regulated by phosphorylation
at multiple sites, which controls both the protein stability by
regulating its ubiquitination (55–57), and its transcriptional
activity (49,51). One further level of control of ATF4
resides in its interaction with binding partners that can directly
inhibit its transcriptional activity, such as CHOP (58), neuron-
al cell death inducible putative kinase (NIPK) (23) and, as we
and others (3) have reported, DISC1. The existence of multiple
mechanisms controlling the production, persistence and activ-
ity of ATF4 indicates the critical importance of tight regula-
tion of ATF4-mediated gene transcription. We and others
(23–25,29,30) have demonstrated that ATF4 activates CRE-
and AARE-mediated transcription at basal cAMP levels,
while, in contrast, ATF4 represses CRE-mediated transcrip-
tion in response to elevated cAMP (3,59). DISC1 inhibits
both the transactivation and repression (3) activities of
ATF4, and is thus likely to be an important modulator of
ATF4-mediated transcription in the brain. Our observation
that the repressive activity of DISC1 is weakened by sequence
variants that influence risk of mental illness suggests that
altered ATF4-mediated transcription may be a contributing
factor to the overall disease risk.
Figure 6. DISC1 does not affect nuclear targeting and protein levels of ATF4. (A) Representative COS7 cells transfected with ATF4 alone (top panels) or in
combination with DISC1 (lower panels). The area delimited by a white rectangle is magnified in the inset. (B) ATF4 protein levels in whole-cell lysates or
nuclear extracts prepared from HEK293 cells transfected with ATF4 alone or in combination with DISC1. The ATF4/DISC1 DNA ratio used in these experi-
ments was the same as that used for the luciferase reporter assays. Loading controls are histone 3 (H3) for whole-cell lysates and nuclear matrix protein p84
for nuclear extracts. The bars represent the average of three independent experiments. Scale bars are 20 mm. The position and size (kDa) of the protein
markers is indicated.
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ATF4 antagonizes the transcriptional activity of CREB, a
key mediator of LTP and LTM (13,15,60,61). Therefore,
through its modulatory effect on ATF4, DISC1 might be
involved in the regulation of the transcriptional events that
mediate synaptic plasticity. This in turn implies that DISC1
variants 37W and 607F may deregulate synaptic plasticity
and cognitive processes through their defective modulation
of ATF4 transcriptional activity. Since cognitive impairment
is a core feature of schizophrenia, this is a potential route by
which these DISC1 variants influence risk of mental illness.
Both DISC1 and ATF4 are implicated in the regulation of
emotional behaviour in rodent models (12,62–67). ATF4 ex-
pression in the nucleus accumbens (NA), a key reward
region in the brain, is induced by amphetamine administration
or restraint stress, and ATF4 overexpression in this region
decreases the behavioural responsiveness to amphetamine
(12). Like its related transcription factor CREB, ATF4 attenu-
ates emotional reactivity and induces depression-like beha-
viours when overexpressed in the NA, clearly indicating that
ATF4 functions as an activator of CRE-driven transcription
Figure 7. Effect of DISC1 variants on the interaction between DISC1 and ATF4. (A) HEK293 cells were transfected with pCG-ATF4 alone or in combination
with the indicated DISC1variants. Exogenous DISC1 was immunoprecipitated using an anti-Flag antibody and detected using an anti-DISC1 antibody
(a-DISC1). Co-precipitating ATF4 was detected with an anti-ATF4 antibody (sc-200). The bars represent the average of three independent experiments.
∗Non-specific band. The position and size (kDa) of the protein markers is indicated. (B) COS7 cells transfected with the indicated variants of DISC1 (green)
and ATF4 (red). The right-hand panels represent the corresponding merged images. The areas delimited by a white square are magnified in the insets. Scale
bars are 20 mm.
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in this brain area (12). Like ATF4, DISC1 modulates the be-
havioural responsiveness to amphetamine in rodent models
(66,68,69), and DISC1 mutations or altered expression are
associated with depression-like behaviours in several mouse
models (62–67). In the light of these findings, it is tempting
to speculate that the role of DISC1 in emotional behaviour
may be at least partly mediated by its modulation of ATF4
transcriptional activity on the CRE. If true, this would imply
that DISC1 variants that interfere with this particular function
of DISC1, such as 37W and 607F, may directly impact on the
regulation of emotional behaviour.
ATF4 is also a key mediator of the integrated stress re-
sponse, and its transcription and translation are strongly upre-
gulated in response to a range of stressors, including amino
acid deprivation, oxidative stress, hypoxia, viral infections,
endoplasmic reticulum stress and mitochondrial dysfunction
(28,70–73). The contribution of damaging environmental
exposures to the risk of developing schizophrenia is well
established, but mechanistically unclear. Maternal starvation,
viral infections and perinatal hypoxia are among the best sup-
ported risk factors for schizophrenia (74), and each of these
exposures could potentially activate the stress responses
mediated by ATF4. It is intriguing to speculate that, by modu-
lating the transcriptional activity of ATF4, DISC1 might con-
tribute to regulation of cellular responses to stress, tipping the
balance towards adaptation or apoptosis. In this scenario, 37W
and 607F substitutions in DISC1 could increase the risk of
mental illness by rendering the brain more susceptible to
stress.
In conclusion, we have identified novel cellular and molecu-
lar phenotypes associated with common and rare DISC1 var-
iants, and highlighted routes by which these psychiatric
illness-associated variants could influence emotional and cog-
nitive processes that are characteristically dysfunctional in
mental illness, and the effects of environmental stressors that
increase the risk of mental illness. Formal testing of gene–
environment interactions has rarely been possible (75), but is
of fundamental importance. Identification of a molecular
mechanism that links the common DISC1 L607F polymorph-
ism to the ATF4-mediated stress response provides an exciting




DMSO and thapsigargin were from Sigma. Primary antibodies
were: anti-Flag (F7425 and F3165) (Sigma), c-Myc (sc-40),
anti-ATF4 (sc-200) (Santa Cruz) and anti-ATF4
(WH0000468M1) (Sigma), a-DISC1 (76), anti-p84 (ab487),
anti-H3 (ab1791), anti-Calreticulin (ab22683), anti-Vimentin
(ab8978) (Abcam) and anti-GAPDH (MAB347) (Millipore).
TO-PRO3 and Mito Tracker Red were from Invitrogen.
Cell culture and transfection
MO3.13 cells (77) were a gift from Adrian Walmsley (Novar-
tis Institute for Biomedical Research, Basel). All cell lines
were cultured in DMEM supplemented with 10% FBS
(Gibco) and maintained in a humidified incubator at 378C
and 5% CO2. Unless otherwise stated, HEK293 and COS7
cells were transfected with Lipofectamine 2000 (Invitrogen)
and SH-SY5Y cells were transfected with FugeneHD
(Roche), according to the manufacturer’s directions.
Plasmids
The ATF4 expression construct pCG-ATF4 (24), encoding
human ATF4, was donated by Adrian Harris (University of
Oxford). pCG-ATF4DRK was obtained by mutating the
DNA-binding domain of human ATF4 in pCG-ATF4
(294RYRQKKR300 to 294GYLEAAA300) by site-directed muta-
genesis. The reporter Som-CRE-luc (Stratagene) and the
TK-Renilla control luciferase vector were gifted by Richard
Killick (King’s College London). The reporter pGL4.23-CRE
was generated by inserting four copies of the Somatostatin
CRE (underlined) and its flanking regions (5′-AGCCTGACGT
CAGAG-3′) upstream of the minimal promoter of the vector
pGL4.23[luc2/minP] (Promega). The reporter vector
pGL4.23-CHOP AARE and its mutant, non-responsive version
pGL4.23-mutCHOP AARE, were generated by site-directed
mutagenesis from pGL4.23[luc2/minP]. Mutagenic primers con-
tained two copies of the core CHOP AARE (underlined) and its
flanking regions: CHOP AARE, 5′-AACATTGCATCATCCCC
GC-3′ and mut CHOP AARE, 5′-AACAATGCATCATCCCC
GC-3′ (31), which only differed for the base in bold. All DISC1
expression constructs were generated from the plasmid
pcDNA4/TO-Flag DISC1, coding for N-terminus Flag-tagged
full-length human DISC1 (isoform L), by site-directed mutagen-
esis. All the site-directed mutagenesis reactions were performed
using the QuikChange II or QuikChange Lightning site-directed
mutagenesis kit (Stratagene), according to the manufacturer’s
directions. All the reporters and expression constructs were veri-
fied by direct sequencing.
Luciferase reporter assays
Most luciferase reporter assays were performed in HEK293
cells because they are a well-characterized model for the
study of the transcriptional effects of ATF4 (30,78) and they
consistently achieve high transfection rates, generating a
strong and replicable luminescence signal. Cells were seeded
in black-walled 96-well plates at a density of 6 × 104/well
(HEK293) or 2.5 × 104/well (MO3.13) and transfected with
Fugene HD (Roche Applied Science) or Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions.
Cells were transfected with 90 ng/well of CRE-luciferase re-
porter plasmid and 9 ng/well of TK Renilla luciferase vector
to control for variation in transfection efficiency. The CRE-
luciferase reporters were Som-CRE-luc for HEK293 cells
and pGL4.23-CRE for MO3.13 cells. The ATF4 expression
plasmids were used at a concentration of 120 ng/well and
15 ng/well for CRE-reporter and CHOP AARE-reporter
assays, respectively. Unless otherwise stated, DISC1 expres-
sion plasmids were used at 81 ng/well. Where necessary, the
empty vector pcDNA4/TO was added to the transfection mix
to bring the total amount of transfected DNA to 300 ng/well.
Background luminescence was measured in cells transfected
with the empty vector pcDNA4/TO, and subtracted from the
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mean readings of each sample. Each transfection was per-
formed in triplicate. Where indicated, drug treatments were
started 32 h after transfection. When DMSO was used as
vehicle, its final concentration in the medium was 0.1% or
lower, and it did not affect cell viability or morphology. Luci-
ferase activity was measured with the Dual Glo Luciferase
Assay System (Promega), following the manufacturer’s proto-
col.
Immunocytochemistry
To stain mitochondria, cells were incubated in 50 nM Mito
Tracker Red in DMEM 10% FBS for 30 min before fixation.
Cells were then fixed in methanol for 5 min at 2208C, fol-
lowed by four washes in cold PBS. Fixed cells were blocked
for 30 min in PBS containing 3% bovine serum albumin
(PBS/BSA), and then incubated for 2 h at room temperature
with the primary antibodies diluted in PBS/BSA. Anti-Flag
antibodies F7425 and F3165 were used at 1:2000 and
1:10.000, respectively. The anti-c-Myc antibody was used at
1:500. The anti-ATF4 antibodies were used at 1:4000
(sc-200) and 1:2.500 (WH0000468M1). Secondary antibodies
were Alexa Fluor goat anti-rabbit IgG 488 and 594 and Alexa
Fluor goat anti-mouse IgG 488 and 594, all used at 1:1000.
TO-PRO3 was used at 1:500. Images were acquired with a
Zeiss LSM510 or a Nikon A1R confocal microscope.
Analysis of DISC1 subcellular distribution
by immunofluorescence
COS7 cells transfected with equal amounts of the indicated
DISC1 expression constructs were stained using an anti-Flag
antibody (F7425) to detect exogenous DISC1, and nuclei
were counterstained with TO-PRO3. Single plane confocal
images of individual transfected cells were acquired using a
Zeiss LSM510 confocal microscope (Zeiss). In each experi-
ment, all the images were acquired using the same confocal
settings. The investigator who acquired the images and per-
formed the analysis was blinded to which variant of DISC1
had been transfected in each cell sample analysed. Image ana-
lysis was performed with IPLab version 3.9.5 r5 (BD Bios-
ciences). For each cell image analysed, the total pixel
intensity of DISC1 staining was measured both in the whole
cell and in the nucleus only. The proportion of DISC1 staining
localized in the nucleus was then calculated as the nucleus/cell
ratio of total pixel intensities in individual cells.
Subcellular fractionation
Subcellular fractions were prepared from SH-SY5Y or
HEK293 cells transfected with the indicated constructs for
72 or 24 h, respectively. In each fractionation experiment, a
small proportion of the cell sample was lysed in RIPA
buffer (150 mM NaCl, 50 mM Tris–HCl, pH 7.5, 1% Nonidet
P-40, 0.1% SDS, 0.5% sodium deoxycholate) supplemented
with a protease inhibitor cocktail (Roche) for subsequent ana-
lysis of the expression level of exogenous proteins by western
blotting. Subcellular fractions were obtained using the Subcel-
lular Protein Fractionation Kit or the NE-PER Nuclear and
Cytoplasmic Extraction Kit (Pierce Thermo Scientific) accord-
ing to the manufacturer’s instructions.
Immunoprecipitation and immunoblotting
For immunoprecipitation, HEK293 cells were lysed in PBS
containing 1% Triton X-100 supplemented with a protease in-
hibitor cocktail (Roche) 24 h after transfection with the indi-
cated plasmids. Immunoprecipitation was performed using
an anti-Flag (F3165) antibody, following a standard protocol
(79). Immunoblotting was performed as described (36).
Chemiluminescent images were captured using the GeneG-
nome imaging system and densitometry was performed
using the Gene Tools software, both from Syngene
(Cambridge, UK). Densitometry was performed in parallel
on duplicate western blots, in a minimum of three independent
experiments. For the western blotting analysis of subcellular
fractions, exogenous DISC1 band densities were first corrected
using appropriate loading controls (nuclear matrix protein p84
for nuclear extracts, GAPDH for cytoplasmic extracts, calreti-
culin for membrane-bound extracts, vimentin for cytoskeletal
extracts), and then divided for the respective GAPDH-
corrected DISC1 band intensities in the corresponding whole-
cell lysates.
Statistical analysis
Unless otherwise specified, data were analysed by one-way
ANOVA followed by Dunnett’s multiple comparison test.
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Supplementary Material is available at HMG online.
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Supplementary Figure 1 (Figure S1) 
 
 
Relative abundance of DISC1 variants in the nucleus of transfected COS7 cells, calculated as the ratio 
between the total pixel intensity of DISC1 staining in the nucleus and the total pixel intensity of 
DISC1 staining in the whole cell. The bars represent mean measurements of 20 cells/variant carried 
out in a single experiment. The black arrow indicates the common long isoform of wild-type (WT) 
DISC1, to which all other variants are compared.  
 
Supplementary Figure 2 (Figure S2) 
 
 
Scatterplot and regression lines of total pixel intensity of DISC1 staining in the whole cell (x-axis, 
independent variable) vs. nucleus (y-axis, dependent variable) in individual COS7 cells transfected 
with wild-type DISC1, DISC1-37W or DISC1-607F. The graph was generated by pooling 
measurements obtained from 50 cells/variant in 3 independent experiments (150 cells/variant in total). 
Pearson r (95% confidence interval) = 0.3337, P<0.0001 (wild-type DISC1); 0.5648, P<0.0001 

















Representative COS7 cells expressing either wild-type DISC1 or DISC1-607F (green). Nuclei (blue) 
are stained with DAPI. The cytoplasmic regions delimited by the white squares are magnified in the 




















Representative SH-SY5Y cells expressing wild-type DISC1, DISC1-37W or DISC1-607F (green). 











Whole cell lysates were obtained from SH-SY5Y cells that were either mock transfected or 
transfected with equal amounts of the indicated DISC1 expression constructs, and analysed by 
Western blotting. DISC1 expression was assessed using the α-DISC1 antibody to ensure that 
comparable total exogenous DISC1 expression was achieved, and the antibody concentration used 
was adjusted so that only exogenous DISC1 could be detected. The position and size (kDa) of the 















Subcellular distribution of Flag-DISC1 (green) and Myc-DISC1 (red) in representative SH-SY5Y 
cells expressing Flag-WT DISC1 in combination with an equal amount of Myc-WT DISC1 (top), 







Supplementary Figure 7 (Figure S7) 
 
Relative luciferase activity in HEK293 cells transfected with the reporters only (CRE) or in 
combination with either human ATF4 or its dominant-negative mutant form ATF4 RK. The data are 













Supplementary Figure 8 (Figure S8) 
 
HEK293 cells were transfected with the reporters only (CRE) or in combination with increasing 
amounts of wild-type DISC1 (reported in brackets as ng/well). Forty-eight hours after transfection, the 
cells were lysed and the relative luciferase activity was measured. The data are normalised to the 
relative luciferase activity in cells transfected with the reporters only. The bars represent the average 














To compare the expression levels of WT DISC1, DISC1-37W and DISC1-607F, whole cell lysates 
were obtained from HEK293 cells transfected with equal amounts of the indicated DISC1 expression 
constructs, and analysed by Western blotting. The loading control is histone 3 (H3). The position and 













Supplementary Figure 10 (Figure S10) 
 
 
HEK293 cells were transfected with the reporters only (AARE or mutAARE) or in combination with 
ATF4. Forty-eight hours after transfection, the cells were lysed and the relative luciferase activity was 














HEK293 cells were treated with 1 M thapsigargin for 16 hours. At the end of the drug treatment, 
nuclear protein extracts were prepared from the transfected cells and analysed by Western blotting. 
Endogenous ATF4 was detected with the sc-200 antibody. The position and size (kDa) of the protein 

















COS7 cells were transfected with pCGATF4 (top two rows), ATF4-Flag (third row) or ATF4-Myc 
(bottom row). Exogenous ATF4 was detected using either anti-ATF4 or anti-tag antibodies, as 
indicated in the figure, and mitochondria were stained with Mitotracker Red.  
